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Mitochondrial diseases are a group of clinically and genetically heterogeneous disorders 
typically associated with abnormal oxidative phosphorylation (OXPHOS). In recent years, next 
generation sequencing technologies have allowed for accurate genetic diagnoses of inherited 
mitochondrial diseases directly from patient DNA by facilitating the identification of potential 
candidate genetic defects in either nuclear or mitochondrial genomes. In such a manner, two 
compound heterozygous sequence variants in COA7, which encodes a putative cytochrome c 
oxidase (Complex IV, COX) assembly factor, and homozygous recessive sequence variants 
in TMCO6, which encodes an uncharacterised protein, were identified in patients presenting 
with classical clinical and biochemical hallmarks of mitochondrial disease. The aim of this work 
was to 1) assess the pathogenicity of the COA7 and TMCO6 mutant variants in causing 
mitochondrial disease, and 2) to investigate the association of the resulting proteins in the 
assembly pathways of complexes of the mitochondrial respiratory chain: Complex IV (CIV, 
COX) for COA7 and Complex I (CI) for TMCO6. 
 
Compound heterozygous mutant variants in COA7 (NM_023077.3:c.410A>G;c.287+1G>T) 
led to total disappearance of its gene product in patient skin fibroblasts, owing to two aberrant 
mRNA transcripts. Loss of COA7 steady-state level correlated with low abundance of certain 
COX subunits, intermediates, monomeric and supercomplex COX species, as well as isolated 
COX enzymatic deficiency. Stable expression of COA7WT in patient fibroblasts by lentivirus-
mediated complementation rescued COX abundance, the quantities of its affected subunits, 
subassembly and supercomplex species, and its activity, to normal levels, confirming the 
pathogenicity of the compound heterozygous COA7 mutant variants. A combination of super-
resolution microscopy and subcellular fractionation and protease digestion studies confirmed 
the intracellular localisation of COA7 to be the mitochondrial intermembrane space.  
 
Secondly, a novel homozygous recessive variant in TMCO6 (NM_018502.5: c.271C>T) was 
identified in a paediatric proband presenting with severe developmental delay, generalised 
hypotonia and progressive cerebral and cerebellar atrophy. Biochemical measurement of a 
skeletal muscle biopsy revealed CI enzymatic deficiency, and patient-derived skin fibroblasts 
showed destabilisation of CI-containing supercomplexes. TMCO6 was found to co-localise 
with the CI holocomplex by 2D-BNGE, and this result was further corroborated by 
immunoprecipitation experiments. Additionally, cellular models for TMCO6 gene silencing and 
overexpression were characterised, and an attempted generation of a knockout cellular model 
is described. Subcellular fractionation and protease treatment experiments determined 
TMCO6 to localise to the mitochondrial inner membrane. A Tmco6-knockout murine model 
was characterised, which exhibited several neurological, physiological and motor debilities, 
isolated CI deficiency in heart and skeletal muscle, and abnormal cardiac electrophysiology. 
Recombinant AAV-mediated expression of wildtype, human TMCO6 rescued the CI deficiency 
and electrophysiological function of 3 month-old knockout mice hearts. In contrast, stable 
expression of the patient mutant protein variant failed to recover the isolated CI deficiency, and 
additionally resulted in severe cardiac fibrosis. Together, these findings causally link ablation 
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BNGE/BN-PAGE blue native polyacrylamide gel electrophoresis 
bp   base pairs 
BSA   bovine serum albumin  
CD68   cluster of differentiation 68 
CDS   coding sequence 
CI   complex I 
CII   complex II 
CIII   complex III 
CIV   complex IV 
CLAMS  comprehensive laboratory animal monitoring system 
CNPase  2', 3'-cyclic nucleotide 3'-phosphodiesterase 
CNS   central nervous system  
COX   cytochrome c oxidase  
CRISPR  clustered regularly interspaced short palindromic repeats 
CS   citrate synthase 
CV   complex V 
Cyt c   cytochrome c 
DAB   3, 3' diaminobenzidine 
DDM   n-dodecyl-β-D-maltoside 
DMEM   Dulbecco’s modified Eagle’s medium  
DNA   deoxyribonucleic acid 
DOX   doxycycline 
DPX   dibutylphthalate polystyrene xylene 
ER   endoplasmic reticulum 
ETC   electron transport chain  
EV   empty vector 
FAD    flavin adenine dinucleotide 
FBS   foetal bovine serum 
Fe-S   iron-sulphur 
FMN   flavin mononucleotide 
FS   FLAG/Streptavidin  
GATK   genome analysis toolkit 
 
 ix 
gDNA   genomic DNA 
GFAP   glial fibrillary acidic protein 
HA   hemagglutinin 
H&E   hematoxylin and eosin 
HEK    human embryonic kidney  
HS   heavy strand 
ICC   immunocytochemistry 
IHC    immunohistochemistry  
IMAGE  integrated molecular analysis of genomes and their expression 
IMM   inner mitochondrial membrane 
IMS   intermembrane space 
KO   knockout 
LS   light strand 
MEFs   mouse embryo fibroblasts 
MELAS mitochondrial encephalopathy, lactic acidosis and stroke-like episodes 
MIA   mitochondrial intermembrane space assembly machinery 
MITRAC  mitochondrial translation regulation assembly intermediate of COX 
mMPT   mitochondrial membrane permeability transition 
MRS   magnetic resonance spectrometry 
mtDNA  mitochondrial DNA 
MTS   mitochondrial targeting signal 
MW   molecular weight 
NAD    nicotinamide adenine dinucleotide 
NBF   neutral buffered saline 
NBT   nitro blue tetrazolium 
nDNA   nuclear DNA 
NGS   next generation sequencing 
OMM   outer mitochondrial membrane 
OXPHOS  oxidative phosphorylation 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDH   pyruvate dehydrogenase 
Pi   inorganic phosphate  
Δp   protonmotive force 
Q, CoQ  ubiquinone, coenzyme Q 
RET   reverse electron transfer 
RNA   ribonucleic acid 
 
 x 
SAM   sorting and assembly machinery 
SDH   succinate dehydrogenase 
SDS-PAGE   sodium dodecyl sulphate polyacrylamide gel electrophoresis 
shRNA   short hairpin RNA 
SOD   sodium dismutase 
TCA   tricarboxylic acid  
Tm   melting temperature 
TIM(M)  translocase of the inner membrane 
TOM(M)  translocase of the outer membrane 
tRNA   transfer RNA 
VDAC   voltage-dependent anion channel  
WB   Western blot 
WES   whole exome sequencing 






Table of Contents 
Declaration ................................................................................................................ iii 
Abstract ...................................................................................................................... v 
Acknowledgements ................................................................................................. vii 
Abbreviations .......................................................................................................... viii 
Table of Contents ..................................................................................................... xi 
Chapter 1 Introduction .......................................................................................... 1 
1.1 General Introduction to Mitochondria .................................................................. 2 
 Origin of Mitochondria .................................................................................................. 2 
 Mitochondrial Discovery, Structure and Dynamics ...................................................... 3 
 ATP Production via OXPHOS ...................................................................................... 7 
 Additional Mitochondrial Functions .............................................................................. 9 
 Bigenomic Regulation of Mitochondria ...................................................................... 11 
1.2 Catalysis and Biogenesis of Complexes I and IV ............................................. 13 
 Complex I ................................................................................................................... 13 
1.2.1.1 N-module ............................................................................................................... 14 
1.2.1.2 Q-module ............................................................................................................... 14 
1.2.1.3 P-module ............................................................................................................... 15 
1.2.1.4 Final Steps of CI Assembly ................................................................................... 15 
 Complex IV/COX ........................................................................................................ 18 
1.2.2.1 Initial COX Subassembly ....................................................................................... 19 
1.2.2.2 MT-CO1 Module .................................................................................................... 19 
1.2.2.3 MT-CO2 Module .................................................................................................... 20 
1.2.2.4 MT-CO3 Module & Final COX Composition .......................................................... 20 
1.3 Supercomplexes and the Mystery of Their Assembly ...................................... 23 
1.4 Mitochondrial Diseases ....................................................................................... 26 
 Definition and Prevalence of Mitochondrial Diseases ................................................ 26 
 Mitochondrial Disease Inheritance ............................................................................. 26 
 Clinical Presentation .................................................................................................. 27 
 Complex I Deficiency ................................................................................................. 27 
 COX Deficiency .......................................................................................................... 29 
 Clinical, Biochemical and Histological Diagnoses ...................................................... 31 
 Genetic Diagnosis ...................................................................................................... 31 
1.5 Identifying & Characterising New Mitochondrial Disease Genes .................... 32 
 Cytochrome c Oxidase Assembly Factor 7 (COA7) ................................................... 32 
 Transmembrane Coil-Coiled Domain 6 (TMCO6) ...................................................... 34 
1.6 Research Aims ..................................................................................................... 35 
Chapter 2 Materials and Methodology ............................................................... 37 
2.1 Biological Materials ............................................................................................. 38 
 Human Subjects ......................................................................................................... 38 
 Cell Lines ................................................................................................................... 39 
2.1.2.1 Skin Fibroblasts ..................................................................................................... 39 
2.1.2.2 Embryonic Cell Lines ............................................................................................. 39 
2.1.2.3 Cancer Cell Lines .................................................................................................. 39 
 
 xii 
2.1.2.4 Haploid Cell Line ................................................................................................... 40 
2.1.2.5 Murine Cell Lines ................................................................................................... 40 
 Tmco6-Knockout Mouse Model ................................................................................. 40 
2.2 Genetic Manipulation and Microbiological Techniques ................................... 42 
 gDNA Extraction from Cultured Cells ......................................................................... 42 
 Whole Exome Sequencing (WES) ............................................................................. 42 
 PCR ........................................................................................................................... 43 
2.2.3.1 Design and Synthesis of Oligonucleotide Primers for PCR ................................... 43 
2.2.3.2 Thermocycling Conditions and PCR ...................................................................... 44 
2.2.3.3 Purification of PCR Products ................................................................................. 44 
 PCR Amplification of Patient Mutations ..................................................................... 44 
 Agarose Gel Electrophoresis ..................................................................................... 45 
 Agarose Gel Extraction and Purification of DNA ........................................................ 46 
 DNA Sequencing and Analysis .................................................................................. 46 
 RNA Extraction and cDNA Retrotranscription ............................................................ 46 
 Ligation of cDNA Sequences into Cloning Plasmids ................................................. 48 
 Competent E. coli Transformation and Plasmid Mini-Preparation ............................. 50 
 Restriction Enzyme Digestion .................................................................................... 51 
 Ligation of DNA into Lentiviral Transfer Plasmids ...................................................... 53 
 Long-Term Storage of Transformed E. coli ................................................................ 53 
 Quantitative Reverse Transcription PCR (RT-qPCR) ................................................ 53 
 CRISPR/Cas9 Genome Editing ................................................................................. 55 
2.3 Cell Culture and Associated Procedures ........................................................... 62 
 Culturing Conditions ................................................................................................... 62 
 Lentiviral Particle Production ..................................................................................... 62 
 Cell Immortalisation ................................................................................................... 65 
 shRNA Knockdown .................................................................................................... 65 
 Lentiviral Transduction for Constitutive Protein Overexpression ............................... 67 
 Inducible Protein Overexpression .............................................................................. 68 
2.4 Cellular Imaging ................................................................................................... 71 
 Live Cell Growth Assay .............................................................................................. 71 
 Immunocytochemistry (ICC) ...................................................................................... 71 
 Super-Resolution Microscopy .................................................................................... 72 
2.5 Animal Model and Associated Procedures ....................................................... 73 
 Genotyping of B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J Mice ................................................... 73 
 Derivation of Mouse Embryonic Fibroblasts (MEFs) .................................................. 74 
 Metabolic Monitoring via CLAMS ............................................................................... 75 
 Treadmill Exhaustion Trials ........................................................................................ 75 
 Rotarod Test .............................................................................................................. 76 
 Hindlimb Clasping Evaluation .................................................................................... 76 
 Pole Test .................................................................................................................... 76 
 Micro-Echocardiography ............................................................................................ 77 
 Preparation of Murine Tissues for Histological & Histochemical Analyses ................ 79 
2.5.9.1 Tissue Preparation and Processing for Skeletal Muscle ....................................... 79 
2.5.9.1.1 Haematoxylin and Eosin (H&E) ........................................................................ 79 
2.5.9.1.2 Nicotinamide Adenine Dinucleotide-Tetrazolium Reductase (NADH-TR) ........ 79 
2.5.9.1.3 Succinate Dehydrogenase (SDH) .................................................................... 80 
2.5.9.1.4 Cytochrome c Oxidase (COX) .......................................................................... 80 
 
 xiii 
2.5.9.2 Tissue Preparation and Processing for Brain, Heart, Liver, and Kidney ............... 80 
2.5.9.2.1 Haematoxylin and Eosin (H&E) Staining .......................................................... 81 
2.5.9.2.2 Picrosirius Red Staining ................................................................................... 82 
2.5.9.2.3 Pathogreen Staining ......................................................................................... 82 
2.5.9.2.4 Immunohistochemistry (IHC) ............................................................................ 82 
 Adeno-Associated Virus (AAV) Transduction ............................................................ 83 
2.6 Protein-Based Techniques .................................................................................. 85 
 Determining Protein Concentration ............................................................................ 85 
 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) ............. 85 
2.6.2.1 Sample Preparation: Whole Cell Lysates from Cultured Cells .............................. 85 
2.6.2.2 Sample Preparation: Homogenates from Frozen Murine Tissues ......................... 85 
2.6.2.3 Running SDS-PAGE .............................................................................................. 86 
 Blue Native Gel Electrophoresis (BN-PAGE) ............................................................. 86 
2.6.3.1 Sample Preparation: Mitoplasts from Cultured Cells ............................................. 86 
2.6.3.2 Sample Preparation: Mitoplasts from Frozen Murine Tissues ............................... 87 
2.6.3.3 First (1D) and Second (2D) Dimension BN-PAGE ................................................ 87 
 Western Blotting ......................................................................................................... 88 
 Immunodetection ....................................................................................................... 88 
 Mitochondrial Isolation ............................................................................................... 91 
2.6.6.1 Sample Preparation from Cultured Cells ............................................................... 91 
2.6.6.2 Sample Preparation from Frozen Murine Tissues ................................................. 91 
 Sub-Mitochondrial Localisation Studies ..................................................................... 92 
 Immunoprecipitation ................................................................................................... 92 
2.7 Mitochondrial Respiratory Chain Functional Assays ....................................... 95 
 Mitochondrial Respiratory Chain Enzymatic Activity Assays ..................................... 95 
2.7.1.1 Sample Preparation from Cultured Cells ............................................................... 95 
2.7.1.2 Sample Preparation from Frozen Murine Tissues ................................................. 95 
2.7.1.3 Measuring Mitochondrial Protein Complex Activities by Spectrophotometry ........ 96 
 In-Gel Activity ............................................................................................................. 98 
 Oroboros .................................................................................................................... 98 
2.8 Statistics ............................................................................................................. 101 
Chapter 3 Compound Heterozygous Mutations in COA7 are Associated with 
COX Deficiency and Mitochondrial Leukoencephalopathy ............................... 103 
3.1 Introduction ........................................................................................................ 104 
3.2 Patient Clinical History and Genetic Investigation ......................................... 105 
3.3 Results ................................................................................................................ 108 
 Confirming Biallelic Mutant Variants in COA7 in Patient Skin Fibroblasts ............... 108 
 Aberrant COA7 mRNA Transcripts Present in Immortalised Patient Cells .............. 109 
 Both COA7 Mutant Variants are Predicted to be Pathogenic .................................. 111 
 Patient Cells Lack COA7 & Show Reduced Levels of Some COX Subunits ........... 113 
 Reduced COX Holocomplex Levels Apparent in Patient Cells ................................ 115 
 Immortalised Patient Skin Fibroblasts Have Isolated COX Deficiency .................... 118 
 Stable Expression of COA7WT Rescues COX Abundance and Enzymatic Activity . 119 
 COA7WT Complementation Rescues COX Assembly in Immortalised Patient Cells 121 
 COA7WT Complementation Rescues COX Enzymatic Activity ................................. 123 
 Endogenous COA7 Localises Specifically to the IMS .............................................. 124 
3.4 Conclusions ........................................................................................................ 129 
 
 xiv 
Chapter 4 Introducing TMCO6, a Gene Found Mutated in a Mitochondrial 
Disease Patient with Severe Complex I Deficiency ............................................ 131 
4.1 Introduction ........................................................................................................ 132 
4.2 Results ................................................................................................................ 133 
 An Introduction to TMCO6 ....................................................................................... 133 
 Patient Clinical History and Genetic Investigation ................................................... 136 
 Homozygous Recessive TMCO6 Mutant Variant is Predicted by Computational 
Analyses to be Strongly Pathogenic ......................................................................................... 139 
 Characterising Patient Fibroblasts by SDS-PAGE and Western Blot Analysis ........ 142 
 Abundances of CI Supercomplex and Subcomplex Species Altered in Immortalised 
Patient Fibroblasts .................................................................................................................... 146 
 TMCO6 Co-Migrates with CI by 2D-BNGE .............................................................. 150 
 CI Enzymatic Activity and O2 Consumption Is Unaffected in Patient Fibroblasts .... 153 
4.3 Conclusions ........................................................................................................ 155 
Chapter 5 Cell-Based Strategies and Cellular Models for  Characterizing 
Human TMCO6 ....................................................................................................... 157 
5.1 Introduction ........................................................................................................ 158 
5.2 Results ................................................................................................................ 159 
 TMCO6 Localises Specifically to the IMM ............................................................... 159 
 Investigating the Effects of TMCO6 Gene Silencing ................................................ 163 
 Investigating the Effects of TMCO6 Gene Overexpression ..................................... 170 
 TMCO6 Physically Interacts with the CI Holocomplex by Immunoprecipitation ....... 176 
 Attempting Generation of TMCO6 Knockout and Knockin Cellular Models ............. 182 
5.3 Conclusions ........................................................................................................ 188 
Chapter 6 Characterisation of a Tmco6-Knockout In Vivo Model ................. 191 
6.1 Introduction ........................................................................................................ 192 
6.2 Results ................................................................................................................ 193 
 Verifying Tmco6 Protein Ablation in a Tmco6-Knockout Murine Model ................... 193 
 Phenotypic Characterisation of Tmco6-KO Mice ..................................................... 196 
6.2.2.1 Skewed Mendelian Segregation of Tmco6-KO Mice ........................................... 196 
6.2.2.2 Tmco6-KO Mice Display Reduced Body Weight and Hindlimb Feet Clasping .... 198 
6.2.2.3 Tmco6-KO Mice Show Impaired Exercise Tolerance and Motor Coordination ... 200 
6.2.2.4 Tmco6-KO Mice Have Decreased Motility and In Vivo Energy Metabolism ........ 204 
 Histological Analyses of Tissues from Tmco6-KO Mice .......................................... 208 
6.2.3.1 Histopathological Alterations Observed in Brains of Tmco6-KO Mice ................. 208 
6.2.3.2 Histochemical and Histological Analyses of Other Tissues of Tmco6-KO mice .. 213 
 Biochemical Investigation of Tmco6-KO Cells and Tissues ..................................... 217 
6.2.4.1 Investigating Mitochondrial Respiratory Chain Activities in Tmco6-KO MEFs .... 217 
6.2.4.2 Investigating Mitochondrial Respiratory Chain Activities in Tmco6-KO Tissues . 218 
 Molecular Investigation of Tmco6-KO Tissues ........................................................ 223 
 Analysis of Cardiac Function and Respiratory Rate in Tmco6-KO Mice .................. 234 
6.3 Conclusions ........................................................................................................ 242 
 
 xv 
Chapter 7 Investigating the Effects of AAV-Mediated Gene Delivery of 
Human Wildtype or Patient Mutant TMCO6 to Tmco6-KO Mice ........................ 244 
7.1 Introduction ........................................................................................................ 245 
7.2 Results ................................................................................................................ 246 
 AAV-mediated Gene Delivery of Human WT and Patient MUT TMCO6 ................. 246 
 Physical and Neuromotor Behaviours of AAV9-Transduced Mice ........................... 248 
 MUT TMCO6 Expression Causes Impaired Locomotor Behaviours In Vivo ............ 253 
 In Vivo Metabolic Evaluation of AAV-Transduced Mice via CLAMS ........................ 255 
 Echocardiography and Electrocardiography of AAV9-Transduced Mice ................. 257 
 Hearts of Tmco6-/- (AAV MUT) Mice Show Severe Cardiac Fibrosis .............................. 263 
 WT TMCO6 Expression Rescues CI Deficiency in Tmco6-/- Hearts Whilst MUT 
TMCO6 Expression Does Not ................................................................................................... 265 
 Molecular Investigation of Hearts from AA9-Transduced Mice ................................ 267 
7.3 Conclusions ........................................................................................................ 269 
Chapter 8 Discussion and Future Aims .......................................................... 271 
8.1 Discussion .......................................................................................................... 272 
 The Revolution of Mitochondrial Disease Gene Discovery by WES ........................ 272 
 Implications of Confirming Pathogenicity and Subcellular Localisation of COA7 .... 274 
 Investigating TMCO6 as a Novel Mitochondrial Disease Protein ............................ 278 
8.2 Future Aims ........................................................................................................ 286 
 COA7 Project Future Aims ....................................................................................... 286 
 TMCO6 Project Future Aims .................................................................................... 287 






























1.1 General Introduction to Mitochondria 
 
 Origin of Mitochondria  
Mitochondria are subcellular organelles that have been crucial to the development and 
existence of eukaryotic life. The phylogenetic origin of mitochondria is an α-proteobacterium 
(Yang et al., 1985; Andersson et al., 1998), which formed an endosymbiotic relationship with 
an archaeal host cell between 1.5 and 2  billion years ago (Sicheritz-Pontén, Kurland, and 
Andersson 1998; Martin 2010). The most likely cause for their union and the mechanism of 
incorporation of the former has been much debated. The endosymbiotic theory (Sagan 1967), 
many versions of which were proposed throughout the 1970s to the 1990s, posits that an 
anaerobic, nucleate and amitochondriate early eukaryotic cell (Cavalier-Smith, 1987) engulfed 
an oxygen (O2)-utilising α-proteobacterium by phagocytosis (Ford Doolittle, 1998), which 
evaded digestion and formed a mutually beneficial relationship with the host in an increasingly 
O2-rich atmosphere (Lane and Martin, 2010). However, recent comparative genomic and 
geochemical evidence instead suggest that the driving force for eukaryogenesis was in fact 
the beneficial exchange of hydrogen (H2) from an α-proteobacterial facultative anaerobe, 
which synthesised H2 by fermentation, but could also respire aerobically in the presence of 
O2, to a H2-dependent archaeal (prokaryotic) host cell (Martin and Müller 1998; Koonin 2010). 
Furthermore, the host and endosymbiont were brought together through syntrophy, where one 
species consumes the end product(s) of metabolism of the other, and not by phagocytosis 
(Martin et al., 2016), with the compartmentalisation of a nucleus occurring afterwards (Mans 
et al., 2004). This hydrogen hypothesis (Martin and Müller 1998), as it is termed, explains 
important factors that the canonical endosymbiotic theory does not, including the discovery 
that mitochondria share the majority of their genes with hydrogenosomes (Embley and Martin, 
2006), mitochondria-like organelles that generate H2 as an end product of adenosine 
triphosphate (ATP) synthesis in several species of anaerobic eukaryote (Lindmark and Müller, 
1973), and the revelation that the Proterozoic ocean was predominantly anoxic at the time 
when eukaryotes arose (Mentel and Martin, 2008). In either case, the endosymbiont conferred 
to the host a set of novel and beneficial metabolic processes that ultimately allowed for the 
adaptation of the host to new environmental niches, and the host, in turn, protected and 
provided ample substrates to the mitochondrial ancestor.  
 
Over time, the majority of the genetic material from the mitochondrial ancestor governing its 
functions and biogenesis was transferred to the genome of the host (Ku et al., 2015), 
consolidating their symbiotic relationship and eliminating organellar autonomy of the 
mitochondrion. Mitochondrial gene transfer resulted in expansion of the nuclear genome, a 
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key factor in the development of more functionally complex organisms (Lane and Martin, 
2010). However, by retaining a small genome of essential genes for ATP production and 
protein synthesis, mitochondria can quickly respond to changes in cellular metabolic demand, 
effectively acting as an “ATP sensor”, and can do so proportionately to the relative influx of 
nuclear-encoded proteins (Amiott and Jaehning, 2006; Richter-Dennerlein et al., 2016). 
Mitochondria have been decisively essential to the evolutionary transition from prokaryotes to 
eukaryotes, directly enabling the vast biodiversity we observe today. 
 
 Mitochondrial Discovery, Structure and Dynamics 
In 1890, Richard Altmann recognised the ubiquitous presence of mitochondria in eukaryotic 
cells, terming them “bioblasts”, and concluded that they were self-replicating "elementary 
organisms" within cells that carried out vital cellular functions (Altmann 1890). The name 
“mitochondrion” was introduced in 1898 by Carl Benda, derived from “mitos” (µίτος, “thread”) 
and “chondros” (χονδρίον, “granule”), referring to the appearance of these structures by light 
microscopy as “threads dotted with grains” (Benda 1898; Ernster and Schatz 1981). In 1912, 
Benjamin Freeman Kingsbury described mitochondria as "a structural expression of the 
reducing substances concerned in cellular respiration", linking the unique shape of these 
organelles with their role in cellular energy metabolism (Kingsbury 1912; Ernster and Schatz 
1981). The first high-resolution images of the internal mitochondrial structure were published 
in the 1950s owing to the development of electron microscopy (Palade, 1953; Sjöstrand, 
1953). Since then, the understanding of mitochondrial morphology, dynamics, bioenergetics 
and other characteristic features and functions has increased substantially. This 
understanding has cemented mitochondria as essential mediators of normal cellular 
physiology, as well as of disease pathology, the latter of which is a role still requiring much 
elucidation (Pagliarini and Rutter, 2013).  
 
Mitochondria consist of two phospholipid bilayers, the outer mitochondrial membrane (OMM) 
and the inner mitochondrial membrane (IMM); between the OMM and IMM lies the 
intermembrane space (IMS), and the IMM encloses a central compartment, the mitochondrial 
matrix (MM) (Palade, 1953; Sjöstrand, 1953; Perkins et al., 1997) (Fig. 1.1). The lipid 
compositions, protein densities and relative permeabilities of the OMM and IMM differ 
considerably. The OMM has a phospholipid composition similar to that of the plasma 
membrane with an approximately 1:1 protein to phospholipid ratio (Parsons and Yano 1967; 
Ernster and Schatz 1981). The OMM acts as the interface between the mitochondrion and the 
cytosol, and so, protects the cell from mitochondrial factors that lead to oxidative stress 
(Pernas and Scorrano, 2016), inflammation (West, Shadel and Ghosh, 2011) and cell death 
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(Danial and Korsmeyer, 2004). Additionally, the OMM mediates physical interaction of a 
mitochondrion with other mitochondria and other organelles, principally the endoplasmic 
reticulum (ER) (Marchi, Patergnani and Pinton, 2014). The OMM is selectively permeable to 
small hydrophilic molecules due to numerous mitochondrial porins, the voltage-dependent 
anion channels (VDAC) (Benz, 1985), which allow selective passage of molecules less than 
6.8 kDa in size (Shoshan-Barmatz et al., 2010). In addition, nuclear-encoded proteins are 
imported into the mitochondria by the translocase of the outer mitochondrial membrane (TOM) 
complex, a multimeric channel that imports unfolded preproteins into the IMS, and from there 
they are translocated to the correct mitochondrial compartment by other translocases and 
assembly machineries (Wiedemann, Frazier, and Pfanner 2004). One such example is the 
sorting and assembly machinery (SAM) complex, which inserts proteins into the OMM 
(Wiedemann et al., 2003).  
 
The second of the mitochondrial membranes, the IMM, is densely packed with protein, with a 
roughly 3:1 protein to phospholipid ratio (Parsons and Yano 1967; Ernster and Schatz 1981), 
and is rich in cardiolipin, similarly to prokaryotic cell membranes (Paradies et al., 2014). The 
IMM contains its own protein import machinery, the translocase of the inner membrane (TIM) 
complexes TIM22 and TIM23, for embedment of proteins into the IMM or import into the MM, 
respectively (Wiedemann, Frazier, and Pfanner 2004). The IMM invaginates into the MM to 
form cristae (folds), which drastically increase its surface area (Mannella, 2006). Cristae are 
structurally organised in part by the mitochondrial contact-site and cristae organising system 
(MICOS) complex (Kozjak-Pavlovic, 2017), which interacts with the SAM complex of the OMM 
to form the mitochondrial intermembrane space bridging (MIB) complex (Huynen et al., 2016). 
Importantly, cristae are the site of mitochondrial aerobic respiration, and subsequent ATP 
synthesis, altogether termed oxidative phosphorylation (OXPHOS), as will be discussed in 
detail in the next section. The IMM is relatively impermeable compared to the OMM, and so 
has developed a sophisticated set of mitochondrial protein carriers for the import, export or 
exchange of specific substrates and reaction products (Kunji, 2004). The tight control of the 
permeability of the IMM allows for the generation and maintenance of an electrochemical 
proton gradient (of H+ ions) during respiration, that is essential for ATP synthesis (Nicholls, 
1974), and for calcium (Ca2+) uptake through the mitochondrial calcium uniporter (Stefani et 




Figure 1.1. Classical mitochondrial structure.  
 
Figure shows a transmission electron micrograph of a single mitochondrion from a pancreatic 
acinar cell of the little brown bat, Myotis lucifugus, sliced longitudinally across its midplane, 
and the surrounding cytoplasm, including the endoplasmic reticulum (ER). A magnified inset 
of a portion of the mitochondrion highlights the outer mitochondrial membrane (OMM) and 
inner mitochondrial membrane (IMM), which lie either side of the intermembrane space (IMS). 
The IMM invaginates into the central mitochondrial compartment, the mitochondrial matrix 
(MM), to form distinctive folds termed cristae (singular: crista), which greatly increase its 
surface area. The cristae are variable in length and shape, and house the proteins necessary 
for mitochondrial energy production (by the coupled processes of the electron transport chain 
and ATP synthesis). This figure was compiled by the author using an electron micrograph 
courtesy of Keith R. Porter (2011) CIL:11397, Myotis lucifugus. CIL Dataset. Available from: 
https://doi.org/doi:10.7295/W9CIL11397.  
 
The IMS, an approximately 20 nm wide space between the OMM and IMM, has protein and 
metabolite concentrations similar to that of the cytoplasm (Kühlbrandt, 2015). The IMS houses 
the majority of cellular cytochrome c (cyt c), which, along with its role in electron transfer during 
OXPHOS, can initiate the death pathway of the cell, apoptosis, upon release into the cytosol 
(Ding and Yin, 2012). The IMS also contains the mitochondrial intermembrane space 
assembly (MIA) complex, which mediates disulphide bond creation in cysteine-rich proteins 
that localise to the IMS, and also the translocation of oxidative proteins that ultimately localise 
to the IMM following transport through the IMS (Stojanovski, Bragoszewski and Chacinska, 
2012). Additionally, the IMS is a site of mitochondrial lipid synthesis (Horvath and Daum, 
2013), detoxification of the reactive oxygen species superoxide by the action of Cu/Zn 
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superoxide dismutase (SOD1) (Fischer et al., 2011), and metal ion exchange between the 
matrix and cytosol (Wiedemann, Frazier, and Pfanner 2004). In contrast to the IMS, the MM 
is extremely protein-rich, with a protein concentration of ~ 500 mg/ml (Kühlbrandt, 2015), and 
serves many mitochondrial anabolic and catabolic reactions, including the tricarboxylic acid 
cycle (TCA) cycle (also named the ‘citric acid cycle’) (Akram, 2014), the biosynthesis of haem 
moieties and iron-sulphur (Fe-S) clusters (Lill et al., 2012), and the synthesis and degradation 
of amino acids (Guda, Guda, and Subramaniam 2007). Importantly, the MM houses the 
mitochondrial DNA (mtDNA) and the ribosomes necessary for mitochondrial protein synthesis 
(Clay Montier, Deng and Bai, 2009). Additionally, the respiratory chain protein complexes each 
protrude into the MM, whereby proton pumping by Complexes I, III and IV results in an 
elevated pH of ~7.2 compared to that of the IMS or cytoplasm (Porcelli et al., 2005). 
 
Mitochondria were originally believed to exist as individual, rod-shaped entities owing to their 
presentation in early electron micrographs (Palade, 1953; Sjöstrand, 1953), but are nowadays 
recognised to form extensive and dynamic networks, with variations in average number, size 
and motility within cells differing between various tissue types (McCarron et al., 2013). For 
example, in skeletal muscle, mitochondria are confined to rows that lie parallel to the 
contractile fibrils (Vendelin et al., 2005), but in neurons, mitochondria often translocate along 
the cytoskeleton from the dendrites to the synapses and vice versa in response to fluctuations 
in energy demands relative to nerve transmission (Barnhart, 2016). Mitochondrial shape, size 
and number per cell are further dictated by the competing processes of fusion, the combination 
of two organelles into one, and fission, division of one organelle into two (Koshiba et al., 2004). 
Eukaryotic cells have no means of de novo mitochondrial synthesis, and so, proliferation can 
only occur from pre-existing mitochondria by fission. The morphology of mitochondria will also 
vary depending on their physiological state (Kuznetsov and Margreiter, 2009); fusion allows 
for the equilibration of mtDNA, proteins and/or metabolites when resources are low, and fission 
makes it possible to isolate damaged mitochondria from the network and target them for 
degradation through selective autophagy, called mitophagy (Pickles, Vigié and Youle, 2018). 
It is not only the external mitochondrial structure that responds to the physiological state of the 
cell and of the organelle. The abundance, width, length and alignment of the cristae of the 
IMM can fluctuate in response to substrate availability, metabolic demand and as a 
consequence of the release of apoptotic signals (Heath-Engel and Shore, 2006). The dynamic 
morphology of mitochondria ultimately allows cells to balance metabolic demand with nutrient 




 ATP Production via OXPHOS 
Arguably, the most essential function of mammalian mitochondria is ATP production via 
OXPHOS (Fig. 1.2). Firstly, a series of redox reactions is carried out by four multimeric protein 
complexes, each embedded within the IMM. These are Complex I (CI), NADH:ubiquinone 
oxidoreductase; Complex II (CII), succinate:ubiquinone oxidoreductase; Complex III (CIII), 
ubiquinone:cytochrome c oxidoreductase; and Complex IV (CIV or COX), cytochrome c 
oxidase) (Hatefi, 1985). Electrons are transferred from protein or molecular donors to 
acceptors from CI or CII to CIII, and then from CIII to CIV (Sazanov, 2015). In the case of CI, 
CIII and CIV, the free energy liberated as electrons travel down the redox potential gradient is 
used to pump protons (H+ cations) across the IMM from the MM to the IMS: 4 H+ ions for CI 
and CIII and 2 H+ ions for CIV (Schultz and Chan, 2001). Two mobile electron carriers, the 
lipophilic molecule coenzyme Q10/ubiquinone (CoQ/Q) (Turunen, Olsson and Dallner, 2004) 
and the hydrophilic protein cyt c (Hüttemann et al., 2011), transfer electrons from CI and CII 
to CIII, and from CIII to CIV, respectively. These processes together are known as the electron 
transport chain (ETC), or mitochondrial respiratory chain. Reduced forms of nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), products of the 
catabolism of carbohydrates, fatty acids and/or amino acids, are key electron donors in the 
ETC, providing electrons at the CI and CII points of entry, respectively (Akram, 2014; Martínez-
Reyes et al., 2016). A protonmotive force (Δp) is generated from the resulting higher 
concentration of protons present in the IMS than in the MM (ΔpH), as well as an asymmetrical 
distribution of electrical charges across the IMM, termed the mitochondrial membrane 
potential (ΔψM) (Mitchell and Moyle, 1969; Dzbek and Korzeniewski, 2008). This protonmotive 
force drives transfer of protons back through the IMM from the IMS to the MM by a fifth protein 
complex, FoF1-ATP synthase (CV) (Elston, Wang and Oster, 1998). OXPHOS is the coupled 
actions of the ETC (CI-CIV) and chemiosmosis (Mitchell, 1961), ultimately leading to the 
production of ATP, the ‘energy currency’ of mammalian cells, from condensation of adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) molecules, catalysed by the F1 catalytic 
domain of ATP synthase (Mitchell, 1961; Walker, 2013). The newly synthesised ATP produced 
in the MM is exchanged for ADP by the ADP/ATP carrier (Kunji et al., 2016), which is located 
in the IMM along with the OXPHOS complexes. Once in the IMS, ATP can pass freely through 
the OMM via VDAC (Bonora et al., 2012). The dephosphorylation of ATP to ADP is a crucial 
means of providing the free energy necessary for a myriad of essential reactions within 






Figure 1.2. The composite structures and reactions involved in mammalian OXPHOS.  
 
Figure depicts the atomic spherical structures and individual reactions of each of the 
complexes of the mammalian mitochondrial OXPHOS system; CI is ovine (PDB ID: 5LNK), 
CII is porcine (PDB ID: 1ZOY), and CIII (PDB ID: 1NTM), CIV (PDB ID: 5B1A) and CV (PDB 
ID: 5ARA) are bovine. Cytochrome c is equine (PDB ID: 5IY5), and ubiquinone is denoted by 
‘Q’, which is its reduced form (QH2) is termed ubiquinol. MM = mitochondrial matrix, IMM = 
inner mitochondrial membrane, and IMS = intermembrane space. CI-CIV comprise the 
electron transport chain (ETC) or ‘mitochondrial respiratory chain’, and ATP synthase is 
responsible for the production of ATP from condensation of adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) molecules. A protonmotive force (Δp) is generated by movement of 
H+ cations from the MM to the IMS. Adapted from Figure 1, Letts and Sazanov 2017. 
 
In normal physiological conditions, OXPHOS is incompletely coupled, whereby protons in the 
IMS can return to the MM independently of ATP synthase in a process known as proton leak, 
which generates heat instead of ATP (Jastroch et al., 2010). Thermogenesis occurs naturally 
through the actions of uncoupler proteins (UCPs), which uncouple ATP synthesis from 
electron transport, dissipating Δp and increasing production of heat (Cannon and Nedergaard, 
2011). UCP1 is one such protein primarily found in brown adipose tissue (Cannon and 
Nedergaard, 2004), and is responsible for adaptive non-shivering thermogenesis typically 
observed in newborn or hibernating mammals (Nedergaard et al., 2001). The ionophore 
carbonyl cyanide m-trifluoromethoxyphenylhydrazone (CCCP) is capable of chemically 
inducing uncoupling of the ETC by disrupting the integrity of the IMM, causing proton leak, 
and prompting the ETC to run at its maximal rate (Benz and McLaughlin 1983). Chemically 
inducible uncoupling is useful for the study of the maximal respiratory rate of isolated 





 Additional Mitochondrial Functions 
In addition to OXPHOS, mitochondria are involved in a number of other crucial metabolic and 
homeostatic processes that will be briefly addressed here. Mitochondria mediate iron 
homeostasis, both its storage and utilisation, in eukaryotic cells, and are also directly involved 
in the biosynthesis of haem moieties and iron-sulphur (Fe-S) clusters (Stehling and Lill, 2013), 
which are metal prosthetic groups found in each of CI, CII and CIII of the mitochondrial ETC. 
Mitochondrial Fe-S cluster synthesis depends on the Fe-S cluster assembly machinery and 
occurs in the MM (Paul et al., 2017). Secondly, all of the 20 amino acids that compose proteins 
have metabolic pathways concerning mitochondria; both catabolic and anabolic reactions are 
associated with the non-essential residues and strictly catabolic reactions are associated for 
the essential ones (Guda, Guda, and Subramaniam 2007). In addition, some steps of the 
synthesis and degradation of nucleotides, particularly as a part of the salvage synthetic 
pathway, occur within mitochondria (Wang 2016). Other metabolic pathways include 
cardiolipin synthesis (Schlame, 2008), essential for the unique composition of the IMM 
membrane, and biosynthesis of quinones (Stefely and Pagliarini, 2017), such as CoQ, and 
steroid hormones (Miller, 2013).  
 
Along with the ER, mitochondria are pivotal organelles in the uptake and regulation of 
intracellular calcium (Carafoli and Lehninger, 1971). Calcium cations (Ca2+) are transported 
through the IMM by the mitochondrial calcium uniporter (MCU), which is activated according 
to free calcium concentration (Chem et al., 2015). Calcium also activates three 
dehydrogenases of the TCA cycle that produce NADH and FADH2: pyruvate dehydrogenase, 
NAD+-dependent isocitrate dehydrogenase, and 2-oxoglutarate dehydrogenase (Traaseth et 
al., 2004). This, in turn, increases the rate of ATP synthesis given the increase of electron 
donors, and shows the tight coordination and feedback mechanism of cellular calcium 
signalling (Tarasov, Griffiths and Rutter, 2012). Calcium, which is essential for processes such 
as muscle contraction (Yamada and Huzel 1988; Brandes and Bers 1997), for example, is 
also a signal molecule for activating a metabolic process that produces the ATP needed to 
sustain further muscle contractions. Calcium overload in mitochondria has been linked to 
activation of cell death by apoptosis (Prudent and McBride, 2017) and as a control of reactive 
oxygen species (ROS) signalling (Hempel and Trebak, 2017). 
 
Electron leak during the ETC is the major source of ROS production in mammalian cells 
(Muller, 2000), and naturally contributes to cellular and organismal senescence (Starkov, 
2008), but if not regulated effectively, this oxidative stress, as it is termed, can lead to 
mitochondrial dysfunction and subsequent pathologies (Dröge, 2002). However, it is now 
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established that ROS also act as signalling molecules in normal biological and physiological 
processes (Murphy, 2009). For example, there is substantial evidence that some ROS are 
essential secondary messengers in innate and adaptive immune cells (West, Shadel and 
Ghosh, 2011; Schieber and Chandel, 2014). Superoxide (O2 •−) is the most prominent free 
radical that is generated by electron leak to diatomic oxygen at certain sites of CI, CII and CIII 
(Martínez-Cayuela, 1995). Superoxide is damaging to Fe-S cluster-containing apoproteins in 
particular, and can lead to the formation of additional reactive species that can damage 
biological molecules including DNA, lipids and proteins (Halliwell and Cross, 1994). 
Generation of ROS from CIV is prevented due to the rapid kinetics of the reduction of O2 to 
two water molecules (Bourens et al., 2013). In normal conditions, superoxide is rapidly 
converted to hydrogen peroxide (H2O2), either spontaneously or enzymatically by SOD1, 
resident in the cytosol and IMS, or superoxide dismutase 2 (SOD2/MnSOD), found only in the 
MM (Murphy, 2009). H2O2 can be further reduced to water by the thioredoxin and 
mitochondrial glutathione peroxidases (Ren et al., 2017). However, superoxide is able to react 
with nitric oxide (NO•), which can diffuse into mitochondria and generate peroxynitrite 
(ONOO−), a highly reactive and damaging radical (Murphy, 2009). Lastly, H2O2 can be reduced 
by different mechanisms to form hydroxyl radicals (OH•), which indiscriminately oxidise lipids, 
proteins and DNA, often leading to genome instability (Dizdaroglu et al., 2002). In humans, 
the balance between superoxide production and dismutation by the SOD family of proteins is 
key for overall health.  
 
Lastly, but importantly, mitochondria are mediators of cell fate, and can effect cell death via 
apoptosis (Ding and Yin, 2012) or via necrosis (Baines, 2010). Apoptosis is “programmed” cell 
death arising from irreparable DNA damage, growth factor inhibition and oxidative stressors 
(such as the ROS described above) (Kanduc et al., 2002; Davis et al., 2010), to name a few 
factors, and is characterised by permeabilization of the OMM that leads to a release of several 
pro-apoptotic proteins from the IMS, namely cyt c (Liu et al., 1996). This activates a cascade 
of caspases that cleave cytosolic proteins and eventually cause lysis of the plasma membrane 
(Kawai et al., 2007). Necrosis is activated by more severe cellular stressors, such as cytosolic 
Ca2+ overload, and prompts the permeabilization of the IMM in a process called mitochondrial 
membrane permeability transition (mMPT) (Kim, He and Lemasters, 2003; Tsujimoto and 
Shimizu, 2007), and leads to the dissipation of the membrane potential of the IMM (Baines, 
2010). Ion deregulation, mitochondrial and cellular swelling, and activation of degradative 
enzymes follow (Manjo and Joris, 1995), the latter of which leads to plasma membrane lysis.  
 
This overview highlights just how integral mitochondria are for survival. Dysregulation of any 
of these functions has the potential to cause disease; however, perturbations to the subunits, 
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assembly factors and co-factors necessary for formation, function or regulation of the 
OXPHOS protein complexes, in particular, are responsible for the majority of clinical cases of 
mitochondrial diseases (Manfredim and Beal, 2006; Wang et al., 2014). 
 
 Bigenomic Regulation of Mitochondria 
As mentioned previously, during eukaryogenesis, the majority of the genetic material from the 
mitochondrial ancestor governing its functions and biogenesis was transferred to the genome 
of the host cell (Ku et al., 2015), consolidating their symbiotic relationship and eliminating 
organellar autonomy of the mitochondrion. In this way, mitochondria exist under bigenomic 
regulation from genes resident in both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) 
(Sinha et al., 2010). Although nuclear mitochondrial genes are the focus of this work, it is 
important to appreciate the contribution made by mtDNA to mitochondrial physiology. In 
humans, mtDNA is a circular, double-stranded DNA loop of 16.6 kilobases (kb), composed of 
a guanine-rich “heavy” strand (HS) and the cytosine-rich “light” strand (LS) (Fig. 1.3) (Andrews 
et al., 1999). The number of mtDNA copies per mitochondrion differs and so too does the 
overall mtDNA copy number per cell depending on its energy demands (Chinnery and Hudson, 
2013). The genes present within the mtDNA are contiguous, separated by one or two non-
coding base pairs between genes and containing no introns (Andrews et al., 1999); the mtDNA 
also has a small, non-coding region termed the displacement loop (D-loop) (Sharma et al., 
2005). In humans, the D-loop houses the origin of replication site of the HS and the 
transcriptional promoters for both the HS and LS. The genetic code of the mtDNA differs 
slightly from the nDNA, and uses 2 stop codons that are not comparable to any of the 3 of the 
nDNA (Temperley et al., 2010). Human mtDNA encodes 37 genes: 22 of them encode transfer 
ribonucleic acids (tRNAs), 2 encode ribosomal RNAs (rRNAs) and 13 encode structural 
subunits of CI, CIII, CIV or CV of the OXPHOS system (Chinnery and Hudson, 2013). CII is 
the only respiratory protein complex to be completely encoded by genes in the nDNA 
(Bezawork-Geleta et al., 2017). The mtDNA is often anchored to the IMM on the MM-facing 
side in nucleoprotein particles termed nucleoids (Bogenhagen, 2012). All other mitochondrial 
proteins required for normal mitochondrial physiology, estimated to be ~ 1,200 in total (Rhee 
et al., 2013), are encoded by the nDNA. The coordination of both genomes is essential for the 





Figure 1.3 The human mitochondrial genome (mtDNA).  
 
The human mtDNA is a circular, double-stranded DNA molecule of ~ 16.6 kb, composed of a 
guanine-rich “heavy” strand (outer) and the cytosine-rich “light” strand (inner). Genes encoding 
core OXPHOS structural subunits of CI, CIII, CIV and CV are as follows: CI subunits ND1, 
ND2, ND3, ND4, ND4L, ND5, and ND6, CIII subunit Cyt b, CIV subunits MT-CO1, MT-CO2, 
and MT-CO3, and CV subunits ATP6 and ATP8. rRNA genes 16S and 12S are located on the 
HS, and tRNA genes are located both on the HS and the LS. OH and OL indicate the origins 
of replication of the HS and LS, respectively, and PH1, PH2 and PL indicate the three 
transcriptional promoters (H = heavy and L = light). Non-coding regions are in white; the D-
loop is situated in the top right. Image extracted from Figure 1, Amorim, Fernandes, and 
Taveira 2019.  
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1.2 Catalysis and Biogenesis of Complexes I and IV 
 
The structural biogenesis and functional proficiency of the five multimeric protein complexes 
of the OXPHOS system require the concerted efforts of a large number of proteins, including 
core and supernumerary structural subunits, and crucially, complex-specific ‘assembly 
factors’, which assist the maturation and assembly of nascent complexes but do not form a 
part of the final structures (Ghezzi and Zeviani 2018). These assembly factors facilitate a 
range of functions, including the synthesis and/or incorporation of haem (Kim et al. 2012), Fe-
S cluster (Ye and Rouault, 2010) and copper ion (Cu++) (Marmocchi et al., 1975) prosthetic 
groups, as well as chaperoning, stabilising and inserting the structural subunits or 
subassembly intermediates in the correct order per complex (Fernández-Vizarra, Tiranti and 
Zeviani, 2009; Nouws et al., 2012). The mechanisms of assembly for each of CI, CII, CIII, CIV 
and CV have been mostly elucidated (Signes and Fernandez-Vizarra 2018); however, some 
assembly factors remain undiscovered, and the roles of several that have been identified 
remain uncharacterised. Due to the focus of this work, only the assembly pathways of CI and 
CIV will be detailed here. 
 
 Complex I 
CI is an essential point of entry for electrons into the mitochondrial ETC, and it functions to 
oxidize NADH, reduce ubiquinone (Q), and transport protons across the IMM (Sharma, Lu, 
and Bai 2009; Hirst 2013), the latter of which contributes to the protonmotive force necessary 
for ATP synthesis by CV (Walker, 2013). CI is an L-shaped multimeric protein complex that, 
in mammals, is composed of 45 individual subunits (comprised of 44 different subunits) 
(Carroll et al., 2006), and is the largest individual integral structure of the OXPHOS system 
with a molecular weight of ~ 970 kDa (Hirst, 2010; Guerrero-Castillo et al., 2017). It contains 
two domain arms: a hydrophilic arm and a hydrophobic arm (Hirst et al., 2003; Berrisford and 
Sazanov, 2009). The hydrophilic arm protrudes into the MM and is a site of NADH oxidation 
by a FMN mononucleotide (Wirth et al., 2016), whereby the resulting electron is transferred 
along a chain or Fe-S clusters to reach a Q-binding site at the interface of both arms (Tocilescu 
et al., 2007), followed by the hydrophobic arm, which is embedded within the IMM and 
mediates proton pumping (Hirst, 2013). Upon receival of an electron pair, Q shuttles these 
electrons to the CIII dimer, CIII2 (Ernster and Dallner, 1995). The catalytic core of CI consists 
of 7 mtDNA-encoded subunits (ND1, ND2, ND3, ND4, ND4L, ND5, and ND6), all located 
within the hydrophobic membrane-embedded arm and involved in proton translocation across 
the IMM, and 7 nDNA-encoded subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, 
NDUFS7, and NDUFS8), all located within the hydrophilic arm, and are responsible for 
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electron transfer via 1 FMN (via NDUFV1) and 7 Fe-S clusters (via all 7 subunits, including 
NDUFV1) (Hirst et al., 2003; Carroll et al., 2006). The remaining 31 subunits of CI, termed 
‘supernumerary’ subunits, are not directly involved in catalysis (Hirst, 2011). The biogenesis 
of CI is a multifaceted and sophisticated process, requiring coordination of an as-yet undefined 
number of assembly factors to mediate holocomplex formation (Guerrero-Castillo et al., 2017). 
Fig. 1.4 shows the currently known pathway of CI biosynthesis, which is accepted to be 
modular (Ugalde et al., 2004; Saada et al., 2009; Guerrero-Castillo et al., 2017), containing 
three separate functional components: the N-module (NADH binding and oxidation), the Q-




The N-module (~ 160 kDa in size) is located at the distal end of the hydrophilic arm, and results 
from the assembly of NDUFV1, NDUFV2, NDUFS1 and NDUFA2, to which NDUFA6, 
NDUFA7, NDUFA12, NDUFS4, NDUFS6 and NDUFV3 are later added (Stroud et al., 2016; 
Guerrero-Castillo et al., 2017). It is the last module to be incorporated (Lazarou et al., 2007), 
and contains both an integral FMN site as a part of NDUFV1 (Bénit et al., 2001), and also 
begins the chain of Fe-S clusters necessary for electron translocation along the hydrophilic 
arm (Tocilescu et al., 2007). The assembly factors necessary for integration of these subunits 
to form the N-module are not known. 
 
1.2.1.2 Q-module 
The Q-module, sandwiched between the N-module and P-module at the interface of both 
domain arms (Vinothkumar, Zhu, and Hirst 2014), forms by interaction of NDUFA5, NDUFS2 
and NDUFS3, to create a 88.9 kDa structure, whereby NDUFS7 and NDUFS8 are then added 
to form a structure of ~ 129 kDa (Guerrero-Castillo et al., 2017; Signes and Fernandez-Vizarra, 
2018). The chaperones NDUFAF3 and NDUFAF4 remain bound to this module until the final 
steps of assembly (Saada et al., 2009). NDUFAF6 also seems to participate in the assembly 
of the Q-module but its exact role is not known (Pagliarini et al., 2008). NDUFAF5 hydroxylates 
an arginine residue of NDUFS7 (Arg 73) (Rhein et al., 2016) and NDUFAF7 demethylates 
NDUFS2 also at an arginine residue (Arg 85) (Rhein et al., 2013; Zurita Rendón et al., 2014). 
Additionally, NUBPL has been shown to deliver Fe-S clusters specifically to N- and Q-module 
subunits, which ultimately make up the Fe-S cluster chain (Sheftel et al., 2009). In the later 
stages of CI assembly, NDUFA9 is added to this module (Guerrero-Castillo et al., 2017), but 





The proton-pumping part of the P-module (termed the PP-module) is embedded within the IMM 
and is comprised of two distinct submodules (termed here as PP-a and PP-b, but are also 
termed ND1 and ND2, respectively, in the literature) (Stroud et al., 2016; Guerrero-Castillo et 
al., 2017; Signes and Fernandez-Vizarra, 2018). Biogenesis of the PP module begins around 
the Q-module by the action of the assembly factor TIMMDC1 (Liu et al. 2018), which remains 
bound to CI subassemblies until the last steps of CI biogenesis (Stroud et al., 2016). Firstly, 
MT-ND1 is added beneath the N-module, followed by NDUFA3, NDUFA8 and NDUFA13 in 
quick succession to create a 283 kDa complex, the PP-a module (Guerrero-Castillo et al. 
2017). Separately, MT-ND2, NDUFC1 and NDUFC2 are combined by the actions of a number 
of assembly factors: NDUFAF1, ECSIT, ACAD9 and COA1 (Stroud et al., 2016; Guerrero-
Castillo et al., 2017), the latter of which is also a COX assembly factor (Mick et al., 2012). 
Then, the MT-ND3 structural subunit is added together with TMEM126B (Heide et al., 2012) 
and TMEM186 (Guerrero-Castillo et al., 2017), to which subunits MT-ND6 and MT-ND4L then 
bind (Signes and Fernandez-Vizarra, 2018). The last assembly stage for the P-module 
involves the incorporation of subunits NDUFA1, NDUFA10 and NDUFS5 by unknown steps 
of assembly (Stroud et al., 2016; Guerrero-Castillo et al., 2017), to create the PP-b structure.  
 
The distal part of the P-module (the PD-module) forms within the IMM and is also comprised 
of two distinct submodules (PD-a and PD-b, as termed here), starting with the incorporation of 
NDUFB1, NDUFB5, NDUFB6, NDUFB10, NDUFB11 and MT-ND4 into the membrane by the 
assembly factors FOXRED1 (Fassone et al., 2010), ATP5SL (Andrews et al., 2013) and 
TMEM70 (Čížková et al., 2008; Jonckheere et al., 2011). The addition of NDUFB4 by an 
unknown assembly factor step completes the PD-a module, which then forms a ~  680 kDa 
subassembly complex with the PP-b module (Guerrero-Castillo et al., 2017). The PD-b module 
is formed separately by the structural subunits MT-ND5, NDUFB2, NDUFB3, NDUFB7, 
NDUFB8, NDUFB9 and NDUFAB1 (Guerrero-Castillo et al., 2017). TMEM261 is implicated in 
the assembly and subsequent stability of the PD-b module (Stroud et al., 2016; Horlbeck et al., 
2018), but no other mediators of the assembly of this submodule are known.  
 
1.2.1.4 Final Steps of CI Assembly 
The final intermediate of CI biogenesis contains the Q-module, complete PP and PD modules 
and only lacks the N-module; it is stabilised by NDUFAF2 as well as the already bound 
assembly factors mentioned above (Ogilvie, Kennaway, and Shoubridge 2005; Vinothkumar, 
Zhu, and Hirst 2014). In the last steps of CI biogenesis, the N-module attaches along with 
various subunits that bind to the outside of the complex including NDUFV3, NDUFS4, 
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NDUFA12 and NDUFS6 (N-module), and NDUFAB1, NDUFA6 and NDUFA7 (Q-module). At 



























Fig. 1.4. Mammalian Complex I Biogenesis. 
 
Cartoon representation of the proposed assembly pathway of CI within the mitochondria. For 
simplicity, the subunits are labelled by omitting the ‘NDUF-‘ portion of the subunit names. N-
module = orange, Q-module = yellow, PP module = green and PD-module = blue. Assembly 
factors are purple. The molecular weights in kilodaltons (kDa) of the various subunits, 
subcomplexes and the holocomplex are included beneath each in black text. Image extracted 






 Figure 1.4 . Mammalian Complex I Biogenesis. 
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 Complex IV/COX 
Complex IV (cytochrome c oxidase; COX) is the terminal enzymatic complex of the ETC that 
acts in oxidising cyt c and then reducing diatomic oxygen to two molecules of water (Wikström, 
Krab and Sharma, 2018). Like CI, these redox reactions are coupled to proton pumping across 
the IMM (Michel, 1998; Soto et al., 2012). Mammalian COX was first crystallised from bovine 
heart and was found to contain 13 subunits (Tsukihara et al., 1996; Yoshikawa, Shinzawa-Itoh 
and Tsukihara, 1998); however, it has since been demonstrated that COX contains a  
fourteenth subunit, NDUFA4 (COXFA4), which was previously thought to be a structural 
subunit of CI, as indicated by its name (Balsa et al., 2012).  
 
The core of the enzyme is formed by three mtDNA-encoded proteins: MT-CO1, MT-CO2 and 
MT-CO3 (Signes and Fernandez-Vizarra, 2018), but only MT-CO1 and MT-CO2 are involved 
in catalysis (Michel, 1998). Buried within the IMM, MT-CO1 contains a haem a group and a 
binuclear haem a3-CuB centre and MT-CO2 contains a CuA centre facing towards the IMS 
(Pacheu-Grau et al., 2015; Signes and Fernandez-Vizarra, 2018). MT-CO3 has no prosthetic 
groups, but is believed to be integral to the stability of the holocomplex (Wikström, Krab and 
Sharma, 2018). The eleven remaining structural subunits, COX4, COX5A, COX5B, COX6A, 
COX6B, COX6C, COX7A, COX7B, COX7C, COX8 and NDUFA4, are each encoded by the 
nDNA and are necessary for the stabilisation of the catalytic core of COX and regulation of its 
activity (Fornuskova et al., 2010; Timón-Gómez et al., 2017). All these subunits contain 
hydrophobic transmembrane regions except COX5A, COX5B, (both MM-facing) and COX6B 
(IMS-facing) (Fontanesi, Soto, and Barrientos 2008). Electrons from reduced cyt c are 
transferred to the CuA centre of MT-CO2, then to the haem a group of MT-CO1 and finally to 
the haem a3-CuB binuclear centre of MT-CO1 (Signes and Fernandez-Vizarra, 2018). In the 
last step of catalysis, O2 that is bound to the haem a3 centre of MT-CO1 is reduced to two 
molecules of water (Michel, 1998). These redox reactions are coupled to proton pumping 
across the IMM, with 4 net H+ ions pumped per electron that enters the complex (Banting and 
Glerum, 2006; Sharma et al., 2017). Currently, the proton exit pathway through COX to the 
IMS is not well defined (Siletsky and Konstantinov, 2012). 
 
COX assembly has been mainly elucidated by studying mutant strains of the yeast S. 
cerevisiae, which has highlighted many of the evolutionarily conserved assembly factors 
involved in COX biogenesis (Tzagoloff and Dieckmann 1990; Banting and Glerum 2006; 
Fontanesi, Soto, and Barrientos 2008). However, it has become apparent that there are some 
differences in the assembly factors present amongst different species, particularly between 
lower order and higher order eukaryotes (Mootha et al., 2003; Vidoni et al., 2017). Study of 
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mouse disease models and patient-derived cell lines have become crucial genetic, molecular 
and experimental bases for the identification and characterisation of higher taxonomic order 
assembly factors that are not known to have yeast orthologues. Like CI biogenesis, the 
assembly pathway of COX is modular (Vidoni et al., 2017; Signes and Fernandez-Vizarra, 
2018), starting with an initial subassembly and followed by generation of three assembly 
modules containing one of each of the mtDNA-encoded subunits (MT-CO1, MT-CO2 and MT-
CO3), as shown in Fig. 1.5. 
 
1.2.2.1 Initial COX Subassembly 
The initial COX subassembly consists of two nDNA-encoded structural subunits, COX4I1 and 
COX5A (Vidoni et al., 2017), and HIGD1A, a human homologue of yeast Rcf1 (Hayashi et al., 
2015; Kadenbach, 2017) that is not a structural subunit, but a positive regulator of COX which 
preserves its function under hypoxic conditions (Hayashi et al., 2015).  
 
1.2.2.2 MT-CO1 Module 
Together, the chaperones and assembly factors involved in the maturation and stabilisation of 
the MT-CO1 subunit form the mitochondrial translation regulation assembly intermediate 
of cytochrome c oxidase (MITRAC) complex (Mick et al., 2012). Firstly, the transmembrane 
assembly factors COX14 and COA3 bind nascent MT-CO1 and aid its insertion into the IMM 
(Mick et al., 2010; Soto et al., 2012). Next, the metallochaperone CMC1 binds copper (Cu) 
and participates in Cu-trafficking to MT-CO1 (Horn, Al-Ali and Barrientos, 2008; Horn et al., 
2010; Bourens and Barrientos, 2017). Haem a biosynthesis is carried out by both COX10 
(Antonicka, Leary, et al., 2003) and COX15 (Antonicka, Mattman, et al., 2003). The exact 
molecular functions of SURF1 (Zhu et al., 1998) and PET117 (Taylor et al., 2017) remain 
unconfirmed, but they have been proposed to be involved in haem a delivery and integration 
after the synthesis of this prosthetic group by COX10 and COX15 (Timón-Gómez et al., 2017; 
Signes and Fernandez-Vizarra, 2018). CuB assembly requires another metallochaperone, 
COX11 (Hiser et al., 2000), and copper ion donation by COX17 (Glerum, Shtanko and 
Tzagoloff, 1996). COX11 is stabilised by COX19 until Cu-transfer (Bode et al., 2015). CMC1 
is released prior to the addition of the factors COA1, SURF1, and MITRAC7 (Pierrel et al., 
2007; Signes and Fernandez-Vizarra, 2018). Other proteins involved in COX biogenesis 
upstream of the assembly of the MT-CO1 module are the multifunctional protein LRPPRC 
(Ruzzenente et al., 2012), which plays a crucial role in translation and maturation of newly 
synthesised mtDNA subunits, and TACO1, a translational activator of MT-CO1 (Richman et 




1.2.2.3 MT-CO2 Module 
The MT-CO2 module is synthesised by its own set of assembly factors before it combines with 
the MT-CO1 module (Signes and Fernandez-Vizarra, 2018). As well as the MT-CO2 structural 
subunit, this module consists of nDNA-encoded structural subunits COX5B, COX6C, COX7C, 
COX8A, and COX7B (Nijtmans et al., 1998); although, the latter is debated in the literature 
(Signes and Fernandez-Vizarra, 2018). Firstly, COX18 is required for membrane insertion of 
MT-CO2 (Bourens and Barrientos 2017), and then COX20 stabilises MT-CO2 prior to 
metalation (Bourens et al., 2014). The assembly of CuA precedes the merging of the MT-CO2 
module with the MT-CO1 module since once they are combined, MT-CO1 and MT-CO2 are 
tightly and strongly associated, barring access to the CuA site by assembly factors (Fontanesi, 
Soto and Barrientos, 2008; Soto et al., 2012). The biosynthesis of the CuA centre of MT-CO2 
occurs in the IMS, where COX17 transfers Cu ions to SCO1 and SCO2 (Glerum, Shtanko and 
Tzagoloff, 1996; Leary et al., 2004; Horn and Barrientos, 2008), which are each bound to the 
IMM but contain IMS-exposed regions for copper binding (Bourens et al., 2014). SCO1 and 
SCO2 then interact with COA6 to form a metallochaperone module that binds to the 
COX20/MT-CO2 intermediate and coordinates insertion of the mature CuA centre (Pacheu-
Grau et al., 2015; Stroud et al., 2015; Ghosh et al., 2016). COX18 is released prior to binding 
of SCO2 and COA6 but it is not known whether it is still bound at the time of SCO1 interaction. 
At this stage, TMEM177 stabilises the MT-CO2 subunit (Lorenzi et al., 2018) and COX16 
binds the MT-CO2/COX20/SCO1/SCO2 subassembly (Aich et al., 2018; Cerqua et al., 2018). 
Once COX5B, COX5C, COX7B, COX7C and COX8A are bound (Vidoni et al., 2017; Signes 
and Fernandez-Vizarra, 2018), COX16 is proposed to aid joining of the MT-CO1 and MT-CO2 
modules (Aich et al. 2018).  
 
The assembly factors MR-1S (Ghezzi et al., 2009; Vidoni et al., 2017), PET100 (Church et al., 
2005; Oláhová et al., 2015), and PET 117 (Renkema et al., 2017) bind at the point of MT-
CO1/MT-CO2 module joining; however their functions have not been fully explicated (Signes 
and Fernandez-Vizarra, 2018).  
 
1.2.2.4 MT-CO3 Module & Final COX Composition 
The MT-CO3 module consists of MT-CO3 and nDNA-encoded structural subunits COX6A, 
COX6B and COX7A2 (Fontanesi, Soto and Barrientos, 2008; Signes and Fernandez-Vizarra, 
2018). No specific assembly factors for this module are known. Following their integration into 
the COX complex, NDUFA4 is added (Pitceathly and Taanman 2018; Balsa et al. 2012; 
Pitceathly et al. 2013) to produce the final COX holocomplex structure (Zong et al., 2018).  
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Other supposed COX factors have been identified, principally from being causal proteins in 
COX deficiency as detected in mitochondrial disease patients (Alston et al., 2017). Some of 
these are FASTKD2 (Ghezzi et al., 2008), CEP89 (van Bon et al., 2013), OXA1L (Thompson 
et al., 2018), and APOPT1/COA8 (Signes et al., 2019); however, the mechanistic roles of each 






Figure 1.5. Model of mammalian COX assembly. 
Figure shows COX modular assembly based on the bovine crystal structure (PDB ID: 2OCC) 
(Yoshikawa, Shinzawa-Itoh and Tsukihara, 1998), and the assembly pathway proposed in 
references (Vidoni et al., 2017) and (Signes and Fernandez-Vizarra 2018). Red = proteins or 
assembly factors found to have pathological mutations in human patients, and yellow = known 
assembly factors. Image extracted from Figure 4, Signes and Fernandez-Vizarra, 2018.  
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1.3 Supercomplexes and the Mystery of Their Assembly 
 
The development of blue native polyacrylamide gel electrophoresis (BN-PAGE or BNGE) in 
the late 1990s revolutionised the way in which scientists could study the assembly and 
naturally occurring configurations of the native complexes of the mitochondrial OXPHOS 
system (Schägger and von Jagow, 1991; Nijtmans, Henderson and Holt, 2002). This 
technique allows for the separation and detection of 1) individual OXPHOS complexes in non-
denaturing conditions, and following solubilisation with the mild anionic detergent digitonin, 
the presence of 2) several supercomplex assemblies, which are distinct combinations of CI, 
CIII2 and CIV (Hirst, 2018) (Fig 1.6). The main stoichiometries of these supercomplexes are 
III2IV1, I1III2, I1III2IV1, also termed the “respirasome” given its ability to undergo electron transfer 
and proton pumping independently of the other OXPHOS complexes (Wu et al., 2016), and 
I2III2IV1, also termed the “megacomplex” (Guo et al., 2017). In recent years, the existence of 
these supercomplexes has been validated by structural homology methods (Dudkina et al., 
2005; Davies, Blum and Kühlbrandt, 2018) and by cryo-electron microscopy (Mourier et al. 
2014; Wu et al. 2016). In fact, the structure of the human megacomplex has been determined 
in this way (Guo et al., 2017). Additionally to the supercomplexes mentioned above, CIV and 
CV have been found to form dimers or oligomers (Wittig and Schägger, 2008; Mourier et al., 
2014), which may be related to stabilisation of cristae morphology (Letts and Sazanov, 2017). 
The reasons for the existence of the supercomplexes have been heavily debated. One 
possibility is that they are necessary for substrate channelling, in which enclosed pools of free 
ubiquinone and cyt c lead to an increased electron transfer efficiency (Alvarez-Paggi et al., 
2017). In addition, the “plasticity model” proposes that the mature complexes associate and 
disassociate in a flexible way to adapt to cellular energy demands (Acín-Pérez et al., 2008). 
However, substrate channelling is not supported by kinetic data (Blaza et al., 2014; Guo et al., 
2018) and, in opposition to the latter, there is evidence that subunits from different complexes 
co-assemble during assembly of the separate complexes (Fernández-Vizarra, Tiranti, and 
Zeviani 2009). For example, CIII2 and CIV have been proposed to bind to an incomplete CI 
scaffold with assembly of CI continuing after this step (Moreno-Lastres et al., 2012). In 
addition, a recent assembly kinetic study using mass spectrometry-based complexomic 
profiling following BN-PAGE found COA1, an established COX assembly factor, to associate 
with CI assembly intermediates (Guerrero-Castillo et al., 2017), suggesting co-assembly of at 
least CI and CIV.  
 
Another hypothesis that has been proposed to explain the existence of the supercomplexes 
is that they minimise production of ROS, evidenced by disruption of the I1III2 supercomplex in 
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bovine heart resulting in increased levels of superoxide (Maranzana et al., 2013). In support 
of this, studies in neurons and astrocytes showed a correlation between the intracellular levels 
of ROS and the amount of CI resident within supercomplexes (Lopez-Fabuel et al. 2016), 
suggesting a ROS-regulated supercomplex assembly system. The supernumerary subunits 
have been proposed to be necessary for the protection of the catalytic core of these enzymes 
from undergoing ROS-mediated damage (Milenkovic et al., 2017). More studies are needed 
to understand the physiological role, regulation and assembly of supercomplexes.  
 
 
Figure 1.6. BNGE analysis aids assessment of OXPHOS complex assemblies. 
 
BN-PAGE and Western blot analysis of digitonin-solubilised mitoplasts from ovine heart are 
separated with labels of the relative positions of the individual OXPHOS complexes and 
supercomplexes (SCs). The different SCs with the respective approximate molecular weights 
and molecular structures are indicated on the right. The CI structure is ovine (PDB ID: 5LNK), 
CII is porcine (PDB ID: 1ZOY), and CIII (PDB ID: 1NTM), CIV (PDB ID: 5B1A) and CV (PDB 
ID: 5ARA) are bovine. Imaged adapted from Figure 2, Letts and Sazanov 2017. 
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The yeast proteins Rcf1, Rcf2 and Rcf3 were the first to be suspected of mediating 
supercomplex assembly (Strogolova et al., 2012; Lundin et al., 2016). However, they are also 
known to be necessary for the individual assembly of COX (Vukotic et al., 2012), and gene 
silencing experiments led to isolated COX deficiency (Lundin et al., 2016), suggesting that 
their effect on supercomplex assembly may be indirectly due to a primary effect on COX. 
HIGD1A and HIGD2A are the mammalian orthologs of Rcf1 (Denko et al., 2000). HIGD1A has 
been found to interact with early assembly intermediates of COX (Vidoni et al., 2017), and 
gene silencing experiments did not affect supercomplex formation (Hayashi et al. 2015). 
However, HIGD2A knock-down by gene silencing led to depletion of III2IV1, suggesting a role 
in supercomplex stabilisation (Chen et al., 2012). Recent work has shown that this is not the 
case, and that HIGD2A in fact functions in the stabilisation of newly translated MT-CO3, and 
its loss leads to turnover of partner subunits found within the MT-CO3 module (see Fig. 1.5) 
(Hock et al., 2019). Whilst this led to a decrease in the abundance of a COX-containing 
supercomplex, it was proven that this supercomplex harboured only misassembled COX 
lacking MT-CO3; therefore, HIGD2A is a classical assembly factor involved in COX assembly, 
and is decidedly not a supercomplex assembly factor (Hock et al., 2019). Another protein of 
considerable debate is COX7A2L, which was proposed to be crucial for insertion of CIV into 
supercomplex structures (Lapuente-Brun et al., 2013), but has since been shown to act as a 
checkpoint for the assembly of CIII2 (Lobo-Jarne et al., 2018). It is worth noting that 
supercomplexes have never been found to contain any of these proteins (Mourier et al. 2014; 
Wu et al. 2016). This is to be expected given that the methods used seek to isolate and purify 
mature multimeric complexes, of which assembly factors are not found. 
 
In summary, supercomplexes are composite protein structures capable of aerobic respiration 
that are readily found in eukaryotes (Lapuente-Brun et al., 2013; Sousa et al., 2016); however, 
at present, their pathway(s) of assembly remain elusive.  
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1.4 Mitochondrial Diseases 
 
 Definition and Prevalence of Mitochondrial Diseases 
Mitochondrial diseases are a group of rare and phenotypically heterogeneous disorders, 
commonly arising from defects in some part of the assembly or function of the OXPHOS 
system (Zeviani and Di Donato, 2004; Gorman et al., 2016). Recent epidemiological studies 
have estimated that the prevalence of mitochondrial diseases owing to mutations in mtDNA-
encoded genes is 1 in 5,000 live births (Thorburn et al., 2004), and in the general adult 
population nDNA-encoded mutations are responsible for cases of mitochondrial diseases in 
2.9 per 100,000 adults (Gorman et al., 2015). Despite impressive development in the 
mitochondrial medicine field in recent years, the genetic bases and pathophysiology of 
mitochondrial diseases remain a mystery for many patients, their families, and their clinical 
teams. In most cases, mitochondrial diseases are progressive and debilitating, with no cure. 
 
  Mitochondrial Disease Inheritance  
Mitochondrial disorders can arise from inherited or de novo mutations in either the mtDNA or 
the nDNA (Zeviani, Spinazzola and Carelli, 2003; Gorman et al., 2015). Mammalian somatic 
cells typically harbour between 103 and 104 mtDNA copies (Stewart et al. 2008), and a single 
mtDNA mutant variant can exist in all mtDNA copies of a mitochondrion (homoplasmy) or in a 
proportion of these (heteroplasmy) (Cree, Samuels and Chinnery, 2009). If the mutant mtDNA 
load exceeds a threshold in which a cell cannot sustain normal respiratory or mitochondrial 
function, mitochondrial disease phenotypes can occur; this is termed the ‘threshold effect’ 
(Stewart and Chinnery 2015). The combination of a decrease in total mtDNA copy number as 
well as asymmetrical segregation of mutant and wildtype mtDNA into a mother’s primordial 
cells during gametogenesis is referred to as the ‘bottleneck effect’, resulting in a variable 
distribution of an mtDNA mutation in newly generated oocytes (Lang, Gray and Burger, 1999).  
 
Together, the threshold and bottleneck effects explain why families with identical mtDNA 
mutations may present with a wide range of clinical presentations and severity of symptoms, 
as well as tissue-specific phenotypes (McFarland, Taylor and Turnbull, 2010; Gorman et al., 
2016). Currently, more than 250 pathogenic mtDNA mutations have been identified (Mito-MAP 
database, www.mitomap.org) and can be classified as either 1) large-scale rearrangements 
(i.e. partial deletions or duplications), that are usually sporadic, or 2) point mutations, that are 
usually maternally inherited (Viscomi and Zeviani, 2017; Ghezzi and Zeviani, 2018). The mode 
of inheritance of mitochondrial diseases arising from mutations in the nDNA can be Mendelian, 
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either autosomal or sex-linked, or non-Mendelian (i.e. through the maternal lineage) (Ghezzi 
and Zeviani, 2018), which complicates molecular diagnosis.  
 
 Clinical Presentation 
Mitochondrial diseases arising from either nuclear or mitochondrial genomes have the 
potential to affect any tissue that has mitochondria; typically these are the central nervous 
system (with associated pathologies termed encephalopathies), the skeletal muscle 
(myopathies), a combination of the two (encephalomyopathies), the heart (cardiomyopathies) 
or the liver (hepatopathies) (Duchen, 2004; Zeviani and Di Donato, 2004; Ghezzi and Zeviani, 
2018), although other organs and systems have been found to be affected. Mitochondrial 
dysfunction has been linked to metabolic disorders that are not classified as canonical 
‘mitochondrial diseases’, including diabetes mellitus (Kelley et al., 2002) and various cancers 
(Gammage and Frezza, 2019). Herein, we define “mitochondrial disease” as any disorder 
arising from inherited mutations in OXPHOS structural subunits, co-factors, assembly factors, 
factors controlling the lipid composition of mitochondrial membranes or the quality control of 
mitochondrial proteostasis, and of course, factors regulating mtDNA maintenance and 
expression, encoded by either the mtDNA or nDNA. Patients with adult-onset mitochondrial 
disease usually display myopathies caused by CNS abnormalities (Gorman et al., 2016), 
whilst infantile or childhood presentations are typically more severe and impact development, 
including cognitive impairment, muscular tone and coordination, and can be further 
characterised by spino-cerebellar ataxia, dystonia, seizures, and respiratory abnormalities 
(Gorman et al., 2016).  
 
 Complex I Deficiency 
CI deficiency is the most frequently occurring OXPHOS complex defect found in children and 
adults, making up approximately a third of all clinical cases (Janssen et al., 2006). 
Presentations correlating with CI deficiency are extremely heterogeneous (Ghezzi and Zeviani 
2018); however, most infantile or paediatric cases fall into one of six phenotypic groups, which 
are 1) Leigh syndrome, 2) fatal infantile lactic acidosis, 3) neonatal cardiomyopathy, 4) 
leukoencephalopathy, 5) pure myopathy, and 6) combined hepatopathy and tubulopathy 
(Loeffen et al., 2000; Ghezzi and Zeviani, 2012). Cases that do not fall into one of these are 
generally classed as “mitochondrial encephalomyopathies with CI deficiency” (Ghezzi and 
Zeviani 2018). Most CI defects remain undefined at the genetic and molecular levels with an 
average successful molecular diagnostic rate of 20 – 40 % of cases (Fernández-Vizarra, 
Tiranti, and Zeviani 2009). Reasons for this include variability in the stringency of the 
biochemical screening and clinical investigation of patients (Challa et al., 2004), and whether 
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the mutant variant(s) are able to be reliably detected by WES or other sequencing strategies 
(Stenton and Prokisch 2018). Table 1.1 lists the assembly factors of CI that have been found 
associated with mitochondrial diseases (Legati et al. 2016; Ghezzi and Zeviani 2018), along 
with their predicted or known functions, and a brief description of the associated clinical 
phenotypes. 
 
Table 1.1 Assembly factors of CI with the proposed role and clinical presentations of each. 
 
Protein OMIM ID Role Associated phenotypes 
    
NDUFAF1 606934 CI chaperone; transient interaction 
with the PP-b module 
Cardiomyoencephalopathy, lactic acidosis; 
leukodystrophy, neuropathy 
NDUFAF2 609653 Stabilizer of late intermediate; 
binds to the N-module 
Leukoencephalopathy with vanishing white 
matter, Leigh syndrome 
NDUFAF3 612911 Interacts with Q-module subunits 
and with NDUFAF4  
Variable phenotypes: macrocephaly, 
severe muscle weakness, myoclonic 
seizures, brain leukomalacia; Leigh 
syndrome 
NDUFAF4 611776 Interacts with Q-module subunits 
and with NDUFAF3 
Encephalopathy, antenatal 
cardiomyopathy, Leigh syndrome 
NDUFAF5 612360 Methyltransferase of NDUFS7 Leigh syndrome, progressive spasticity 
NDUFAF6 612392 Assembly/stability of the Q 
module 
Leigh syndrome 
NDUFAF7 615898 Methyltransferase of NDUFS2; 
stabilizer of early intermediate(s) 
Pathologic myopia 
ACAD9 611103 Interacts with NDUFAF1, ECSIT 
and TMEM126B in PP-b module 
Cardiomyopathy, encephalopathy, lactic 
acidosis, exercise intolerance 
FOXRED1 613622 Involved in PD-a assembly; forms 
a complex with ATP5SL 
Leigh syndrome; microcephaly and 
cardiomyopathy 
TIMMDC1 615534 Assembly of multiple subunits of 
PD-a module 
Variable neurological phenotypes: Leigh 
syndrome; seizures, hypotonia, deafness, 
peripheral neuropathy, nystagmus 
TMEM126B 615533 Assembly of late-stage PD-b 
module 
Exercise intolerance; cardiomyopathy and 
renal tubular acidosis 
NUBPL 613621 Facilitates the assembly of Fe–S 
cofactors and subunits in CI 










 COX Deficiency 
Mutations in the mtDNA-encoded subunits MT-CO1 (Herrero-Martín et al., 2008), MT-CO2 
(Kytövuori et al., 2017), and MT-CO3 (Mkaouar-Rebai et al., 2011) are associated with more 
than 20 distinct pathological phenotypes owing to COX deficiency, the most common of which 
are myopathy, anaemia, amyotrophic lateral sclerosis-like syndrome, and mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) (Rak et al., 2016). 
Mutations in the nDNA-encoded COX subunits are uncommon and until the first mutation was 
discovered in COX6B1 relatively recently (Massa et al., 2008), they were thought to be 
embryonic lethal. Pathological mutations in COX4I2 (Shteyer et al., 2009), COX6A1 (Tamiy et 
al., 2014), COX6B1 (Massa et al. 2008), COX7B (Indrieri et al., 2012), COX8A (Hallmann et 
al., 2016) and NDUFA4 (Pitceathly et al. 2013) have since been identified. The majority of 
isolated COX deficiencies to date are caused by mutations in genes encoding COX assembly 
factors and co-factors responsible for the biosynthesis, coordination and integration of metal 
prosthetic groups (Ghezzi and Zeviani, 2018). Table 1.2 summarises the COX assembly 




Table 1.2 Assembly factors of CIV with the proposed role and clinical presentations of each. 
 
Protein OMIM Role Associated phenotypes 
SURF1 185620 Formation of the early MTCO1 
subcomplexes 
Leigh syndrome 
COA3 614775 Interaction with early COX 
intermediates and assembly 
factors 
Exercise intolerance and neuropathy 
COA5 613920 Involved in a very early step of 
the COX assembly 
Fatal neonatal cardiomyopathy 
COX14 614478 Coupling synthesis of MTCO1 
with assembly into COX 
holoenzyme 
Respiratory and neurologic distress, 
metabolic acidosis and neonatal 
death 
COX20 614698 Involved in early steps of the 
COX assembly; interaction with 
MTCO2 
Ataxia and muscle hypotonia, 
dystonia-ataxia 
PET100 614770 Involved in intermediate stage of 
COX assembly 
Psychomotor delay, seizures, 
hypotonia, and Leigh syndrome 
PET117 614771 Coupling Heme a synthase 
activity to COX assembly. 
Interaction with PET100 
Neurodevelopmental regression 
APOPT1 616003 Unknown Leukoencephalopathy 
COA6 614772 Copper homeostasis and 
transport to CIV 
Fatal infantile 
cardioencephalomyopathy 
SCO1 603644 Incorporation of copper atoms in 
the catalytic sites of the nascent 
CIV 
Infantile encephalopathy, neonatal 
hepatopathy, ketoacidotic comas 
SCO2 604272 Incorporation of copper atoms in 




COX10 602125 Heme A synthesis (conversion 
of heme b into heme o) 
Leigh syndrome, proximal renal 
tubulopathy, hypertrophic 
cardiomyopathy, sensorineural 
deafness, metabolic acidosis 
COX15 603646 Heme A synthesis (conversion 
of heme o into heme a) 









 Clinical, Biochemical and Histological Diagnoses 
Mitochondrial diseases present a diagnostic challenge for both clinicians and scientists due to 
their phenotypic and genetic heterogeneity. However, several imaging, biochemical and 
histological methods are routinely used to aid in their diagnosis. Magnetic resonance imaging 
(MRI) and proton MR-spectroscopy (MRS) are important tools for the detection of structural 
or biochemical abnormalities in mitochondrial disease patients (Saneto, Friedman and Shaw, 
2008). Biochemical deficiencies in one or more OXPHOS complexes are commonly found in 
mitochondrial disease patients (Ghezzi and Zeviani 2018). These enzymatic deficiencies can 
be detected biochemically using tissue homogenates or purified mitochondria from muscle or 
cutaneous biopsies, or by using patient-derived cultured cells (Rodenburg 2011), or lastly, by 
histopathological analyses using fixed tissue sections (Challa et al., 2004). Another useful 
biochemical disease marker is increased lactate levels in the blood and/or cerebrospinal fluid, 
caused by a reduction of pyruvate to lactate, utilising the reduced NADH formed during 
glycolysis (Finsterer and Zarrouk-Mahjoub, 2018). Experimentally, molecular analyses, such 
as SDS-PAGE and BN-PAGE, and subsequent immunodetection of proteins by Western 
blotting, help to determine changes in the abundance and assembly of each of the OXPHOS 
complexes, their subunits, subassemblies and various supercomplexes, as has been 
demonstrated widely throughout the literature. 
 
 Genetic Diagnosis 
Genetic diagnosis of mitochondrial diseases is notoriously difficult due to the bigenomic 
regulation of mitochondria, as previously described, with a pathogenic gene variant potentially 
being found in either mitochondrial or nuclear genomes (Gorman et al., 2016). Recently, whole 
exome sequencing (WES) and bioinformatic filtering steps have allowed for the detection of 
mitochondrial disease genes not previously known to localise to the mitochondria or have 
mitochondrial functions (Stenton and Prokisch, 2018). The stalwart techniques of 
homozygosity mapping (Seelow et al., 2009), used for identifying recessive traits in 
consanguineous families, and Sanger sequencing of single genes or panels of suspected 
candidate genes (Wortmann et al., 2017), are both effective strategies still used today, but 
they are comparatively laborious and time-consuming methods that rely on a narrowing down 
of potential genetic candidates, either from selecting genes based on a characteristic clinical 
phenotype or from knowing the aetiology of a disease within a family (Stenton and Prokisch, 
2018). In contrast, WES allows for the unbiased sequencing of all exonic regions of the human 
genome, in which ~85 % of known monogenic disease-causing mutations are found (Botstein 
and Risch, 2003), and along with downstream bioinformatic filtering, it has been integral to the 
rapid rate of discovery of new mitochondrial disease genes in recent years. 
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1.5 Identifying & Characterising New Mitochondrial Disease Genes 
 
More than 300 individual human genes have been implicated in causing mitochondrial 
diseases (Stenton and Prokisch, 2018). More recently, the advent of WES has allowed the 
detection of nDNA-encoded assembly factors only found in Metazoan species, including 
APOPT1 (recently renamed COA8) (Signes et al., 2019), LRPPRC (Cui et al., 2019), and 
TMEM126B (Alston et al., 2016). Much of what is currently known regarding human OXPHOS 
protein complex assembly, for instance that of CIII and CIV, has been possible due to genetic 
manipulation and study of orthologues in model organisms such as baker’s yeast, 
Saccharomyces cerevisiae (McEwen et al., 1993; Stoldt et al., 2018). Importantly, CI is not 
present in S. cerevisiae, and most of the investigation of its biogenesis has been carried out 
in other model organisms, e.g. the fruit fly, Drosophila melanogaster (Garcia et al., 2017) or 
by genetic characterisation of CI-deficient patients (Zeviani and Di Donato, 2004). This is 
because, in order to identify and characterise OXPHOS assembly factors and associated 
proteins that have evolved only in organisms of higher taxonomic orders, suitable genetic 
models must be used, including patient-derived cultured cell lines and in vivo animal models, 
particularly recombinant mice (Fernández-Vizarra, Tiranti, and Zeviani 2009).  
 
In this work, two probands that had been preliminarily diagnosed with mitochondrial diseases 
by means of clinical, biochemical and/or histopathological findings (as will be detailed in 
Chapters 3 and 4) were selected for enrolment in this study following the failure of mtDNA 
Sanger sequencing and deep sequencing of a panel of > 250 pre-selected OXPHOS-related 
nuclear genes to yield any potential genetic candidates. WES was undertaken to examine the 
entire exome of these individuals; this strategy successfully identified mutant variants in two 
genes that are only found to be present in metazoans, and also, that had never before been 
associated with mitochondrial disease, or in fact, any human disease pathology. These two 
genes, COA7  and TMCO6, were found to be associated with severe CIV and CI deficiencies, 
respectively. 
 
 Cytochrome c Oxidase Assembly Factor 7 (COA7) 
Cytochrome c oxidase assembly factor 7 (COA7; C1orf163, SELRC1 or RESA1), was first 
identified in a proteomics screen of proteins whose steady-state levels were significantly 
reduced after knockdown of cristae-forming proteins SAM50 and mitofilin (Kozjak-Pavlovic et 
al., 2014). COA7 is a member of the HCP β-lactamase protein family, and has known 
homologues in chordates, arthropods, nematodes, cnidarians and echinoderms 
(HomoloGene: 11317). The COA7 gene, located at genetic locus Chr 1 p32.3 (NC_000001.11: 
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52,684,449 - 52,698,347), produces a single 1,581 bp mRNA transcript (NM_023077.3) from 
3 coding exons (Fig. 1.7 A.). The resulting protein (NP_075565.2) consists of 231 amino acids 
and is cysteine-rich in its native form, containing 13 individual cysteines. Although the tertiary 
structure of human COA7 is unknown, homology modelling has predicted the presence of five 
Sel1-like repeats (Interpro ID: IPR006597), which are short α-helical domains involved in 
protein-protein interactions. The human primary COA7 protein sequence, with labeled Sel1-






Figure 1.7. COA7 gene composition and annotated COA7 primary protein sequence.  
 
(A.) The COA7 gene (NC_000001.11: 52,684,449 - 52,698,347) is composed of 3 coding 
exons and 2 intronic regions, and yields a single mRNA of 1,581 bps (NM_023077.3). (B.) 
The COA7 protein (NP_075565.2) is predicted to contain 5 SEL1-like tetratricopeptide repeat 
domains as labelled (grey boxes) (Interpro ID: IPR006597), and 13 cysteines (red text). 
 
Kozjak-Pavlovic et al. performed preliminary analyses of COA7 localisation and function via 
knockout and knockdown studies in HeLa cells, which suggested a putative role for it in COX 
assembly (Kozjak-Pavlovic et al., 2014). Cellular subfractionation and membrane swelling 
experiments revealed that COA7 is a soluble protein localising to the mitochondria, specifically 
the IMS, but this result was somewhat unclear given the lack of a suitable experimental control. 
Gene silencing in HeLa cells significantly reduced the steady-state levels of several COX 
subunits, and 1D-BNGE showed reduction in the amount of fully assembled COX. There were 
weaker reductive effects on subunits of CI and CIII, and no discernable effects on the 


















of COA7-knockout HeLa cells indicated reduced COX activity by approximately 66 % relative 
to controls. Following doxycycline (DOX)-induced gene silencing for 7 days, isolation of 
mitochondria and incubation with radioactively labeled CI, CIII, COX and CV subunits, it was 
determined that total COX assembly was reduced by ~50 % and progressed slower than 
biogenesis of CI, CII, CIII and CV. It is worth noting that COA7 knockdown had no effect on 
mitochondrial morphology, membrane potential or protein import (Kozjak-Pavlovic et al., 
2014). At the time of this research, no other information existed regarding the structure, 
function, intracellular localisation, protein interactors, mitochondrial protein import or role in 
human disease pathology of COA7. 
 
 Transmembrane Coil-Coiled Domain 6 (TMCO6) 
Transmembrane and coiled-coil domains 6 (TMCO6, other aliases: PRO1580, HQ1580 and 
FLJ39769.1) is a nuclear-encoded protein found only in vertebrates, including mammals, 
birds, reptiles, amphibians, and bony and cartilaginous fishes (Homologene ID: 12431). The 
TMCO6 gene (NC_000005.10: 140,596,529 – 140,647,411) is situated at genetic locus Chr 5 
q31.3, and contains 12 exons that are predicted to encode  two main protein isoforms of 493 
(NP_060972.3) and 499 (NP_001287909.1) amino acids (aas). The discovery of the two 
TMCO6 coding sequences (NM_018502.5 and NM_001300980.1, respectively) came from its 
cDNA sequences, sequenced as a part of genome-wide mRNA screening studies of human 
and murine transcriptomes (Strausberg et al., 2002; Ota et al., 2004). TMCO6 has since been 
found to be expressed in all human tissues (https://www.proteinatlas.org/ENSG00000113119-
TMCO6/tissue). However, presently, no seminal literature or research has been published 
regarding TMCO6, including its structure, intracellular localisation or its role in normal cellular 
physiology or human disease pathology. Consolidation and evaluations of all available 




1.6 Research Aims  
 
The genetic aetiology of mitochondrial diseases remains a mystery in approximately two thirds 
of clinical cases (Ghezzi and Zeviani, 2018). This could be due, in part, to the existence of 
unique OXPHOS assembly factors in humans that are not present in lower taxonomic order 
eukaryotes, which have served as the primary genetic and experimental bases for 
understanding OXPHOS complex assembly to date (Schägger, 2002; Banting and Glerum, 
2006). The advent of WES and other next generation sequencing technologies has made it 
possible to identify as-yet undiscovered mitochondrial disease genes present only in higher 
order eukaryotes.  
 
The three main aims of this work are: 1) to determine the pathogenicity of compound 
heterozygous mutant variants in COA7 (NM_023077.3:c.410A>G;c.287+1G>T) and a  
singular homozygous recessive mutation in TMCO6 (NM_018502.5: c.271C>T) relating to 
COX or CI deficiency, respectively, in two unrelated mitochondrial disease patients, 2) to 
assess whether COA7 and TMCO6 are novel mitochondrial disease proteins, and 3) to 
characterise the potential roles of each of these proteins in COX or CI biogenesis. 
 
In Chapter 3, I describe the identification and characterisation of the first pathogenic mutations 
in COA7, a putative COX assembly factor (Kozjak-Pavlovic et al., 2014). Additionally, super-
resolution microscopy and submitochondrial fractionation and protease digestion experiments 
were carried out to confirm the intramitochondrial localisation of COA7, which is the IMS. 
 
In Chapter 4, I introduce TMCO6, a gene identified through WES to be mutated in a paediatric, 
male proband with severe CI deficiency. Firstly, I discuss what is currently known regarding 
the gene structure, evolutionary conservation, protein isoforms and key structural features of 
TMCO6. I then describe the patient’s clinical history and characterise alterations to CI 
biogenesis and formation of CI-containing supercomplexes in primary and immortalised 
patient cells, despite presence of TMCO6 in these cells and no discernible CI deficiency or 
impairment of aerobic respiration in these cells. Lastly, TMCO6 was found to co-migrate with 
CI by 2D-BNGE using mitochondrial protein extracts from immortalised patient cells.  
 
In Chapter 5, I detail the generation of overexpression and knockdown cellular models to 
assess the role of TMCO6 in normal mammalian physiology. Furthermore, I confirm that 
TMCO6 localises only to the mitochondria, and specifically to the IMM. I also verify the co-
migration of endogenous TMCO6 with CI observed by 2D-BNGE in these cells, and 
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corroborate this result with immunoprecipitation experiments, which showed physical 
interaction between TMCO6 and CI N-module subunit NDUFS6. Lastly, attempted generation 
of knockout and patient mutant knockin HAP1 cell lines is described. 
 
Chapter 6 describes the phenotypic characterisation of a Tmco6-knockout murine model, 
which emulated the symptoms of the human patient and revealed tissue-specific cardiac and 
muscular CI deficiencies, not observed in any other tissue that was tested, as well as severe 
histopathological abnormalities in the brain, and a significant reduction in body weight, size 
and fitness. 
 
Lastly, the work of Chapter 7 concerns the successful functional complementation of Tmco6-
KO mice with the human wildtype gene, TMCO6. No such recovery was observed for mice 
stably expressing the patient mutant protein variant (NP_060972.3: p.Arg91Cys). This, along 
with exacerbation of cardiac dysfunction and a novel phenotype of cardiac fibrosis, confirms 




















Chapter 2  




2.1 Biological Materials 
  Human Subjects 
Patients that had been diagnosed with mitochondrial diseases by means of clinical, 
biochemical and morphological investigations were enrolled in the present study (NGSP001-
NGSP125) following referral to the Neurological Institute Carlo Besta (Milan, 
Italy). Histological analyses and measurements of respiratory chain and pyruvate 
dehydrogenase (PDH) enzymatic activities were performed in-house according to standard 
procedures. Based on the resulting biochemical profiles, as well as mtDNA characterisation, 
obtained using fibroblasts, skeletal muscle, or both, patients were divided into one of the 
following groups: Complex I deficiency, Complex II deficiency, Complex III deficiency, 
Complex IV deficiency, Complex V deficiency, multiple complex deficiencies, Coenzyme Q10 
deficiency, mtDNA multiple deletions and/or depletion, and PDH deficiency. All patients were 
screened for mtDNA mutations by Sanger sequencing, and were additionally screened for a 
set of ~ 250 nuclear genes associated with the specific biochemical or molecular (mtDNA) 
defect and/or clinical presentation. In no case were mutations found that suggested a 
pathogenic role. Two patients, one with Complex IV deficiency and another with Complex 
I deficiency, were selected for further investigation. A custom panel of genomic regions 
corresponding to the transcribed sequences of 132 nuclear-encoded genes (including exons 
and UTR regions) that had previously been associated with mitochondrial disorders or to be 
candidate genes that took part in the defective molecular pathways were additionally 
sequenced, yielding no genetic candidates. Informed consent for further genetic investigation 
at the MRC Mitochondrial Biology Unit (Cambridge, UK) was obtained from the parents of both 




 Cell Lines 
2.1.2.1 Skin Fibroblasts 
Primary skin fibroblasts from two mitochondrial disease patients (see section 2.1.1) were 
kindly provided by Daniele Ghezzi from the Neurological Institute “Carlo Besta” (Milan, Italy). 
WES (as detailed in section 2.2.2) revealed compound heterozygous mutant variants in 
COA7: a paternally inherited nucleotide transition variant (NM_023077.3: c.410A>G), resulting 
in a tyrosine to cystine amino acid substitution (NP_075565.2:p.Tyr137Cys), and a maternally 
inherited G>T transversion affecting the first intronic nucleotide of the exon 2/intron 2 splice 
junction (NM_023077.3:c.287+1G>T, p.(?)). Primary skin fibroblasts from a second patient 
harboured homozygous recessive mutations in TMCO6 (NM_018502: c. 271C>T), resulting 
in an arginine to cysteine amino acid substitution (p.Arg91Cys). Four control human skin 
fibroblast cell lines were used in this work; two alongside the mutant COA7 patient cells 
(termed here as Controls 1 and 2), provided by Dr. Erika Fernandez-Vizarra, and an additional 
two alongside the mutant TMCO6 patient cells (termed here as Controls A and B, for clarity), 
provided by Dr. Aurelio Reyes.  
 
2.1.2.2 Embryonic Cell Lines 
Human embryonic kidney 293T (HEK 293T) cells (Sigma-Aldrich®) were used for the 
production of lentiviruses (section 2.3.2), sub-mitochondrial localisation studies (section 
2.6.7), and immunoprecipitation (section 2.6.8.). Flp-In™ HEK-293 cells (Invitrogen™), 
derived from HEK 293T cells, were used for shRNA-mediated knockdown of endogenous 
TMCO6 (section 2.3.4) and inducible overexpression of the TMCO6 protein, C-terminally 
tagged with either HA or FLAG/STREP (section 2.3.5). 
 
2.1.2.3  Cancer Cell Lines 
HeLa epithelioid cervical cancer cells (Sigma-Aldrich®) and 143B human osteosarcoma cells 
(Thermo Fisher Scientific Inc., UK) were used for confocal microscopy (section 2.4.2). HeLa 
cells constitutively overexpressing HA-tagged COA7 protein were kindly generated and 
provided by Dr. Cristiane Beninca and used exclusively for super-resolution microscopy 




2.1.2.4 Haploid Cell Line 
HAP1 cells (Horizon Discovery Group plc., UK), a near-haploid human cell line derived from 
the male chronic myelogenous leukaemia (CML) KBM-7 cell line (Kotecki, Reddy and 
Cochran, 1999), were used for CRISPR/Cas9 experiments (section 2.2.15). 
 
2.1.2.5 Murine Cell Lines 
Primary MEFs were derived as per section 2.5.3 and spontaneous immortalisation of primary 
MEFs occurred after several passages, as previously described (Amand et al. 2016). 
 
 Tmco6-Knockout Mouse Model  
A transgenic Tmco6-knockout mouse model, B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J, was obtained for 
use in this work from the Knockout Mouse Phenotyping Project (KOMP2) repository (Stock No. 
028602, The Jackson Laboratory, USA) (Koscielny et al., 2014), and chosen in order to study 
the effects of TMCO6 ablation on development, physiology, neuromuscular control and 
mitochondrial metabolism at the tissue and organism levels. The ZEN-Ub1 Velocigene 
cassette, a lacZ reporter construct derived from Escherichia coli (E. coli) that contains a 
neomycin resistance (neoR) selection cassette, was inserted via homologous recombination 
between positions 36,894,829 and 36,901,908 of Chromosome 18 (Genome Build37) in 
embryonic murine stem cells of the C57BL/6NJ genetic background (see Fig. 2.1). Cre-
mediated excision of the neoR selection cassette was achieved by selective crossing with a 
mouse line that constitutively expressed Cre recombinase, B6N.Cg-Edil3Tg(Sox2-cre)1Amc/J (Stock 
No. 014094, The Jackson Laboratory). This process yielded a 7,080 bp deletion within Tmco6 
(NC_000084.6: 36,735,019 – 36,742,400), disrupting all coding exons and intervening 
sequences, and led to complete loss of endogenous protein expression.  
All experiments and procedures were conducted according to the Animals (Scientific 
Procedures) Act 1986 under UK Home Office licenses PPL 70/7538 and P6C97520A, and 
approved by local ethical review. Mice were housed in a temperature- and humidity-controlled 
animal care facility (Phenomics Laboratory, Forvie Site, Cambridge Biomedical Campus, 
Cambridge, CB2 0PY), under a 12 h light/dark cycle with access to water and standard chow 
ad libitum. Mice were monitored weekly to examine changes to body condition and general 
health. Metabolic, neurological and motor phenotypes resulting from Tmco6 protein ablation 





Figure 2.1. Generation of a Tmco6-knockout transgenic mouse line.  
Transgenic Tmco6-knockout mice (B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J) were generated as 
schematically depicted above by The Jackson Laboratory, as a part of the KOMP2 initiative. 
Homologous recombination replaced 7,080 bp of Tmco6 (NC_000084.6: 36,735,019 – 
36,742,400) with a ZEN-UB1 lacZ reporter cassette and neoR selection cassette. Removal of 
the selection cassette was achieved by selective crossing with a mouse line that expressed 
Cre recombinase, B6N.Cg-Edil3Tg(Sox2-cre)1Amc/J (Stock No. 014094, The Jackson Laboratory). 
This process yielded a final genetic construct with the initial 105 bp of Tmco6 exon 1, followed 
by the E. coli lacZ gene and a poly-adenylation signal, and the last 137 bp of Tmco6 exon 12, 




2.2 Genetic Manipulation and Microbiological Techniques 
 
 gDNA Extraction from Cultured Cells 
In all cases, gDNA was extracted and purified using the Wizard® Genomic DNA Purification 
Kit and protocol (Catalogue Number: A1120, Promega). Briefly, plasma membranes and 
nuclei were lysed, and RNA digested by RNAse treatment. Protein was removed by salt 
precipitation, and gDNA was concentrated and desalted by means of isopropanol 
precipitation. All gDNA was eluted in 50 µl Buffer elution buffer (EB) (10 mM Tris-Cl, pH = 8.5) 
and DNA concentrations estimated by NanoDrop™ 8000 Spectrophotometer (Thermo 
Scientific™, Thermo Fisher Scientific, UK) at λ = 260/280. 
 
 Whole Exome Sequencing (WES) 
DNA library preparation was carried out entirely by Dr. Aurelio Reyes using an initial 50 ng of 
template gDNA obtained from cultured human patient skin fibroblasts for the construction of 
pair-ended DNA libraries, as previously described (Legati et al., 2016), using the Nextera Rapid 
Exome Capture kit (Illumina) and following manufacturer’s instructions. Downstream 
bioinformatic analysis of perspective variants was performed by Dr. Alan Robinson and the MRC 
MBU Bioinformatics Group. For WES, an Illumina MiSeq platform was used with 12 pM template 
DNA libraries and 1 % 12.5 pM PhiX control libraries. Libraries were run several times until 12-
15 gigabytes of data per template sample were obtained. Resulting sequences (in the form of 
FASTAQ files) were aligned to the human genome (hg19) sequence using the Burrows-Wheeler 
Aligner (BWA) software (version 0.7.5) in the "mem" mode for long paired-end 
reads. The MarkDuplicates program from Picard tools was used to identify duplicate sequences 
in the resulting SAM files. Base quality scores were determined using the BaseRecalibrator from 
the Broad Institute’s genome analysis toolkit (GATK): https://www.broadinstitute.org/gatk/.  
 
Sequences surrounding previously confirmed or potential indels were identified and realigned 
further using the IndelRealigner feature, also from the Broad Institute’s GATK. Potentially 
pathogenic variants were identified by using the HaplotypeCaller feature of the GATK. Indels 
and single nucleotide polymorphisms were evaluated and scored separately by using the Variant 
Quality Score Recalibration (VQSR) feature of the GATK using an in-house database of patient 
exomes, and a "ts_filter" of 90.0 %. Heterozygous and homozygous variants were separated. If 
a variant had a Phred-based genotype score (PL) of less than 30, then it was assigned as both 
heterozygous and homozygous. Heterozygous variants were phased using HAPCUT software 
(version 0.5). All variants were filtered and annotated using Annovar software. Variants with an 
allelic frequency of greater than 2 % were discarded, as were variants in intronic and intergenic 
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regions, or those within protein-coding regions that were synonymous. The following 
annotations were added per variant: RefSeq ID, gene name and description, the predicted 
presence or absence of a mitochondrial targeting presequence (MTS) (using Mitoprot, 
TargetP and IPSort prediction tools), descriptions of the patient phenotypes and any available 
clinical information (using ClinVar and OMIM databases), the predicted pathogenicity scores 
(using PolyPhen, SIFT and MutationTester tools), and the relative allelic frequency (ESP, 1000 
Genomes, CG69, dbSNP138, and ExAC databases). The most likely causal genetic variant(s) 
per patient exome identified by WES were amplified by PCR (section 2.2.3) from patient skin 
fibroblasts and validated by Sanger sequencing (section 2.2.7). 
 
 PCR  
2.2.3.1 Design and Synthesis of Oligonucleotide Primers for PCR 
SnapGene® software (GSL Biotech LLC, Chicago, Illinois, USA) was used to visualise a 
plasmid sequence or genomic region of interest. Oligonucleotide primers were designed 
manually, considering the following parameters: 
 
• Primer Length – designed to be around 20 bp to enable a compromise between high 
sequence fidelity and low likelihood of mispriming.  
• Total GC Content – the proportion of guanine (G) and cytosine (C) nucleotide bases per 
primer was selected to be 60 % or higher; G and C bases are bound by 3 hydrogen bonds 
as opposed to 2 connecting adenosine (A) and thymine (T) bases, leading to stronger 
bonding (Boland and Ratner, 1995). 
• GC Clamp – 1 or 2 G’s or C’s were selected to terminate the 3’ end of each primer in order 
to strengthen the intermolecular binding at this point and create an anchor from which the 
Taq polymerase could replicate the sequence/gene region of interest. 
• Melting temperature (TM) – defined as the temperature at which one half of the double-
stranded DNA dissociates to single strands was determined approximately by the 
following equation:  
   TM = 4(nG + nC) + 2(nA + nT) 
where n = number of nucleotide bases. Primer TMs were selected to fall within a 
range of 55 to 65 oC, with F and R primer pairs not differing by more than 1.5 oC. 
The annealing temperature per reaction was typically 2 oC lower that the lesser TM 
of the primer pair. 
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• Secondary structures – intramolecular or intermolecular interactions within primers or 
between primers can lead to little or no product yield. Secondary structures include 
hairpins, self-dimerization, and cross dimerization with the paired primer. Secondary 
structure formation potential was determined using the OligoEvaluator™ sequence 
calculator (Sigma-Aldrich®). 
• Cross homology – primers must not nonspecifically amplify off-targets. To ensure this, 
primer sequence homology to other genomic regions was determined using the NCBI 
Basic Local Alignment Search Tool (BLAST): https://blast.ncbi.nlm.nih.gov/Blast.cgi. 
 
2.2.3.2 Thermocycling Conditions and PCR 
All PCR reactions were performed using a Biometra TRIO Thermocycler (Thistle Scientific, 
Germany) with thermostable Taq polymerase to enzymatically amplify a specific DNA 
sequence of interest by three temperature-mediated steps: 1) denaturation of the double-
stranded template DNA, 2) annealing of specific forward (F) and reverse (R) oligonucleotide 
primers to the region of interest on both denatured strands and 3) extension of replicate DNA 
sequences by the Taq polymerase  (Saiki et al., 1985). Primer sequences, the specific Taq 
polymerase used, and the thermocycling conditions per experiment are stated in tables within 
the relevant subsections of Chapter 2. Primers were synthesised by Merck, Sigma-Aldrich® 
and delivered dry and desalted. Denaturation occurred at either 94 or 95 oC, annealing 
between 55 and 65 oC (determined by primer TM, as per section 2.2.2.1), and extension was 
carried out at 72 oC in all cases. 
 
2.2.3.3 Purification of PCR Products 
Following PCR, DNA fragments between 100 bp and 10,000 bp in size were purified from 
other reaction mixture components using the QIAquick PCR Purification kit (Qiagen), and 
corresponding protocol. Briefly, a bind-wash-elute procedure was followed, in which a high-
salt binding buffer was added to the PCR sample to facilitate binding of DNA to the QIAquick 
spin column, a silica-based membrane; impurities were eliminated over several ethanol-based 
washing steps. Pure DNA was then eluted using a low-salt elution buffer or dH20. 
 
 PCR Amplification of Patient Mutations 
Purified gDNA from patient primary skin fibroblasts (see section 2.1.2.1) was used as a 
template for PCR amplification (see section 2.2.3.2) of the two heterozygous mutations of 
COA7, at the exon 2/intron 2 junction (primer set 1) and within exon 3 (primer set 2), and the 
single homozygous recessive transition mutation of TMCO6 within exon 3 (primer set 3). PCR 
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was performed for 50 µl reactions containing gDNA (50-100 ng/reaction) or dH20 (negative 
control), 1mM dNTP mix (0.2mM each dNTP), 1.25 units (U) GoTaq® polymerase (5 U/µl final 
concentration), 1X Green GoTaq® Reaction Buffer and 1 µM of each primer (listed in Table 
2.1) as per the corresponding GoTaq® PCR protocol (Promega, USA) under conditions 
detailed in Table 2.2. 
 
Table 2.1 Primers for PCR amplification of patient mutations 
 
Primer Sequence (5’ à 3’) 
COA7 Exon 2/Intron 2 F CAA GTC CCC ACT GCG AGC AG 
COA7 Exon 2/Intron 2 R TGC CTG CGA GAC CCT TCT GC 
COA7 Exon 3 F GAG ACA TTT AGG TTG TGC CC 
COA7 Exon 3 R GTA CAG AAC ACC CAG ATA AAG 
TMCO6 Exon 3 F GAT TCT CTG TCC ACT CCA CTG C 
TMCO6 Exon 3 R CAC TCT CCA CGA TCA GGT TAC C 
 
Table 2.2 Thermocycling conditions for PCR amplification of patient mutations 
 
Step Temperature Duration hh 
Hot Start 95oC 3 min  
Denaturation 95oC 30 sec      
  X 35 cycles Annealing 56oC 30 sec 
Extension 72oC 1 min 
Final Extension 72oC 5 min  
Hold 12oC ∞  
 
 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used for the separation of DNA fragments by size: 0.8 % for 
plasmids, 1.0 % for all general applications and 1.5 % for small fragments, < 300  bp in size. 
Gels were cast with the appropriate weight per volume (w/v) of agarose (InvitrogenTM), 
dissolved in 75 ml Tris/Borate/EDTA (TBE) buffer (89 mM Tris-borate, 100 mM boric acid, 2 
mM ethylenediaminetetraacetic acid (EDTA)) and 7.5 μl 10,000 X SYBR Safe dye 
(InvitrogenTM). PCR products containing GoGreen® master mix were loaded directly; all other 
PCR products and DNA samples were first mixed with 5 X GelPilot® DNA loading buffer 
(Qiagen) or 6X DNA gel loading dye (InvitrogenTM). A 1kb Plus DNA ladder (InvitrogenTM) was 
used for fragment size determination, and samples were electrophoresed at 90 V (EM100, 
Mini Gel Unit, Engineering & Design Plastics, UK) for approximately 40-50 min with 1X TBE 
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as the running buffer. An ultraviolet (UV) light transilluminator (Gel Doc™ Imaging System, 
Bio-Rad, UK) was used to visualize the electrophoresed DNA in all cases. 
 
 Agarose Gel Extraction and Purification of DNA 
PCR products were extracted from 0.8 - 1.5 % w/v agarose-TBE gel slices using the QIAquick 
Gel Extraction Kit (Qiagen), and corresponding protocol. Slices were weighed, dissolved by 
heating at 50 oC for 10 min in QG buffer (5.5 M guanidine thiocyanate and 20 mM Tris-HCl (pH 
= 6.6)) with a pH indicator. DNA fragments were then purified identically as per section 2.2.3.3 
by silica membrane binding of DNA in high-salt conditions and elution with low-salt buffer or 
water. The purification procedure removes primers, nucleotides, proteins, oils, salts, agarose, 
and other contaminants from the DNA by several ethanol-based washes. 
 
 DNA Sequencing and Analysis 
Sequencing of PCR products and cloned plasmids was carried out using the dideoxy-chain 
termination method (Sanger, Nicklen and Coulson, 1977) by a commercial service (Source 
Bioscience Ltd, Cambridge, UK). Resulting query sequences were aligned with a desired 
template sequence using SnapGene® software or the BLAST sequence alignment tool, Blast® 
nucleotide suite: https://blast.ncbi.nlm.nih.gov/Blast.cgi. 
 
 RNA Extraction and cDNA Retrotranscription  
Total RNA from cultured cells or frozen murine tissues was extracted using the TRIzolTM Plus 
RNA Purification Kit and the PureLink™ RNA Mini Kit (both from InvitrogenTM), as per 
manufacturer’s instructions. Briefly, TRIzol, a monophasic solution of phenol and guanidinium 
isothiocyanate, solubilises all membranes whilst also denaturing proteins. The addition of 
chloroform to the mixture separates total RNA into the aqueous phase. The RNA is then 
purified by column purification and eluted in RNAse-free water. Treatment with 1 µl TURBOTM 
DNase (Ambion®, Life Technologies™) for 30 min at 37 oC removes any trace DNA. 
Retrotranscription was performed using the Omniscript Reverse Transcription (RT) Kit and 




Table 2.3. Omniscript Reverse Transcription Reaction Solution 








Buffer RT 10X 1X 2 
dNTPs 5 mM 0.5 mM each 2 
Oligo dT primer (Sigma-Aldrich®) 10 µM 1 µM 2 
Omniscript Reverse Transcriptase 1 U/µl 0.2 U/µl 1 
Random Hexamer (Invitrogen™) 50 µM 10 µM 0.2 
RNA template (variable) 0.1 µg/µl 5 
RNAsin® RNase inhibitor (Promega) 40 U/µl 10 U/µl 0.25 
RNase-free H20 - - 7.55 
   TOTAL: 20 µl 
 
 
RT reactions, containing 2 µg template RNA in each case, were incubated for 1 h at 37 oC, 
and further incubated for 5 min at 95 oC. The resulting cDNA mixtures were diluted to 50 µl 
with dH20 and amplified by PCR with PFU TurboTaq® polymerase (Agilent Technologies, UK). 
Primers, reagents and thermocycling conditions used for cDNA retrotranscription are detailed 
in Tables 2.4 – 2.6, respectively. 
 
Table 2.4. PCR primers for cRNA amplification 
 
 
Primer Sequence (5’ à 3’) 
COA7-cDNA-F AGA ACA TGG AGG TGG AGT GC 
COA7-cDNA-R CCT TGG CCT CAT CCT TAT CA 
TMCO6-cDNA-F TGC AAC CAG GCC CGA AG 





Table 2.5. PCR reagents for cDNA Amplification 
 
 
Reagent Stock Concentration Working Concentration Volume (µl) 
10X PFU Buffer 10X 1X 5 
1mM dNTPs 10 µM each 250 µM 1 
F primer 10 µM 1 µM 1 
R primer 10 µM 1 µM 1 
PFU TurboTaq 2.5 U / µl 0.05 U/ µl 1 
dH20 - - 40 
   TOTAL: 50 µl 
 
 
Table 2.6. PCR thermocycling conditions for cDNA amplification 
 
Step Temperature Duration  
Hot Start 95oC 2 min  
Denaturation 95oC 30 sec  
X 31 cycles 
Annealing 55oC 30 sec 
Extension 72oC 3 min 
Final Extension 72oC 10 min  
Hold 4oC ∞  
 
 
 Ligation of cDNA Sequences into Cloning Plasmids 
Wildtype full coding sequence (CDS) COA7 cDNA was obtained commercially from the 
Integrated Molecular Analysis of Genomes and their Expression (IMAGE) cDNA library 
(IMAGE ID: 4430419/IRATp970-0D0921D, Source Bioscience Ltd). Approximately 200 ng of 
cDNA was used as a template for PCR amplification with the BIOTAQ™ DNA Polymerase 
(Bioline Reagents Ltd, London, UK), which possesses 5’ à 3’ exonuclease activity and leaves 
an ‘A’ overhang such that the PCR product is suitable for effective integration into TA cloning 
vectors.  PCR reactions were set up as detailed in Table 2.7 and thermocycling conditions 
were optimized for two specific reactions (Table 2.9). F and R primers (Table 2.8) were 
designed to insert Pme I and Bgl II restriction sites at the start and end of the WT-COA7 cDNA 
sequence, respectively; a second PCR reaction was performed using a different reverse primer 
encoding a downstream hemagglutinin (HA) epitope tag: 5' TAC CCA TAC GAC GTC CCA 





Table 2.7. PCR reagents for introducing flanking restriction sites to cDNA sequences 
Reagents included in the BIOTAQ™ DNA Polymerase kit are in italics; all reagents from 
other sources are cited accordingly. 
 
Reagent Volume (µl) Final concentration 
BIOTAQ™ Reaction Buffer (10X) 5 1X 
MgCl2 (50 mM) 2.5 2.5 mM 
dNTP Mix (10 mM each)  
(Catalogue number: 10297018, Invitrogen™) 
1 0.2 mM each 
Forward primer (10 µM) (Merck, Sigma-Aldrich®) 2 0.4 µM 
Reverse primer (10 µM) (Merck, Sigma-Aldrich®) 2 0.4 µM 
Template cDNA (Bioline Reagents Ltd) 4 1 ng/µl 
BIOTAQ™ DNA polymerase (5 U/µl) 0.25 1.25 U 
Nuclease-Free Water (Ambion®) Up to 50 total   
 
 
Table 2.8. PCR primers for restriction site sequence amplification 
 
Primer Sequence (5’ à 3’) 
COA7-PmeI-F GTT TAA ACG AAC CAT GGC CGG CAT GG 
COA7-BglII-R AGA TCT CAA GCA CTT TGT TGC CTG G 
COA7-HA-BglII-R AGA TCT CAA GCG TAA TCT GGA ACA TCG TAT GGG TAC CCA AAT GTT 
AAG GGT TGG 
 
 
Table 2.9. PCR thermocycling conditions for restriction site sequence amplification 
 
 
Step Temperature Duration  
Hot Start 95oC 3 min  
Denaturation 95oC 30 sec  
X 30 cycles 
Annealing 58oC 30 sec 
Extension 72oC 3 min 
Final Extension 72oC 10 min  
Hold 4oC ∞  
 
Amplified WT-COA7 and WT-COA7-HA PCR products, both with flanking Pme I and Bgl II-
compatible restriction sites, were resolved by agarose gel electrophoresis (section 2.2.5) (1 
% w/v agarose) and the desired DNA fragments excised and purified (see section 2.2.6). 
Either WT-COA7 or WT-COA7-HA (~670bp) sequences were ligated into the linearized 
pCR™2.1-TOPO® cloning vector (Fig 2.2) via a 5 min reaction at RT with 1 µl purified PCR 
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product, 1 µl NaCl salt solution, 1 µl pCR™2.1-TOPO® vector and 3 µl dH20 (as per the TOPO® 
TA Cloning® Kit, Thermo Fisher Scientific). The pCR™2.1-TOPO® cloning vector contains 3´ 





Figure 2.2 Cloning vector for Taq-amplified PCR products.  
 
The pCR2.1-TOPO cloning plasmid contains 3’ T-overhangs for direct ligation of a Taq-
amplified PCR product, a T7 promoter, M13 forward and reverse primer sites for sequencing, 
EcoR I restrictions sites on either side of the PCR insert site, kanamycin and ampicillin 
resistance genes, and the lacZ gene α-subunit for X-gal screening.  
 
 
 Competent E. coli Transformation and Plasmid Mini-Preparation 
Two separate 50 µl aliquots of Subcloning Efficiency DH5α™ competent E. coli cells (Thermo 
Fisher Scientific) were transformed with 2 µl of WT-COA7-pCR™2.1-TOPO® or WT-COA7-
HA-pCR™2.1-TOPO® plasmids. This was done by an initial incubation on ice for 30 min, heat 
shock at 42 oC in a water bath for 45 sec, and further incubation on ice for 5 min. Addition of 
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200 µl super optimal broth with catabolic repressor (SOC) (2 % tryptone, 0.5 % yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) to the 
transformed bacteria, and subsequent growth for 1 h at 37 oC with shaking at 225 rpm allowed 
production of ampicillin (Amp) resistance. Separately, agar plates made with lysogeny broth 
(LB) (1 % tryptone, 0.5 % yeast extract, and 10 mM NaCl), containing 100 µg/ml ampicillin, 
were covered topically with 40 µl X-gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) 
stain (Catalogue Number: R0404, Thermo ScientificTM), which indicates correct reporter gene 
expression by staining false positive colonies dark blue. After the surface of these plates had 
dried completely, 100 µl of the transformed bacterial solutions were spread onto each plate 
and incubated O/N at 37 oC. Positive (white) colonies (n = 5 for each plasmid) were then picked 
with a sterile loop and cultured in 5 ml LB, containing 100 µg/ml amp, in a shaking incubator 
(225 rpm) at 37 oC O/N.  
 
 Restriction Enzyme Digestion  
WT-COA7-pCR™2.1-TOPO® and WT-COA7-HA-pCR™2.1-TOPO® plasmids were isolated 
and purified from bacterial suspensions (see section 2.2.10) using the QIAgen® plasmid 
miniprep kit (Qiagen). 10 μg of each were digested with Pme I and Bgl II restriction enzymes 
(1 U/μl) (New England Biosciences®, New England Biolabs Ltd, UK) at 37 oC for 3 h in 
sequential reactions since they required separate buffers: 1X CutSmart® buffer for Pme I and 
NEBuffer 3.1 for Bgl II (both from New England Biosciences®). Bgl II was used in this step 
since the preferred enzyme, BamH I, recognized a restriction site within the COA7 and COA7-
HA sequences. Pme I-digested WT-COA7 and WT-COA7-HA DNA products were purified with 
the QIAspin® DNA Purification Kit, as per section 2.2.3.3. Bgl II digestion followed, and the 
purified and linearised DNA was resolved on a 1.0 % w/v agarose-TBE gel via electrophoresis 
(see section 2.2.5) to confirm presence of the insert. Gel extraction and purification of the 
interest followed (see section 2.2.6). In two separate reactions, pWPXLd lentiviral plasmids 
(gift from the Trono lab, Salmon et al. 2000) in which the GFP sequence was substituted with 
a puromycin or hygromycin B resistance cassette (pWPXLd-IRES-PuroR or pWPXLd-IRES-
HygroR, respectively; Fig. 2.3 A. and B.) was dually digested with Pme I and BamH I in NEB 





Figure 2.3 pWPXld transfer vectors for generating COA7-overexpressing cell lines.  
 
(A) pWPXLd-IRES-PuroR and (B) pWPXLd-IRES-HygroR plasmids encode PuroR or HygrR 
genes for selection in mammalian systems and AmpR for selection in bacterial systems. A 
desired insert of interest (not shown but cloned between Pme I- and BamH I sites) is flanked 
by LTR sequences to facilitate construct integration into the host genome, an RRE site 
allowing lentiviral replication, and an internal ribosome entry site (IRES) for transcription of 
several genes to one mRNA transcript. Eukaryotic EF-1α and bacterial SV40 promoters, and 
a Woodchuck hepatitis virus post-transcriptional enhancer (WPRE) element enable 





 Ligation of DNA into Lentiviral Transfer Plasmids 
BamH I and Bgl II restriction enzymes generate compatible 5’ overhang ends (Cost and 
Cozzarelli, 2007); therefore, 37.5 ng Pme I- and Bgl II-digested WT-COA7 and WT-COA7-HA 
PCR products were ligated into 50 ng Pme I- and BamH I- linearised pWPXLd-IRES-PuroR or 
pWPXLd-IRES-HygroR in 20 μl reactions using T4 DNA ligase (New England Biosciences), as 
per manufacturer’s instructions. Ligation (at 16 oC O/N) in 1X T4 reaction buffer with 6 U/μl T4 
ligase was achieved using a 1:3 vector to insert ratio and resulted in two distinct lentiviral 
plasmid constructs: COA7WT-pWPXLd-Ires-PuroR and COA7WT-HA-pWPXLd-Ires-HygroR. 
 
 Long-Term Storage of Transformed E. coli  
Microbank™ vials (Pro-Lab Diagnostics), porous beads in cryo-preservation fluid, were used 
for the long-term storage of transformed E. coli. A young colony (between 18-24 h after plating) 
was picked and used to inoculate the beads and fluid, which were stored long-term at - 80 °C. 
 
 Quantitative Reverse Transcription PCR (RT-qPCR)  
TMCO6 gene expression was assessed by RT-qPCR for Flp-In™-293T cells that had 
undergone shRNA-mediated gene silencing (see section 2.3.4) and for validating total loss 
of endogenous Tmco6 gene expression in 3 month-old Tmco6 KO mice (see section 2.1.3).  
 
TaqMan® gene expression assays were used, which utilise the 5’ exonuclease activity of Taq 
polymerase to cleave a dual-labelled hybridisation probe during the extension phase of 
traditional PCR (Kim, 2001). TaqMan® hybridisation probes consist of a complimentary primer 
sequence for a given cDNA target sequence, flanked by a 5’ reporter fluorophore, 6-
carboxyfluorescein (FAM), and a 3’ quencher molecule, 6-carboxy-tetramethylrhodamine 
(TAMRA). Upon binding its target sequence, Taq polymerase extends the primer sequence to 
synthesize a nascent strand. Dually, its 5’ to 3’ exonuclease activity degrades the hybridisation 
probe and TAMRA quencher molecule, in turn liberating the FAM reporter fluorophore. 
Fluorescence detected at 518 nm resulting from the cleaved reporter is directly proportional 
to the amount of cDNA template present in the reaction (Nolan, Hands and Bustin, 2006).  
 
A commercially available human-targeted TaqMan® Gene Expression Assay 
(Hs00382836_m1, Thermo Fisher Scientific) was used to quantify relative abundance of 
TMCO6 mRNA transcripts in four shRNA knockdown cell lines (shRNA 1-4), and in empty 
vector (EV) and non-mammalian negative (-) controls. Total RNA was extracted and 
retrotranscribed to cDNA (as per section 2.2.8). The relative abundances of each of these 
were normalised against levels of human glyceraldehyde 3-phosphate dehydrogenase 
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(GAPDH) (TaqMan® Gene Assay ID: Hs02758991_g1), a stably and constitutively expressed 
house-keeping enzyme essential for glycolysis. For verifying total loss of Tmco6 expression in 
knockout mice, total RNA was extracted from brain tissue and retrotranscribed to cDNA (as 
per section 2.2.8). A mouse-specific gene expression assay targeted for Tmco6 (TaqMan® 
Gene Assay ID: Mm00511056_m1) was used, and gene expression levels for WT (n = 2), HET 
(n = 1) and KO (n = 3) mice were normalised against expression levels of myosin heavy chain 
10 (Myh10) (TaqMan® Gene Assay ID: Mm00805131_m1), a non-muscle myosin stably 
expressed in the brain. Reactions were set up as per manufacturer’s guidelines, in volumes of 
20 µl containing 1X TaqMan® Gene Expression Assay (see Table 2.10), 1X TaqMan® Gene 
Expression Master Mix, 100 ng cDNA template, and adjusted with RNase-free water.  
 
Table 2.10. Gene Expression Assays for RT-qPCR 
 
Gene TaqMan Gene Assay ID Amplicon Sequence (5' à 3') 
Human 
GAPDH 
Hs02758991_g1 CAG TCC ATG CCA TCA CTG CCA CCC AGA AGA 
CTG TGG ATG GCC CCT CCG GGA AAC TGT GGC 




Hs00382836_m1 GGT GCA GCA GTT CCT GCG GCA AGC CCA GCG 
GGG GAC AGA GGA AAA GGA GAG AGA G 
Murine 
Tmco6 
Mm00511056_m1 GTC CAG CAG TTC CTT CGG CTC GCC CAA CGG 
GGG ACA GAT GAA AAG GAG AGG GAG AAG GCT 
CTG GTC AGC CTT CGT CGA GGC TTG CAG C 
Murine 
Myh10 
Mm00805131_m1 GAG AAG GCT AAT GCC AGG ATG AAG CAG CTT 
AAA CGA CAG TTG GAA GAG GCT GAG GAA GAG G 
 
 
Each 20 µl reaction mixture was transferred to individual wells of a 96-well plate, which was 
sealed and loaded into a 7900HT RT-QPCR System (Applied Biosystems, Thermo Fisher 
Scientific, USA). Three technical replicates were performed per gene concurrently for both the 
gene of interest and respective loading control. Thermocycling conditions were 95°C for 10 
min (initial denaturation), followed by 40 cycles of 95 °C for 15 s (denaturation) and 60 °C for 
1 min (annealing and extension). The extension cycle at which fluorescence becomes 
detectable is termed the cycle of threshold (Ct) (Figure 2.4). The Ct value was then used to 
calculate relative gene expression using Double Delta Ct analysis, as previously described 






Figure 2.4 RT-qPCR florescence intensity progression.  
 
The point at which fluorescence exceeds the signal threshold is called “Ct” (cycle of threshold) 
and correlates to the initial DNA template amount. The lower the Ct value, the more initial 
template cDNA present. 
 
 
 CRISPR/Cas9 Genome Editing 
In this work, CRISPR/Cas9 technology was used to edit the genome of HAP1 cells (see 
section 2.1.2.4) by both nonhomologous end joining (NHEJ) in order to generate a TMCO6 
knockout cellular model, as well as homology-directed repair (HDR) in order to generate a 
knock-in for the human patient mutation (NM_018502: c.271C>T, NP_060972.3:p.Arg91Cys) 
with the aid of a specific single-stranded donor oligonucleotide (ssODN). A specific sgRNA 
was designed using the CHOPCHOP software (http://chopchop.cbu.uib.no/) (Montague et al., 
2014; Labun et al., 2019) to target a region of exon 3 within the human TMCO6 gene 
(GenBank ID: 55374): sgRNA1 (5’ GGT GCT GCA AGC CTC GAC GAA GG 3’). 
Oligonucleotide primers were designed (as per section 2.2.2.1) to contain the forward and 
anti-parallel sequence for sgRNA1, with specialised flanking sequences (in green) as 
described by Ran et al. (Ran et al. 2013) (Table 2.11). 2 µM per oligonucleotide were 
combined with 5 µl (10X) T4 DNA ligase, diluted to 50 µl with nuclease-free dH20, and 
annealed by heating to 95 oC for 5 min, followed by gradual cooling at a rate of 0.1 oC sec-1 to 




Table 2.11. PCR primers for annealing sgRNAs 
 
 
Primer Sequence (5’ à 3’) 
TMCO6 sgRNA top CAC CGG GTG CTG CAA GCC TCG ACG AAG G  
TMCO6 sgRNA bottom AAA CCC TTC GTC GAG GCT TGC AGC ACC C 
 
Annealed oligonucleotides were ligated into the pSpCas9(BB)-EGFP plasmid (Addgene ID: 
48138, a gift from Feng Zhang; Fig 2.5) that had been digested with 1 U/µl Bbs I (Catalogue 
number: R0539S, New England Biosciences®) in 1X NEBuffer® 2.1 buffer for 1 h at 37 oC. 
Ligated plasmids were transformed into DH5α™ competent E. coli cells and purified from 
resultant colonies as per section 2.2.10. Correct integration of the desired sequences was 
confirmed by Sanger sequencing (section 2.2.7) using the U6 forward primer (sequence: 5’ 




Figure 2.5 CRISPR expression vector. 
  
The pSpCas9(BB)-2A GFP (PX458) plasmid (Addgene ID: 48138) encodes S. pyogenes Cas9 
nuclease, with an N-terminal 3X FLAG tag, a C-terminal EGFP tag, and a 3’ polyA tail from 
bGH. The Cas9 gene is followed downstream by an AAV2-derived ITR, and is under the 
control of a hybrid CMV promoter. A Bbs I/Bbs I sgRNA cloning site is encoded upstream of 
this, with a sgRNA scaffold, under control of a U6 promoter. The AmpR gene allows for 




HAP1 gDNA was extracted as per section 2.2.1 and ~500 bp surrounding the target region 
within exon 3 was amplified in a 50 µl reaction by PCR with the primers, reagents and 
thermocycling conditions detailed in Tables 2.12 - 2.14, respectively.  
 
Table 2.12 PCR primers for amplifying HAP1 TMCO6 exon 3 
 
 
Primer Sequence (5’ à 3’) 
TMCO6 ScPr F CTC CAC TGC AAG GTA GAT GCT TAT TAG T 
TMCO6 ScPr R GCT CAT GCA GGC ACC GAG 
 
Table 2.13 Reagents for PCR amplification of HAP1 TMCO6 exon 3 
 
 
Reagent Volume (µl) Final concentration 
LA PCR Buffer (Mg2+ free) (10X) 5 1X 
MgCl2 (50 mM) 4 4 mM 
dNTP Mix (2.5 mM each)  8 0.4 mM 
TMCO6 ScPr F (10 µM)  4 0.8 µM 
TMCO6 ScPr R (10 µM) 4 0.8 µM 
gDNA (200 ng/µl) 1 4 ng/µl 
Takara LA Taq (5 U/µl) 0.5 2.5 U 
Nuclease-Free Water (Ambion®) 23.5 - 
 
Table 2.14 PCR thermocycling conditions amplifying HAP1 TMCO6 exon 3 
 
 
Step Temperature Duration  
Hot Start 95oC 3 min  
Denaturation 95oC 30 sec  
X 35 cycles 
Annealing 60oC 45 sec 
Extension 72oC 1 min 
Final Extension 72oC 5 min  
Hold 4oC ∞  
 
The Guide-it™ Complete sgRNA Screening System (Catalogue number: 632636, Takara Bio 
Europe) was followed as per manufacturer’s instructions to screen the efficiency of sgRNA1 to 
cut its desired gDNA sequence in vitro. 5 µl Guide-It™ scaffold template was combined with 1 
µM sgRNA1 F primer (Table 2.15) and diluted to a final volume of 25 µl with nuclease-free 
dH20. This solution was added to a commercial aliquot of High Yield PCR EcoDry premix and 
amplified as per Table 2.16. 5 µl of the PCR product mixture was resolved by agarose gel 
electrophoresis (see section 2.2.5) (1.8 % w/v agarose) and the resulting ~140 bp band, 
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containing the sgRNA1 sequence in a template DNA backbone, were purified with the included 
NucleoSpin Gel and PCR Clean-Up kit. In vitro transcription of the sgRNA-encoding template 
followed, as per Table 2.17. Each 20 µl mixture was incubated at 42 oC for 1 h. 
 
Table 2.15 PCR primers for amplification of sgRNA-encoding scaffold template 
 
69 bp primer for integrating sgRNA1 into a DNA template backbone, including a T7 promoter 




Primer Sequence (5’ à 3’) 
TMCO6 sgRNA1 GCG GCC TCT AAT ACG ACT CAC TAT AGG GGG TGC TGC AAG CCT 
CGA CGA GTT TTA GAG CTA GAA ATA GCA  
 
Table 2.16 PCR conditions for amplification of a sgRNA-encoding scaffold template 
 
 
Step Temperature Duration  
Hot Start 95oC 1 min  
Denaturation 95oC 30 sec X 33 cycles  
 
Annealing and Extension 68oC 1 min 
Final Extension 68oC 1 min 
 
Table 2.17 PCR conditions for amplification of a sgRNA-encoding scaffold template 
 
Reagent Volume (µl) Final concentration 
Purified PCR fragment  1 5 ng/µl 
Guide-It™ Transcription Buffer 7 1X 
Guide-It™ T7 Polymerase Mix  3 1X 
RNase-free dH20  9 0.8 µM 
 
Following transcription, 1 µl TURBOTM DNase (Ambion®, Life Technologies™) was added to 
the mixture and incubated for 30 min at 37 oC to remove template DNA. RNase-free water 
was added to a volume of 100 µl, and an equal volume of phenol:chloroform:isoamyl alcohol 
in a 25:24:1 ratio, equilibrated in 10 mM Tris (pH = 8.0) + 1 mM EDTA, was then added. The 
reaction was mixed by vortex and centrifuged at 12,000 rpm for 2 min at RT. The supernatant, 
containing the sgRNA, was collected into a fresh, sterile 1.5 ml Eppendorf tube and 100 µl of 
chloroform added. The mixture was centrifuged again as above, and the supernatant collected 
again. 10 µl 3M sodium acetate and 100 µl pure isopropanol were then added and incubated 
for 5 min at RT. Purified sgRNA was pelleted at 15,000 rpm for 5 at RT, washed with 80 % 
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ethanol, centrifuged again as above, and air-dried for ~15 min. Pellets were resuspended in 
20 µl RNAse-free dH20, and the concentration of sgRNA1 was estimated by NanoDrop™ 8000 
spectrophotometer (λ = 260). Cleavage reactions were then immediately set up as per Table 
2.18 with 100 ng of the amplified and purified HAP1 TMCO6 exon 3 region (generated as per 
Tables 2.12 - 2.14) and 20 ng purified sgRNA1. An identical reaction was run concurrently 
using a 2 kbp control DNA fragment and control sgRNA. Experimental and control reactions 
were incubated for 1 h at 37 oC. Cleavage was halted immediately following this by incubation 
at 70 oC for 10 min. Entire reaction volumes were loaded into individual wells of a 1 % w/v 
TBE-agarose gel, with uncleaved DNA fragments loaded alongside as negative controls.  
 
Table 2.18 sgRNA in vitro cleavage reaction conditions 
 
Reagent Volume (µl) 
HAP1 gDNA PCR-amplified DNA template Equivalent to 100 ng 
Purified sgRNA Equivalent to 20 ng 
Guide-It™ Recombinant Cas9 Nuclease 1 
10X Cas9 Reaction Buffer 1 
10X BSA 1 
RNase-free PCR-grade dH20 Up to 10 
 
Following successful in vitro cleavage by sgRNA1 of the template gDNA region as determined 
by agarose gel electrophoresis, 1.5 x 105 HAP1 cells were seeded per well of a 6-well culturing 
plate and allowed to adhere completely at 37 oC for 24 h. For generating a knockout by NHEJ, 
100 ng of purified sgRNA1/pSpCas9(BB)-2A GFP (PX458) plasmid was diluted into 250 µl 
Opti-MEM™ (Catalogue number: 51985034, Gibco™). A ratio of 3:1 TurboFectin 8.0 reagent 
(Catlogue number: TF81001, Origene) was added to the mixture, mixed by inversion, and 
incubated for 15 min at RT. The mixture was the pipetted dropwise per well. The plate was 
then rocked laterally in all directions for 30 secs manually, and incubated at 37 oC for 24 h. 
For generating a knock-in of the patient mutation by HDR, the same process was followed but 
an additional 10 µM of ssODN (Table 2.19) was added to the 250 µl sgRNA1/pSpCas9(BB)-









Table 2.19 ssODN encoding the patient mutation (c.271C>T) and a Sac I restriction 
enzyme site within human TMCO6 exon 3 
 
 
Primer Sequence (5’ à 3’) 
ssODN1 CCC TGC CCT GAA CTC CAG GTG CAG CAG TTC CTG CGG CAA GCC CAG 
CGG GGG ACA GAG GAA AAG GAG AGA GAG GGG GCT CTG GTC AGC CTT 
TGT CGA GGC TTG CAG CAC CCT GAA ACA CAG CAA ACC TTC ATC CGG TCA 
GTG TGG ATG GTG TGG TGG AGG GAG GAG TTG GAG CTC TGA GGG ATG 
 
Cells were trypsinised, cell density determined by the Countess II™ FL cell counter (Life 
Technologies) and solutions diluted to a final concentration of 1 x 106 cells/ml with fresh HAP1 
culturing media (see section 2.3.1). 10 µg/ml 7-aminoactinomycin D (7-AAD) (Catalogue 
number: A1310, Invitrogen™) nucleic acid stain was added to the solutions and incubated for 
15 min at 37 oC. 7-AAD is a membrane impermeant fluorescent dye excluded by viable cells, 
but able to enter semi-permeable apoptotic or dead cells. Cells that had been correctly 
transfected with the sgRNA1/pSpCas9(BB)-2A GFP (PX458) plasmid expressed GFP. 
Following 7-AAD staining, the HAP1 cells were sorted by fluorescence-activated cell sorting 
(FACS), gating for GFP-positive and 7-AAD-negative cell populations for sgRNA1 and 
sgRNA1 + ssODN1 subtypes. Approximately 500 GFP-positive, live cells were distributed into 
individual wells of a 96-well plate (Corning, Costar), containing pre-warmed IMDM media 
supplemented with 20 % FBS. Cells were cultured for approximately 2 week, undisturbed until 
detection of a cell colony in any well, wherein cells were trypsinised and seeded into 24-well 
and then 6-well culturing plates. Cells were labelled by their 96-well plate column and row 
designation (Ex.: A1 for column ‘A’, row ‘1’), and KO or MUT for the knockout or patient mutant 
knock-in subtypes, respectively. 
 
Screening of TMCO6-KO HAP1 cells was performed by SDS-PAGE (section 2.6.2) and 
immunodetection by Western blotting (section 2.6.4) for the endogenous TMCO6 protein, 
using the antibody and conditions specified in Table 2.29. Clones with observed decreases in 
native TMCO6 expression were cultured further, and their gDNA extracted (see section 
2.2.1). PCR amplification of the target region followed using the primers, reagents and 
thermocycling conditions as per Tables 2.12 – 2.14, and Sanger sequencing (section 2.2.7) 
was performed using the TMCO6 ScPr F primer (Table 2.12).  
 
Screening of TMCO6 knock-in cells was performed by gDNA extraction (see section 2.2.1), 
PCR amplification of the target region using the primers, reagents and thermocycling 
conditions as per Tables 2.12 – 2.14, and then restriction digestion with 1 U/µl Sac I 
(Catalogue number: R0156S, New England Biosciences®) in 1X NEBuffer® 1.1 buffer for 3 h 
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at 37 oC. A non-synonymous mutation was introduced into the ssODN to create an artificial 
Sac I restriction site, which did not alter the reading frame or order of the resulting amino acid 
sequence, in order to streamline the process of screening. Sac I-digested fragments were 
loaded onto 1 % w/v TBE-agarose gels and resolved via electrophoresis (see section 2.2.5). 
Any candidate clones resulting from this screening were then sent for Sanger sequencing 




2.3 Cell Culture and Associated Procedures 
 Culturing Conditions 
All cells were cultured at 37 °C in a humidified incubator under 5 % CO2, and harvested or 
split with 10 % Trypsin/EDTA (TE) (GibcoTM) at confluence. Fresh media was added every 3 
to 4 days to cells yet to reach confluence.  
Human primary and immortalised skin fibroblast cell lines (section 2.1.2.1), HEK 293T cells 
(section 2.1.2.2), HeLa cells (section 2.1.2.3), 143B cells (section 2.1.2.3) and MEFs 
(section 2.1.2.5) were cultured in ‘standard culturing medium’: 4.5 g/L D-glucose and 1 mM 
sodium pyruvate-enriched 1X Dulbecco's Modified Eagle Medium (DMEM), supplemented 
with 2 mM GlutaMAXTM, 10 % foetal bovine serum (FBS), 100 units/ml penicillin and 100 μg/ml 
streptomycin (P/S) (all from GibcoTM, Thermo Fisher Scientific, UK). COA7 patient fibroblasts, 
as well as their counterpart controls, were additionally given 50 μg/ml uridine (Sigma-Aldrich®, 
Merck, UK) since cells with COX deficiency are known to suffer impaired activity of 
dihydroorotate dehydrogenase, a mitochondrial enzyme that catalyses an essential step of de 
novo pyrimidine biosynthesis and whose activity is coupled to the MRC (Evans and Guy, 
2004). Uridine supplementation is speculated to bypass this rate-limiting step, allowing cells 
to undergo DNA replication normally (Desler, Lykke and Rasmussen, 2010). The pWPXLd-
IRES-PuroR and pWPXLd-IRES-HygroR vectors (see Fig. 2.7) used for lentiviral transduction 
(see section 2.3.5) conferred puromycin or hygromycin B resistance, respectively; therefore, 
cell lines transduced with either of these vectors were selected for by addition of puromycin 
(1 μg/ml) or hygromycin B (100 μg/ml) (both from GibcoTM) to the normal culturing media. HEK 
293T cells with inducible overexpressing forms of wildtype or patient TMCO6 (see section 
2.3.6) were cultured with 10 % dialysed, tetracycline-free FBS (Biochrom, Berlin, Germany), 
and selected for by 1 μg/ml blasticidin S (GibcoTM) and 100 μg/ml hygromycin. shRNA-
knockdown TMCO6 HEK 293T cell lines (see section 2.3.4) were selected for by puromycin 
(1 μg/ml) added to standard culturing media. HAP1 cells (section 2.1.2.4) were exclusively 
grown in Iscove's Modified Dulbecco's Media (IMDM) (GibcoTM) supplemented with 10 % FBS 
and 5 % PBS. Lastly, MEFs (section 2.1.2.5) were cultured in standard culturing media with 
25 µg/ml of the antifungal drug, amphotericin B (GibcoTM).  
 
 Lentiviral Particle Production 
Lentiviral particles were produced by cotransfection of HEK 293T cells with the following 
plasmids: packaging plasmid psPAX2 (Addgene ID: 12260, Fig. 2.6 A.), envelope plasmid 
pMD2.G (Addgene ID: 12259, Fig. 2.6 B.), and a pWPXLd-based transfer plasmid. Four 
different transfer plasmids were used for constitutive protein overexpression: COA7-pWPXLd-
Chapter 2 
63 
IRES-PuroR, COA7-HA-pWPXLd-IRES-HygroR, and counterpart pWPXLd-IRES-PuroR and 
pWPXLd-IRES-HygroR empty vector (EV) controls (generated as detailed in sections 2.2.9 - 
2.2.12). 
 
Producer HEK 293T cells were seeded at a concentration of 2 x 106 cells per 100 mm petri 
dish and allowed to adhere completely. Following this, the packaging, envelope and a desired 
transfer plasmid were mixed with FuGENE® HD transfection reagent (Promega, Southampton, 
UK) and 1X DMEM as per Table 2.20. This mixture was incubated at RT for 30 min and 
subsequently added to the media of producer HEK 293T cells after incubation with 25 ug/ml 
chloroquine for 1h. After 8 h incubation at 37 oC, the transfection media was replaced with 
standard culturing media (see section 2.3.1). Cells were incubated at 37 oC in a humidified 5 
% CO2 atmosphere for 48 h. After this time, the media, now containing newly synthesised 
lentiviral particles encapsulating the desired expression construct, was collected, cell debris 
pelleted by centrifugation (3,000 rpm for 5 min at RT), and the resulting supernatant filtered 
for contaminants through a 0.45 µm PVDF syringe filter (Elkay Laboratory Products (UK) Ltd, 
Basingstoke, UK). A second collection and purification of lentivirus was performed as above 
by centrifugation (3,000 rpm x 5 min, RT) and filtering through a 0.45 µm PVDF syringe filter 
after another 24 h incubation with standard culturing medium. Lentiviruses from either the first 
or second collections were used directly to transduce human skin fibroblast cells (see section 
2.1.2.1), or frozen at -80 oC until future use.  
 




Transfer plasmid  Corresponding to 10 µg 
Packaging plasmid (psPAX2) Corresponding to 6.55 µg 
Envelope plasmid (pMD2.G) Corresponding to 3.5 µg 
FuGENE FUGENE: plasmid DNA ratio of 3:1 (60 µl) 
1X DMEM Adjusted to 1 ml 






Figure 2.6 Packaging and envelope plasmids used for the second-generation lentiviral 
expression system.  
 
(A) psPAX2 (Addgene ID: 12260) packaging plasmid encodes the polymerases/proteins 
necessary for synthesising pseudoviral capsids. (B) pMD2.G (Addgene ID: 12259) envelope 
plasmid encodes vesicular stomatitis virus GP (VSV-G) glycoproteins, allowing for effective 





 Cell Immortalisation 
Primary cells have a finite replicative capability (Hayflick and Moorhead, 1961; Howard, 1996); 
therefore, patient and control human skin fibroblasts were immortalised by lentiviral 
transduction with the pLOX-Ttag-iresTK plasmid, obtained from Didier Trono (Tronolab; 
Addgene plasmid No: 12246), and performed as previously described (Salmon et al., 2000). 
This retroviral construct allows for immortalisation of primary cells by expression of the 
replicative large T antigen (TAg) from Simian virus 40 (SV40) (Sompayrac and Danna, 1991; 
Cavender et al., 1995), which induces malignant transformation of cells. Following 
transduction, cells underwent at least five passages to allow immortalised cells to overtake 
residual primary culture. 
 
 shRNA Knockdown 
Gene silencing for TMCO6 was achieved through short hairpin RNA (shRNA)-mediated RNA 
interference (RNAi), a means of targeted mRNA-degradation utilising the cell’s RNA-induced 
silencing complex (RISC), followed by endogenous nuclease activation, as previously 
described (Moore et al., 2010). In this work, four different short hairpin RNA (shRNA) variants 
specific for TMCO6 mRNA, already cloned into the pLKO.1-Puro vector (Addgene ID: 8453, 
Fig 2.7), were purchased from the MISSION® TRC1 library (MISSION® shRNA Library, Sigma-
Aldrich®). Plasmid vectors were delivered as bacterial glycerol stocks (E. coli in 1X Terrific 
Broth (TB) containing 100 µg/ml carbenicillin and 15 % glycerol) and vectors were purified 
using the QIAprep Spin Miniprep Kit (Catalogue number: 27104, Qiagen Ltd, Manchester, 
UK), as per manufacturer’s instructions. Two relevant controls were used alongside these: 1) 
an empty vector (EV) control, the MISSION® pLKO.1-puro control vector (Catalogue Number: 
SHC001), encoding no shRNA sequence, and 2) a non-mammalian negative (-) control, the 
MISSION TurboGFP shRNA Control Vector (Catalogue Number SHC004), which encodes an 
shRNA sequence for Turbo green florescent protein (GFP), derived from crustacean 







Figure 2.7 Vector for generation of shRNA-knockdown cell lines.  
 
The pLKO.1-Puro 3rd generation lentiviral vector (Addgene ID: 8453) encodes Puro-resistance 
and ampicillin (Amp)-resistance genes, for selection in mammalian or bacterial systems, 
respectively, and encodes U6 and human phosphoglycerate kinase (hPGK) promoters, a 
central polypurine tract (cPPT) motif for increased transduction of non-dividing cells, and Psi 
RNA packaging signal. The vector includes a 3’ self inactivating (SIN) long terminal repeat 
(LTR), 5’ LTR, Rev response element (RRE) for lentiviral replication and three origins of 
replication. 
 
Lentiviral particles were produced by lentiviral production (as per section 2.3.2) by co-
transfection of 2 x 106 producer HEK 293T cells with psPAX2 packaging (Fig. 2.6 A.) and 
pMD2.G envelope (Fig. 2.6 B.) plasmids, but this time with a pLOX.1-Puro-based transfer 
vector (Fig 2.7) encoding one of the four TMCO6-specific or two control shRNA sequences 
(Table 2.21). Lentiviral transduction of HEK 293T cells using filtered lentivirus was performed 
as per section 2.3.5, and cells that had successfully taken up the lentiviral vectors were 





Table 2.21. MISSION® shRNA sequences encoded within plasmid vector pLKO.1-Puro 
 
 
Name Catalogue Number Target  shRNA Sequence (5' à 3') 
EV SHC001 - - 
- SHC004 TurboGFP CCG GCG TGA TCT TCA CCG ACA 
AGA TCT CGA GAT CTT GTC GGT 
GAA GAT CAC GTT TTT 
shRNA-1 TRCN0000138674 Human TMCO6 Ex 10 CCG GGT ATC TAA CGT GGT GAG 
CGT ACT CGA GTA CGC TCA CCA 
CGT TAG ATA CTT TTT TG 
shRNA-2 TRCN0000138522 Human TMCO6 Ex 9 CCG GCC TCA ACA ACC TCA CTG 
CAA ACT CGA GTT TGC AGT GAG 
GTT GTT GAG GTT TTT TG 
shRNA-3 TRCN0000138363 Human TMCO6 3' 
UTR- Ex 12 
CCG GCA CAC CTA AGC CAA GAC 
CTT TCT CGA GAA AGG TCT TGG 
CTT AGG TGT GTT TTT TG 
shRNA-4 TRCN0000134999 Human TMCO6 Ex 10 CCG GCA AAC AGT CCT AGT TTC 
TGT ACT CGA GTA CAG AAA CTA 
GGA CTG TTT GTT TTT TG 
 
 
 Lentiviral Transduction for Constitutive Protein Overexpression 
Constitutive protein overexpression in cultured cells was achieved by a second-generation 
lentiviral expression system for the COA7 patient and Control 1 immortalised skin fibroblasts. 
Cells were seeded at a density of 2 x 106 cells per 10 cm3 petri dish and allowed to adhere for 
at least 24 h. Filtered lentiviral supernatant (see section 2.3.2) was mixed with 8 µg/µl 
polybrene (Sigma-Aldrich®), to increase the efficiency of transduction, and added to the target 
cell media for 24 h. Cells that had successfully taken up the lentiviral vectors were selected 
for by addition of 1 µg/ml puromycin or 100 µg/ml hygromycin B antibiotics to standard 
culturing medium (see section 2.3.1) for another 24 h, and continuously thereafter.  
 




Table 2.22. Constitutive protein-overexpressing cell lines 
•  
Cell Line Name Parental Cell Type Overexpression Transfer Vector 
P1i-COA7WT Immortalised skin fibroblast COA7WT-pWPXLd-IRES-PuroR 
P1i-COA7HA Immortalised skin fibroblast COA7HA-HA-pWPXLd-IRES-HygroR 
P1i-EV Immortalised skin fibroblast pWPXLd-IRES-PuroR 
P1i-EVHygro Immortalised skin fibroblast pWPXLd-IRES-HygroR 
C1i-COA7WT Immortalised skin fibroblast COA7WT-pWPXLd-IRES-PuroR 
C1i-COA7HA Immortalised skin fibroblast COA7HA-pWPXLd-IRES-HygroR 
C1i-EV Immortalised skin fibroblast pWPXLd-IRES-PuroR 
C1i-EVHygro Immortalised skin fibroblast pWPXLd-IRES-HygroR 
 
 
 Inducible Protein Overexpression 
Tetracycline (Tet)-inducible overexpression of human TMCO6 was accomplished using the 
Flp-InTM T-RexTM Core Kit (InvitrogenTM), which is a conditional recombination system that 
relies on the Saccharomyses cerevisiae-derived recombinase Flp (O’Gorman, Fox and Wahl, 
1991). Flp-In™-293 cells (InvitrogenTM) contain an integrated Flp recombination target (FRT) 
site that allows for locus-specific integration of a DNA sequence by Flp-mediated homologous 
recombination. Flp-In-293™ cells were co-transfected with pcDNA5/FRT/TO© genomic 
expression vectors (plasmid template shown in Fig. 2.8 A.), in which eight variants of TMCO6 
were cloned, and the non-integrating Flp-encoding plasmid, pOG44 (Fig. 2.8 B.).  
 
TMCO6 has two predominant mRNA transcript isoforms that yield protein products, termed 
here as TMCO6.1 (Ensembl Transcript ID: ENST00000394671.7, 493 aa product) and 
TMCO6.2 (Ensembl Transcript ID: ENST00000252100.6, 499 aa product). It is unknown if 
one of these is expressed in a greater abundance, and whether there is tissue-specificity or 
separate functional roles for either translated isoform, so both were considered when 
overexpressing TMCO6. In addition to the two wildtype TMCO6.1 and TMCO6.2 isoforms, the 
human patient mutation, c.C271T, was introduced into either of these. These four TMCO6 
variants (TMCO6.1-WT, TMCO6.1-R91C, TMCO6.2-WT and TMCO6.2-R91C) were each C-
terminally tagged with HA (see section 2.2.9 for sequence) or separately, FLAG/STREP (FS) 
(peptide sequence: DYKDDDDK/WSHPQFEK), to generate 8 different TMCO6 transgenes: 
TMCO6.1-WTHA, TMCO6.2-WTHA, TMCO6.1-R91CHA, TMCO6.2-R91CHA, TMCO6.1-WTFS, 






Figure 2.8 Genomic integration vector and Flp-encoding vector for Tet-inducible 
expression of proteins in mammalian cells.  
 
(A.) pcDNA™5/FRT/TO® (Catalogue Number: V652020, Invitrogen™) contains a hybrid 
CMV/TetO2 inducible promoter, a multiple cloning site (MCS) with restriction sites for cloning 
a range of transgenic sequences of interest, a bGH polyA sequence, an FRT site for Flp-
mediated integration into a Flp-In™ T-REx™ host cell line, an SV40 polyA sequence and 
finally, AmpR and HygR genes for antibiotic selection. (B.) pOG44 (Catalogue Number: 
V600520, Invitrogen™) encodes yeast-derived Flp recombinase, under control of a CMV 





These were ligated into HindIII and BamHI-digested pcDNA5/FRT/TO© vectors, using the T4 
DNA ligase (New England Biosciences), as per manufacturer’s instructions. Ligation (at 16 oC 
O/N) in 1X T4 reaction buffer with 6 U/μl T4 ligase was achieved using a 1:3 (vector:insert) 
ratio, as directed, and was performed by Dr. Aurelio Reyes. The resulting plasmids were used 
to co-transfect 2 x 106 Flp-In™-293 cells using Lipofectamine 3000 reagent® (Life 
Technologies™, Thermo Fisher Scientific, UK), as per manufacturer’s instructions. Each 
transgene was under the control of a Tet-inducible hybrid CMV promoter, so that transcription 
is only initiated in the presence of Tet or its derivative effector compound doxycycline (DOX), 
as previously described (Gossen et al., 1995). Flp recombinase, expressed transiently by the 
pOG44 plasmid prior to antibiotic selection, mediates the insertion of the expression 
constructs above into the nuclear genome at the FRT site by homologous recombination. This 
insertion also interrupts the parental Flp-In™-293 cell’s zeocin-resistance cassette and 
instead introduces hygro- and blasticidin (blast)-resistance genes. Cells correctly transfected 
were selected for with addition of 100 ug/ml hygromycin B and 1 μg/ml blasticidin S to the 




2.4 Cellular Imaging 
 Live Cell Growth Assay 
Cell growth was assessed by phase contrast light microscopy using an IncuCyte HD 
instrument (Essen Bioscience, UK). Cell density was determined by Countess II™ FL Cell 
counter (Life Technologies) and 2 x 104 cells per cell line were seeded in duplicate in a 6-well 
culturing plate (Corning® Costar®). Images were captured at 16 locations per well every 4 
hours for 7 days, with duplicates averaged per time point. Growth curves were graphed using 
Prism 7.0 software. 
 
 Immunocytochemistry (ICC)  
ICC analysis was used to demonstrate the presence and subcellular localisation of 
endogenous TMCO6. HeLa or 143B cells were counted as per section 2.4.1 and 
approximately 2.5 x 104 cells seeded onto glass coverslips in separate wells of a 6-well 
culturing plate. Cells were incubated at 37 oC in 5 % humidified CO2 for 24 h prior to cell 
fixation. Cells were given a preliminary wash with 2ml 1X DMEM. For visualisation of the 
mitochondrial network, MitoTrackerTM Red CMXRos (InvitrogenTM) was added to the culturing 
media at a final concentration of 80 nM and incubated for 20 min at 37 ºC. Cells were washed 
with 2 ml DMEM, and fixed with 1 ml 4 % weight/vol (w/v) paraformaldehyde (PFA) for 15 min 
at RT on a shaking platform, washed 3X with 2 ml PBS at RT for 5 min per wash, and 
permeabilised for 5 min at RT with permeabilization buffer (1X PBS with 0.3 % vol/vol Triton 
X-100 (Fisher Bioreagents, Fisher Scientific, Louborough, UK) and 5 % FBS). Coverslips were 
then washed 6X with 1 ml PBS over a 5 min period, followed by incubation with 1 ml primary 
Anti-TMCO6 (Catalogue Number: 20117-1-AP, Proteintech Group Inc, Rosemont, Illinois, 
USA) rabbit polyclonal antibody (1:500 dilution), diluted in 1X PBSS (1X PBS + 5 % FBS) for 
2 h at RT. Coverslips were washed 6X with 2 ml PBSS for 5 min per wash, and then incubated 
with Alexa Fluor 647 goat anti-rabbit IgG secondary antibody (Catalogue Number: A21245, 
Invitrogen™) (1:200 dilution) for 1 h at 37 oC. Coverslips were washed 3X with 2 ml PBSS for 
5 min per wash and then with 1X PBS for 5 min once at RT. Coverslips were mounted with 20 
µl ProLongTM Diamond antifade mountant with 4',6-diamidino-2-phenylindole dihydrochloride 
(DAPI) (InvitrogenTM) nuclear stain, and left to dry O/N at RT under an opaque cover. Images 
were acquired using the A1/A1R Confocal Microscope System (Nikon UK Ltd, Kingston upon 
Thames, UK) with a 63x 1.40 numerical aperture oil immersion objective by Dr. Aurelio Reyes. 




 Super-Resolution Microscopy 
In order to determine COA7 intramitochondrial localisation, 5 x 104 HeLa cells constitutively 
overexpressing COA7-HA were seeded onto glass coverslips placed into individual wells of a 
12-well culturing plate (Corning® Costar®) the day prior to fixation and sample preparation. 
Cells were fixed with 4 % w/v PFA in standard culturing media (see section 2.3.1) for 30 min 
at 37 oC, washed 3X with 1 ml 1X PBS at RT and permeabilised with 1 ml permeabilization 
buffer (see section 2.4.2) for 5 min at RT. Permeabilised cells were washed again 3X with 1 
ml PBS at RT, and subsequently immunostained with anti-TOM20, anti-Aconitase, anti-CO1 
and anti-COA7 antibodies (see section 2.6.4), all at a dilution of 1:300 for 1 h at RT under an 
opaque cover. Respective secondary antibodies, Alexa Fluor 647 goat anti-rabbit IgG 
(Catalogue Number: A21245, Invitrogen™) or Alexa Fluor 488 goat anti-mouse IgG 
(Catalogue Number: A11029, Invitrogen™), were incubated also at a dilution of 1:300 for 1 h 
at RT. Coverslips were mounted with ProLongTM Diamond antifade mountant (Catalogue 
Number: P36965, InvitrogenTM). Acquisition of 3D Z-stacks was performed using a Nikon N-
SIM microscope with SR Apo TIRF 100x 1.49 N.A. objective. Images were acquired and then 
processed using Imaris 9.0 XT software by Dr. Cristiane Beninca (Microscope Facility 
Manager, MRC MBU, University of Cambridge, Cambridge, UK). 
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2.5 Animal Model and Associated Procedures 
 Genotyping of B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J Mice 
Ear biopsies were routinely collected at the time of weaning for the dual purposes of individual 
identification and genotyping. Genomic DNA (gDNA) was extracted per biopsy using the 
Maxwell® 16 Tissue DNA Purification Kit and Maxwell® 16 (AS1000) instrument (Promega, 
UK), with the associated protocol for DNA purification from tissues. For knockout (Tmco6-/-, 
KO) and heterozygous (Tmco6+/-, HET) mice, the latter 441 base pairs (bp) of the ZEN-UB1 
cassette (section 2.1.3) and 55 bp of murine TMCO6 exon 12 (in the 3’ UTR region) were 
amplified by polymerase chain reaction (PCR) (see section 2.2.3) to produce a 496 base pair 
(bp) DNA fragment. For HET and wildtype (Tmco6+/+, WT) mice, the entirety of TMCO6 exons 
3 and 4, as well as the interceding intronic sequence, were amplified to yield a 384 bp DNA 
fragment. Primers, conditions and reagents used are specified in Tables 2.23-2.25. PCR 
products were resolved by agarose gel electrophoresis (see section 2.2.5) for approximately 
50 min at 90 volts (V), and the respective genotypes assigned to each animal.  
 
Table 2.23. Primers for genotyping B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J mice 
 
Primer Sequence 5' à 3' 
Wildtype F CCT GTT CTG GGA TCC AGG T 
Wildtype R AGG TGA GGA GGT AGG AAG TCG 
Mutant F CGG TCG CTA CCA TTA CCA GT 





Table 2.24. Thermocycling conditions for genotyping B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J  mice 
 
 
Step Temp (°C) Time 
 
1 94 2 min 
 
2 94 20 sec 
 
3 65 15 sec Steps 2-4 X 10 cycles 
4 68 10 sec 
 
5 94 15 sec 
 
6 60 15 sec Steps 5-7 X 28 cycles 
7 72 10 sec 
 
8 72 2 min 
 
9 10 ∞ 
 
 
Table 2.25. Reagents for genotyping B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J mice 
 
Reagent Volume (μl) 
GoGreen®  Master Mix (5 x) 5 
25 mM dNTPs (10 x) 2.5 
DMSO (100 %) 1.25 
F WT Primer (20 μM) 2 
R WT Primer (20 μM) 2 
DNA template (25 ng/µL) 2 
dH20 10 
GoTaq® DNA polymerase (5 u/µL)* 0.25 
TOTAL: 25 
 
 Derivation of Mouse Embryonic Fibroblasts (MEFs) 
MEFs were derived from females 11.5 to 12.5 days following detection of a post-copulation 
plug. The pregnant female was culled by cervical dislocation, the abdominal wall and uterus 
dissected, and whole embryonic sacs retrieved and placed into 4 oC phosphate buffered saline 
(PBS), lacking both Ca2+ and Mg2+ (Gibco®, Thermo Fisher Scientific Inc., UK).  
All procedures from this point onwards were performed in a tissue culture hood using sterilized 
surgical tools and reagents. Individual embryos were removed from the surrounding yolk sac, 
transferred to separate wells of a 6-well culturing plate (Costar®, Corning®, USA) and 
submerged in 1 ml 4 oC PBS. Under 4X magnification (Nikon SMZ1000 light microscope, 
Nikon UK Ltd, UK), all viscera, limbs and tail were removed per embryo. Heads were isolated 
for gDNA extraction and genotyping (as per section 2.5.1). Remaining soft tissues were 
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minced into 1 - 2 mm pieces with scissors, transferred to a 15 ml Falcon tube (Sarstedt, 
Germany) containing 5ml sterile 4 oC PBS, and pelleted for 5 min (300 x g) at room 
temperature (RT). A second wash was performed as above with 5ml sterile 4 oC PBS (5 min, 
300 x g, RT). The resulting pellet was resuspended in 1 ml digestion solution: 2 mg/ml 
collagenase type IV (Gibco®) in standard culturing medium (see section 2.3.1), supplemented 
with 25 µg/ml amphotericin B (Gibco®). Solutions were incubated in a 37 °C water bath (Grant 
Instruments, UK) for 60-90 min, until individual tissue pieces were no longer visible. Solutions 
were regularly mixed with a P1000 micropipette every 15-20 minutes.  Cells were then washed 
with 5 ml 37 oC PBS, pelleted for 5 min (300 x g at RT), diluted into a final volume of 15 ml 
MEF culturing medium (as per section 2.3.1). MEFs were transferred to individual 15 cm3 
Petri dishes (Corning®) and cultured at 37 oC in a humidified atmosphere with 5 % CO2. 
 
 Metabolic Monitoring via CLAMS 
The Oxymax Comprehensive Lab Animal Monitoring System (CLAMS) (Columbus 
Instruments, Ohio, USA) allows for non-invasive and automated measurement of numerous 
metabolic and behavioural parameters including VO2 (total volume of oxygen consumed, 
ml/Kg/hr), VCO2 (total volume of carbon dioxide produced, ml/Kg/hr), locomotor activity in the 
x-, y- and z-planes (measured by infrared beam, with each break in the beam defined as a 
‘count’) and total consumption of food and water (measured as accumulated change in mass 
(g) and volume (ml), respectively) over time. Tmco6 KO mice and control littermates were 
placed into individual cages of the CLAMS with access to food and water ad libitum. Mice 
were monitored over a 36 h period composed of two 12 h night cycles and one 12 day cycle. 
Data per parameter were collected automatically every 10 min, averaged per animal and 
normalised to body weight, and analysed separately for day and night 12 h cycles.  
 
 Treadmill Exhaustion Trials 
The LE8710 series treadmill (Panlab, Harvard Apparatus, Barcelona, Spain) was used to 
evaluate exercise capability and endurance (Castro and Kuang, 2017). Mice underwent 
acclimatisation for two consecutive days prior to testing. Each mouse was placed into 
individual, closed chambers on top of a treadmill conveyor belt, fixed at a 10 ° inclination angle, 
and forced to maintain a walking speed of 11 meters per minute (m/min) for 10 min.  A 
motivational ‘air puff’ (LE8711 Air Puff Control, Panlab, Harvard Apparatus, Barcelona, Spain) 
was activated when mice made contact with a metal grid at the base of the treadmill belt, 
encouraging continuation of the task. For the test, mice were run at an initial speed of 11 
m/min for 3 min, followed by continuous increase of 0.3 m/min to a maximum speed of 75 
m/min or until exhaustion was reached. Exhaustion was defined as 10 ‘falls’ onto the metal 
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grid within 1 minute, or continuous triggering of the air puff for more than 5 s (indicating failure 
to continue the task). Speed increase was controlled automatically by the accompanying 
SeDaCom 2.0 software. The distance in meters reached at exhaustion was recorded manually 
per animal. Upon test completion, mice were returned to their home cages for a minimum of 
24 h before any further experiments were conducted. 
 
 Rotarod Test 
A well-established motor performance test using a rotarod apparatus (Model 46700, Ugo 
Basile®, Varese, Italy) was performed to assess neuromuscular coordination and balance 
(Ingram and Reynolds, 1986). Acclimatisation was performed for two consecutive days prior 
to testing. Mice were placed into individual segments on a suspended, cylindrical treadmill rod 
for 5 min statically, and then forced to maintain a walking speed of 10 rpm/min for 5 min. If a 
mouse fell from the rod, or faced oppositely to the intended direction of travel, they were 
orientated correctly to continue the adaptation until completion. For the test, three separate 
trials were run per animal with gradual acceleration in speed from 2 to 40 rpm over 5 min. The 
latency to fall (s) was recorded manually per animal for each of the three trials, and an average 
of these was used in subsequent analyses. Mice were returned to their home cage between 
trials for 30 min minimum, with unrestricted access to food and water. Upon test completion, 
mice were returned to their home cages for at least 24 h before any further experiments were 
conducted. 
 
 Hindlimb Clasping Evaluation 
Hindlimb clasping is commonly observed in murine models of neurodegenerative disease 
(Guyenet et al., 2010) and can be used to mark neurological symptom progression with age. 
Mice were suspended in the air by the base of the tail facing downwards for 10 s with the 
ventral side of the animal visible to the observer. A normal response was classified as 
hindlimbs remaining outstretched and away from the abdomen, and a positive pathological 
response was defined as both hindlimbs retracting fully towards the abdomen for a continuous 
period of 5 s or longer.  
 
 Pole Test 
The pole test assesses motor agility and bradykinesia (Rial et al., 2014), the impaired ability 
to move the body or limbs in a coordinated manner on command. Mice were placed head-
upward on the top of a vertical rough-surfaced pole (diameter: 10 mm; height: 50 cm). The 
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base of the pole was positioned within the home cage, and mice were tasked to orientate 
themselves downwards and descended the pole completely. Three acclimatisation trials were 
conducted the day prior to testing by placing the mouse head-downward at the top of the pole. 
The total time (in seconds) taken to orientate downward and descend the pole was recorded 
for three separate tests per animal, and an average of these was used in subsequent 
analyses. Videos were taken per animal and are available upon request.  
 
 Micro-Echocardiography 
Cardiovascular function and physiology were evaluated by echocardiography using the Vevo 
770® High Resolution Imaging System (VisualSonics, Inc., Toronto, Canada) and a 30 MHz 
RMV 707B transducer scanhead. Mice were anaesthetised non-invasively in an induction 
chamber with 5 % vol isoflurane gas mixed in 100 % O2, and then secured in a supine position 
with limbs outstretched on a heated VEVO mouse handling platform under constant 2 % vol 
isoflurane gas. A temperature probe was inserted rectally to monitor body temperature. Heart 
rate (HR) was recorded continuously by electrocardiogram (ECG) contact pads connected to 
each paw (see Fig. 2.9 D. for a representative trace). The chest hair of each mouse was 
removed with an electrical razor followed by depilatory cream, and ultrasound gel was then 
applied. A standardized protocol was followed by Stephen Moore (Research Assistant, Nick 
Morrell Laboratory, University of Cambridge, UK) to systematically image and measure 
various parameters from parasternal short axis (Fig 2.9 A.) and long axis (Fig 2.9 B.) views, 
and an apical four-chamber view (Fig 2.9 C.) in the pulsed-wave (PW) doppler or motion (M) 
modes, as previously described (Gao et al., 2011). Mice were then cleaned of any gel or 
residual tape, woken up with exposure to ambient air in a recovery cage, and returned to their 
home cages. Aortic ejection time (AET) (ms), left ventricle (LV) myocardial performance index 
(MPI), mitral valve (MV) atrial (A) and early (E) peak wave flows (mm/s), MV E/A peak ratio, 
right ventricular outflow tract (RVOT) mean velocity (VTI) (mm/s), RVOT pressure gradient 
(mmHg), cardiac output (CO) (ml/min), ejection fraction (EF) (%), fraction shortening (FS) (%), 
HR (bpm), stroke volume (SV) (μl), and volumes expelled in diastole and systole (V;d, V;s) 
(μl) were calculated by the Vevo LAB and Auto LV Analysis software packages (VisualSonics). 






Figure 2.9. Views used for micro-echocardiography and a representative ECG trace.  
 
Echocardiography was performed using the Vevo 770® High Resolution Imaging System 
(VisualSonics, Inc., Toronto, Canada) and a 30 MHz RMV 707B transducer scanhead. 
Imaging was performed on 3- to 12-month old mice, as previously described (Gao et al., 2011), 
to obtain parasternal (A.) short axis and (B.) long axis views, as well as an (C.) apical four-
chamber view, per animal. AV = aortic valve, LA = left atrium, LV = left ventricle, MV = mitral 
valve, RA = right atrium, RV = right ventricle, and TV = tricuspid valve. (D.) A representative 
wildtype murine ECG trace for the C57Bl/6J strain shows each discrete segment of a heart 
beat starting with the P wave, indicating atrial depolarization and contraction, followed by the 
QRS complex, correlating with depolarisation of the ventricles and ventricular contraction, the 
J-point at which ventricular depolarisation finishes, and finally, the T wave, which marks 
ventricular repolarisation. The time intervals between any of these events is denoted by the 
corresponding letters, as specified below the trace; abnormal interval values are readily used 





 Preparation of Murine Tissues for Histological & Histochemical Analyses 
Preparation of tissues and subsequent anatomical, histological and histochemical analyses 
were performed primarily by Raffaele Cerutti, with assistance by Dr. Aurelio Reyes. 
 
2.5.9.1 Tissue Preparation and Processing for Skeletal Muscle  
All histological and histochemical studies for skeletal muscle samples were performed on 
murine gastrocnemius muscles, snap-frozen by immersion in isopentane that had been cooled 
with liquid nitrogen. Samples were stored at -80 oC until use. For preparation of sections, each 
sample was mounted onto a specimen disk with optimal cutting temperature compound, and 
sectioned at to 8 μm thickness with a cryostat at -20 oC. Sections were then subjected to one 
of four histological methods, as detailed below. 
 
2.5.9.1.1 Haematoxylin and Eosin (H&E)  
H&E staining is the most common histological method that shows overall structure of a tissue 
in relation to its composite fibres, the intracellular distribution of nuclei, and the presence of 
fibrous and adipose cells, inflammatory cells and vacuoles, or vascular and neural 
components. Nuclei are stained blue, muscle fibres pink and the connective tissues a lighter 
pink. Sections were placed in Mayer’s haematoxylin for 5 min, rinsed with tap water for 3 min, 
and then placed in 1 % eosin-Y solution for 15 secs. Sections were briefly washed with tap 
water, and then dehydrated with a series of ascending alcohol concentrations (70 – 100 %). 
Finally, stained sections were cleared in xylene and mounted with dibutylphthalate polystyrene 
xylene (DPX), a synthetic non-aqueous mountant. 
 
2.5.9.1.2 Nicotinamide Adenine Dinucleotide-Tetrazolium Reductase (NADH-TR)  
For the study of NADH reductase activity in sectioned skeletal muscle samples, nitroblue 
tetrazolium (NBT) was used as an electron acceptor, which produces a deep blue final colour 
at the site of enzymatic activity. The intensity of the signal produced by the NBT histochemical 
reaction is a reflection of the number of NADH-metabolising mitochondria within a fibre. This  
produces a characteristic checkboard pattern of fibre types. It is important to note that the 
sarcoplasmic reticulum is also stained during this process. Sections were incubated in a damp 
atmosphere for 1 h at 37 oC in 10 ml of NADH-TR incubation medium (1 mg/ml NADH and 1 
mg/ml NBT in 200 mM Tris-HCl buffer (pH = 7.4)). Sections were then briefly rinsed in tap 
water, dehydrated with a series of ascending alcohol concentrations, and finally, cleared with 




2.5.9.1.3 Succinate Dehydrogenase (SDH)  
SDH histochemistry was also performed with NBT as an electron acceptor. Sections were 
incubated in a damp atmosphere for 30 min at 37 oC in 5 ml of SDH incubation medium (35.2 
mg/ml succinate, 1.22 mg/ml NBT, 61 μg/ml PMS and 65 μg/ml sodium azide in 100 mM 
sodium phosphate buffer (pH = 7.0)). Sections were briefly rinsed in tap water, dehydrated 
with a series of ascending alcohol concentrations, and finally, cleared with xylene and 
mounted with DPX. 
 
2.5.9.1.4 Cytochrome c Oxidase (COX) 
For the histochemical evaluation of COX activity, diaminobenzidine (DAB) was used as an 
electron acceptor to produce a brown end product for visualisation. The COX histochemical 
reaction reveals differences in mitochondrial number and their relative distribution in different 
fibre types as well as demonstrates whether certain fibres are devoid of COX activity. Sections 
were incubated in a damp atmosphere for 40 min at 37 oC in COX incubation medium (5 μM 
DAB and 100 μM cytochrome c in 100 mM sodium phosphate buffer (pH = 7.4)). Sections 
were rinsed in tap water, dehydrated with a series of ascending alcohol concentrations, 
cleared with xylene and mounted with DPX. 
 
2.5.9.2 Tissue Preparation and Processing for Brain, Heart, Liver, and Kidney 
Formaldehyde, in the form of 10 % neutral buffered formalin (NBF), is the most common 
fixative for the majority of histopathological analyses. Formalin stabilizes cell structures by 
introducing covalent crosslinks between proteins. In this work, mice were anesthetised by 
intraperitoneal injection of Euthasol® (390 mg/ml pentobarbital and 50 mg/ml sodium 
phenytoin) (Esteve, Barcelona, Spain). Perfusion was performed through the circulatory 
system. Each mouse was first exsanguinated with phosphate-buffered saline (PBS) and then 
perfused with NBF. The tissues were then dissected and further fixed in NBF for at least 48 
hours. Hearts from non-perfused mice were excised and fixed by long-term immersion in NBF. 
Tissues were processed with a Leica ASP300S Tissue Processor using either the “Small” 
(Table 2.26) or “Biopsy” (Table 2.27) protocols and infiltrated with Tissue Infiltration Medium 
paraffin (Leica). All sections were cut on a Leica RM2245 semi-automated rotary microtome 
to a thickness of 4 µm. After drying, the sections were stained with H&E, picrosirus red or 




Table 2.26. Small Protocol for the Leica ASP300S Tissue Processor 
 
Station Solution Duration Temperature Pressure/vacuum 
1 70 % ethanol 30 min RT yes 
2 80 % ethanol 30 min RT yes 
3 95 % ethanol 30 min RT yes 
4 95 % ethanol 30 min RT yes 
5 100 % ethanol 30 min RT yes 
6 100 % ethanol 30 min RT yes 
7 100 % ethanol 30 min RT yes 
8 Xylene 30 min RT yes 
9 Xylene 1 h RT yes 
10 Paraffin 30 min 60 oC yes 
11 Paraffin 30 min 60 oC yes 
12 Paraffin 1 h 60 oC yes 
 
 
Table 2.27. Biopsy Protocol for the Leica ASP300S Tissue Processor 
 
Station Solution Duration Temperature Pressure/Vacuum 
1 70 % ethanol 10 min RT no 
2 80 % ethanol 15 min RT no 
2 95 % ethanol 15 min RT no 
4 95 % ethanol 15 min RT no 
5 100 % ethanol 15 min RT no 
6 100 % ethanol 15 min RT no 
7 Xylene 10 min RT no 
8 Xylene 10 min RT no 
9 Xylene 10 min RT no 
10 Paraffin 15 min 60 oC yes 
11 Paraffin 15 min 60 oC yes 
12 Paraffin 15 min 60 oC yes 
 
 
2.5.9.2.1 Haematoxylin and Eosin (H&E) Staining 
Sections were deparaffinized, hydrated, placed in Mayer’s haematoxylin for 15 min, rinsed 
with tap water for 3 min, and then placed in 1 % eosin-Y solution for 35 s. Sections were briefly 
washed with tap water, dehydrated with a series of ascending alcohol concentrations, cleared 
in xylene and mounted with DPX. 
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2.5.9.2.2 Picrosirius Red Staining 
Sirius red F3B (C.I. 35780) is a strong anionic dye that stains collagen by reacting with basic 
groups present in the collagen molecule (Junqueira, Bignolas and Brentani, 1979). A solution 
in picric acid provides red staining of collagen and a yellow background. Sections were 
incubated with 0.1 % Sirius red F3B in a saturated solution of picric acid for 1 h at room 
temperature. Sections were then washed with 0.5 % acetic acid, dehydrated, cleared and 
mounted with DPX. 
 
2.5.9.2.3 Pathogreen Staining 
Pathogreen stain™ (Catalogue Number: 80027, Biotium) is an anionic green histofluorescent 
dye that stains degenerating neurons by an unknown mechanism similarly to Fluoro-Jade® 
(Schmued and Hopkins, 2000). Paraffin sections were de-waxed and hydrated. Slides were 
incubated in a 0.06 % potassium permanganate solution for 10 min, rinsed twice with distilled 
water and further incubated in distilled water for 2 min. Slides were then incubated for 10 min 
in 1X Pathogreen™ staining solution (1:1000 stock in 0.1 % acetic acid), rinsed three times 
for 1 min each with distilled water and then air-dried on a slide warmer at 50-60 oC for at least 
5 min. Finally, sections were cleared in xylene and mounted with DPX. 
 
2.5.9.2.4 Immunohistochemistry (IHC) 
IHC is an antibody-based method that allows for visualisation of the specific distribution and 
localization of biomarkers and differentially expressed proteins in different parts of a tissue 
section. There are numerous IHC techniques that can be used to localize and demonstrate 
tissue antigens. The polymer chain two-step indirect method was employed here (NovolinkTM 
Polymer Detection System, Leica Biosystems) for unconjugated primary antibodies against 
GFAP (Sigma-Aldrich 1:1000), ubiquitin (Abcam 1:5000), CD68 (Abcam 1:100), CNPase 









 Adeno-Associated Virus (AAV) Transduction 
Systemic delivery of recombinant AAV serotype 9 (AAV9) vectors in adult mice was achieved 
by tail-vein intravenous injection to produce robust, long-term expression of either 1) the 
human wild-type TMCO6 cDNA sequence (NM_018502) (AAV WT), or 2) the human patient 
homozygous recessive variant (NM_018502: c.271C>T) (AAV MUT), both with a downstream 
HA epitope tag (see section 2.2.9 for the peptide sequence). Two vectors, AAV2-HSA-
TMCO6-cDNA-HA and AAV2-HSA-TMCO6_MUT-cDNA-HA (Fig. 10), were kindly generated 
and provided by Dr. Aurelio Reyes (Senior Investigator Scientist, Mitochondrial Medicine 
Laboratory, MRC MBU, University of Cambridge, UK). AAV9 particles were synthesized by 
the AAV Vector Core of the Telethon Institute of Genetics and Medicine (TIGEM, Naples, Italy) 
and suspended in storage buffer (1X PBS with 350 mM NaCl + 5 % D-Sorbitol (both from 
Sigma-Aldrich®, UK)) until use. A titre of 4.5 x 1011 genome copies was administered by tail-
vein intravenous injection by Dr. Carlo Viscomi (Senior Investigator Scientist, Mitochondrial 
Medicine Laboratory, MRC MBU, University of Cambridge, UK) to weaned KO or WT mice at 
5-8 weeks of age. Mice were immobilised, and blanching of the tail-vein was used to verify 
successful injection. This process led to the creation of 4 distinct transgenic groups: Tmco6-/- 
(AAV WT), Tmco6-/- (AAV MUT), Tmco6+/+ (AAV WT), and Tmco6+/+ (AAV MUT). Mice were culled and tissues 






Figure 2.10 Plasmid used for recombinant AAV9 injection in adult mice.  
 
pAAV-HSA-TMCO6-cDNA-HA (AAV WT) or a mutant variant form, pAAV2-HSA-TMCO6pat-
cDNA-HA (AAV MUT), were used for systemic delivery of 4.5 x 1011 genome copies of either 
recombinant AAV9 variant to weaned KO (TMCO6-/-, n = 4 per group) and WT (TMCO6+/+, n 
= 3 per group) mice, aged 5-8 weeks. Each plasmid contains a 3’ poly-adenosine (poly A) tail 
from bovine growth hormone (bGH), flanked by AAV2-derived inverted terminal repeats 
(ITRs), and is under the control of a hybrid cytomegalovirus (CMV) and lac z promoter. 
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2.6 Protein-Based Techniques  
 Determining Protein Concentration 
Protein concentrations for whole cell lysates were estimated by NanoDrop™ 8000 
Spectrophotometer (l = 280 nm) and for those derived from murine tissues, a modified version 
of the Lowry protein assay, the DC™ Protein Assay (Bio-Rad), was used. The absorbance of 
the protein samples with unknown concentration and of seven BSA standards in a 
concentration range from 0 to 2 mg/ml were measured at l= 750 nm with a SpectraMax 
Plus384 plate reader (Molecular Devices, Sunnyvale, CA, USA). The absorbances were 
plotted against the concentrations of the known standards, and the resulting calibration curve 
used to extrapolate the unknown protein concentrations by use of their absorbance values. 
 
 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2.6.2.1 Sample Preparation: Whole Cell Lysates from Cultured Cells 
Cultured cells (≥ 2 x 106 cells) were harvested by trypsinisation (Trypsin-0.5 % EDTA) in a 
sterile culture hood, washed twice with PBS and pelleted by centrifugation at RT (300 g x 5 
min). Cell pellets were lysed with 2 % n-dodecyl-β-D-maltoside (DDM) in 4 oC PBS containing 
1X cOmpleteTM mini EDTA-free Protease Inhibitor Cocktail (Roche, UK). Lysates were mixed 
by continuous rotation at 4 ºC for 15 min using an PTR-35 orbital shaker (Grant Bio™, UK) 
and then centrifuged (20,000 x g for 20 min at 4 ºC). Supernatants, containing solubilised 
cellular proteins, were transferred to sterile 1.5 ml Eppendorf tubes and protein concentration 
determined (see section 2.6.1). Samples were stored at -20 oC until use. 
 
2.6.2.2 Sample Preparation: Homogenates from Frozen Murine Tissues 
Frozen murine tissues were weighed and ~50 mg pieces cut finely with a scalpel. Tissue 
pieces were suspended in 10 volumes cold organ lysis buffer (pH = 7.4, Table 2.28) and 
homogenised by the gentleMACS™ Dissociator (Miltenyi Biotec, Bergisch Gladbach, 
Germany) with the recommended setting per tissue type. Following this, a ‘soft spin’ at (500 g 
for 5 min at 4 oC) was performed to remove extracellular fibrous debris. Supernatants were 
transferred to sterile 1.5 ml Eppendorf tubes and protein concentration determined (see 





Table 2.28. Organ lysis buffer for murine tissue homogenate preparation 
 
 
Reagent Final concentration 
0.5 M HEPES, pH = 7.4 50 mM 
10 % Triton X-100 1 % 
100 mM sodium orthovanadate (Na3VO4·2H2O) 10 mM 
1M sodium fluoride (NaF) 100 mM 
0.5 M EDTA 10 mM 
20 % SDS 0.1 % 
5M sodium chloride (NaCl) 50 mM 
200 mM PMSF 2m M 
1 tablet PhosSTOP™ phosphatase inhibitor (Roche) 1X 
 
2.6.2.3 Running SDS-PAGE 
Cell-derived protein lysates (10 – 40 μg) were mixed with an equal volume of 2X Laemmli 
Loading Dye (100 mM Tris-HCl (pH = 6.8), 2 % w/v SDS, 20 % w/v glycerol, 10 % w/v β-
mercaptoethanol, and 100 μg/ml bromophenol blue (all from Sigma-Aldrich®)), and incubated 
for 5 min at RT. Tissue-derived homogenates (5 – 10 μg) were mixed with 10 X NuPAGE™ 
sample reducing agent and 4X NuPAGE™ LDS sample buffer (Invitrogen™), and incubated 
for 10 min at 70 oC. Both cell- and tissue- derived protein samples were separated under 
denaturing conditions by SDS-PAGE using either 12 % or 4-12 % gradient precast 
polyacrylamide NuPAGE® Bis-Tris gels (Invitrogen™). NuPAGE® MOPS SDS Running Buffer 
(1X: 50 mM MOPS, 50 mM Tris Base, 0.1 % SDS, 1 mM EDTA, pH 7.7) was used for 
separation of proteins >20 kDa in size; NuPAGE® MES SDS Running Buffer (1X: 50 mM MES, 
50 mM Tris Base, 0.1 % SDS, 1 mM EDTA, pH 7.3) was used for the separation of proteins ≤ 
20 kDa in size (both from Invitrogen™). In all cases, gels were run at 120V for 1-2 h at RT, 
with 10 μl Precision Plus Protein™ All Blue Standard (Bio-Rad, UK) for size comparison. 
 
 Blue Native Gel Electrophoresis (BN-PAGE) 
BNGE uses a mild non-ionic detergent to solubilise proteins and intact protein complexes 
embedded within biological membranes (Wittig, Braun and Schägger, 2006). In this work, 
mitochondrial respiratory complexes were analysed from mitoplasts from freshly harvested 
cultured cells or snap-frozen murine tissues.  
 
2.6.3.1 Sample Preparation: Mitoplasts from Cultured Cells 
Plasma membranes of cultured cells were permeabilised with 8 mg/ml digitonin (DIG) for 10 
minutes at 4 oC. Cytosolic proteins were removed by two cycles of 1 ml PBS washes and 
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centrifugation (10,000 x g for 5 min at 4oC). Proteins embedded within the mitochondrial IM 
were suspended in 50 mM Bis-Tris-HCl (pH = 7.0) and 1.5 M aminocaproic acid, and 
solubilised with 1 % DIG or 2 % DDM in PBS, as previously described (Calvaruso, Smeitink 
and Nijtmans, 2008). Finally, membrane fragments and non-soluble material were pelleted by 
centrifugation (18,000 x g for 30 min at 4oC) and discarded. Supernatants were either prepared 
immediately or stored at -80 oC. 
 
2.6.3.2 Sample Preparation: Mitoplasts from Frozen Murine Tissues  
Frozen murine tissue (~ 50 mg) were homogenised in 10 volumes of Medium A (320 mM 
sucrose, 1mM EDTA, 10mM Tris-Hcl, pH 7.4) in a 5 ml Dounce-type glass homogeniser using 
a manually-driven glass or Teflon pestle, 5-15 strokes depending on the tissue type. The 
homogenates were centrifuged (800 x g for 5 minutes at 4 ºC) to remove nuclei and 
extracellular debris. The supernatant was collected and centrifuged at higher speed (9,000 x 
g for 10 min at 4 ºC) to obtain mitochondria-enriched pellets, which were resuspended in 
equivalent volumes of Medium A. Protein concentration was determined per sample (see 
section 2.6.1) and mitochondria were pelleted again (9,000 x g for 5 minutes at 4 ºC.), 
followed by resuspension in volumes of 1.5 M aminocaproic acid and 50 mM Bis-Tris/HCl (pH 
= 7) to obtain a final protein concentration of 10 mg/ml. Samples were solubilised with 1.6 mg 
of DDM or 4 mg of DIG per mg of protein, incubated on ice for 5 mis, and centrifuged (18,000 
x g for 30 min at 4 ºC). Supernatants were either prepared immediately or stored at -80 oC. 
 
2.6.3.3 First (1D) and Second (2D) Dimension BN-PAGE 
Supernatants from solubilised mitoplasts were mixed with sample buffer (750 mM 
aminocaproic acid, 50 mM Bis-Tris, 0.5 mM EDTA, and 5 % Coomassie® G 250 (Serva, UK)) 
to generate BN-PAGE samples. These samples were resolved by 3-12 % gradient Novex® 
NativePAGE gels (Invitrogen™), run for 1 h at 150 V in Cathode Buffer A (50 mM tricine, 15 
mM Bis-Tris (pH = 7.0), and 0.02 % Coomassie® G 250), and further run for 1-2 h at 200 V 
(~8mA) in Cathode Buffer B (50 mM Tricine, 15 mM Bis-Tris (pH = 7.0), and 0.002 % 
Coomassie® G 250). In the case of 1D BN-PAGE, after the run, samples were electro-
transferred to methanol-activated PVDF membranes and immunoblotted (as described in 
sections 2.6.4 and 2.6.5). For 2D BN-PAGE, individual lanes were cut using a scalpel and 
incubated with denaturing solution (1 % β-mercaptoethanol and 1 % SDS) for 1 h at RT. 
Treated lanes were inserted into individual 1.0 mm x 1D wells of 4-12 % gradient NuPage® 





 Western Blotting 
 Proteins separated by SDS-PAGE, 1D-BNGE and 2D-BNGE were electroblotted to methanol-
activated polyvinyl difluoride (PVDF) membranes via wet electrotransfer: 100 V for 1 h at 4 oC. 
Electrotransfer of SDS-PAGE gels (pre-cast and from the NuPAGE range (Invitrogen™)), 
including 2D-BNGE gels, was performed using 1X Tris-Glycine Transfer Buffer (50 ml 20X 
Tris-Glycine stock buffer (30.3 g Tris, 114.2 g Glycine), 200 ml Methanol, 1.25 ml 20 % SDS 
and filled to 1 L with dH20) and the Mini-PROTEAN® Tetra Cell system (Mini Trans-Blot® 
Module, Bio-Rad, UK). 1D BNGE gels (pre-cast and from the NativePAGE range 
(Invitrogen™)) were electro-transferred using 1X bicarbonate transfer buffer (10 mM NaHCO3 
and 3 mM NaCO3). 
 
 Immunodetection 
 Membranes were blocked with 5 % milk in PBS-0.1 % Tween® 20 (NBS Biologicals, UK) 
(PBST) for 1 h, washed three times with PBST (for 10 min, 5 min and 5 min intervals, 
respectively) and immobilised proteins were immunodetected by primary antibodies (full list in 
Table 2.29). Each antibody was diluted in 3 % BSA, and incubated O/N at 4 oC. Membranes 
were washed as above and secondary antibody detection of the primary antibody was 
performed using anti-mouse (Catalogue Number: W4021, Promega), anti-rabbit (Catalogue 
Number: W4011, Promega) or anti-rat antisera (Catalogue number SC-2006, Santa Cruz 
Biotechnology Inc., Dallas, Texas, USA), as appropriate, with each conjugated to the enzyme 
horseradish peroxidase (HRP) and diluted 1:2,000 in 0.1 % milk. Membranes were washed 
three times with PBST (for 10 min, 5 min and 5 min intervals, respectively) and Amersham 
ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences, UK) were used to 
detect the HRP signal by chemiluminescence, as per manufacturer’s instructions. Bands per 
protein signal were visualised using X-ray film (Fujifilm, Tokyo, Japan) for different lengths of 
exposure and developed using an automated film processor (ECOMAX, Protec, Germany), or 
imaged digitally with the Amersham Imager 680 blot and gel imager (GE Healthcare, Bio-




Table 2.29. Antibodies used for immunodetection 
 
Antigen Type Dilution Company Catalogue Number 
ACAD9 Mouse polyclonal 1:1,000 Abcam ab72655 
ACO2 Mouse monoclonal 1:10,000 Abcam 6F12BD9 
AIF Mouse monoclonal 1:10,000 Santa Cruz sc-13116 
ATP5A Mouse monoclonal 1:1,000 Abcam ab110273 
β-ACTIN Mouse monoclonal 1:5,000 Abcam ab8224 
β-TUBULIN Rabbit polyclonal 1:10,000 ProteinTech 100094-1-AP 
COA7 Rabbit polyclonal 1:1,000 Atlas Antibodies HPA028154 
COX4 Mouse monoclonal 1:3,000 Abcam ab14744 
COX5A Mouse monoclonal 1:1,000 Abcam ab110262 
COX5B Mouse monoclonal 1:1,000 Abcam ab110263 
CS Rabbit polyclonal 1:1,000 Abcam ab96600 
CYT C Mouse monoclonal 1:1,000 ProteinTech 66264-1-Ig 
ETFB Rabbit polyclonal 1:1,000 Abcam ab232815 
ECSIT Rabbit polyclonal 1:1,000 Abcam ab21288 
FLAG Rabbit polyclonal  1:1,000 Sigma Aldrich F7425 
FOXRED1 Rabbit polyclonal 1:1,000 Invitrogen PA5-61178 
GAPDH Mouse monoclonal 1:5,000 Abcam ab8245 
GRP75 Mouse monoclonal 1:1,000 Abcam ab2799 
HA Rat monoclonal 1:1,000 Roche 11 867 431 001 
LRPPRC Rabbit polyclonal 1:1,000 Abcam ab97505 
MT-CO1 Mouse monoclonal 1:1,000 Abcam ab14705 
MT-CO2 Mouse monoclonal 1:1,000 Abcam ab110258 
NDUFA2 Rabbit polyclonal 1:1,000 Atlas antibodies HPA035933 
NDUFA3 Rabbit polyclonal 1:200 Invitrogen PA5-61390 
NDUFA9 Mouse monoclonal 1:1,000 Invitrogen 20C11B11B11 
NDUFA9 Mouse monoclonal 1:1,000 Abcam ab14713 
NDUFA10 Rabbit polyclonal 1:1,000 Invitrogen PA5-22348 
NDUFA11 Rabbit polyclonal 1:1,000 Novus biologicals NBP2-58831 
NDUFA12 Rabbit polyclonal 1:1,000 Sigma SAB2701046 
NDUFAB1 Rabbit monoclonal 1:1,000 Invitrogen PA5-30099 
NDUFB3 Rabbit monoclonal 1:1,000 Abcam ab202585 
NDUFB8 Mouse monoclonal 1:1,000 Abcam ab110242 
NDUFB11 Rabbit monoclonal 1:1,000 Abcam ab183716 
NDUFAF1 Rabbit polyclonal 1:1,000 Abcam Ab198186 
NDUFAF2 Rabbit polyclonal 1:1,000 Invitrogen PA5-63019 
NDUFAF3 Rabbit polyclonal 1:1,000 Invitrogen PA5-72636 
NDUFS1 Rabbit polyclonal 1:1,000 Abcam ab102552 
NDUFS2 Mouse monoclonal 1:1,000 Abcam ab110249 
NDUFS3 Mouse monoclonal 1:1,000 Abcam ab110246 
NDUFS6 Rabbit Polyclonal 1:1,000 Abcam ab230464 
NDUFS8 Mouse monoclonal 1:1,000 Santa Cruz Sc-515527 
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NDUFV1 Rabbit polyclonal 1:1,000 Abcam ab203208 
POLG Rabbit monoclonal 1:1,000 Abcam ab128899 
SDHA Mouse monoclonal 1:1,000 Abcam ab14715 
SDHB Mouse monoclonal 1:10,000 Abcam ab14714 
SF2 Rabbit polyclonal 1:1,000 Abcam ab38017 
SOD2 Mouse monoclonal 1:2,000 Abcam ab16956 
TIMM23 Goat polyclonal 1:1,000 Santa Cruz Sc-14046 
TMCO6 Rabbit polyclonal 1:1,000 ProteinTech 20117-1-AP 
TMCO6 Rabbit Polyclonal 1:1,000 Novus Biologicals NBP1-57660 
TOMM20 Rabbit monoclonal 1:10,000 Abcam ab186734 
TOMM70 Mouse polyclonal 1:1,000 Abcam ab89624 
TUBB Mouse monoclonal 1:1,000 Sigma-Aldrich WH020 
UQCRC1 Rabbit polyclonal 1:1,000 Abcam ab96333 
UQCRC2 Mouse monoclonal 1:2,000 Abcam ab14745 




























 Mitochondrial Isolation 
 
2.6.6.1 Sample Preparation from Cultured Cells  
About 4 x 108 cultured cells were harvested by trypsinisation (Trypsin-0.5 % EDTA) and 
washed with 5 ml of 4 oC PBS twice (300 x g for 5 min at RT). The resulting pellet was 
resuspended in an equivalent volume of hypotonic buffer (IB 0.1X: 3.5 mM Tris-HCl, pH 7.8, 
2.5 mM NaCl, 0.5 mM MgCl2) so that 1 g cells = 1ml hypotonic buffer. Cells were homogenised 
with a motor-driven Teflon pestle (~1000 rpm for 10-15 strokes) at 4 oC. Immediately following 
this, 1/10th of the initial volume of cells of hypertonic buffer (IB 10X: 350 mM Tris–HCl, pH 7.8, 
0.25 M NaCl, 50 mM MgCl2) was added to make the solution isotonic. Homogenates were 
transferred to a 15 ml Falcon tube and centrifuged (1,000 x g for 5 min at 4 °C) in order to 
pellet unbroken cells, extracellular debris and nuclei. The supernatant, containing intact 
mitochondria, was transferred to a clean 15 ml Falcon tube and the remaining pellet was 
homogenised again, as above. Supernatants from both homogenisations were pooled and 
centrifuged once more to remove remaining extracellular debris and nuclei (1,000 x g for 5 
min at 4 °C). Supernatants were transferred to four 1.5 ml Eppendorf tubes and mitochondria 
were then pelleted by centrifugation in a refrigerated microfuge (13,000 rpm, 2 min at 4 °C). 
The supernatant obtained after this spin contained cytosolic proteins and was kept for 
posterior analysis for both sub-mitochondrial localisation studies (section 2.6.7) and 
immunocapture (section 2.6.8). Pellets were washed 4-5 times with 1 ml cold PBS (13,000 
rpm for 2 min at 4 °C), and mitochondria resuspended in filtered 4 oC Medium A (0.32 M 
sucrose, 1 mM EDTA, and 10 mM Tris-HCl, pH 7.4) for sub-mitochondrial localisation studies, 
and in sterile 1X sterile PBS for immunocapture.  
 
2.6.6.2 Sample Preparation from Frozen Murine Tissues  
Cut pieces of frozen mouse organs (~ 50 mg) were weighed, and minced finely with sterilised 
surgical scissors on a platform cooled to 4 oC on top of ice.  Tissue pieces were suspended in 
10 volumes of Medium A (see section 2.6.6.1). A glass Elvehjem potter, cooled in ice, and a 
Teflon pestle was used to homogenate liver and brain samples; a glass pestle was used 
instead for heart and skeletal muscle. Homogenisation was performed manually until no tissue 
pieces remained per tissue type (6-15 strokes depending on the tissue softness), performed 
on ice. Homogenates were transferred to a 15 ml Falcon tube and centrifuged (1,000 x g for 
5 min at 4 °C) to remove unbroken cells, extracellular debris and nuclei. The supernatant, 
containing intact mitochondria, was transferred to a clean 15 ml Falcon tube and the remaining 
pellet was homogenised again, as above. Supernatants from both homogenisations were 
pooled and centrifuged once more to remove remaining extracellular debris and nuclei (1,000 
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x g for 5 min at 4 °C). Supernatants were transferred to eight 1.5 ml Eppendorf tubes and 
mitochondria were then isolated by centrifugation in a refrigerated microfuge (13,000 rpm for 
2 min at 4 °C). The supernatants were discarded and pellets washed twice with 1 ml cold PBS 
(13,000 rpm, 2 min at 4 °C).  
 
 Sub-Mitochondrial Localisation Studies 
Mitochondria from cultured HEK 293T cells were isolated as described in section 2.6.6.1, and 
the mitochondrial preparations were portioned into multiple 200 µg aliquots suspended to a 
final volume of 200 µl with Medium A (see section 2.6.6.1). Two identical aliquots were treated 
with increasing concentrations of DIG (0, 75, 150, 300, 600 and 1200 µg/ml) for 10 min at 4 
°C. Proteins in the IMS or IMM facing the IMS become more accessible to proteolysis with the 
increasing concentrations of DIG; IMM proteins facing the matrix and matrix-localising proteins 
would be spared in these treatments. One aliquot of each pair was immediately centrifuged 
(9,000 x g for 10 min at 4 ºC) following DIG incubation, and supernatants were collected while 
the pellets were washed twice with 200 µl Medium A. The second aliquot was further incubated 
with 150 µg/ml of trypsin for 30 min at RT, to degrade all unprotected, solubilised proteins. 
Proteolysis was halted by addition of a protease inhibitor cocktail (cOmpleteTM Protease 
Inhibitor Cocktail, Roche) and samples were centrifuged (13,000 x g for 2 min at 4 ºC) and 
washed twice with 1X PBS. All pellets were finally solubilised in 1 % SDS and the presence 
or absence of proteins of interest in each of the treated samples was analysed by SDS-PAGE 
(section 2.6.2), Western blotting (section 2.6.4) and immunodetection (section 2.6.5). 
 
 Immunoprecipitation 
Mitochondrial isolation from cultured cells was performed as per section 2.6.6. ‘Whole cell 
lysates’ (WC) and a ‘cytosolic fraction’ (C) were collected for each cell line per experiment. 
Mitochondrial pellets were resuspended in 500 µl 1X PBS, and protein quantification 
performed using the DC assay (see section 2.6.1). Mitochondria were pelleted (12,500 x g 
for 2 min at 4 oC) and resuspended with a relative volume of cold PBS to achieve a final protein 
concentration of 5.5 mg/ml. An equivalent amount for 0.5 mg protein was removed and 
designated the ‘mitochondrial fraction’ (M). A 50X protease inhibitor cocktail (cOmpleteTM 
Protease Inhibitor Cocktail, Roche) was added per suspension, and for every 180 μl of 
solution, 20 µl 10 % DDM was added. Solutions were incubated on ice for 30 min to solubilise 
membrane-embedded proteins and centrifuged at high speed (20,000 x g for 30 min at 4 oC) 
in a tabletop microfuge. Supernatants, containing all mitochondrial-localising proteins, were 
incubated O/N at 4 oC on a rotator with ~100 µl of a 1:2 antibody-bead slurry using one of the 
following: 1) the Complex I Immunocapture Kit (Abcam ID: ab109711C, Abcam, Cambridge, 
UK), 2) anti-TMCO6 polyclonal rabbit antibody (Proteintech ID: ID: 20117-1-AP, Proteintech), 
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or 3) anti-HA Pierce™ magnetic beads (Catalogue Number: 88836, Thermo Scientific™). The 
anti-TMCO6 antibody was crosslinked to magnetic beads at least 24 h prior to use by means 
of the Pierce Crosslink Magnetic IP/Co-IP kit (Catalogue Number: 88805, Thermo 
Scientific™), as per manufacturer’s instructions.  
 
For mitochondrial suspensions incubated with the Complex I immunocapture kit, beads were 
incubated with solubilised mitochondrial protein for at least 18 h and then pelleted (500 x g for 
1 min at 4 oC). An aliquot of the bead ‘supernatant’ (S) was collected, as was a portion of the 
‘beads’ (B). Beads were washed with 1 ml wash buffer ( X PBS + 0.5 % DDM) and pelleted 
(500 x g for 1 min at 4 oC). This process was repeated 4 to 5 times and wash fractions collected 
and labelled sequentially (W1-W[X]). Bound proteins were then suspended in elution buffer 
(1X PBS + 1 % SDS), mixed for 10 min at RT with constant agitation using a vortex, and beads 
were pelleted by centrifugation (500 x g for 1 min at 4 oC). Eluted protein within the supernatant 
was collected and labelled elution 1 (E1). A second elution was performed as above and the 
supernatant labelled elution 2 (E2). Protein concentrations for all collected fractions were 
determined by DC assay (see section 2.6.1). 
 
For anti-TMCO6 antibodies crosslinked to Pierce™ magnetic beads, beads were incubated 
with solubilised mitochondrial protein for at least 18 h and then pelleted (500 x g for 1 min at 
4 oC). An aliquot of the B and S fractions were collected. Washes were then performed by 
adding 1 ml wash buffer (same as for the CI immunocapture kit), and placing tubes into a 
magnetic tube rack for 1 min at RT. Supernatants were collected and labelled W1-W[X] for up 
to five washes. In order to avoid denaturing conditions, low-pH glycine was used for elution; 
this limited the pull down of unspecific IgG’s in the eluates and limited the likelihood of 
removing the crosslinked ‘bait’ antibodies by agitation. Tubes were incubated on ice for 20 
min without mixing using 200 µl 0.1M glycine (pH = 2). A second elution was performed as 
above and the supernatant labelled elution 2 (E2). Protein concentrations for all collected 
fractions were determined by DC assay (see section 2.6.1). 
 
For the anti-HA Pierce™ crosslinked magnetic beads, an aliquot of the B and S fractions were 
collected after at least 18 h incubation on a rotator at 4 oC. A magnetic tube rack was used for 
all washes, as detailed above. Elution was performed using 15 µl of anti-HA competing peptide 
(100 µg mixture, Catalogue ID: AB3254, Milipore, Merck), amino acid sequence: 
YPYDVPDYA, incubated for 20 min on ice, with the resulting eluate labelled ‘E1’. A second 
elution (E2) was performed with 100 µl 0.1 M glycine (pH = 2) (20 min on ice) to ensure that 




The presence or absence of proteins in the eluates was analysed by SDS-PAGE (section 




2.7 Mitochondrial Respiratory Chain Functional Assays  
 Mitochondrial Respiratory Chain Enzymatic Activity Assays 
Specific activities (µM of substrate consumed per minute) of the mitochondrial respiratory 
chain complexes CI-CIV, and that of matrix-localising enzyme citrate synthase (CS), was 
measured spectrophotometrically for DIG-treated cells and homogenised frozen murine tissue 
samples. Protein concentration and path length per each 200 µl reaction was also determined 
spectrophotometrically; these values, the known extinction coefficient (ε) of each reaction, and 
the determined absorbances (l) per reaction were used to calculate the specific biochemical 
activities of each sample using the Beer-Lambert law: 
 
Δ𝐴𝑏𝑠	 × 	𝑡𝑜𝑡𝑎𝑙	𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛	𝑣𝑜𝑙𝑢𝑚𝑒	(𝑚𝑙)
𝜖 × 𝑠𝑎𝑚𝑝𝑙𝑒	𝑣𝑜𝑙𝑢𝑚𝑒	(𝑚𝑙) ×	[𝑝𝑟𝑜𝑡](𝑚𝑔𝑚𝑙!") × 𝑝𝑎𝑡ℎ𝑙𝑒𝑛𝑔𝑡ℎ(𝑐𝑚)
 
 
The specific activities of CI-CIV were each normalised against the relative activity of CS. 
Technical replicates (n ≥ 3) were performed per sample under the same temperature and 
using the same reaction buffer. 
 
2.7.1.1 Sample Preparation from Cultured Cells 
Harvested cells were solubilised in 400 µl Buffer A (20mM MOPS, 250mM sucrose, pH 7.4) 
and an equal volume of 0.2 mg/ml DIG. Homogenates were kept on ice for 5 min and 
centrifuged (5,000 x g for 3 min at 4°C). The supernatant was discarded and the mitochondria-
enriched pellet was resuspended in 600 µl Buffer B (Buffer A + 1mM EDTA), incubated on ice 
for 5 min and centrifuged (10,000 x g for 3 min at 4 °C) to generate mitoplasts. The pellet was 
stored at −80 °C until use. Once thawed on ice, pellets were resuspended in 200 µl 10 mM 
potassium phosphate (PK) buffer (pH = 7.4) and snap frozen in liquid nitrogen and then 
thawed in a 37°C water bath three times successively to disrupt the mitochondrial membranes. 
Protein concentration was determined by DC assay, as described in section 2.6.1. Samples 
were loaded into individual wells of a 96-well plate and placed on ice. 
 
2.7.1.2 Sample Preparation from Frozen Murine Tissues 
Frozen murine tissues (~50 mg) were minced into small pieces with sterilised surgical scissors 
and then homogenised in 15 volumes of Medium A in a glass Dounce-type homogeniser using 
a manually-driven glass pestle (~15 strokes). Homogenates were centrifuged (800 x g for 5 
min at 4 °C) and supernatants were snap frozen immediately in liquid nitrogen. For the 
experiment, pellets were thawed on ice initially and then snap frozen and quickly thawed 
between liquid nitrogen and a 37°C water bath for three consecutive freeze-thaw cycles. 
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Protein concentration was determined as described in section 2.6.1, and samples were 
loaded into individual wells of a 96-well plate and placed on ice. 
 
2.7.1.3 Measuring Mitochondrial Protein Complex Activities by Spectrophotometry 
Kinetic spectrophotometric measurement of CI was performed at 30 °C (l = 340 nm) to follow 
NADH oxidation over 2 min. Oxidised NADH (NAD+) is not detectable at this wavelength so 
the ‘disappearance’ of NADH following the addition of CoQ was measured. Cell-derived 
samples were incubated in CI buffer (Table 2.30) for 2 min and tissue homogenates in the 
same buffer for 10 min prior to measurement. The CI-inhibitor rotenone was then added and 
incubated for at least 1 min, and a second measurement under the same conditions was taken 
as a baseline for all non-CI linked NADH oxidation. The difference between these values was 
calculated relative to the extinction coefficient of the reaction (εNADH340nm = 6.81 (mlnmol-1cm), 
volume and concentration of the sample, and path length through each well per measurement 
to account for any inconsistencies in pipetting. 
 
Table 2.30 CI enzymatic activity reaction buffer 
 
Reagent Reagent Manufacturer | CN Final Concentration 
PK buffer (pH = 8.0) - 20 mM 
NADH (in dH20) Roche | 10107735 0.2 mM 
Sodium azide (NaN3) (in dH20) Sigma-Aldrich® | S8032 1 mM 
BSA (in dH20 + EDTA 10 mM pH 7.4) Sigma-Aldrich® | A6003 1 mg/ml 
CoQ (in 10 % EtOH) Sigma-Aldrich® | C7956 50 µM 
Rotenone (in 25 % EtOH) Sigma-Aldrich® | R8875 5 µM 
 
 
Kinetic spectrophotometric measurement of CII was performed using the mixture detailed in 
Table 2.31. Measurement was performed at 30 °C by following the reduction rate of DCPIP 
(an electron acceptor); l= 600 nm for 2 min. εDCPIP600nm = 19 mlnmol-1cm. Addition of CoQ 
followed to measure MRC-linked CII activity in particular. 
 
Table 2.31 CII enzymatic activity reaction buffer 
 
 
Reagent Reagent Manufacturer | CN Final Concentration 
PK buffer (pH = 7) - 50 mM 
Potassium cyanide (KCN) (in dH20) Sigma-Aldrich® | 31252 1.5 mM 
2,6-Dichlorophenolindophenol (DCPIP)  Sigma-Aldrich® | D1878 0.1 mM 
Sodium succinate (in dH20) Sigma-Aldrich® | S2378 16 µM 
CoQ (in 10 % EtOH) Sigma-Aldrich® | C7956 50 µM 
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Kinetic spectrophotometric measurement of CIII was performed using the mixture detailed in 
Table 2.32 in 96-well plates at 30 °C by following the reduction of cytochrome c (electron 
acceptor); l= 550 nm for 2 min. εNADH340nm = 21 mlnmol-1cm. 
 
Table 2.32 CIII enzymatic reaction buffer 
 
 
Reagent Reagent Manufacturer | CN Final Concentration 
PK buffer (pH = 7.4) - 50 mM 
NaN3 (in dH20) Sigma-Aldrich® | S8032 1.5 mM 
BSA (in dH20 + EDTA 10 mM pH 7.4) Sigma-Aldrich® | A6003 0.1 mM 
Cytochrome c (in dH20) Sigma-Aldrich® | C7752 16 µM 
Reduced decylubiquinone (DBH2) Sigma-Aldrich® | D7911 50 µM 
 
Kinetic spectrophotometric measurement of CIV was performed using the mixture detailed in 
Table 2.33 in 96-well plates at 37 °C by following oxidation of cytochrome c (electron donor); 
l= 550 nm for 2 min. εCytc550nm = 18.5 mlnmol-1cm. 
 
Table 2.33 CIV enzymatic reaction buffer 
 
 
Reagent Reagent Manufacturer | CN Final Concentration 
90-95 % reduced cytochrome c (1.3 mg/ml) 
(in 50 mM KP buffer (pH = 7)) 
Sigma-Aldrich® | C7752 50 mM 
 
Kinetic spectrophotometric measurement of CS was performed using the mixture detailed in 
Table 2.34 in 96-well plates at 30 °C. The absorbance of thionitrobenzoic acid (TNB), the main 
reaction product of CoA and 5-dithio-bis-(2)-nitrobenzoic acid (DTNB) is proportional to the 
amount of liberated CoA and indicates the relative activity of CS; l= 412 nm for 2 min. εTNB412nm 
= 13.8 mlnmol-1cm. 
 
Table 2.34 CS enzymatic reaction buffer 
 
 
Reagent Reagent Manufacturer | CN Final Concentration 
Tris-HCl buffer (pH = 8) - 75 mM 
DTNB (in 187.5 mM Tris-HCl (pH = 8)) Sigma-Aldrich® | D8130 0.1 mM 
Triton X-100 Roche | 11332481001 0.1 % 
Acetyl-CoA Sigma-Aldrich® | A2181 0.4 mM 




 In-Gel Activity 
In-gel activity assays were utilised to visually indicate differences in mitochondrial complex 
activities for cultured cells or murine tissues, following principles first described by Zerbetto et 
al. (Zerbetto, Vergani and Dabbeni-Sala, 1997). 1D-BNGE was performed as per section 
section 2.6.3, and gels were then directly submerged in 10 ml of either CI detection solution 
(0.1 M Tris-HCl pH 7.4, 0.14 mM NADH, and 1 mg/ml nitro blue tetrazolium (NBT, Sigma-
Aldrich), or CIV detection solution (50 mM PK buffer pH 7.4, 1 mg/ml 3,3′-diaminobenzidine 
(DAB) (Sigma-Aldrich®), 24 U/ml catalase (Sigmal-Aldrich®), 1 mg/ml cytochrome c (Sigma-
Aldrich®), 75 mg/ml sucrose (Acros Organics)), and incubated for 2 h at RT. Gels were digitally 
scanned at the desired band intensity. 
 
 Oroboros 
Mitochondrial O2 consumption rate was measured for live cultured cells and fresh murine 
brains using an Oxygraph-2k respirometer (Catalogue number: 10023-02, Oroboros 
Instruments, Innsbruck, Austria), which contains two chambers in which dissolved O2 is 
measured in real-time by an amperometric oxygen electrode.  
 
For cultured immortalised skin fibroblasts, cells were trypsinised, counted by Countess II™ FL 
Cell counter (Life Technologies) and 2.5 x 106 cells were suspended in 2.5 ml warmed 
standard culturing medium (section 2.3.1) to yield a final cell density of 1 x 106 cells/ml. Both 
chambers of the apparatus were calibrated for ~1 h at 37 oC with 2.0 ml standard culturing 
medium immediately prior to measurement. Cell suspensions were then added to the separate 
chambers, which were closed and any residual media aspirated. Basal respiration was 
recorded for 2 min at 37 oC with 775 rpm stirring, followed by addition of 5 µl 1 mM oligomycin 
(Catalogue number: O4876, Sigma-Aldrich®) diluted in H20 with a Hamilton syringe, in order 
to inhibit ATP synthase and determine oxygen consumption solely due to OXPHOS. Addition 
of 10 µl 250 µM carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Catalogue number: 
C2759, Sigma-Aldrich®) (diluted in EtOH) followed via Hamilton syringe three times 
successively, and once with 5 µl CCCP, to uncouple the respiratory chain and induce maximal 
respiration. Combined addition of 2 µl 1 mM rotenone (in EtOH) (Catalogue number: R8875, 
Sigma-Aldrich®) and 2.5 µl 2.5 mM Antimycin A (in EtOH) (Catalogue number: A8674, Sigma-
Aldrich®) then inhibited Complexes I and III, respectively, to effectively halt the respiratory 
chain activity. A representative trace of this experiment is available in Fig. 2.11 A. 
 
For murine tissues, whole brains were excised quickly and suspended in 4 oC filtered Medium 
A (see section 2.6.6.1) until sample preparation. Brains were then transferred to Medium A + 
0.2 % fatty-acid free BSA, added immediately prior to homogenisation so that 1 g tissue = 5 
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ml buffer, and homogenised manually using a Teflon-glass Elvenhiem potter (~6 strokes). All 
homogenisations occurred on ice and were followed by mitochondrial isolation as per section 
2.6.6.2. Protein concentrations were determined by DC assay (section 2.6.1). 0.25 mg/ml of 
isolated mitochondria was used for measurements. Chambers were calibrated with 2 ml of 
MiR05 buffer (Table 2.35) at 37 oC with a stirring rate of 775 rpm for ~1 h immediately prior to 
measurement.  
 
Table 2.35 MiR05 respiration buffer 
 
 
Reagent Reagent Manufacturer | CN Final Concentration 
EGTA Sigma-Aldrich® | E4378 0.5 mM 
MgCl2 · 6 H2O Sigma-Aldrich® | M9272 3 mM 
Lactobionic acid Sigma-Aldrich® | L2398 60 mM 
Taurine Sigma-Aldrich® | T0625 20 mM 
Potassium phosphate monobasic Sigma-Aldrich® | P5655 10 mM 
HEPES Sigma-Aldrich® | H7523 20 mM 
Sucrose Sigma-Aldrich® | 84097 110 mM 
Fatty acid-free BSA Sigma-Aldrich® | A6003 1 mg/ml 
 
Basal respiration was measured until O2 flux remained constant, followed directly by addition 
of 5 µl 2 M pyruvate, 4 µl 50 mM malate and 10 µl 2 M glutamate via Hamilton syringes. 
Baseline respiration was recorded until a linear O2 consumption rate was reached. To 
determine CI-linked respiration, 5 µl 1 mM ADP was added to the Oxygraph-2k chambers until 
a linear flux was reached (~5 min), followed by addition of 1 μl 1 mM rotenone to inhibit CI 
activity. 20 µl of 1 M succinate was then added to determine CII-linked respiration. Two 
successive addition of 5 µl 250 µM CCCP followed to induce maximal respiration via 
uncoupling. ATP activity was then inhibited by the addition of 5 μl 1 mM oligomycin. Lastly, 1 
μl 2.5 mM antimycin A was added to inhibit CIII and halt respiration. A representative trace of 
this experiment is available in Fig. 2.11 B. Duplicates were performed per homogenate using 
both of the two Oxygraph-2k chambers to eliminate the variability of the different electrodes 
used, and values were averaged per each substrate or inhibitor added. Posterior analysis was 





Figure 2.11 Representative traces for measuring mitochondrial O2 consumption rates.   
 
An Oxygraph-2k respirometer was used to (A.) measure O2 flow for cultured cells suspended 
in standard culturing media at 37 oC, as follows: 1) basal respiration was recorded for ~2 min 
until a constant O2 flux was reached, 2) ATP synthase activity was inhibited after 5 µl addition 
of 1 mM oligomycin, 3) total uncoupling of the respiratory chain followed by three additions of 
10 µl 250 µM CCCP, 4) and one further addition of 5 µl CCCP to confirm no further change in 
O2 flux, and finally, 5) inhibition of CI and CIII was achieved by addition of 2 µl 1 mM rotenone 
and 2.5 µl 2.5 mM antimycin A, respectively. (B.) Equivalent measurements for isolated 
mitochondrial from murine tissues, suspended in MiR05 buffer (Table 2.33) at 37 oC, were 
performed as follows: 1) basal respiration was recorded ~10 min until O2 flux remained 
constant, followed by addition of 2) 5 µl 2 M pyruvate, 3) 4 µl 50 mM malate and 4) 10 µl 2 M 
glutamate and baseline respiration was recorded. To determine CI-linked respiration, 5) 5 µl 
1 mM ADP was added, followed by 6) addition of 1 μl 1 mM rotenone to inhibit C I activity. 7) 
20 µl of 1M succinate was then added to determine CII-linked respiration. 8) Two successive 
addition of 5 µl 250 µM CCCP followed to induce maximal respiration via uncoupling. 9) ATP 
activity was then inhibited by the addition of 5 μl 1 mM oligomycin. Lastly, 10) 1 μl 2.5 mM 






Graphical visualisation of data and all statistical analyses were performed with GraphPad 
Prism software (versions 7.0 and 8.0). All numerical data for n = 3 or greater is expressed as 
mean ± standard error (SEM) or mean ± standard deviation (SD), as labelled in each figure 
legend. The numbers of biological replicates per sample per figure are also included in the 
figure legends. Results were analysed by unpaired Student t-tests for 2 experimental groups 
with error bars representing range of values, and by one-way or two-way analysis of variance 
(ANOVA) as appropriate for greater than 2 experimental groups. For one-way ANOVA, 
Tukey’s multiple comparison post-hoc test was routinely applied, and for two-way ANOVA, 
Sidak’s multiple comparison post-hoc test was routinely applied. The statistical procedure 
used for each set of results will be mentioned either in-text and/or in the corresponding figure 
legends. In all cases, p-values < 0.05 were considered statistically significant, with the 
following system used for denoting statistical significance:  
















Chapter 3  
Compound Heterozygous Mutations in COA7 are Associated 





COA7 (NC_000001.11: 52,684,449 - 52,698,347) encodes a soluble protein (NP_075565.2) 
that is present only in Metazoans, which is translated from 3 coding exons of one known 
mRNA transcript (NM_023077.3). The COA7 protein is predicted to contain 5 SEL1-like 
tetratricopeptide repeats (Interpro ID: IPR006597), which are likely to mediate interactions 
with partner proteins. The distribution of these domains is shown in  Fig. 1.7 B.. COA7 was 
first characterized following its detection in a screen for proteins that bound the cristae-forming 
MIB components SAM50 and Mitofilin, with subsequent shRNA-mediated COA7 gene 
silencing in HeLa cells yielding a decrease in fully assembled COX abundance and its 
enzymatic activity by approximately 66 % (Kozjak-Pavlovic et al., 2014). Cellular fractionation 
and membrane swelling experiments revealed that COA7 was a soluble protein localising only 
to the mitochondria, specifically to the IMS; however, this finding, although indicative, was not 
confirmative given the lack of a suitable experimental control. At the time this research was 
conducted, no other published literature existed concerning the structure, function, 
mechanism of action, binding partners, intracellular transport nor involvement in human 
disease pathology of COA7. Herein, I describe the compound heterozygous mutant variants 
in COA7 (NM_023077.3:c.410A>G;c.287+1G>T) detected in a mitochondrial disease patient 
presenting with mitochondrial leukoencephalopathy and COX deficiency, and I also verify its 




3.2 Patient Clinical History and Genetic Investigation 
An Italian female proband (b.1996) was born at term after a normal pregnancy, the only child 
of healthy, unrelated parents. The perinatal period was uneventful and her early physiological 
development was considered to be normal. At 12 months of age, psychomotor delay became 
evident, and she did not start walking autonomously until 22 months of age, with poor balance 
and frequent falls. At 3 years of age, she developed a demyelinating sensorimotor peripheral 
neuropathy, and a brain MRI disclosed supratentorial leukodystrophy (white matter 
degeneration). At 10 years of age, her walking difficulties worsened, and limb weakness and 
tremor ensued. Neurological evaluation revealed dysarthria (unclear speech), dysmetria 
(uncoordinated limb movement), hyporeflexia of the four limbs, with muscle wasting. She was 
able to walk only for a few steps with an ataxic gait, supported by orthopaedic ankle-foot aids. 
Mild cognitive impairment was also documented (IQ 75, WISC-R scale). The clinical evolution 
was slowly progressive. At her last follow-up examination at 19 years of age, she had 
developed a marked dorsal-lumbar scoliosis. Additionally, neurophysiological evaluation 
confirmed worsening of her mixed axonal demyelinating peripheral neuropathy. MRI scans of 
the brain and spinal cord at 19 years of age showed extensive cavitation in the cerebral white 
matter, with no effects to the cerebellum and brainstem (Fig. 3.1 A. i-ii). The spinal cord was 
atrophied but had no obvious focal lesions (Fig. 3.1 A. iii). Cerebrospinal fluid lactate was 
found elevated to 2.995 mM (n.v. 0.8 – 2.1 mM) and histological analysis of a skeletal muscle 
biopsy showed hypotrophy of type IIA muscle fibres. Finally, biochemical activity 
measurements of patient muscle and cutaneous biopsies by spectrophotometry revealed 






Figure 3.1 T2- FLAIR MRI sequences of the brain and spinal cord.  
 
An Italian female proband (b. 1996) underwent T2-FLAIR MRI brain and spinal cord scans at 
19 years of age that revealed (i) cavitation of the cerebral white matter, (ii) no obvious defect 
to the midbrain including the cerebellum and brainstem, and (iii) atrophy of the spinal cord. 
Sequences acquired by clinicians at the Neurological Institute “Carlo Besta” (Milan, Italy). 
 
Taken together, the clinical progression and biochemical findings suggested a mitochondrial 
disease origin. After initial Sanger sequencing of the mtDNA at the “C. Besta” Neurological 
Institute (Milan, Italy), which revealed no plausible gene candidates, the patient’s genomic 
DNA was subjected to whole exome sequencing (WES) at the MRC Mitochondrial Biology Unit 
(Cambridge, UK). This process identified 13 nDNA-encoded genes with either homozygous 
recessive or two compound heterozygous recessive variants. COA7 was determined to be the 
only gene of these that encoded a protein localising to mitochondria. The following compound 
heterozygous mutations were detected in COA7: an A>G transition in exon 3 
(NM_023077.3:c.410A>G), predicted to result in a missense tyrosine to cysteine amino acid 
substitution (p.Tyr137Cys), and a G>T transversion affecting the first intronic nucleotide of the 
exon 2/intron 2 boundary (NM_023077.3:c.287+1G>T), affecting an essential nucleotide of the 
splice site consensus sequence (Fig. 3.2 B.). These variants had not previously been reported 
in the ExAc or Clinvar databases. Genetic interrogation of the parents’ genomic DNA followed 
in order to confirm the parental origin of the two mutant alleles. Sanger sequencing of the two 
regions of interest within COA7 (at the exon2/intron2 boundary, and within exon 3) was carried 
out for both parents; the c.410A>G mutant variant was inherited from the father and the 







Figure 3.2 Compound heterozygous mutations in COA7. 
 
(A.) A family pedigree of an Italian female proband (b. 1996) who inherited a c.410A>G 
transition mutation within exon 3 of COA7 (NC_000001.11: 52,684,449 - 52,698,347) from her 
father, resulting in a tyrosine to cysteine amino acid substitution, p.Tyr137Cys, and a 
c.287+1G>T transversion affecting the first intronic nucleotide of the exon 2/intron 2 boundary 
from her mother. (B.) The latter was predicted to disrupt splice site consensus recognition 
sequence at the exon 2/exon 3 splice junction. The position of the affected nucleotide is 
indicated by a red arrowhead. The percentage frequency for the occurrence of the nucleotide 






 Confirming Biallelic Mutant Variants in COA7 in Patient Skin Fibroblasts 
We first verified that both of the COA7 gene mutations were present in cultured patient-derived 
skin fibroblasts. Purified genomic DNA was obtained from patient (P1) or control (C1) cells, 
and used as templates to generate two PCR fragments: 1) a 296 bp fragment from position 
5,419 to position 5,714 of the COA7 gene (NC_000001.11: 52,684,449 - 52,698,347), which 
spanned exon 2 and the exon 2/intron 2 boundary, and 2) a 723 bp fragment from position 
10,121 to position 10,843, spanning part of the coding region of exon 3 (Fig. 3.3 A. and B.). 
Sanger sequencing of these two different PCR fragments confirmed the presence of a 
heterozygous G à T transversion mutation at nucleotide 247 + 1, and a heterozygous A à G 
transition mutation at position 410, for P1 compared with the control human cDNA COA7 






Figure 3.3. Verifying compound heterozygous mutations in COA7.  
 
(A.) Map of the genomic structure of human COA7 (NC_000001.11: 52,684,449 - 52,698,347, 
genetic locus: Chr 1, p 32.2), marking the positions of the PCR-amplified regions for the exon 
2/intron 2 boundary (highlighted in green) and within exon 3 (highlighted in blue). (B.) PCR 
products were amplified from P1 and C1 skin fibroblast gDNA and a blank control reaction (-
). Fragments were separated by agarose gel electrophoresis, and run alongside a 1 kilobase 
(Kb) DNA marker (M) (Invitrogen™, UK) for size comparison (as labelled). Gels were digitally 
visualized via UV transilluminator. (C.) Sections of chromatograms produced by Sanger 
sequencing (Source Bioscience, UK) confirm the presence of the compound heterozygous 
COA7 mutations in P1 that had been originally identified by WES. 
 
 
 Aberrant COA7 mRNA Transcripts Present in Immortalised Patient Cells  
In order to assess the consequences of the genomic mutations at the COA7 transcript level, 
total mRNA was extracted from immortalised patient (P1i) and control (C1i) skin fibroblast cells, 
retrotranscribed, and the resulting COA7 cDNA sequence(s) were amplified by PCR using 
primers that should produce a single amplification product of 567 bp. PCR products were 
resolved by agarose gel electrophoresis, and revealed two bands for P1i of approximately 








Figure 3.4. COA7 cDNA amplification by PCR reveals two mRNA transcript isoforms in 
immortalised patient skin fibroblasts.  
 
Control (C1i) and patient (P1i) COA7 cDNA was retrotranscribed from purified mRNA and 
amplified by PCR. PCR products for both C1i and P1i were separated by size by agarose gel 
electrophoresis with a 1 Kb Ladder (Invitrogen™, UK) run alongside for size comparison. Gels 
were visualized by UV transilluminator. Arrows indicate two distinct bands present for P1i. 
 
Next, the single band for the control (C1i) and the two individual bands for the patient (P1i) 
were excised, the cDNA purified, and then each of the three were subjected to Sanger 
sequencing using the same primers that had been used for amplification. As shown in Fig. 3.5 
A., the paternally inherited variant (NM_023077.3:c.410A>G) was verified in the larger of the 
two bands of P1i, compared to the counterpart sequence for C1i. It caused an in-frame TAC 
à TGC codon change, coding for a missense tyrosine to cysteine amino acid substitution 
(NP_075565.2:p.Tyr137Cys). Secondly, as shown in Fig. 3.5 B., the maternally inherited 
nucleotide substitution at the exon 2/intron 2 splice junction (NM_023077.3:c.247+1G>T) led 
to an aberrant mRNA transcript with an in-frame 141-bp deletion of the entirety of exon 2. Its 
translation product is only 184 amino acids in length, with a deletion of 47 residues from 
positions 37 to 84 of the wildtype protein sequence (NP_075565.2:p.Cys37_Gly84del), which 




Figure 3.5. Consequences of COA7 compound heterozygous mutations on mRNA 
transcript and primary protein sequences.  
 
Purified COA7 cDNA retrotranscribed from control, C1i, and patient, P1i, total RNA was 
subjected to Sanger sequencing (Source Bioscience, UK). Compared to the wildtype mRNA 
transcript, the two patient COA7 mutations resulted in (A.) a TACàTGC codon change in the 
paternally inherited mRNA variant, resulting in a p.Tyr137Cys missense mutation at the 
protein sequence level, and (B.) a 141 bp deletion at the mRNA level in the maternally 
inherited variant, leading to skipping of the entirety of exon 2 (p.Cys37_Gly84del). The latter 
resulted in a 47 aa-long deletion between positions 37 and 84 of the wildtype protein 
sequence. Mutant effects are labelled in red; and wildtype sequences/positions in black.  
 
 Both COA7 Mutant Variants are Predicted to be Pathogenic 
Fig. 3.6 A. shows a Clustal Omega (version 1.2.1) multiple sequence alignment for the C1i 
wildtype primary protein sequence compared to both maternal and paternal P1i mutant alleles. 
Notably, the maternal mutant variant with the 47-amino acid long deletion is missing the 
majority of the first and part of the second predicted SEL1 domains (Interpro ID: IPR006597, 
Fig 1.7 B.). Additionally, Tyr137 resides within the third SEL1 domain and is conserved 
amongst vertebrates, including mammals, reptiles, birds and amphibians, as well as in some 
species of annelids (HomoloGene ID: 11317) (Fig. 3.6 B.). There is no known conservation of 
COA7 in invertebrate animals, bacteria, fungi nor plants. A tyrosine to cysteine substitution is 
likely to have a considerable destabilizing effect given that COA7 is already cysteine-rich in its 
native form (13 cysteines within 231 residues); ultimately, the addition of an extra thiol group 
could drastically interfere with its intrinsic disulphide bridge secondary structure, as will be 







Figure 3.6. Multiple sequence alignment of mutant COA7 primary protein sequences and 
evolutionary conservation of tyrosine residue 137.  
 
(A.) Clustal O (version 1.2.1) multiple sequence alignment shows the primary protein 
sequence of wildtype COA7 (WT-COA7) compared with the maternal and paternal patient 
mutant isoforms, Mat-COA7 and Pat-COA7. The maternally inherited 47 aa-long deletion is 
highlighted in red, the paternally inherited YàC missense mutation in blue, and each of the 5 
SEL1 domains is labelled above. (B.) Multiple sequence alignment with various orthologues 
reveals that Tyr137 (Y137) is evolutionarily conserved amongst mammals (human and 
mouse), amphibians (African clawed frog), birds (turkey) and reptiles (American alligator), and 
some species of the order Annelida, including the roundworm. Each residue in the alignment 
is assigned a colour corresponding to its respective biochemical properties: blue = negatively 





 Patient Cells Lack COA7 & Show Reduced Levels of Some COX Subunits  
In order to assess the molecular consequences of the two mutations on COA7 protein steady-
state level and stability (see Section 3.3.3), we extracted total protein lysates from P1, C1 and 
C2 (another control primary skin fibroblast cell line). As shown in Fig. 3.7 A., SDS-PAGE and 
subsequent immunodetection after Western blotting resulted in no detection of COA7 in P1 
cells relative to both controls in three biological replicates. Additionally, densitometric 
quantification (Fig. 3.7 B.) determined a statistically significant reduction in the abundance of 
CIV (COX) subunits COX5B and MT-CO2, with all averaged values normalised to the relative 
abundance of the loading control GAPDH per cell line. Interestingly, there was a small but 
reproducible increase observed in the abundance of NDUFB8 in P1 cells, an accessory subunit 
of CI not involved in its catalysis but found essential for the oligomerisation of CI with CIII and 
CIV (Wu et al., 2016), although this difference was not significant by statistical analysis (n = 
3). There were no qualitative or quantitative differences observed in levels of CI subunit 
NDUFS3, CII subunit SDHA, or CIII subunits UQCRC1 and UQCRC2 (n = 2 for each). The 
relative abundance of LRPPRC, a multifunctional protein with an essential role in the 
translation and stability of mtDNA-encoded COX subunits (Xu et al., 2004; Cui et al., 2019) 







Figure 3.7. Loss of COA7 correlates with decresed steady state levels of COX subunits.  
 
(A.) SDS-PAGE was used to resolve 15 μg of whole cell protein lysates from primary patient 
skin fibroblasts (P1), and two control cell lines (C1 and C2) under denaturing conditions. WB 
analysis followed for CI subunits NDUFS3, NDUFB6 and NDUFB8, CII subunit SDHA, CIII 
subunits UQCRC1 and UQCRC2, CIV subunits MT-CO1, MT-CO2, and COX5B, COX 
assembly factor, LRPPRC, cytosolic loading control (L.C.) GAPDH, and COA7, using the 
primary antibodies, concentrations and conditions detailed in Table 2.29. (B.) Densitometric 
quantification was performed using the Fiji ImageJ software Gel Analysis feature. Data are 
presented for NDUFS3, UQCRC1, UQCRC2, MT-CO1 and COX5B (all n = 2) as mean ± range 
and NDUFB8, COA7 and MT-CO1 (all n = 3) as mean ± SD. Statistical analysis: two-way 
ANOVA with the post-hoc Tukey multiple comparison test applied. Legend: p <0.005 = *** and 





















 Reduced COX Holocomplex Levels Apparent in Patient Cells 
In order to avoid cellular senescence and facilitate an increase in the rate of proliferation of the 
cell lines, primary fibroblasts were subjected to immortalisation (see section 2.3.3). Following 
the observation that depleted COA7 steady-state level was found in primary patient cells that 
also displayed reduced quantities of COX subunits, SDS-PAGE was performed as before and 
the same differences were observed (data not shown). 1D-BNGE was performed in order to 
determine whether the same trend was true for the abundance of the COX holocomplex and 
the other protein complexes of the respiratory chain. Mitochondrial protein extracts from both 
primary (Fig. 3.8 A.) and immortalised (Fig. 3.8 B.) cell lines were analysed to confirm that the 
mutant phenotype was not lost or diminished during the immortalisation process. Mitochondrial 
protein extracts solubilised with 1 % DDM from the primary and immortalised patient cell lines, 
P1 and P1i, showed considerable reduction in the abundance of monomeric COX (CIV) 
(immunodetected by MT-CO1) and the CIII2+CIV supercomplex (immunodetected by MT-CO1 
for both and also UQCRC2 in the case of the immortalised samples) compared to the 
respective control. As shown by the relative abundances of CII (immunodetected by SDHB), 
the loading of both sets of samples was equal. Immortalised samples revealed that there are 
no observable decreases in abundance of any of the other complexes of the mitochondrial 
respiratory chain: CI, CII or CIII2. In fact, the quantity of CIII2 appears increased, as has been 






Figure 3.8. Total Abundance of COX and COX-Containing Supercomplexes Are 
Decreased Following Reduced COA7 Steady-State Levels.  
 
(A.) 1D-BNGE was performed with approximately 100 μg of mitochondrial protein from primary 
patient (P) and control (C) mitoplasts, solubilised with 1 % DDM. Samples were resolved under 
non-denaturing conditions on a 3 – 12 % gradient Novex® NativePAGE gel. Immunodetection 
followed for detection of CIV and CII holocomplexes with antibodies indicated in parentheses. 
(B.) The same process was followed for immortalised patient (P1i) and control (C1i) cell lines 
with subsequent 1D-BNGE and WB analysis using primary antibodies against NDUFB8 (CI), 
UQCRC2 (CIII), MT-CO1 (CIV) and SDHB (CII) (for antibody details, see Table 2.29). 
 
2D-BNGE was then performed to determine whether the decrease in COX amount was due to 
stalled assembly or destabilisation of COX before the point of complete assembly. Protein 
samples from immortalised patient (P1i) and control (C1i) skin fibroblasts were solubilised from 
the IMM of mitoplasts with 1 % DDM. Samples were then resolved in the first dimension as in 
Fig. 3.8, and then subjected to further separation of the individual members of each complex 
in the second dimension under denaturing conditions by SDS-PAGE. Immunodetection of the 
mtDNA-encoded COX subunits MT-CO1 and MT-CO2 and nDNA-encoded subunit COX5A 
followed, with CII subunit SDHB acting as a loading control. As shown in Fig. 3.9, total 
abundance of COX intermediates and subassemblies, monomeric COX, and two COX-
containing supercomplex species, CIII2 + CIV and CI + CIII2 + CIV, were all reduced in the 
patient compared to the control. Importantly, there is no accumulation or abnormal segregation 
of COX intermediates in the patient. Rather, we observed a ‘global’ reduction in the 
abundances of COX intermediate species, the holocomplex and COX-containing 
supercomplexes. Additionally, COA7 could not easily be detected in 2D-BNGE due to 
nonspecific protein recognition of the polyclonal endogenous antibody, so it was not possible 







Figure 3.9. 2D-BNGE shows global reduction of COX intermediates, COX holocomplex 
and COX-containing supercomplexes in immortalised patient cells 
 
2D-BNGE was performed with approximately 200 μg of 1 % DDM-solubilised mitochondrial 
protein from immortalised patient (P1i) and control (C1i) skin fibroblast mitoplasts. Samples 
were run in the first dimension on NativePage 3-12 % gradient gels (as per section 2.6.3), 
and in the second dimension under denaturing conditions by SDS-PAGE (see section 2.6.2), 
with 1X MOPS running buffer. MT-CO1, MT-CO2, COX5A and SDHB primary antibodies were 
used for immunodetection (see Table 2.29 for antibody manufacturer details, and 
concentrations and conditions used for each). LMW = Low Molecular Weight, and HMW = 









 Immortalised Patient Skin Fibroblasts Have Isolated COX Deficiency 
As part of the mitochondrial disease diagnostic pipeline, respiratory chain enzymatic activities 
relative to that of citrate synthase (CS) were measured in both cutaneous and skeletal muscle 
biopsies. COX showed 33 % and 36 % residual activities with respect to the control reference 
levels, in skin fibroblasts and skeletal muscle respectively; whereas the activities of the 
remainder of the mitochondrial respiratory chain complexes were within the normal ranges. 
Following immortalisation we confirmed the conservation of the COX deficiency in the patient 
cell line (P1i). As shown in Fig. 3.10, P1i COX/CS activity was significantly decreased 





Figure 3.10. COX deficiency was validated in P1i skin fibroblasts.  
     
COX activity was determined spectrophotometrically for immortalised patient skin fibroblasts 
(P1i) compared with two control cell lines (C1i and C2i), as described in section 2.7.1, and 
normalised against the activity of citrate synthase (CS) per cell line. Data is presented as mean 
± SEM for n = 3 replicates. One-way ANOVA with the post hoc Tukey multiple-comparison 
test confirmed statistically significant reduction in P1 COX/CS activity compared to both C1i 









 Stable Expression of COA7WT Rescues COX Abundance and Enzymatic 
Activity  
In order to determine whether the loss-of-function mutations in COA7 were indeed the cause 
of the observed isolated COX deficiency in the patient cells, a functional complementation 
assay was performed using the wildtype (COA7WT) cDNA sequence. For this, patient-derived 
(P1i) and control (C1i) immortalised skin fibroblasts were transduced with lentiviral particles 
containing an expression vector encoding the wild-type COA7 cDNA sequence (COA7WT-
pWPXLd-Ires-PuroR). As a negative control, the pWPXLd-Ires-PuroR empty vector (EV) was 
used to discard any possible effects caused merely by the transduction and selection 
processes. The COA7WT-pWPXLd-Ires-PuroR plasmid was generated as per sections 2.2.9 – 
2.2.12 and the correct insertion of the COA7WT cDNA sequence was confirmed by Sanger 
sequencing prior to lentiviral particle generation. Lentiviral particles were produced in HEK 
293T cells, by co-transfection of the pWPXLd-based expression vectors with the lentiviral 
second generation pSPAX2 packaging and pMD2.G envelope plasmid vectors (Salmon et al., 
2000). Subsequent transduction and antibiotic selection with 1 μg/ml puromycin yielded 4 cell 
lines: C1i-COA7WT, C1i-EV, P1i-COA7WT, and P1i-EV. 
 
SDS-PAGE, Western Blot and immunodetection were performed to determine the steady-state 
protein levels of COA7 relative to various subunits of the other OXPHOS complexes (CI, CII, 
CIII and CV) for immortalised fibroblast patient, P1i, and control, C1i, cell lines transduced with 
either the COA7WT cDNA sequence or the empty vector (EV) negative control (Fig. 3.11). 
Firstly, overexpression of COA7 in C1i-COA7WT and P1i-COA7WT cell lines was successful, 
and yielded a similar protein abundance in both. Secondly, the levels of MT-CO2 were clearly 
increased in P1i-COA7WT to within normal levels compared to C1i and C2i control cell lines. 
There is no such complementation in the P1i-EV negative control. This indicates that the 
absence of COA7 in the patient cells is directly related to the observed low levels of MT-CO2. 
The steady-state levels of COX subunits MT-CO1 and COX5A are not as severely affected as 
those of MT-CO2, suggesting that this subunit is a major target of COA7. Lastly, there were 
no observable effects of COA7 absence or complementation on relative abundances of 
individual subunits belonging to the other OXPHOS complexes: NDUFS3 (CI), SDHA (CII), 






Figure 3.11. Complementation of immortalised patient fibroblasts with COA7WT 
successfully restores MT-CO2 steady-state levels.  
 
10 μg of whole cell protein lysates from C1i and C2i controls, C1i-COA7WT, C1i-EV, P1i, P1i-
COA7WT and P1i-EV cell lines were separated by size under denaturing conditions by SDS-
PAGE. WB analysis followed to detect the relative abundances of COA7, CI subunit NDUFS3, 
CII subunit SDHA, CIII subunit UQCRC2, CIV subunits MT-CO1, MT-CO2, and COX5A, CV 
subunit ATP5A and a GAPDH loading control (L.C.) (see Table 2.29 for primary antibody 











 COA7WT Complementation Rescues COX Assembly in Immortalised Patient Cells 
1D-BNGE and Western blot analysis was used to observe changes in the relative abundances 
of fully assembled COX in the COA7WT-complementated immortalised skin fibroblast cell lines. 
As is evident in Fig. 3.12, P1i-COA7WT cells have an increased amount of COX relative to the 
P1i cells, within the range of both C1i and C2i controls. Interestingly, overexpressing COA7WT 
in a control cell line, C1i-COA7WT, produced a reduction in the abundance of the COX 
holocomplex, suggesting that the COA7 steady-state level must exist in a physiological range 
with too little or too much COA7 affecting COX assembly or stability. Anti-SDHB 




Figure 3.12. COA7WT Rescues COX Abundance in Immortalised Patient Fibroblasts.  
 
1D-BNGE was performed with approximately 100 μg of mitochondrial protein from C1i, C2i, 
C1i-COA7WT, C1i-EV, P1i, P1i-COA7WT and P1i-EV immortalised skin fibroblast cell lines, 
solubilised with 1 % DDM. Samples were resolved as per section 2.6.3. Immunodetection of 
COX and CII complexes was performed by WB analysis with primary antibodies against MT-
CO1 (CIV) and SDHB (CII) (see Table 2.29 for primary antibodys and concentrations used). 
 
Furthermore, 2D-BNGE analysis (Fig. 3.13) revealed an overall increase in levels of 
monomeric COX and in the CIII2 + COX supercomplex, through immunodetection of MT-CO1 
and MT-CO2 subunits, for P1i-COA7WT cells compared to the negative control cell line, P1i-
EV. There also seems to be more intermediate species as immunodetected by MT-CO1, with 
a pattern comparable to the control C1i cell line (Fig. 3.9). Separately, immunodetection with 
an anti-HA primary antibody for patient and control cells overexpressing COA7HA revealed that 
COA7 does not co-migrate with any of the mature respiratory chain protein complexes, 
including COX (Fig. 3.14). Instead it was only immunodetected as a single spot focalising to 
the low molecular weight portion of the gel. It was reproducibly not found to co-localise with 






Figure 3.13. 2D-BNGE shows recovery of the levels of COX intermediates, COX and 
COX-containing supercomplexes in patient cells stably overexpressing COA7WT.  
 
2D-BNGE was performed with approximately 200 μg of DDM-solubilized mitochondrial protein 
prepared from immortalised skin fibroblast patient cells transduced with an empty vector (P1i-
EV) and patient cells stably overexpressing COA7WT (P1i-COA7WT). Samples were resolved 
in the first dimension using NativePage 3-12 % gradient gels as per section 2.6.3, and in the 
second dimension under denaturing conditions by SDS-PAGE (see section 2.6.2), with 1X 
MOPS running buffer. MT-CO1, MT-CO2, and SDHB primary antibodies were used for 
immunodetection (see Table 2.29 for antibody manufacturer details, and concentrations and 






Figure 3.14. 2D-BNGE shows no co-migration of COA7 with COX and a COX-containing 
supercomplex in patient cells stably overexpressing COA7HA.  
 
2D-BNGE was performed with approximately 200 μg of DDM-solubilized mitochondrial protein 
prepared from immortalised skin fibroblast patient or control cells stably overexpressing 
COA7HA (P1i-COA7HA or C1i-COA7HA) or empty vector control cell lines for each (P1i-EV and 
COA7-EV). Samples were resolved in the first dimension using NativePage 3-12 % gradient 
gels as per section 2.6.3, and in the second dimension under denaturing conditions by SDS-
PAGE (see section 2.6.2), with 1X MOPS running buffer. Anti-HA and anti-COX4 primary 
antibodies were used for immunodetection (see Table 2.29 for antibody manufacturer details 




 COA7WT Complementation Rescues COX Enzymatic Activity  
Following on from the observed rescue of COX subunit levels (Fig 3.11), COX abundance 
(Fig 3.12), and the quantity of COX intermediate assembly species and supercomplexes (Fig 
3.13), COX/CS specific activity was measured spectrophotometrically for C1i, C1i-COA7WT, 
C1i-EV, P1i, P1i-COA7WT and P1i-EV immortalised skin fibroblast cell lines (Fig 3.15). 
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COX/CS activity in patient cells stably overexpressing COA7WT (P1i-COA7WT) was significantly 
increased, relative to patient cells transduced with an empty vector control (P1i-EV), which 
remained as low in quantity as for the non-transduced patient cells, P1i. Ultimately, the stable 
expression of COA7WT in patient-derived cells is able to restore COX activity to nearly normal 
levels, proving that the compound heterozygous mutations found in COA7 (NM_023077.3: 
c.410A>G;287+1G>T) are indeed responsible for the observed COX deficiency in the patient.  
 
 
Figure 3.15. COX activity is rescued in patient cells after complementation with COA7WT.  
 
COX activity was determined spectrophotometrically (see section 2.7.1) for C1i, C1i-COA7WT, 
C1i-EV, P1i, P1i-COA7WT and P1i-EV immortalised skin fibroblast cell lines. COX specific 
activities were normalised against the relative activity of citrate synthase (CS). Data are 
presented as mean ± SEM for n = 3 replicates per cell line. * p < 0.05, ** p < 0.01, determined 
by one-way ANOVA with the post hoc Tukey multiple-comparison test applied. 
 
 Endogenous COA7 Localises Specifically to the IMS 
Following the discovery of the first pathogenic mutations in COA7, we sought to confirm the 
protein’s submitochondrial localisation. As a first approach, we used trypsin digestion of 
mitoplast fractions generated with two different concentrations of digitonin. After protease 
digestion, the samples were separated by SDS-PAGE and analysed by Western blotting and 
immunodetection (Fig. 2 F., Martinez Lyons et al. 2016). In our analyses, COA7 was 
completely protected from trypsin digestion in all mitoplast fractions, similarly to the MM 
marker CS, whereas the IMS marker cytochrome c was clearly reduced. This led us to 
conclude localisation to the MM, rather than the IMS as originally proposed by Kozjac-Pavlovic 
et al. However, recent evidence that COA7 is an interactor of CHCHD4/MIA40, the principal 
component of the disulphide-relay system responsible for the import and targeting of IMS 
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proteins (Mohanraj, et al. 2019), led us to reconsider this finding and attempt to resolve this 
contradiction. Mitochondrial sub-fractionation by hypotonic shock and protease digestion 
assays proved not to be trivial. COA7 was found to be fairly protease-insensitive and so often 
appeared unaffected in all fractions regardless of treatment. Secondly, finding a suitable 
hypotonic/digitonisation condition which would entirely disrupt the OMM whilst leaving the IMM 
intact was a challenge. Therefore, we opted for two biochemical approaches, one using 
protease digestion and the other only using OMM solubilisation by digitonin. In addition, we 
used super-resolution microscopy of HA-tagged COA7 in a COA7HA overexpressing HeLa cell 
line relative to markers for each of mitochondrial compartments to resolutely confirm the 
intramitochondrial localisation of COA7.  
 
For the first of the biochemical experiments, a range of digitonin (DIG) concentrations were 
used to gradually open the OMM of isolated mitochondria from HEK 293T cells, performed by 
10-minute incubations on ice in each case, and both the pellet and supernatant fractions were 
collected after ultracentrifugation (Fig. 3.16 A.). COA7 is detectable in the supernatant 
fractions from 150 μg/ml DIG onwards, with associated decrease in the pellet fractions. This 
is similar to the behaviour of OMM protein translocase of the outer mitochondrial membrane 
20 (TOMM20) and IMS proteins apoptotic-inducing factor (AIF) and cytochrome c (CYT C). 
Importantly, the COX proteins MT-CO2 and COX4, resident in the IMM, and the soluble MM 
protein superoxide dismutase 2 (SOD2), were not released into the supernatant with any 
amount of digitonin. Secondly, when the same procedure was followed but with the 
subsequent addition of 150 μg/ml trypsin to each fraction for 30 min at RT (Fig. 3.16 B.), 
TOMM20 was quickly digested, even without the addition of DIG, and the IMS proteins AIF 
and CYT C, IMM protein COX4 and MM protein SOD2 were degraded from 75 or 150 μg/ml 
DIG onwards. COA7 followed this pattern. Taken together, these two parallel experiments 
strongly indicate that COA7 is an IMS protein. Due to its protease resistance, small amounts 
of the protein are still detectable even after incubation with 1.2 mg/ml DIG + 150 μg/ml trypsin 
and after addition of 1 % Triton + 150 μg/ml trypsin. However, a smaller band is detectable in 
the fractions incubated with > 600 μg/ml DIG and in the 1 % Triton + trypsin control, indicating 
partial digestion of the protein. These results explain the lack of protease digestion in our 
original experiment, given that only 20 and 50 µg/ml DIG concentrations were used as 
standard practice and no control for complete membrane solubilisation (1 % Triton) was used 
on that occasion. In is also worth mentioning that COA7 was ever only found in the 






Figure 3.16. HEK293 Mitochondrial sub-fractionation and protease protection assays. 
 
Mitochondria were isolated from HEK 293T cells as previously described (Fernández-Vizarra 
et al., 2010) and the mitochondrial preparation was divided into multiple aliquots of 200 μg of 
mitochondrial protein each. (A.) Western blot and immunodetection analysis of the pellet and 
supernatant samples from isolated mitochondria solubilised with increasing concentrations of 
DIG: 0, 75, 150, 300, 600 and 1,200 μg/ml. (B.) Western blot and immunodetection analysis 
from mitochondria solubilised with increasing amounts of DIG (as in A.) or with 1 % Triton X-
100, and further treated with 150 μg/ml of trypsin for 30 min at RT, as indicated. WC: Whole 














Super-resolution fluorescence microscopy was employed to independently determine the 
submitochondrial localisation of COA7. All cell preparation, imaging and subsequent analyses 
were performed by Dr. Cristiane Benincá. As shown in Fig. 3.17, HA-tagged COA7 co-
localises with the IMS marker SMAC (see insets), a part of the SMAC/DIABLO dimer involved 
in caspase activation in the apoptotic pathway (Du et al., 2000). The signal corresponding to 
COA7HA was clearly distinct from that of the OMM marker TOMM20, the IMM marker COX8A, 
and a MM-localising photoactivatable GFP construct, mtPAGFP, which all displayed 




Figure 3.17. HeLa cells show COA7 co-localisation with an IMS marker.  
 
Immunofluorescence and super-resolution microscopy was performed as described 
(Mohanraj et al., 2019). N-SIM super-resolution micrographs show 0.6 μm Maximum Intensity 
Projection (0.15 μm per Z-stack) of HeLa cells expressing COA7-HA, immunostained for the 
OMM marker TOMM20-DsRed, IMS marker SMAC/DIABLO, IMM marker COX8A-DsRed, or 
transfected with a matrix targeted photoactivatable GFP construct (mtPAGFP) (MM). Scale 
bars: 5 μm and 0.5 μm in inset images. Images acquired and post-processed entirely by Dr. 








This work: 1) confirmed the pathogenicity of two novel COA7 mutations, 2) established a role 
for COA7 in maintaining normal COX stability and activity, and 3) unequivocally determined 
the subcellular and intramitochondrial localisation of COA7 to the IMS.  
 
Compound heterozygous mutations in COA7 (NM_023077.3:c.410A>G;c.287+1G>T) were 
detected by WES and downstream bioinformatic filtering in a proband presenting with 
progressive leukoencephalopathy and isolated COX deficiency. Sanger sequencing analysis 
of the COA7 gene of the proband and her parents confirmed the presence of the biallelic 
mutations and allowed assignment of parental origin to each. These were a paternally-inherited 
A>G transition mutation in exon 3 (NM_023077.3:c.410A>G;), coding for a tyrosine to cysteine 
amino acid substitution (NP_075565.2:p.Tyr137Cys) and a maternally-inherited G>T 
transversion at the exon 2/intron 2 splice site junction (NM_023077.3:c.287+1G>T) with 
unknown consequence on the resulting mRNA transcript(s) and protein primary sequence(s). 
Two different aberrant mRNA transcripts were determined to be expressed in the patient 
following RNA extraction and retrotranscription to cDNA; one lacked the entirety of exon 2, 
arising from the maternal allelic variant, and resulted in an in-frame deletion of 47 amino acids 
from position 37 of the primary protein sequence (NP_075565.2:p.Cys37_Gly84del), and the 
paternally inherited transcript variant encoded a TAC à TGC codon change, leading to a 
tyrosine to cysteine amino acid substitution (NP_075565.2:p.Tyr137Cys). Both variants are 
predicted to be strongly pathogenic by computational analyses. The maternal variant disrupted 
the majority of the first and part of the second predicted SEL1 domains. The paternal mRNA 
transcript variant encoded a change to a highly conserved tyrosine residue within the third 
SEL1 domain. 
Indeed, primary and immortalised patient skin fibroblasts revealed total absence of COA7 
steady-state level by SDS-PAGE. The abundance of COX subunits MT-CO2, COX5B, and to 
a lesser extent, MT-CO1, were decreased. Subunits from the other respiratory chain 
complexes and the COX assembly factor LRPPRC revealed no alterations. 1D-BNGE showed 
a clear reduction in the abundance of free COX and a COX-containing supercomplex species 
(CIII2 + CIV). No accumulation of COX intermediates or subassemblies were detectable by 2D-
BNGE, and COA7 was not found to co-migrate with the mature COX holocomplex, but the 
same global reduction in COX subunit quantities observed by SDS-PAGE was evident. 
Biochemical evaluation of cultured immortalised patient fibroblasts confirmed the significant 
COX deficiency of approximately 66 %, in line with that observed in isolated mitochondria from 
patient cutaneous and skeletal muscle biopsies. 
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Lentiviral complementation with COA7WT successfully rescued COX abundance and its 
enzymatic activity to normal levels. COA7WT overexpression in a wildtype fibroblast control cell 
line resulted in reduced COX abundance and some reduction in enzymatic activity, suggesting 
that overexpression as well as depletion of COA7 is deleterious. Patient fibroblasts 
complemented with COA7WT showed no difference in the abundances of MT-CO1 and COX5A 
COX subunits, involved in early stage COX biogenesis, but revealed a marked increase in the 
abundance of MT-CO2 to control levels, suggesting that the main target of COA7 is MT-CO2 
and/or the MT-CO2 module, inserted in the intermediate stages of COX assembly (Fig. 1.5).  
Lastly, a combination of super-resolution microscopy and cellular fractionation and protease 
digestion experiments confirmed that the intracellular localisation of COA7 is the IMS.  
The publication of this research (Martinez Lyons et al. 2016) led to the subsequent 
identification and diagnosis of other mitochondrial disease patients whose symptoms were a 
result of pathogenic mutations in COA7, all of whom exhibited COX deficiency, leukodystrophy 
and spinal cord atrophy (Higuchi et al., 2018). It also prompted the characterisation of the 
mitochondrial import of the COA7 protein, which does not contain a conventional mitochondrial 
targeting sequence, into the IMS, as well as research into the detrimental effects of the mutated 
variants in the import process (Mohanraj et al., 2019). These findings and their interpretations 

















Chapter 4  
Introducing TMCO6, a Gene Found Mutated in a Mitochondrial 





The work described in this chapter concerns TMCO6 (Transmembrane and Coiled-Coil 
Domains 6; NC_000005.10: 40,596,529–140,647,411), an uncharacterised, nuclear-encoded 
protein found only in vertebrates, including mammals, birds, reptiles, amphibians, and bony 
and cartilaginous fishes (Homologene ID: 12431). The TMCO6 cDNA sequence was initially 
discovered through genome-wide mRNA screening of human and mouse transcriptomes 
(Strausberg et al., 2002; Ota et al., 2004). It has since been found to be expressed in all human 
tissues (https://www.proteinatlas.org/ENSG00000113119-TMCO6/tissue). However, to date, 
no seminal literature or research has been published regarding TMCO6, its role in normal 
cellular physiology or human disease pathology. The first aim of this work was to perform an 
in silico investigation into TMCO6 to compile the available information regarding its gene 
structure, conservation, different protein isoforms and key structural features. The second aim 
was to assess the molecular and metabolic consequences of a novel point mutant variant 
identified in TMCO6 (NM_018502: c.271C>T) by WES in a Bangladeshi male adolescent 




 An Introduction to TMCO6 
The human TMCO6 gene (Locus: Chr 5, q31.2; NC_000005.10: 140,596,529 – 140,647,411) 
contains 12 coding exons and gives rise to two mRNA isoforms, termed here as TMCO6.1 
(NM_018502.5, 493 aa product) and TMCO6.2 (NM_001300980.1, 499 aa product). These 
isoforms originate from alternative splicing at the exon 6/exon 7 slice junction (Fig. 4.1) with 
gene products TMCO6.1 and TMCO6.2 differing by six in-frame amino acids (PASASS) from 
position 230 of the primary protein sequence. The human TMCO6 protein has been found to 
be ubiquitously expressed in all tissues (https://www.proteinatlas.org/ENSG00000113119-
TMCO6/tissue); however, it is not known whether there is tissue-specificity, difference in levels 




Figure 4.1 TMCO6 encodes two protein isoforms by alternative splicing. 
 
The TMCO6 gene (Locus: Chr 5, q31.2; NC_000005.10: 140,596,529 – 140,647,411) contains 
12 exons, which produce two mRNA isoforms, TMCO6.1 (NM_018502.5, 493 aa product) and 
TMCO6.2 (NM_001300980.1, 499 aa product) by alternative splicing at the exon 6/exon 7 
slice junction. 
 
At the protein level, TMCO6 is predicted to contain several structural features (as annotated in 
Fig 4.2). An arginine-rich region spans the first 110 amino acids of the protein, with a fifth of 
these (21 in total) in both TMCO6.1 and TMCO6.2 being arginine residues. Mitochondrial 
targeting signal (MTS) prediction programs did not predict the presence of an N-terminal MTS. 
Instead, the first 52 amino acids are annotated to make up an importin-β binding (IBB) domain 
(Interpro ID: IPR002652), typically found in members of the α-importin protein family, all known 
members of which localise to the nucleus. These proteins are known to form a heterodimer 
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complex with β-importin. Whilst β-importin mediates interaction with the nuclear pore complex, 
α-importin binds the nuclear localisation signal (NLS) of their cargo allowing for import into the 
nucleus from the cytosol (Lott and Cingolani, 2011). In addition to the IBB sequence predicted 
in TMCO6, a related structural motif, the armadillo (ARM) domain, is also present in this 
protein. Within both isoforms, there are up to 5 predicted ARM repeats (InterPro ID: 
IPR000225), a ~42 amino acid motif that does not show amino acid conservation, but 
characteristically folds into two or three separate α-helices (Huber, Nelson and Weis, 1997). 
Multiple tandem ARM repeats typically form a superhelical solenoid structure (ARM-type fold, 
Interpro: IPR016024), and can mediate a wide range of intracellular functions that require 
protein-protein interaction (Choi and Weis, 2005). Although the tertiary structure of TMCO6 is 
unknown, and structural homology modelling programs such as SWISS-MODEL did not return 
any significant matches from input of either TMCO6.1 or TMCO6.2 query sequences, the 
PSIPRED 2.0 (Jones, 1999) secondary structure prediction tool confidently predicted the 
presence of 34 α-helices, 27 of which were assigned the highest possible confidence score 
(indicated by the blue bars above the corresponding amino acids in Fig. 4.2). A further 6 α-
helices were predicted with less confidence, and are not included. Overall, this secondary 
structure fits well with the secondary structure described in proteins from the α-importin family.  
 
TMCO6 was initially described as a transmembrane protein, giving it its name. In support of 
this, the online tool Protter (Omasits et al., 2014) predicted the presence and distribution of 
two transmembrane regions (positions 338–358 and 386–406) towards the C-terminus of the 
protein. Another prediction tool, SACS MEMSAT2, only predicts one transmembrane domain 
in a different region (positions 274-290). However, others, including the Human Protein Atlas 
Transmembrane prediction tool, predict no transmembrane regions. It is worth noting that none 
of the α-importin proteins described to date are known to be membrane-embedded or 
membrane-associated proteins. Only experimental evidence will be able to provide an answer 
to this apparent incongruity (described in Chapter 5). In summary, TMCO6 is found in humans 
in two main isoforms, TMCO6.1 and TMCO6.2, which are both predicted to contain a large 
number of α-helices. The majority of these α-helices are likely to make up several ARM 
repeats, in turn leading to a solenoid-like tertiary structure. What is still unknown is whether 
TMCO6 does indeed localise to the nucleus, or if it localises to one or more other cellular 
compartments. Additionally, it is unclear whether TMCO6 contains at least one transmembrane 





Figure 4.2 Annotation of predicted structural features of TMCO6. 
 
The primary protein sequences encoded by mRNA transcripts TMCO6.1 (NM_018502.5 493 
aa product) and TMCO6.2 (NM_001300980.1, 499 aa product) are aligned above, with the six 
differing in-frame amino acids highlighted in purple. An arginine-rich region (each individual 
arginine highlighted in green) is present in the first 110 amino acids. A predicted importin-β 
binding domain (IBB) (blue) is annotated to occur in the first 52 amino acids. There are 5 
armadillo (ARM) helices (yellow) predicted by the InterPro database from residues 96 – 137, 
180 – 220, 225 – 268, 326 – 369 and 371 – 410. PSIPRED 2.0 secondary structure prediction 
was used to predict the abundance and distribution of secondary structural features, yielding 
only α-helices (the positions of which are denoted by the blue bars); only amino acids with the 
highest confidence scores for involvement in an α-helix are shown, yielding 27 distinct helices 
(an additional 6 predicted with less confidence are not shown). Lastly, topology prediction with 
Protter (Omasits et al., 2014) predicts the presence of two transmembrane regions (each 




 Patient Clinical History and Genetic Investigation 
A male paediatric proband of Bangladeshi descent was born at term to consanguineous 
parents. He presented in infancy with nystagmus (involuntary eye movement), generalised 
hypotonia, hyporeflexia and severe developmental delay. At 7 months of age, magnetic 
resonance imaging (MRI) disclosed extensive cortical and subcortical hypomyelination. At 12 
months of age, he developed epilepsy, dystonia (uncontrolled muscle spasms), spasticity 
(involuntary muscle contraction), and axial hypotonia (abnormally low muscle tone), with no 
acquisition of language or motor milestones. An MRI scan at 16 months of age (Fig. 4.3 A.) 
showed progression of the hypomyelination and cerebral atrophy. Magnetic resonance 
spectroscopy (MRS) (Fig. 4.4) performed at the same time revealed an increase in 
intraventricular lactate (22 mg/dl, n.v. 9-19 mg/dl) and a reduction of N-acetyl aspartate (NAA), 
the most prominent MRS signal abnormalities observed in mitochondrial disorders (Lunsing et 
al., 2017). Visual evoked potentials demonstrated a defect in nerve conduction with latency 
delay and low voltage. Cardiac ultrasound excluded the presence of cardiomyopathy at that 
time, but no echocardiographic or electrocardiographic scans were performed. At his last 
follow-up appointment at 7 year of age, neurophysiological evaluation showed worsening of 
the dystonia and spasticity and another MRI scan (Fig. 4.3 B.) revealed progression of the 
cerebral atrophy with involvement of subtentorial areas. Biochemical activity measurement of 
a skeletal muscle biopsy determined Complex I (CI) deficiency (5.58 nmol/min/mg, n.v. 13 - 
24) and reduced citrate synthase (CS) activity (37 nmol/min/mg, n.v. 80-120). 
 
In combination, the clinical presentation, MRS spectra and biochemical data strongly 
suggested mitochondrial involvement in the disease. After initial Sanger sequencing of the 
patient’s mtDNA at the Neurological Institute “Carlo Besta” (Milan, Italy) and further sequencing 
of a panel of 132 nuclear-encoded genes associated with mitochondrial disease, particularly 
OXPHOS deficiency, no plausible genetic candidates were found. The patient’s DNA was 
subjected to WES and subsequent bioinformatic analyses at the Medical Research Council 
Mitochondrial Biology Unit (MRC-MBU, Cambridge, UK). A total of 1,366 individual SNPs were 
identified, 179 of which were nonsynonymous or stop-gain mutations and a further 27 of these 
had gene products of strongly predicted or known mitochondrial localisation. TMCO6 was 
determined to be the most likely causal gene candidate of these, with a homozygous recessive 
missense mutation in exon 3 (NM_018502.5:c.271C>T) leading to an arginine to cysteine 
amino acid substitution (NP_060972.3:p.Arg91Cys) (Fig. 4.5). This variant has not been 
previously reported in the ExAc or Clinvar databases. Single heterozygous mutations were 





Figure 4.3 Patient T2- FLAIR MRI sequences reveal hypomyelination and cerebral and 
cerebellar atrophy. 
 
T2-FLAIR MRI (i) transverse supratentorial, (ii) coronal and (iii) sagittal sequences were 
imaged at (A.) 16 months and (B.) 7 years of age. Cortical and subcortical hypomyelination, 
and progressive cerebral and cerebellar atrophy (the latter is indicated by yellow arrowheads) 
were evident. The brain stem and spinal cord were spared. Sequences acquired and compiled 








Figure 4.4 Patient magnetic resonance spectrometry (MRS) intraventricular spectra.  
 
MRS was carried out at 16 months of age on the lateral ventricles of the brain to determine 
the metabolic status of this region, and to compliment the results of counterpart MRI imaging 
(see Fig 4.1). An N-acetyl aspartate (NAA) peak, occurring at 2.00 to 2.05 parts per million 
(ppm), was decreased signifying a reduction in overall neuronal density since it is an amino 
acid abundant in the brain and primarily localising to neuronal tissues. Additionally, a lactate 
peak was detected at 1.3 ppm, signifying increased anaerobic respiration. A choline peak 
detected at 3.20 ppm serves as a marker of cell membrane integrity and cellularity, and was 
normal. Lastly, a creatine peak (3.03 ppm), which is a marker of intracellular energy state and 
routinely used as a reference standard for characterising other peaks, was also normal. 







Figure 4.5 Family pedigree for a mitochondrial disease patient with a homozygous 
recessive missense mutation in TMCO6. 
 
Figure shows a family pedigree for an adolescent male proband of Bangladeshi descent (b. 
2008) that exhibited CI deficiency in skeletal muscle, infantile-onset epilepsy, nystagmus, 
dystonia, spasticity, generalised hypotonia and severe developmental delay. WES analysis 
found a homozygous recessive mutation in exon 3 of TMCO6 (NM_018502.5: c.271C>T) in 
the patient, encoding a missense arginine to cysteine amino acid substitution at position 91 of 
the primary protein sequence (NP_060972.3: p.Arg91Cys). The probands’ parents are 
consanguineous as denoted by the double line, and have the mutation in heterozygosity. The 
proband has an older sister who is heterozygous for the mutation. 
 
 Homozygous Recessive TMCO6 Mutant Variant is Predicted by Computational 
Analyses to be Strongly Pathogenic  
In order to confirm the presence of the homozygous recessive mutation found by WES in 
patient-derived primary skin fibroblasts supplied for use in this work, genomic DNA was 
purified from these cells and used as genetic templates for PCR-based amplification of the 
mutant region within exon 3 of TMCO6. Sanger sequencing confirmed the presence of a single 
C>T nucleotide transition in homozygosity (Fig. 4.6 A.), encoding an in-frame CGT>TGT 
codon change from an arginine to a cysteine residue affecting the 91st amino acid of the 
TMCO6 primary protein sequence (NP_060972.3: p.Arg91Cys). This change is predicted to 
be strongly pathogenic by bioinformatic analyses, yielding a Polymorphism Phenotyping v 2 
(PolyPhen-2) score of 0.997  (max. score = 1.000) (Fig. 4.6 B.) (Adzhubei et al., 2010), and a 
Functional Analysis through Hidden Markov Models (FATHMM)-MKL score of 0.923 (max 




            








Figure 4.6 The TMCO6 point mutation was verified in cultured primary patient fibroblasts 
and is predicted to be highly pathogenic by bioinformatic analyses. 
  
(A.) Sections of chromatograms generated by Sanger sequencing of exon 3 of TMCO6 
amplified from genomic DNA purified from patient and control primary skin fibroblasts 
confirmed the C>T nonsynonymous point mutation originally identified by WES. (B.) The 
PolyPhen-2 online tool (available from: http://genetics.bwh.harvard.edu/pph2/) predicts 
whether an amino acid substitution will have an effect on the structure and function of a human 
protein. Variants with scores of 0 - 0.15 are predicted to be ‘benign’, scores of 0.15 - 0.85 are 
‘possibly deleterious’ and scores > 0.85 are predicted to be ‘probably damaging’ (Adzhubei et 
al., 2010). The score for the patient mutation is 0.997. (C.) FATHMM-MKL is a predictive tool 
for pathogenicity (available from: http://fathmm.biocompute.org.uk) based on a machine 
learning approach that scores the functional consequences of non-coding and coding DNA 
variants based on 10 selected elements from the Encyclopaedia of DNA Elements (ENCODE) 
database. Scores < 0.5 are classed as ‘neutral’, scores ≥ 0.5 as ‘potentially deleterious’ and 
scores ≥ 0.7 are classed as ‘pathogenic’ (Shihab et al., 2015). The score for the patient 






Following on from this, the CLUSTAL Omega (version 1.2.4) multiple sequence alignment tool 
(available from: https://www.genome.jp/tools-bin/clustalw) was used to compare the affected 
region of the wildtype TMCO6 human primary sequence (NP_060972.3) with the sequences 
of nine orthologs chosen to represent mammals, birds, reptiles, amphibians, and fish (Fig. 4.7). 
Arg91 of the human primary protein sequence (indicated by the red arrowhead) is ubiquitously 
conserved amongst the sampled species. TMCO6 is not known to be present in invertebrate 
animals, plants, bacteria nor fungi, and no UNIPROT entries for these were found. Additionally, 
the affected arginine falls within a predicted α-helix. Repeating the PSIPRED 2.0 secondary 
structure prediction with the mutated primary protein sequence did not suggest a change in 




Figure 4.7. Multiple sequence alignment of mammalian TMCO6 shows conservation of 
Arg91.  
  
A multiple sequence alignment for amino acids 56 – 110 of the human TMCO6.1 primary 
sequence (NP_060972.3) compared to 9 vertebrate orthologs representing a range of 
taxonomic classes was created using the CLUSTAL Omega (version 1.2.4) online tool. The 
position of the patient p.Arg91C mutant amino acid substitution is indicated by a red arrow. An 
asterisk (*) denotes conservation of an amino acid amongst all query species, a colon (:) 
denotes conservation of amino acids with similar biochemical properties, a period (.) denotes 
amino acids with weakly similar biochemical properties, and no symbol indicates no predicted 
conservation of residues at that position. Each residue in the alignment is assigned a colour 
corresponding to its respective biochemical properties: blue = negatively charged, magenta = 
positively charged, red = hydrophobic, and green = hydrophilic or polar. Secondary structure 
prediction for the human TMCO6 protein was carried out using the PSIPRED 2.0 online tool 
(available from: http://bioinf.cs.ucl.ac.uk/psipred/) (Jones, 1999). The residues with the 
highest possible confidence score for the prediction of involvement in an α-helix are annotated 
by the blue bar above the sequence. The affected arginine falls within an α-helix. Repeating 
the PSIPRED 2.0 secondary structure prediction with the mutated primary protein sequence 





 Characterising Patient Fibroblasts by SDS-PAGE and Western Blot Analysis 
Since this is, to our knowledge, the first time TMCO6 had been linked to mitochondrial disease 
or human disease pathology of any kind, a preliminary molecular assessment of the patient 
cells was carried out. 
 
Firstly, whole cell lysates were extracted from patient-derived skin fibroblasts (P) and two 
control primary fibroblast cell lines (Controls A and B). Equivalent quantities of protein were 
separated by size under denaturing conditions by SDS-PAGE. Western blotting and 
immunodetection was performed in order to determine the steady-state levels of TMCO6, CI 
subunits from each of the modules, CI assembly factors, as well as various subunits of the 
other OXPHOS complexes (CII-CV).  
 
As evident in Fig 4.8, the steady-state level of endogenous TMCO6 normalised to the cytosolic 
loading control GAPDH is decreased by approximately a third in patient cells. Additionally, 
quantities of the CI subunits NDUFS3 (Q-module), and NDUFA11 (PP-module) were also 
reduced to varying extents. NDUFV1 (N-module), NDUFA9 (N-module/Q-module border) and 
NDUFB8 (PD-module) showed no observable differences in quantity. The relative abundances 
of CI assembly factors ACAD9 and NDUFAF3, involved in intermediate to late-stage CI 
biogenesis, were also decreased by ~ 55 and ~ 35 %, respectively. Reduction in protein levels 
for subunits of other respiratory chain complexes, namely SDHA and SDHB (CII), UQCRC1 
and UQCRC2 (CIII), and MT-CO1, MT-CO2 and COX4 (CIV), were observed, which led us to 
question whether mitochondrial mass was affected. Indeed, mitochondrial loading control 
TOMM20 was decreased but the abundances of CS and HSP60 were unaffected compared 
to counterpart controls. From this initial experiment, it is not possible to determine whether the 
mutant form of TMCO6 is directly impacting the steady-state levels of these subunits or 







Figure 4.8. Decrease in TMCO6 protein steady-state level found alongside a reduction 
in CI, CII, CIII, and CIV subunits, CI assembly factors and mitochondrial mass markers 
in patient primary fibroblasts. 
 
SDS-PAGE was performed as per section 2.6.2 with 10 μg of protein from whole cell lysates 
obtained from patient-derived skin fibroblasts (P), and two control skin fibroblast cell lines (A 
and B). WB analysis followed for immunodetection of TMCO6, CI subunits NDUFA9, 
NDUFA11, NDUFB8, NDUFS3, and NDUFV1, CI assembly factors ACAD9, ECSIT, 
NDUFAF1 and NDUFAF3, CII subunits SDHA and SDHB, CIII subunits UQCRC1 and 
UQCRC2, CIV subunits MT-CO1, MT-CO2, and COX4, CV subunit ATP5A, mitochondrial 
loading controls (L.C.) CS, HSP60 and TOMM20, and cytosolic L.C. GAPDH using the primary 
antibodies and concentrations detailed in Table 2.29. At least three biological replicates have 
been analysed; one representative image for each protein is shown here. The corresponding 
module of each CI subunit is indicated by a coloured square, see legend. Densitometric 
quantification of the band intensities relative to the signal for GAPDH were calculated with the 
















































































Patient and control primary fibroblasts were subjected to immortalisation in order to avoid 
cellular senescence and also to increase the rate of proliferation (see section 2.3.3). No 
differences in cellular morphology or growth rate were observed compared to control cell lines. 
SDS-PAGE analysis was performed as before, with more CI subunits and assembly factors 
immunodetected (Fig 4.9). Again, reduction in the steady-state level of TMCO6 was observed 
in patient cells normalised to the signal of the cytosolic loading control, GAPDH. Densitometric 
quantification showed reductions in CI subunits NDUFS1 (N-module), NDUFA9, NDUFS2, and 
NDUFS3 (Q-module), NDUFA10 and NDUFA11 (PP-module), the CI assembly factors ACAD9, 
NDUFAF1, NDUFAF2, and NDUFAF3. The levels of the subunits of the PD module, NDUFB3, 
NDUFB8 and NDUFB11, were only slightly reduced compared to controls. Various subunits of 
the other respiratory complexes and all chosen markers for mitochondrial mass, HSP60, CS 
and TOMM20, showed decreases. We concluded from this that mitochondrial mass was very 
likely decreased in patient cells. Importantly, primary and immortalised patient fibroblasts 
showed comparable differences indicating that the immortalisation process had not led to a 
loss of the mutant phenotype. It was unclear at this stage whether mitochondrial mass was 






Figure 4.9. A reduction in the quantities of additional subunits of Complex I and CI 
assembly factors was observed in patient immortalised fibroblasts. 
SDS-PAGE was performed as per section 2.6.2 with 15 μg of protein from whole cell lysates 
obtained from immortalised patient (Pi), and control (Ai and Bi) skin fibroblast cell lines. WB 
analysis followed for detecting TMCO6, CI subunits NDUFA9, NDUFA10, NDUFA11, 
NDUFAB1, NDUFB3, NDUFB8, NDUFB11, NDUFS1, NDUFS2, and NDUFS3, CI assembly 
factors ACAD9, ECSIT, FOXRED1, NDUFAF1, NDUFAF2 and NDUFAF3, CII subunits SDHA 
and SDHB, CIII subunit UQCRC1, CIV subunits MT-CO1 and MT-CO2 and mitochondrial 
loading controls (L.C.) CS, HSP60 and TOMM20, and cytosolic L.C. GAPDH using the primary 
antibodies and concentrations detailed in Table 2.29. At least three biological replicates have 
been analysed; one representative image for each protein is shown here. The corresponding 
module of each CI subunit is indicated by a coloured square, see legend (bottom right). 
Densitometric quantification of the band intensities relative to the signal for GAPDH were 








































































































 Abundances of CI Supercomplex and Subcomplex Species Altered in 
Immortalised Patient Fibroblasts 
Next, we sought to investigate the effect of the observed reduction in steady-state levels of 
OXPHOS subunits (Figs. 4.8 and 4.9) on relative levels of the respiratory chain complexes, 
and their respective subcomplexes or supercomplexes for both primary and immortalised 
patient cell lines. The endogenous anti-TMCO6 antibody did not recognise the native protein, 
so it was not possible to detect a signal for native TMCO6 or study its co-localisation with any 
of the mature respiratory chain complexes by 1D-BNGE. 1D-BNGE, Western blotting and 
immunodetection with an anti-NDUFB8 primary antibody revealed little difference in the 
amount of CI holocomplex between primary or immortalised patient-derived cells (P, Pi) 
compared to two control (A, Ai and B, Bi) fibroblast cell lines, for mitoplasts solubilised with 1 
% DDM (Fig. 4.10 A.), with the signal of CI normalised against that of CII (immunodetected by 
SDHB). Since quantity of mitochondrial protein was routinely used to normalise the loading of 
samples, and not quantity of cells, it is possible that this process masked any reduction in 
levels of all the respiratory chain complexes owing to reduced mitochondrial mass. This result 
did show that there is a 1:1 ratio for each of CI, CII, CIII2 and CIV between the patient cells and 
the two controls for both primary and immortalised cell lines. Long exposure of 
immunodetection of NDUFB8 (PD-module) in DDM-treated mitoplasts revealed no change in 
the amount of the CI holocomplex, but it did show a relative increase in the quantity of a 
subassembly product of ~680 kDa (denoted by the red arrowhead) in the patient versus both 
controls (Fig. 4.10 B.). This fits with the expected size of the NDUFB8-containing PP-b/PD-
a/PD-b subassembly complex (Fig. 1.4). Immunodetection of NDUFS3 (Q-module) also 
revealed no change in the amount of the CI holocomplex in primary and immortalised patient 
cells (Fig. 4.10 C.). A ~900 kDa subcomplex (indicated by the green arrowhead), 
corresponding to the size of CI lacking the N-module but with assembly factors still bound, was 
decreased, and the quantity of a~740 kDa subcomplex (indicated by the blue arrowhead), 
corresponding to the expected size of the Q/PP module, showed no changes in quantity for 
patient cells relative to controls. The amount of a ~400 kDa subcomplex (indicated by the 
orange arrowhead), corresponding to the size of the Q/PP-a module, is slightly elevated in 
patient cells. Together, these results suggest a role for TMCO6 in the assembly or the 






Figure 4.10. Primary and immortalised patient cells show no change in monomeric CI 
abundance, but exhibit an increase in a NDUFB8-containing subcomplex.  
 
(A.) 1D-BNGE was performed with approximately 120 μg of mitochondrial protein treated with 
1 % DDM from primary or immortalised patient (P, Pi) and control (A, Ai and B, Bi) skin 
fibroblast cell lines. Samples were resolved using 3 – 12 % gradient Novex® NativePAGE gels 
as per section 2.6.3. Immunodetection of native CI, CII, CIII2, CIV and the CIII2 + CIV 
supercomplex was performed by WB analysis by successive incubations with primary 
antibodies against NDUFB8, SDHB, UQCRC2, and MT-CO1, respectively (for antibody 
manufacturer details and concentrations used for each, see Table 2.29). Long exposure of 
immunodetection of NDUFB8 (right) revealed a ~680 kDa protein subcomplex species (red) 
elevated in patient cells, but no differences to the relative abundance of the CI holocomplex 
between patient and control cell lines for both primary and immortalised cells. (C.) 
Immunodetection of NDUFS3 in primary and immortalised cells were also showed no change 
in amount of the CI holocomplex, and an overexposed image of the immortalised samples 
shows decrease of the ~900 kDa band (green), no change in quantity of a ~740 kDa 





Given that the primary and immortalised patient cells showed equivalent molecular 
phenotypes, immortalised cells were used for all additional investigation into alterations to CI 
stability and assembly by 1D-BNGE analyses. Immunodetection of NDUFS1 (N-module) in 
mitochondrial protein extracts from immortalised cell lines solubilised with DDM showed a 
reduction in the amount of fully assembled CI (Fig. 4.11), relative to the loading control, CII. 




Figure 4.11. Immortalised patient cells show reduction in CI holocomplex abundance 
following immunodetection of NDUFS1.  
 
1D-BNGE was performed with approximately 120 μg of mitochondrial protein treated with 1 % 
DDM from immortalised patient (Pi) and control (Ai and Bi) skin fibroblast cell lines. Samples 
were resolved using 3 – 12 % gradient Novex® NativePAGE gels as per section 2.6.3. 
Immunodetection of native CI, CII, CIII2, CIV and the CIII2 + CIV supercomplex was performed 
by WB analysis by successive incubations with primary antibodies against NDUFS1, SDHB, 
UQCRC1, and MT-CO1, respectively (for antibody manufacturer details and concentrations 
used for each, see Table 2.29). CI holocomplex abundance, and to a lesser extent that of CIV 
and the CIII2 + CIV supercomplex, showed reductions in the patient sample relative to controls. 
 
 
Mitochondrial protein extracts from immortalised patient and control cells treated with a milder 
non-ionic detergent, digitonin (DIG), again showed no reduction in the amount of the fully 
assembled CI following immunodetection of NDUFB8 (Fig. 4.12 A.). However, preparation with 
DIG revealed a significant decrease in the quantities of several CI-containing supercomplexes. 
The presence of a subcomplex species of ~400 kDa was also detectable in the patient sample 
signifying destabilisation or stalled assembly of CI or a CI-containing supercomplex species 
containing NDUFB8. Abundances of monomeric CII, dimeric CIII2 and monomeric CIV were 
equivalent between patient and control cell lines. Immunodetection of NDUFS3 (Fig. 4.12 B.) 
also showed a reduction in the abundance of CI-containing supercomplex species to a lesser 
extent, and the absence of detection of a ~900 kDa subassembly product in patient cells 
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(indicated by the green arrowhead), likely to be CI lacking the N-module with assembly factors 
attached (Fig. 1.4). There was no accumulation of other bands, suggesting that the 400 kDa 
band detected with NDUFB8 contains a subset of the PP-b/PD-a/PD-b subcomplex, in line with 
the results reported above (Fig. 4.10). The abundances of CIII2 and the CIII2 + CIV 
supercomplex were unaffected. Together, these results suggest disruption of assembly or 
association of CI with the other respiratory chain complexes, and potential destabilisation or 





Figure 4.12. CI-containing supercomplexes reduced in immortalised patient fibroblasts.  
 
1D-BNGE was performed with approximately 120 μg of mitochondrial mitoplasts treated with 
1 % DIG from immortalised patient (Pi) and control (Ai and Bi) skin fibroblast cell lines. 
Samples were resolved using 3 – 12 % gradient Novex® NativePAGE gels as per section 
2.6.3. Immunodetection of native CI, CII, CIII2, CIV and the CIII2 + CIV supercomplex was 
performed by WB analysis with primary antibodies against NDUFB8 (A.), NDUFS3 (B.), 
SDHB, UQCRC2, and MT-CO1 (for antibody manufacturer details and concentration and 
conditions used for each, see Table 2.29). A reduction in CI-containing supercomplex species 
were observed for both antibodies, as was the absence of a ~900 kDa band (indicated by the 





 TMCO6 Co-Migrates with CI by 2D-BNGE 
2D-BNGE, Western blotting and immunodetection was then performed to assess whether 
TMCO6 co-localises with any of the mitochondrial protein complexes or their subcomplexes. 
Importantly, this analysis revealed co-migration of endogenous TMCO6 specifically with the CI 
holocomplex (Fig. 4.13) (indicated by the blue arrows), which was detected by an anti-
NDUFS3 primary antibody in both primary patient and control samples solubilised with 1 % 
DDM, and not with any of the other respiratory chain complexes. Patient cells displayed more 
unassociated or ‘free’ TMCO6 (indicated by the green arrows) in the low molecular weight 
region than the control. Densitometric quantification determined that whilst 71 % of the TMCO6 
signal was co-migrating with NDUFS3 in the control cells, only 25 % was found co-migrating 
in the patient cells. This result suggests that the NP_060972.3:p.Arg91Cys mutation may 
impair or destabilize TMCO6, affecting its ability to associate with the CI holocomplex. 
Furthermore, a ~900 kDa subcomplex product (indicated by the red arrow), again likely to be 
CI lacking the N-module with assembly factors attached, is also detected when 
immunodetecting with NDUFS3 in the patient but not in the control. The membranes were 
successively immunoblotted with anti-UQCRC1 (recognising CIII), anti-MT-CO1 (CIV) and 
anti-SDHB (CII) antibodies, with no significant changes to the quantities or assembly of CII, 
CIV, CIII2 and the CIII2 + CIV supercomplex (*) observed between the patient and the control. 
SDHB was used as a loading control.  
 
The same process was performed again as for Fig. 4.13, with the sample samples, but 
membranes were immunodetected for a greater number of proteins. CI subunit NDUFB8 (PD-
module) was immunodetected as well as NDUFS3 (Q-module), and in addition to this, CII 
subunit SDHA, CIII subunit UQCRC1 and CIV subunits MT-CO1 and MT-CO2 were 
immunodetected to show the distribution  the mature respiratory chain complexes CI, CI, CIII2, 
CIV and the CIII2 + CIV supercomplex (Fig. 4.14). The relative distribution of all subunits for 
the patient were comparable to the control, with slight differences observed in the relative 
amounts of several of the subunits, namely a decrease in the amount of NDUFB8 (PD module, 
CI) and SDHA (CII), and an increase in the amounts of UQCRC1 (CIII2, and CIII2 + CIV), and 
MT-CO1 (CIV, CIII2 + CIV), and no observable difference in the amount of NDUFS3 (Q-
module, CI). However, 2D-BNGE is not strictly a quantitative method so any differences In 
abundances must be interpreted with cautious, lest they be a result of using less antibody or 
from longer primary antibody incubation time for one membrane compared to another, etc. 
What can be concluded is that there seems to be no loss of any of the mature complexes 






Figure 4.13. TMCO6 co-migrates with the  mature CI holocomplex. 
 
2D-BNGE was performed with approximately 250 μg of mitochondrial protein (+ 1 % DDM) 
prepared from patient and control A primary skin fibroblasts. Samples were run in the first 
dimension using NativePAGE 3-12 % gradient gels as per section 2.6.3, and then resolved 
under denaturing conditions by SDS-PAGE (with 1X MOPS running buffer). Membranes were 
sequentially immunodetected with TMCO6, SDHB (CII), NDUFS3 (CI), UQCRC1 (CIII2), and 
MT-CO1 (CIV) primary antibodies (details in Table 2.29). The asterisks (*) denote 






Figure 4.14. 2D-BNGE shows similar migration of OXPHOS subunits and for patient and 
control skin fibroblasts.  
 
2D-BNGE was performed with approximately 250 μg of mitochondrial protein (+ 1 % DDM) 
prepared from patient and control A primary skin fibroblasts. Samples were run in the first 
dimension using NativePAGE 3-12 % gradient gels as per section 2.6.3, and then resolved 
under denaturing conditions by SDS-PAGE (with 1X MOPS running buffer). Membranes were 
sequentially immunodetected with SDHA (CII), NDUFS3 and NDUFB8 (CI), UQCRC1 (CIII2), 
and MT-CO1 and MT-CO2 (CIV) primary antibodies (details in Table 2.29). The asterisks (*) 





 CI Enzymatic Activity and O2 Consumption Is Unaffected in Patient Fibroblasts 
The next aim of this initial investigation was to conclude whether there were differences in 
specific CI enzymatic activity and mitochondrial oxygen (O2) consumption for the patient 
immortalised fibroblasts. 1D-BNGE analysis of mitochondrial protein extracts solubilised with 
1 % DDM was performed in duplicate, with one gel subjected to Western blotting and 
immunodetection and the other incubated in NADH/NBT CI detection solution (Fig. 4.15 A.). 
This qualitative analysis revealed no differences in CI specific activity, corresponding with no 
changes in overall CI abundance, relative to CII as a loading control. Specific biochemical 
activity for CI, CII and CIV were then determined quantitatively by spectrophotometry for two 
biological replicates (Fig. 4.15 B.). CIII values were not sufficient for analysis. Again, no 
significant differences were observed in the specific activity of CI, as determined by two-way 
ANOVA with Sidak’s post hoc test applied. Importantly, these values were normalised to CS. 
It is possible that these cells have less overall CI activity due to a reduction in mitochondrial 
mass, and indeed raw values indicated this was the case compared to both controls before 
normalisation to CS; however, if mitochondrial mass is normalised by taking into account CS 
activity, the proportional CI/CS value is equivalent for Pi, Ai and Bi cell lines. The specific 
activities measured for CII and CIV in Pi cells were also considered to be non-significant 
compared to both Ai and Bi controls.  
 
Following this, mitochondrial aerobic respiration was measured by Oroboros (Fig. 4.15 C.). No 
differences in basal or maximal (uncoupled) O2 consumption was detected in three biological 
replicates using comparable quantities of suspended cultured cells. These data together 
conclude no CI-specific or other mitochondrial respiratory defect in this cell type, perhaps 
owing to the relatively low energy demands of fibroblasts. In support of this, the CI deficiency 
detected in the patient was only determined in skeletal muscle, and not in any other tissue, 
including a cutaneous biopsy. Further models for the study of this protein and its potential 
involvement in CI assembly, stability and/or function were necessary, including knockdown, 
overexpression and knockout cellular models (Chapter 5), and a recombinant murine knockout 






Figure 4.15. OXPHOS activity and oxygen consumption unaltered in patient fibroblasts.  
 
(A.) 1D-BNGE was performed in duplicate with approximately 120 μg of mitochondrial protein 
extracts treated with 1 % DDM from patient (Pi) and control (Ai and Bi) immortalised skin 
fibroblast cell lines. For one gel, each of the respiratory chain protein complexes were 
immunodetected successively by Western blotting using antibodies raised against the 
subunits in brackets: CI (NDUFB8), CIII2 (UQCRC1), MT-CO1 (CIV) and SDHB (CII) (antibody 
details in Table 2.29). The second gel was submerged in NADH/NBT stain (see section 2.7.2) 
to visually assess specific CI activity. No difference in activity was observed by this qualitative 
method. (B.) Specific enzymatic activity for CI, CII and CIV, each normalised to the activity of 
citrate synthase (CS), was measured for Pi, Ai and Bi cell lines as per section 2.7.1. Data are 
presented as mean ± range (n = 2). One-way ANOVA with Tukey’s multiple comparisons test 
revealed no significant differences. (C.)  Mitochondrial O2 consumption rate was measured for 
live cultured patient (Pi) and control (Ai) immortalised skin fibroblasts using an Oxygraph-2k 
respirometer (Oroboros Instruments, Innsbruck, Austria) as per section 2.7.3. Basal = 
mitochondrial O2 consumption rate at body temperature, Leak = ATP-independent O2 
consumption, and Uncoupled = maximal respiration after addition of the uncoupler carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) (C2759, Sigma-Aldrich®). Data are presented as 
mean ± SEM (n = 3). No differences in basal or maximal respiration were detected for the 









This work: 1) presents what is currently known regarding the conservation, gene structure, 
expression and structural features of the uncharacterised protein TMCO6, and 2) investigates 
the molecular and metabolic consequences of a homozygous recessive mutation in TMCO6 
in patient-derived skin fibroblasts. 
 
At the time of this work, TMCO6 is a completely uncharacterised, nuclear-encoded protein 
found in Metazoans. It is ubiquitously expressed amongst all human tissues as two main 
isoforms, TMCO6.1 and TMCO6.2, which produce gene products that differ by 6 in-frame 
amino acids from position 230 of the primary protein sequence. TMCO6 is expected to form 
up to 5 armadillo (ARM) repeats that likely produce a superhelical ARM-type fold tertiary 
structure. Transmembrane predictions are contradictory, suggesting occurrence of two, one or 
no transmembrane regions situated towards its C-terminus. Its intracellular localisation is 
unknown, requiring experimental confirmation (see Chapter 5). 
A novel mutant variant in TMCO6 (NM_018502.5: c.271C>T,p.Arg91Cys) was identified by 
WES as the most likely causal genetic candidate in a paediatric proband presenting with 
severe psychomotor delay, nystagmus, epilepsy, and progressive hypomyelination of cortical 
and subcortical brain regions. Biochemical activity measurements of a skeletal muscle biopsy 
determined CI deficiency (5.58 nmol/min/mg, n.v. 13 - 24) and reduced CS activity (37 
nmol/min/mg, n.v. 80-120), suggesting a mitochondrial disease origin. Sanger sequencing 
confirmed the presence of a recessive point mutation in TMCO6 in homozygosity in the patient 
and in heterozygosity in both parents. Additionally, the mutation was predicted by in silico 
analyses to be highly pathogenic. A multiple sequence alignment for human TMCO6 and nine 
vertebrate orthologs showed strong conservation of the affected arginine residue (Arg91).  
TMCO6 steady-state level was found to be partially decreased in patient cells, but still present. 
Subunits from all respiratory chain complexes showed a decrease in their relative abundances 
to varying extents, suggesting a reduction in overall mitochondrial mass. This was supported 
by a reduction in mitochondrial mass markers HSP60, CS and TOMM20. 1D-BNGE showed 
no change in the abundance of the CI holocomplex following immunodetection of NDUFB8 (PD 
module) or NDUFS3 (Q-module) in DDM-solubilised mitoplast samples. However, 
immunodetection with NDUFS1 (N-module) showed some reduction in fully assembled CI 
abundance and immunodetection with NDUFB8 revealed accumulation of a CI subcomplex in 
the patient. Digitonin-solubilised samples revealed a clear reduction in the abundance of CI-
containing supercomplexes. We also observed loss of a ~950 kDa species and the presence 
of an additional NDUFB8-containing subassembly/degradation product in the patient sample.  
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2D-BNGE analysis demonstrated co-migration of TMCO6 with CI. The distribution of subunits 
of CI, CII, CIII and CIV were similar between patient and control cells. Free/unassociated 
TMCO6 was detected in the low molecular weight portion of the membrane in both samples, 
but the relative quantity was increased in the patient. This result suggests that the 
NP_060972.3:p.Arg91Cys mutant variant may impair or destabilize TMCO6, affecting its ability 
to associate with the CI holocomplex. 
In-gel activity (qualitative) and biochemical evaluation by spectrophotometry (quantitative) 
determined no specific CI enzymatic activity deficiency in this tissue type. Additionally, no 
differences in CII or CIV specific activities were determined. Oxygen consumption was 
unchanged in both basal conditions and following uncoupling of the respiratory chain.  
Although computational analyses predicted a high likelihood of pathogenicity for the TMCO6 
mutant variant, patient fibroblasts revealed only mild molecular and biochemical phenotypes. 
The severe CI deficiency observed in the patient was only determined in skeletal muscle, and 
no other tissues from the patient were analysed. This suggests that, as also described for other 
mitochondrial diseases, the effects of the mutant form are only observable in tissues with 
higher demands in aerobic respiration than skin fibroblasts. Importantly, this preliminary 
investigation revealed possible physical interaction between TMCO6 and CI in vivo. To provide 
further support to this result, immunoprecipitation experiments for endogenous TMCO6 and 
for the native CI complex were performed (Chapter 5). Additionally, several other cellular 
models (Chapter 5) and a Tmco6-knockout mouse model (Chapter 6) were studied to 
elucidate the consequences of alterations in TMCO6 abundance on mitochondrial physiology 
















Chapter 5  
Cell-Based Strategies and Cellular Models for  





The work presented in this chapter concerns cell-based strategies and cellular models for the 
study of the TMCO6 protein. Our first aim was to determine the specific intracellular 
localisation of TMCO6 through a combination of immunocytochemistry, performed using HeLa 
and 143B cell lines, and subcellular fractionation, protease digestion and salt gradient 
experiments, using HeLa and HEK 293T cells. Proving mitochondrial localisation of TMCO6 
was crucial for allowing it to be considered a contender as the causal protein responsible for 
the severe CI deficiency detected in a human mitochondrial disease patient with a 
homozygous recessive mutation in TMCO6 (described in Chapter 4). Secondly, I describe the 
generation and subsequent characterisation of shRNA knockdown and doxycycline-inducible 
overexpression cellular models, and the attempted generation of a CRISPR/Cas9 knockout 
model, all used to further investigate the association of TMCO6 with Complex I (CI). In 
particular, we sought to interrogate the consequences of alterations to TMCO6 expression on 
CI stability, the abundance of the CI monomer, its subunits, subassembly intermediates and 
supercomplex species, and its specific enzymatic activity. Lastly, immunoprecipitation for 
endogenous TMCO6 and the native CI holocomplex were used in tandem to assess whether 
there is in fact physical interaction between the two, as originally suggested by 2D-BNGE in 
patient primary skin fibroblasts (Fig. 4.12). This strategy was also used to identify potential 





 TMCO6 Localises Specifically to the IMM 
In order to establish the specific intracellular localisation of TMCO6, two independent methods 
were undertaken. Firstly, immunocytochemistry (ICC) of fixed HeLa and 143B cancer cell lines 
was performed to compare the signal of a primary antibody that recognises endogenous 
TMCO6 with nuclear (DAPI) and mitochondrial (MitoTracker) markers. As shown in Fig 5.1, 
the signal for endogenous TMCO6 co-localises faithfully with MitoTracker, but not with DAPI 
in both cell lines. Independently, subcellular fractionation of HeLa and HEK 293T cells was 
performed by hypotonic shock and differential centrifugation to separate mitochondrial, 
cytoplasmic and nuclear fractions from whole cell protein lysates. As shown in Fig. 5.2, SDS-
PAGE and Western blot analysis showed TMCO6 to be present only in the whole cell protein 
lysates and mitochondrial fractions, similarly to the known nuclear-encoded mitochondria-
localising protein SDHA, and not in either nuclear or cytoplasmic fractions, unlike SF2 or TUBB, 
respectively. Both of these results strongly indicate that endogenous TMCO6 localises 
specifically to the mitochondria in cultured human cells. Despite the annotated IBB domain 
predicted at the N-terminal of the protein (Fig. 4.2), TMCO6 was not found to localise to the 




Figure 5.1 TMCO6 localises to the mitochondria in HeLa and 143B cells by ICC. 
 
ICC was performed as per section 2.4.2 to visualise the subcellular localisation of 
endogenous TMCO6 in HeLa or 143B cells relative to the mitochondrial network, as stained 
by MitoTrackerTM Red CMXRos and nuclei, as stained by DAPI (both from InvitrogenTM). 
Images were acquired using the A1/A1R Confocal Microscope System (Nikon UK Ltd, 
Kingston upon Thames, UK) with a 63x 1.40 numerical aperture oil immersion objective. 
Images were post-processed and compiled using Fiji Image J software (Schindelin et al. 





Figure 5.2 TMCO6 localises to the mitochondria in HeLa and HEK 293T cells. 
 
Subcellular fractionation by differential centrifugation was performed as per section 2.6.7 in 
order to separate whole cells from both HeLa and HEK 293T, here shown as protein lysates 
(L), into mitochondrial (M), cytosolic (C), and nuclear (N) fractions. SDS-PAGE was performed 
as per section 2.6.2, followed by Western blotting (section 2.6.4) and immunodetection 
(section 2.6.5) with anti-TUBB, anti-SDHA, anti-SF2, and anti-TMCO6 primary antibodies 
(see Table 2.29 for manufacturer details and concentrations used). 
 
Next, we sought to determine the specific intramitochondrial localisation of TMCO6, again by 
a two-part method. Firstly, isolated mitochondria from HEK 293T cells were subjected to 
hypotonic shock or membrane solubilisation with two concentrations of digitonin, 20 or 50 
μg/ml. Trypsin digestion of each sample was performed as indicated in Fig. 5.3. The OMM 
protein TOMM70 is degraded in all cases of trypsin treatment, regardless of membrane 
swelling or solubilisation of the OMM. TIM23, part of the TIM23 translocase complex of the 
IMM that protrudes into the IMS, is degraded partially in all conditions of trypsin treatment, 
and more so after membrane swelling of the OMM by hypotonic shock or solubilisation of the 
OMM by digitonin treatment. SDHB, known to localise to the IMM, and ETFB, known to localise 
to the MM, are protected in all conditions of protease treatment or membrane 
rupture/solubilisation. TMCO6 is protected in all cases of trypsin treatment or OMM membrane 
disruption similarly to these markers. This result indicates TMCO6 either localises to the 







Figure 5.3 TMCO6 is protected from trypsin digestion following OMM swelling and 
solubilisation with digitonin. 
 
Subcellular fractionation by differential centrifugation was performed as per section 2.6.7 in 
order to isolate mitochondria from HEK 293T cells. Mitochondria were separated into aliquots 
of equal protein amount and subjected to hypotonic shock or digitonin solubilisation (with 20 
or 50 μg/ml digitonin, as indicated), and either collected immediately or further incubated with 
25 μg/ml trypsin. SDS-PAGE was performed as per section 2.6.2, followed by Western 
blotting (section 2.6.4) and immunodetection (section 2.6.5) with anti-TOM70, anti-TIM23, 
anti-SDHB, anti-ETFB, and anti-TMCO6 primary antibodies (see Table 2.29 for manufacturer 
details and concentrations used). 
 
Following on from this, intact mitochondria isolated from HEK 293T cells were subjected to 
digitonin treatment to create mitoplasts, containing only the IMM and MM. Mitoplasts were 
sonicated to disrupt the IMM, and centrifuged to result in a pellet, containing all membrane-
embedded or membrane-tethered IMM proteins, and a supernatant fraction, containing all 
soluble MM proteins. Pellets and supernatants were then incubated in low-salt (150 mM) or 
high-salt (500 mM) conditions, to gradually dissociate proteins from their resident membrane, 
or 2 % SDS, to confirm disruption of the IMM since all proteins would then be accessible for 
denaturation by SDS. All fractions were analysed by SDS-PAGE and Western blotting, as 




Figure 5.4 TMCO6 is a membrane-bound protein which can be dissociated from the 
membrane with the addition of salt. 
 
Subcellular fractionation by differential centrifugation was performed as per section 2.6.7 in 
order to isolate mitochondria from HEK 293T cells. Intact mitochondria were sonicated and 
then separated into aliquots of equal protein amount and incubated with nothing, one of two 
different concentrations of salt (150 mM or 500mM) or 2 % SDS, as indicated. Aliquots were 
then centrifuged once more and resulting pellet (P) and supernatant (s) fractions were 
collected. SDS-PAGE was performed as per section 2.6.2, followed by Western blotting 
(section 2.6.4) and immunodetection (section 2.6.5) with anti-NDUFB8, anti-ETFB, anti-
LRPPRC, anti-POLG1, anti-ACAD9, anti-NDUFAF1, anti-NDUFAF2 and anti-TMCO6 primary 
antibodies (see Table 2.29 for manufacturer details and concentrations used). 
 
As shown in Fig 5.4, TMCO6 is primarily found in the membrane fraction of untreated 
mitoplasts. With increasing salt gradient, TMCO6 can be dissociated from the membrane into 
the soluble fraction, similarly to the CI assembly factor NDUFAF2 and the nucleoid proteins 
LRPPRC and POLG1, and in clear contrast to other CI assembly factors like ACAD9 and 
NDUFAF1. In combination, these experiments suggest that TMCO6 is a mitochondrial protein, 
localising to the IMM, which is tethered to the membrane and not embedded given its 




 Investigating the Effects of TMCO6 Gene Silencing 
To begin to investigate the role of TMCO6 in CI assembly and stability, RNA interference 
(RNAi) was performed by lentiviral transduction of HEK 293T cells with four different short 
hairpin RNAs (shRNAs) specific for human TMCO6 (shRNA1 – 4, see Table 2.21 for details). 
Two control vectors were used alongside these: an empty vector (EV) control, encoding no 
shRNA sequence, and a non-mammalian negative (-) control, encoding an shRNA sequence 
for a synthetic version of GFP derived from the crustacean Pontellina plumata. Following 
selection of successfully transduced cells by puromycin treatment, we first sought to quantify 
the extent of TMCO6 gene silencing. Total RNA was extracted from each of the six cell lines, 
retrotranscribed to cDNA and then subjected to RT-qPCR (procedure and components 
detailed in section 2.2.14) in technical triplicates to quantify the relative abundance of TMCO6 
mRNA transcripts normalised to the relative abundance of GAPDH mRNA transcripts. 
Quantification was performed using the DDCt method (Fig 5.5) and revealed that shRNA-1 
was the least effective of the four shRNAs, producing only a ~35 % reduction in TMCO6 gene 
expression, whereas the other three shRNAs (shRNA-2, shRNA-3 and shRNA 4) produced 
reductions of between 80 – 95 %.  
 
  
Figure 5.5 TMCO6 mRNA transcript abundances after TMCO6 shRNA knockdown.  
 
RT-qPCR was performed as per section 2.2.14 to quantify TMCO6 mRNA transcript 
abundance in four shRNA knockdown cell lines for TMCO6 and two control cell lines, and 
empty vector (EV) control and a non-mammalian-targeted shRNA control, relative to mRNA 
transcript abundances for GAPDH. shRNA-1 is the least effective of the four, producing only 
~ 35 % reduction. shRNA-2, shRNA-3 and shRNA-4 each produced reductions in TMCO6 

























































Next, the protein levels for TMCO6 and the loading control GAPDH were determined by 
immunodetection following SDS-PAGE and Western blotting using whole cell protein lysates 
obtained from each of the four shRNA-knockdown cell lines and both controls. As shown in 
Fig 5.6, densitometric quantification revealed approximately 70 % residual abundance of 
TMCO6 in shRNA-1, 20 % for shRNA-2, 40 % for shRNA-3 and 30 % for shRNA-4. All 
knockout cell lines were found to recover TMCO6 expression to normal levels compared to 
the two control cell lines relatively quickly; therefore, all experiments performed with these 




Figure 5.6 TMCO6 protein abundances after TMCO6 shRNA knockdown.  
 
SDS-PAGE, Western blot analysis and immunodetection using anti-TMCO6 and anti-GAPDH 
primary antibodies (see Table 2.29 for antibody details) for whole cell protein lysates from four 
HEK 293T TMCO6-knockdown cell lines (shRNA1-4), and empty vector (EV) and non-
mammalian negative (-) controls. Shown underneath is densitometric quantification of the 
TMCO6 signal normalised to the GAPDH signal for each cell line, calculated with the Fiji Image 
J software (Schindelin et al., 2012) using the Gel Analysis integrated function. Data are 
presented as mean ± SEM (n = 3).  
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We also observed a slower growth rate for shRNA-2 and shRNA-3 cell lines cultured in 
glucose-rich media, compared to the empty vector and non-mammalian controls, and the 
shRNA-1 cell line, following TMCO6 gene silencing (Fig. 5.7.). shRNA-1 grew comparably to 
both experimental controls, most probably given that it had only a mild reduction in TMCO6 
abundance. shRNA-4 was also tested but the results varied greatly, so was discounted from 
analysis. These differences in growth speeds for shRNA-2 and shRNA-3 cell lines compared 




Figure 5.7 Growth curves for shRNA-knockdown cell lines vs. controls in glucose-rich 
culturing media.  
 
Growth rate for empty vector, non-mammalian control, shRNA-1, shRNA-2 and shRNA-3 cell 
lines cultured in glucose-rich media was assessed by phase contrast light microscopy using 
an IncuCyte HD instrument (Essen Bioscience, UK) in technical triplicates, as per section 
2.4.1. Statistical analysis: * p < 0.05, ** p < 0.01, *** p < 0.005, **** p <0.001, calculated by 
one-way ANOVA with the Tukey post hoc test applied, performed as per section 2.7. 
 
Next, 1D-BNGE was performed to assess differences in the abundance and distribution of the 
mitochondrial respiratory chain protein complexes by size. As shown in Fig 5.8 A., native CI 
abundance is partially decreased for shRNA-2, shRNA-3 and shRNA-4 cell lines compared to 
the non-mammalian and empty vector controls, and the ineffective knockdown cell line, 
shRNA-1. However, the largest observable difference was in the abundance of CI-containing 
supercomplexes. The CIII2 + CIV supercomplex band is also reduced to some extent, whereas 
both CIII2 and CIV quantities are comparable to the abundances of the two controls. CI in-gel 


















































3 samples. This qualitative result was corroborated quantitatively by spectrophotometric 
analyses (Fig 5.8 B.). TMCO6 gene silencing resulted in an isolated CI deficiency of ~ 40 % 
in shRNA-2, shRNA-3 and shRNA-4 cell lines in two biological replicates. Specific activities 


























Figure 5.8 Abundance of native CI and CI-containing supercomplexes was reduced in 
three shRNA-knockdown cell lines, as was specific CI enzymatic activity. 
 
(A.) 1D-BNGE, Western blot analysis and immunodetection using anti-NDUFB8 (recognising 
CI), anti-UQCRC2 (recognising CIII), and anti-CO1 (recognising CIV) (see Table 2.29 for 
antibody details) for mitochondrial protein extracts treated with 1 % DDM from four HEK 293T 
TMCO6-knockdown cell lines (shRNA1-4), and empty vector (EV) and non-mammalian 
negative (-) controls. CI in-gel activity (above) was performed as per section 2.7.2 on an 
identical gel. (B.) Specific enzymatic activities for CI, CII, CIII and CIV were measured as per 
section 2.7.1 for EV, -, shRNA-1, shRNA-2 shRNA-3 and shRNA-4 cell lines and normalised 
to the specific activity of citrate synthase (CS) per cell line. Data are presented as mean ± 
range (n = 2 biological replicates). Statistical analysis: ** p < 0.01, *** p < 0.005, calculated by 
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Since we had observed an increased presence of some CI subcomplexes, and also, TMCO6 
dissociation from fully assembled CI in patient fibroblasts, we wanted to investigate these 
aspects in gene silenced cells. A fraction of TMCO6 co-localises with native CI by 2D-BNGE 
in the control and knockdown cell lines (Fig. 5.9). This finding corroborates the co-localisation 
seen for control and patient-derived primary skin fibroblasts (Fig 4.12). However, the 
proportion of TMCO6 co-migrating with fully assembled CI is higher in empty vector and non-
mammalian HEK 293T control cell lines than in shRNA-3 and shRNA-4 TMCO6-knockdown 
cell lines, calculated by quantifying the relative amounts of S1, S2 and CI for each cell line out 
of 100 %. As shown in Fig. 5.9, the amount of TMCO6 colocalising with CI in knockdown cell 
lines is reduced between 20 – 30 % by densitometric quantification compared to both controls, 
and there is an equivalent increase in the relative quantity of the smaller of two sub-assembly 
intermediates. This result suggests TMCO6 dissociation from fully assembled CI in this cell 








Figure 5.9 Reduced fully assembled CI and subassembly accumulation in TMCO6-
knockdown HEK 293T cell lines 
 
(A.) 2D-BNGE, Western blot analysis and immunodetection of mitochondrial protein extracts 
treated with 1 % DDM from empty vector and non-mammalian 293T control and two shRNA-
knockdown cell lines using anti-TMCO6 and anti-NDUFS3 (recognising CI) primary antibodies 
(see Table 2.29 for antibody details). (B.) Densitometric quantification of the TMCO6 signals 
for subassembly 1 (S1), subassembly 2 (S2) and Complex I (CI) for each of the four cell lines, 
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 Investigating the Effects of TMCO6 Gene Overexpression 
A doxycycline-inducible overexpression system for human TMCO6 was generated in Flp-InTM 
HEK 293T cells in order to investigate the function of TMCO6. For this, we studied both major 
isoforms, TMCO6.1 (NM_018502.5, 493 aa product) and TMCO6.2 (NM_001300980.1, 499 
aa product), as well as the addition of the human patient mutation (NM_018502.5: c.271C>T), 
into both of these in order to determine whether the mutant protein affected CI stability or 
enzymatic activity. These four TMCO6 variants (TMCO6.1-WT, TMCO6.1-R91C, TMCO6.2-
WT and TMCO6.2-R91C) were each C-terminally tagged with HA (peptide sequence: 
YPYDVPDYA), or FLAG/STREP (FS) (peptide sequence: DYKDDDDK/WSHPQFEK), to 
generate 8 distinct inducible TMCO6 transgenes: TMCO6.1-WTHA, TMCO6.2-WTHA, 
TMCO6.1-MUTHA, TMCO6.2-MUTHA, TMCO6.1-WTFS, TMCO6.2-WTFS, TMCO6.1-MUTFS, 
and TMCO6.2-MUTFS.  
 
SDS-PAGE and WB analysis (Fig 5.10 A.) shows the outcome of 48-hour incubations of four 
HEK 293T cell lines either expressing FLAG-tagged wildtype (WT) or mutant (R91C) TMCO6, 
TMCO6.1-WTFLAG, TMCO6.1-R91CFLAG, TMCO6.2-WTFLAG, and TMCO6.2-R91CFLAG, with 
three different concentrations of doxycycline (DOX). The signal for FLAG-tagged TMCO6 was 
detectable only in induced cell lines, and non-induced (0 ng/ml DOX, - DOX) controls showed 
no ‘leakage’ of the FLAG-tagged TMCO6 gene products by SDS-PAGE. 2.5 ng/μl DOX was 
selected for subsequent experiments given its reproducible effectiveness and lack of effect on 
growth rate of the cell lines.  
 
Samples resolved under non-denaturing conditions by 1D-BNGE (Fig 5.10 B.) revealed that 
the majority of FLAG-tagged TMCO6 was detectable in the low molecular weight region of the 
gel, with far more detected for isoform TMCO6.1 than for TMCO6.2; however, some of the 
FLAG-tagged TMCO6 signal co-migrated into at least two discrete high molecular weight 
bands (indicated by the red arrowheads). These bands are most probably caused by 
nonspecific binding of the anti-FLAG primary antibody, since the signal was also found to 
varying extents in the non-induced controls. Given the intensity of these unspecific bands, it 
was not possible to discern co-migration of the TMCO6-FLAG signal with that of CI subunits 
NDUFB8 and NDUFS3, or any CI subassembly intermediates by 1D-BNGE or 2D-BNGE 
analyses (data not shown). Next, we sought to determine the effect of overexpression of 
wildtype and mutant TMCO6 on the relative abundances of CI subunits and assembly factors, 




        
 
Figure 5.10 Overexpressing wildtype or mutant TMCO6.1 and TMCO6.2 in HEK 293T cells.   
 
(A.) SDS-PAGE, Western blot analysis and immunodetection was performed for 10 μg of 
whole cell protein extracts from HEK 293T cell lines with inducible TMCO6 transgenes for 
TMCO6.1 or TMCO6.2, each with either wildtype (WT) or patient mutant (R91C) sequences. 
Anti-FLAG and anti-GAPDH primary antibodies were successively immunoblotted on the 
same membranes (see Table 2.29 for antibody details). (B.) 1D-BNGE, Western blot analysis 
and immunodetection followed using an anti-FLAG (recognising TMCO6.1-WTFS, TMCO6.1-
MUTFS, TMCO6.2-WTFS, and TMCO6.2-MUTFS) primary antibody (see Table 2.29 for antibody 
details). Mitochondrial protein from four HEK 293T overexpression cell lines, TMCO6.1 WT, 
TMCO6.1 R91C, TMCO6.2 WT and TMCO6.2 R91C, following incubation with 2.5 ng/μl DOX 
for 48 h or equivalent cell lines that were non-induced (- DOX) were solubilised with 1 % DDM 








SDS-PAGE, Western blot analysis and immunodetection was performed using 10 μg of whole 
cell protein extracts from transduced HEK 293T cell lines following inducible expression of 
TMCO6.1 or TMCO6.2 transgenes, each with either the wildtype (WT) (NM_018502.5/ 
NM_001300980.1) or the patient mutant (c.271C>T) cDNA sequences. As shown in Fig. 5.11 
A., FLAG-tagged WT and Arg91Cys (R91C) forms of TMCO6 were only present in the DOX-
treated cell lines showing that the inducible expression system had been successful, as 
immunodetected by use the endogenous anti-TMCO6 antibody. Unexpectedly, the 
overexpression of epitope-tagged TMCO6 had a respective increase in the abundance of 
endogenous TMCO6 levels (Fig. 5.11 A.) (as indicated by the red arrowheads) in DOX-treated 
TMCO6.1 WT, TMCO6.1 R91C, TMCO6.2 WT and TMCO6.2 R91C cell lines treated with 
DOX. This trend was not seen for the parental HEK 293T + DOX negative control (blue 
arrowhead). This finding is supported by densitometric quantification for intensity of TMCO6 
or TMCO6-FLAG bands relative to the cytosolic loading control, GAPDH (Fig. 5.11 B.). In 
addition, this densitometric quantification revealed that the expression of TMCO6.1 (either WT 
or R91C variants) was between two- and three-fold higher than for both variants of TMCO6.2, 
despite treatment with the same concentration of DOX for an equivalent length of time. All 
induced cell lines showed a clear increase in TOMM20 (Fig. 5.11 A.), supported by 
densitometric quantification (Fig. 5.11 B.), suggesting an increase in overall mitochondrial 
mass. However, this trend was also observed for the parental HEK 293T + DOX control, and 
so it is not possible to credit this change to TMCO6 expression. Instead, the increase in 
mitochondrial mass could be merely an effect of DOX treatment, which has previously been 
shown to alter mitochondrial proteostasis and function (Luger et al., 2018). The abundances 
per cell line of NDUFA9 (Q module) followed the expression pattern for TMCO6 faithfully, more 
so than for any of the other CI subunits, assembly factors or subunits of the other respiratory 
chain complexes. The other subunits that showed variable differences in abundance were 
NDUFB8, and to a lesser extent NDUFB11 (both PD module). However, amounts of NDUFB8 
and NDUFB11 with or without DOX treatment are similar for all cell lines, ie. there is no 
increase or decrease observed following the addition of DOX for any of the cell lines. No 
striking differences in abundance were observed in any of the CI assembly factors or subunits 








Figure 5.11 Characterising inducible expression of wildtype or mutant TMCO6.1 and 
TMCO6.2 in Flp-In™ HEK 293T cells by SDS-PAGE and WB analysis 
 
(A.) SDS-PAGE (4-12 % NuPAGE Bis-Tris, Thermo Fisher Scientific), Western blot analysis 
and immunodetection of 10 μg of whole cell protein lysates from parental HEK 293T cells or 
four HEK 293T overexpression cell lines, TMCO6.1 WT, TMCO6.1 R91C, TMCO6.2 WT and 
TMCO6.2 R91C, following incubation with 2.5 ng/μl DOX for 48 h or equivalent cell lines that 
were non-induced (- DOX). (B.) Densitometric quantification was carried out for TMCO6, 
FLAG-tagged TMCO6 and TOMM20 signals were normalised to the signal for GAPDH per 
cell line. Bars corresponding to non-induced cell lines are solid colours, and those 
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No differences in CI activity was detected by in-gel activity for any of the inducible TMCO6 
overexpression cell lines compared to the parental HEK 293T negative controls following 2.5 
ng/μl DOX treatment for 48 h (Fig 5.12 A.). 1D-BNGE was performed again for separate 
samples prepared with equivalent cell quantities (8 x 106 cells per cell line) (Fig 5.12 B.). This 
showed increased overall mitochondrial mass for the induced cell lines as all complexes were 
upregulated when induced with DOX. Following this, 1D-BNGE and Western blot analysis was 
used again to determine the abundance of CI, immunodetected by NDUFA9, normalised to 
the signal for CII, immunodetected by SDHB, for three biological replicates of samples loading 
accorded to equal quantity of mitochondrial protein (150 ug per cell line) (Fig 5.12 C.). 
Densitometric analysis showed no significant differences in CI levels normalised to CII levels 
by 1D-BNGE. CI was immunodetected by NDUFA9 (Q-module boundary) in particular to see 
whether the trend in protein level seen by SDS-PAGE (Fig. 5.11) would correlate with 
differences in overall CI abundance, but this proved not to be the case.  
 
In summary, this inducible overexpression model did not yield many clues about the function 
or involvement of TMCO6 in CI stability or activity. The unspecific binding of the anti-FLAG 
antibody made specific recognition of high molecular weight complexes by BNGE difficult, and 
DOX treatment was affecting overall mitochondrial mass, perhaps masking any reduction in 
mitochondrial mass in the cell lines overexpressing the mutant TMCO6.1 or TMCO6.2 
isoforms. What we could conclude is 1) that TMCO6.1 is the predominantly overexpressed 
isoform in this cell type, abundant at two- to three-fold higher levels than TMCO6.2, and 2) the 
FLAG-tagged patient mutant variant of both TMCO6 isoforms is stably expressed at 
detectable levels, but at a slightly lower abundance than the wildtype variant, which is identical 
to what we had seen in the patient skin fibroblasts by recognition of the endogenous protein 







Figure 5.12 Overexpressing wildtype or mutant TMCO6 isoforms does not affect CI 
amount or activity when normalised to mitochondrial mass. 
 
(A.) 1D-BNGE and Complex I in-gel activity were carried out as per sections 2.6.3 and 2.7.2 
for equivalent protein quantities of DDM-treated mitochondrial proteins from HEK 293T cells 
and inducible TMCO6-overexpressing HEK 293T cell lines expressing wildtype (WT) or 
mutant (R91C) versions of the TMCO6.1 and TMCO6.2 isoforms. (B.) 1D-BNGE was 
performed as before with samples prepared from equal quantities of cells (8 x 106 in total), 
and WB analysis followed using anti-NDUFB8 (CI), anti-UQCRC1 (CIII), anti-CO1 (CIV) and 
anti-SDHB (CII) primary antibodies (see Table 2.29 for antibody details). (C.) 1D-BNGE was 
performed again as for B., and densitometric quantification was carried out for the band 
intensities of NDUFA9 (recognising CI) per cell line relative to SDHA (recognising CII). Bars 
corresponding to non-induced cell lines are solid colours, and those corresponding to induced 
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 TMCO6 Physically Interacts with the CI Holocomplex by Immunoprecipitation 
Given the result that endogenous TMCO6 co-localised with fully assembly CI by 2D-BNGE in 
patient fibroblasts (Fig. 4.13), the same process was carried out with HEK 293T cells in order 
to assess whether co-localisation was found in other types of human cells (Fig. 5.13). Indeed 
this was the case, as shown for CI immunodetected by NDUFS1 (N-module), NDUFS3 (Q-
module) and NDUFB8 (PD module). Given this finding and their replicative speed/ease to 
harvest, HEK 293T cells were chosen for use in in vitro immunoprecipitation experiments.  
 
 
Figure 5.13. 2D-BNGE shows co-migration of TMCO6 and CI subunits in HEK 293T cells.  
 
2D-BNGE was performed with approximately 200 μg of mitochondrial protein (+ 1 % DDM), 
prepared from commercial HEK 293T cells. Samples were run in the first dimension using 
NativePAGE 3-12 % gradient gels as per section 2.6.3, and then resolved under denaturing 
conditions by SDS-PAGE (with 1X MOPS running buffer). Membranes were sequentially 
immunodetected for TMCO6, NDUFS1 (N-module), NDUFS3 (Q-module), and NDUFB8 (PD 
module) primary antibodies (details in Table 2.29).  
 
Mitochondrial proteins isolated from HEK 293T cells were subjected to immunoprecipitation 
by three different methods: using 1) the Complex I Immunocapture Kit (Abcam ID: ab109711C, 
Abcam, Cambridge, UK), pre-bound to silica beads, 2) the anti-TMCO6 polyclonal rabbit 
antibody (Proteintech ID: ID: 20117-1-AP, Proteintech), recognising endogenous TMCO6 and 
crosslinked to Pierce™ magnetic beads and 3) anti-HA antibody (Catalogue Number: 88836, 
Thermo Scientific™) for detecting TMCO6.1HA in Flp-In™ HEK 293T cells following inducible 
expression with DOX treatment (as described in section 5.2.3 for a FLAG-tagged variant), 
crosslinked to Pierce™ magnetic beads. HA-tagged TMCO6.1 was used instead of FLAG-
tagged TMCO6 since the antibody for anti-HA is more specific in its recognition. 
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As shown in Fig. 5.14, TMCO6 was found in the eluted fraction following immunoprecipitation 
with a commercial CI immunocapture kit (one representative image of three biological 
replicates is shown). As expected, the presence of subunits from all CI modules were also 
found in the eluted fraction to a greater extent than for TMCO6. These include NDUFS1 (N-
module), NDUFA3 (Q-module). NDUFS8 (PP module) and NDUFB8 (PD module). Subunits of 
CII (SDHA), CIII (UQCRC1) and CIV MT-CO1) were not detected in the eluted fraction in any 
experiment. CI structural subunits are enriched in the eluted fraction compared to the 
mitochondrial fraction (M) and the supernatant (S). By contrast, most of the TMCO6 protein is 
retained in the S fraction and a small but significant proportion associates to CI. These results 
verify the observation that part of the TMCO6 pool is associated with CI as seen by 2D-BNGE, 
and strongly supports that TMCO6 does in fact physically interact with CI in vivo. Two IgG 
bands of ~28 kDa and ~54 kDa size were readily detected in all eluted fractions, due to the 
method of elution using the protein denaturant SDS, making visualisation of proteins of these 
sizes not possible. I repeated visualisation of equivalent samples using a goat anti-rabbit 
secondary antibody that should not have recognised the two IgG bands, but unfortunately this 
was not the case. In addition, the unspecific band at ~54 kDa (marked with an asterisk in Fig. 
5.14) was present regardless of the elution strategy used, including incubation with 1 % SDS 






Figure 5.14. TMCO6 is immunocaptured by the CI holocomplex. 
 
Mitochondria were isolated from HEK 293T cells, as previously described (Fernández-Vizarra 
et al., 2010), and 0.5 mg mitochondrial protein incubated with Complex I Immunocapture 
beads (Abcam ID: ab109711C, Abcam, Cambridge, UK), as per section 2.6.8. Fractions from 
whole cell lysates (WC), cytosolic proteins (C), mitochondrial proteins (M), DIG-solubilised 
mitochondrial protein incubated with CI immunocapture beads (B), the supernatant of this 
incubation containing all non-bound protein (S), five washes (W1-5) and the eluted fraction 
(E), prepared with incubation with 1 % SDS. For abbreviations, see legend. The ~54 kDa IgG 
band detected by the secondary antibody is marked with and asterisk (*). 
 
Following on from this, we sought to determine which CI subunits in particular interreacted 
with TMCO6. As a first attempt, immunoprecipitation was performed with the endogenous anti-
TMCO6 antibody bound to magnetic beads, incubated with HEK 293T mitochondrial protein 
extract and eluted with pH = 3.0 glycine or 1 % SDS. However, the expression of native 
TMCO6 is naturally very low, making it difficult to detect even TMCO6 in the eluted fractions 
regardless of the method of elution or starting amount of mitochondrial protein used.  
 
Therefore, another immunoprecipitation strategy was devised, utilising a finding we observed 
in Flp-In™ HEK 293T cells overexpressing FLAG-tagged TMCO6 (section 5.2.3) that 
overexpression of epitope-tagged TMCO6 also increased the steady-state level of the 
endogenous protein. Therefore, expression of HA-tagged TMCO6.1, was induced by DOX 
treatment for 48 h prior to extracting total mitochondrial protein and incubating these 
mitochondrial protein extracts with anti-HA-crosslinked magnetic beads. This second strategy 
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had another advantage in that a synthetic HA-competitor peptide could be used to elute the 
HA-bound proteins, and this elution strategy yielded no IgG unspecific bands by SDS-PAGE 
and Western blot analysis, making specific recognition of TMCO6HA clearer than for the 
endogenous protein (given that the epitope-tagged TMCO6 proteins were ~ 55 kDa in size, 
similarly in size to the larger of the  IgG bands). As shown in Fig. 5.15, TMCO6HA only partly 
localises to the mitochondria, with the majority detected in the cytosolic fraction. This could be 
due to impaired mitochondrial import of the protein with the epitope tag. Regardless, TMCO6 
HA was detectable in the eluted fraction following incubation of mitochondrial proteins with anti 
HA-beads. When the anti-TMCO6 antibody was used for immunodetection, most of the signal 
was mitochondrial but no TMCO6 band was found in the eluted fraction, perhaps due to the 
amount present being under the detection limit. However, a slightly bigger band corresponding 
to TMCO6HA could easily be detected by Western blot analysis, suggesting that more HA-
tagged TMCO6 species were bound to CI in these cells than endogenous TMCO6. In addition, 
several CI antibodies were immunodetected by Western blotting following SDS-PAGE and 
none of these were detectable in the eluted fractions, achieved by two different elution 
strategies (E1 = HA competitor peptide, and E2 = 1 % SDS).  
 
The antibodies that recognise native CI in the CI immunocapture kit cocktail are not reported 
by the manufacturer (Abcam), which made it difficult to pinpoint which CI subunit(s) or 
interactors were found to immunoprecipitate endogenous TMCO6 by CI immunocapture (Fig. 
5.14). Upon contacting the manufacturer, one of the antibodies they believe to be involved in 
the cocktail, but are not certain, is NDUFS6 (N-module). As shown in Fig. 5.16, NDUFS6 was 
detectable in both E1 and E2 fractions following long exposure. We concluded from this that 
TMCO6 does interact with NDUFS6, but it is possible it also interacts with other CI subunits 
or with known CI assembly factors. This line of inquiry requires more rigorous proteomic 






Figure 5.15. TMCO6HA was initially not found to bind CI subunits by SDS-PAGE 
 
Mitochondria were isolated from Flp-In™ HEK 293T cells, as previously described 
(Fernández-Vizarra et al., 2010), after overexpression of HA-tagged TMCO6.1 as per section 
2.3.6. Following this, 0.5 mg mitochondrial protein was incubated with anti-HA Pierce™ 
magnetic beads overnight at 4 oC, and bound proteins washed and eluted the following day 
as per section 2.6.8. Equivalent amount of proteins from whole cell protein lysates (WC), 
cytosolic fractions (C), mitochondrial fractions (M), DIG-solubilised mitochondrial protein 
extracts incubated with CI immunocapture beads (B), the supernatant of this incubation 
containing all non-bound protein (S), five washes of immunocaptured proteins (W1-5) and the 
eluted protein fractions E1, prepared with incubation with a competing HA peptide (Catalogue 
ID: AB3254, Milipore, Merck), and E2, prepared with incubation in low-pH glycine (pH = 2.0) 
were separated by SDS-PAGE (section 2.6.2) and proteins immunodetected by Western 





Figure 5.16. NDUFS6 is immunocaptured by HA-tagged TMCO6. 
 
Mitochondria were isolated from Flp-In™ HEK 293T cells, as previously described 
(Fernández-Vizarra et al., 2010), after overexpression of HA-tagged TMCO6.1 as per section 
2.3.6. Following this, 0.5 mg mitochondrial protein was incubated with anti-HA Pierce™ 
magnetic beads overnight at 4 oC, and bound proteins washed and eluted the following day 
as per section 2.6.8. Identical samples as in Fig 5.15 were separated by size by SDS-PAGE 
(section 2.6.2) and subjected to immunodetection by Western blotting with anti-HA or anti-
NDUFS6 antibodies (see Table 2.29). The location of NDUFS6 at the N-module/Q-module 
perimeter is shown in the cartoon beneath (image replicated from apart of Fig. 7, Guerrero-




 Attempting Generation of TMCO6 Knockout and Knockin Cellular Models 
CRISPR/Cas9 technology was used in this work to attempt to generate TMCO6 knockout and 
knockin cell lines using HAP1 cells, a near-haploid human cell line derived from the male 
chronic myelogenous leukaemia (CML) KBM-7 cell line (Kotecki, Reddy and Cochran, 1999). 
HAP1 cells were chosen since they contain only one allelic target, making gene editing simpler 
than for diploid cells. Briefly, the RNA-guided nuclease Cas9, from the Streptococcus 
pyogenes clustered regularly interspaced short palindromic repeats (CRISPR) adaptive 
immune system, is directed by a single-stranded guide RNA (sgRNA), composed of a scaffold 
and a spacer sequence, to a complimentary ~20 bp target sequence within a genome, which 
is followed by a 3 bp protospacer adjacent motif (PAM) sequence (5’ [N]GG 3’). Upon 
successful sequence recognition and binding by the Cas9/sgRNA complex, the Cas9 enzyme 
undergoes a conformational change and creates a double stranded break ~3 bp upstream of 
the PAM site, sequence: [N]GG (Jinek et al., 2012), which is then repaired by one of two 
mechanisms: 1) nonhomologous end joining (NHEJ), which commonly introduces indel 
mutations into the site of repair that impact the open reading frame, or 2) homology-directed 
repair (HDR), which with the aid of a specific single-stranded donor oligonucleotide (ssODN), 
mediates precise genetic editing at the site of interest. Both mechanisms were employed here 
in order to attempt to generate a TMCO6 knockout HAP1 cellular model, as well as a knock-
in HAP1 cell line for the human patient mutation (NM_018502.5: c.271C>T) (Fig. 5.17).  
 
An sgRNA sequence, sgRNA1 (sequence: 5’ GGT GCT GCA AGC CTC GAC GAA GG 3’), 
targeted to exon 3 of the human TMCO6 gene (GenBank ID: 55374), was designed using the 
CHOPCHOP online tool (http://chopchop.cbu.uib.no/) (Montague et al., 2014; Labun et al., 
2019). Despite not having the highest quality score, determined by factors such as its fidelity 
to the target sequence and presence of a downstream PAM sequence, sgRNA1 allowed for 
convenience in generating both a knockout and, with the addition of a specific ssODN, a 
knock-in for the human patient mutation at the same genetic locus. Firstly, I ligated separate 
forward and reverse primers containing reserve complement sgRNA1 sequences, containing 
both the 20 bp spacer sequence targeting TMCO6 exon 3 and the prerequisite scaffold 
sequences for Cas9 binding, as per the protocol devised by Ran et al. (Ran et al. 2013). Next, 
these ligated sequences were amplified by PCR and cloned into a commercial plasmid vector 
encoding the S. pyogenes Cas9 enzyme, pSpCas9(BB)-EGFP (Addgene ID: 48138, a gift 





Figure 5.17 Schematic representation of CRISPR/Cas9 technology for targeting Exon 3 of 
human TMCO6.  
 
Cas9 binds to the scaffold sequence of an sgRNA to form a Cas9:sgRNA ribonucleoprotein 
complex. Then, the spacer sequence of the sgRNA (yellow) guides the complex to the target 
genomic sequence (light blue), whereby Cas9 cleaves the double-stranded DNA after 
recognition of an upstream protospacer adjacent motif (PAM) (green) 3 bp before the start of 
the spacer sequence (orange). As shown above, this process was employed for cleavage of 
a site within exon 3 of TMCO6 in HAP1 cells. After a Cas9-mediate double-stranded break of 
the genomic DNA at this local, two repair pathways (dark blue) could be followed. For 
generation of a TMCO6 knockout, the non-homologous end joining (NHEJ) pathway 
commonly introduces insertion/deletion (indel) mutations into the site of repair that may impact 
the open reading frame. For generation of a knock-in for the patient mutation (p.Arg91Cys), 
homology-directed repair (HDR), which with the aid of a specific single-stranded donor 
oligonucleotide (ssODN), mediates precise genetic editing at the site of interest. Here, a 183 
bp ssODN was used to span the middle of exon 3, where the mutated base pair was located 
centrally, and towards the 3’ end it encodes an artificial, synonymous Sac I restriction site, not 
naturally present in this region. This restriction site was used to streamline screening of clones 





Following verification that the cloning of sgRNA1 into pSpCas9(BB)-EGFP had been 
successful by restriction digestion and agarose electrophoresis (data not shown), the Guide-
it™ Complete sgRNA Screening System (Catalogue number: 632636, Takara Bio Europe) 
was then used to screen the efficiency of sgRNA1 to cut its desired genomic site in vitro. 
Genomic DNA was extracted from HAP1 cells and purified before being subjected to PCR-
based amplification of the region of interest spanning TMCO6 exon 3, with a resulting fragment 
of ~500 bp (see section 2.2.15 for thermocycling conditions, primers and reaction details). In 
vitro transcription of the pSpCas9(BB)-EGFP-sgRNA1 plasmid followed, and the resulting 
sgRNA1 transcript purified. Cleavage reactions were set up including the HAP1 purified 
genomic DNA fragment, purified sgRNA1 and Cas9 enzyme. This reaction was run alongside 
a positive control, the WhitescriptTM (Takara Bio Europe) 2 kb control vector, with the addition 
of a corresponding control sgRNA. As shown in Fig. 5.18, sgRNA1 was able to cut the HAP1 
genomic sequence at the desired locus. Similarly to the positive control, the cleavage was 
imperfect since a portion of the full ~500 bp fragment was still detectable, suggesting it is as 




Figure 5.18 In vitro cleavage by sgRNA1/Cas9 of its target genomic site was successful. 
 
The Guide-it™ Complete sgRNA Screening System (Catalogue number: 632636, Takara Bio 
Europe) was used to assess the efficiency of sgRNA1 to cut its desired genomic site in vitro. 
Agarose gel electrophoresis confirms partial in vitro cleavage of HAP1 genomic DNA within 
exon 3 of TMCO6, similarly to a 2 kb positive DNA control and corresponding sgRNA. A 1 kb 
DNA ladder (L) (Invitrogen™, UK) was used for size comparison (as labelled). Gels were 
digitally visualized via UV transilluminator. 
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For generating a knockout by the NHEJ pathway, 100 ng of purified pSpCas9(BB)-EGFP-
sgRNA1 plasmid was transfected into HAP1 cells by means of the TurboFectin 8.0 reagent 
(Catlogue number: TF81001, Origene) and corresponding protocol. For generating a knock-
in of the patient mutation by HDR, the same process was followed but with the addition of 10 
µM of a specific ssODN (Table 2.19), encoding the patient CàT transition mutation and a 
downstream synthetic, synonymous Sac I restriction site. Cells that had been transfected with 
the pSpCas9(BB)-EGFP-sgRNA1 plasmid expressed GFP, which could can be used for cell 
sorting. Additionally, cells were stained with 7-AAD, a membrane impermeant fluorescent dye 
taken up only by apoptotic or dead cells. The transfected and 7-AAD stained cells were sorted 
by fluorescence-activated cell sorting (FACS) (Fig. 5.19), performed entirely by the Cambridge 
Institute for Medical Research’s Flow Cytometry Core Facility, gating for GFP-positive and 7-
AAD-negative cell populations for sgRNA1 and sgRNA1 + ssODN1 subtypes. For each, 
approximately 500 GFP-positive/7-AAD negative live cells were distributed into individual 





Figure 5.19 FACS gating for HAP1 cells transfected with pSpCas9(BB)-EGFP-sgRNA1 and 
stained with 7-AAD. 
 
For selection of live HAP1 cells successfully transfected with the pSpCas9(BB)-EGFP-
sgRNA1 plasmid, FACS was performed at the Cambridge Institute of Medical Research’s Flow 
Cytometry Core Facility. (A.) Cells were firstly gated for 7-AAD-negative populations, so that 
only live cells were selected. In addition (B.), two groups of GFP-positive populations were 
chosen to segregate GFP-high (green square) and GFP-low (grey square) cell populations. 
GFP-negative cells (pink square) were routinely discarded. This process was performed for 
both knockout and knockin strategies.  
 
 
A.  B.  
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Screening of TMCO6-KO cells was performed by SDS-PAGE using whole cell protein extracts 
and immunodetection of the endogenous TMCO6 protein. Fig. 5.20 shows screening of 50 
colonies showing ubiquitous presence of the TMCO6 protein signal. In total, 98 colonies were 
screened in this way, and 30 of the colonies that showed the greatest decreases in TMCO6 
abundance relative to GAPDH were subjected to gDNA extraction, amplification of the TMCO6 
exon 3 region by PCR and Sanger sequencing (using the same primers that were used for 
amplification of the HAP1 TMCO6 exon 3 fragment shown in Fig. 5.18). Unfortunately, there 
were no observed changes to the wildtype gene sequences for any of these, indicating that 
cleavage by sgRNA1/Cas9 had been unsuccessful. Since successful uptake of the plasmid 
had been proven by the GFP-positive gating during FACS, it is most likely that sgRNA1 could 
not find or bind its target sequence within the native genomic DNA as it had done in vitro. 
However, we cannot rule out at this stage the possibility that TMCO6 knockout cells were not 




Figure 5.20 SDS-PAGE revealed unsuccessful TMCO6-knockout in HAP1 cells.  
 
SDS-PAGE (4-12 % NuPAGE gels, Invitrogen™), Western blot analysis and immunodetection 
using anti-TMCO6 and anti-GAPDH primary antibodies (see Table 2.29 for antibody details) 
was performed for 15 ug of whole cell protein lysates from one empty vector (EV) control (only 
transfected with pSpCas9(BB)-EGFP plasmid) and 98 HAP1 knockout (KO) cell lines that had 
been transfected with pSpCas9(BB)-EGFP-sgRNA1 (a representative 50 are shown). TMCO6 
was detected in all cell lines relative to GAPDH indicating failure of target binding or PAM 
recognition or double-stranded cleavage by sgRNA1/Cas9. 
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Screening of TMCO6 knock-in cells was performed by gDNA extraction, PCR amplification of 
the target region using the primers, reagents and thermocycling conditions as per Tables 2.12 
– 2.14, and then restriction digestion with 1 U/µl Sac I (Catalogue number: R0156S, New 
England Biosciences®). Fig. 5.21 shows Sac I-digested genomic DNA fragments for 15 of the 
total 78 colonies screened by this method, with no successful digestion shown. It is likely that 
if the cleavage by the sgRNA1/Cas9 ribonucleoprotein complex was unsuccessful, as inferred 
from the knockout process, then the ssODN could not successfully bind to its target site 
allowing for replication of the intended patient mutant variant (CàT). 
 
 
Figure 5.21 Sac I-digested HAP1 genomic fragments show unsuccessful integration of 
the patient mutation in attempted knockin HAP1 cell lines. 
 
PCR products were amplified from genomic DNA purified from HAP1 knockin (KI) cell lines, 
transfected with pSpCas9(BB)-EGFP-sgRNA1 plasmid + a specific ssODN for integration of 
the patient mutant into the HAP1 genome. After Sac I digestion, fragments were separated by 
agarose gel electrophoresis, and run alongside a 1 kilobase (Kb) DNA ladder (L) (Invitrogen™, 
UK) for size comparison (as labelled). Gels were digitally visualized via UV transilluminator. 
 
We concluded from this that another sgRNA sequence was necessary. As previously stated, 
we chose a spacer sequence that had did not have the highest quality score in order to enable 
both knockout and knockin generation at the same genetic. However, despite confirming 
sgRNA1/Cas9 cleavage on the desired genomic site in vitro (Fig. 5.18), it seems another 
sgRNA with higher sequence fidelity and access to a suitable PAM site is necessary. At the 
time of these results, work had begun with a Tmco6-knockout mouse strain (Chapter 6), and 
so attempted generation of a knockout HAP1 cellular model ceased in order to focus on this 





This work: 1) proved the subcellular localisation of TMCO6, 2) described CI deficiency and CI 
destabilisation in a cellular model of TMCO6 gene silencing, 3) described the molecular and 
biochemical consequences of a TMCO6 overexpression model, 4) confirmed physical 
interaction between CI and TMCO6 via immunoprecipitation experiments, and 5) detailed the 
process for attempting to create a TMCO6 knockout cellular model.  
 
Firstly, confocal microscopy revealed that TMCO6 localises to the mitochondria, specifically 
the IMM. Secondly, shRNA-mediated TMCO6 gene silencing led to reduced abundance of CI-
containing supercomplex species, and an increase in TMCO6-containing CI intermediates, and 
a ~40 % reduction in CI specific enzymatic activity. Successful shRNA-knockdown cell lines 
displayed impaired cellular growth rate in glucose-rich media. 
Inducible overexpression of TMCO6.1 (NM_018502.5) and TMCO6.2 (NM_001300980.1) 
transcript isoforms, either with wildtype or patient mutant (c.271C>T) sequences, led to a 
correlated increase in the steady-state level of endogenous TMCO6. Overexpression of FLAG-
tagged TMCO6 isoforms, and wildtype/mutant variants of these, did not affect overall CI 
abundance or specific activity relative to total mitochondrial mass. Any differences in 
mitochondrial mass between TMCO6-overexpressing and non-induced or control cell lines 
were thought to be an effect of the DOX induction method. 
Generation of TMCO6 knockout and knockin cellular models were unsuccessful due to either 
incorrect target binding, PAM site recognition or Cas9-mediated cleavage at the correct 
genomic site. However, it is possible that TMCO6 protein ablation in these cells is non-viable. 
TMCO6 co-localises with CI by 2D-BNGE in HEK 293T cells, as had been found to be the case 
in skin fibroblasts. 
Immunoprecipitation experiments using a native CI immunocapture kit reproducibly identified 
TMCO6 in the eluted protein fraction, confirming the physical interaction between TMCO6 and 
CI that was originally seen by 2D-BNGE using mitochondrial protein extracts from patient 
derived fibroblasts and HEK 293T cells. NDUFS6, which localises to the N-module/Q-module 
boundary of CI, is immuno-precipitated by HA-tagged TMCO6 in vitro.  
The confirmation of the intracellular localisation of TMCO6 specifically to the IMM was crucial 
for allowing TMCO6 to be considered a contender as the causal protein for the severe CI 
deficiency detected in the human mitochondrial disease patient described in Chapter 4. 
Secondly, shRNA-mediated TMCO6 gene expression knockdown further supported that 
TMCO6 affects CI stability and activity, producing a ~40 % reduction in its specific biochemical 
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activity by spectrophotometry and resulting in a loss of fully assembled CI and CI-containing 
supercomplexes, as shown by 1D-BNGE. The immunoprecipitation experiments that showed 
that endogenous TMCO6 physically interacts with the native CI holocomplex warrants further 
investigation to determine the specific CI subunit interactors, as discussed in Chapter 8. 
Although generation of a TMCO6-knockout cellular model was not achieved by CRISPR/Cas9, 
a transgenic Tmco6-knockout mouse model was used to study the effects of Tmco6 ablation 
on development, physiology, neuromuscular coordination and tissue-specific histopathology 

















Chapter 6  





As described in previous chapters, a novel mutation in TMCO6 (NM_001300980.1:c.271C>T, 
p.Arg91Cys) was identified by WES in a paediatric male proband presenting with severe 
psychomotor delay, spasticity, dystonia, generalised hypotonia, epilepsy, and progressive 
demyelination of cortical and subcortical brain regions. A skeletal muscle biopsy revealed 
severe CI deficiency to a third of normal levels, although this same deficiency was not observed 
in patient-derived fibroblasts. TMCO6 was subsequently found to co-localise with the CI 
holocomplex by 2D-BNGE in these cells, and this result was corroborated by 2D-BNGE and 
immunoprecipitation experiments in HEK 293T cells, confirming physical interaction between 
TMCO6 and CI. Biochemically, shRNA-mediated gene silencing of human TMCO6 in Flp-In™ 
HEK 293T cells caused a reduction in CI activity by 40 % relative to control values. Both the 
shRNA-knockdown cell lines and patient skin fibroblasts showed an increase in subassembly 
intermediates/degradation products, and a reduction in the levels of CI-containing 
supercomplexes by both 1D-BNGE and 2D-BNGE analyses, suggesting either destabilisation 
of the fully assembled holocomplex or stalled assembly at some stage prior to complete 
assembly. Despite these findings, the link between TMCO6 and CI biogenesis and function 
remained unclear. The work described in this chapter concerns the characterisation of a 
commercially available Tmco6-knockout murine model. Our first aim was to evaluate the 
physiological and behavioural phenotypes of Tmco6 ablation at the whole-organism level. 
Next, histological preparations and biochemical analyses were performed to discern 
differences in the structural architecture or in respiratory chain activities of post-mitotic tissues, 
respectively. Echocardiography and electrocardiography were performed to assess whether 





 Verifying Tmco6 Protein Ablation in a Tmco6-Knockout Murine Model  
A transgenic Tmco6-knockout mouse model (B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J) was used in this 
work to study the effects of Tmco6 ablation on mitochondrial CI biogenesis and activity, and 
subsequently, development, physiology, neuromuscular coordination, and metabolism at the 
whole-organism and tissue-specific levels.  
 
For generation of this strain, the ZEN-Ub1 Velocigene cassette, a lacZ reporter construct 
derived from E. coli, flanked by a neomycin resistance (neoR) selection cassette, was inserted 
via homologous recombination between positions 36,894,829 and 36,901,908 of Chromosome 
18 (Genome Build37) in mice embryonic stem cells of the C57BL/6NJ genetic background. 
Cre-mediated excision of the neoR selection cassette was then achieved by selective crossing 
with a mouse line that constitutively expressed Cre recombinase. This multi-step process 
yielded a 7,080 bp deletion within Tmco6, disrupting all coding exons and intervening genomic 
sequences (see Fig. 2.1). 
 
Firstly, for verification of gene disruption at the genomic level, and for all genotyping of progeny, 
we used two sets of primers to amplify either exons 3 and 4 of the Tmco6 gene, yielding a 384 
bp product (Fig. 6.1 A.), or part of the ZEN Ub1 reporter cassette and the downstream 
remainder of Tmco6 exon 12/3’ UTR (Fig. 6.1 B.). This strategy confirmed the absence of 
essential coding exons and verified the presence of the transgenic reporter construct in 






Fig. 6.1 PCR verifies absence of two essential Tmco6 exons. 
 
Figure shows the characteristic presentation of genotyping results for heterozygous (HET), 
homozygous wildtype (WT) or homozygous knockout (KO) mice. PCR was performed as per 
section 2.5.1 using genomic DNA extracted from ear biopsies of mice, taken on the day of 
weaning, and a negative control reaction (-). Two different pairs of primers were used 
(sequences specified in Table 2.23) for PCR amplification of (A.) 384 bp spanning Tmco6 
exons 3 and 4 and the intervening intronic sequence, or (B.) 496 bp covering a proportion of 
the ZEN Ub1 gene cassette, the latter part of Tmco6 exon 12 and a part of the 3’ untranslated 
region (UTR). Fragments were separated by size via agarose gel electrophoresis, and 
samples were run alongside a 1 kb DNA marker (M) (Invitrogen™, UK) for fragment size 
comparison (as labelled). Gels were visualized by a UV transilluminator. 
 
We then sought to confirm the loss of Tmco6 gene expression by RT-qPCR using cDNA 
retrotranscribed from total RNA from liver (Fig. 6.2). Specific TaqMan gene expression assays 
for Tmco6 and a housekeeping gene, Myh10 were used; the amplicon sequences for each are 
detailed in Table 2.10. This strategy showed no gene expression of Tmco6 in knockout mice 
(n = 3), but revealed ample expression in both wildtype (n = 2) and heterozygous (n = 1) mice 
for three technical replicates per animal. This result suggested that the knockout mice do in 
fact completely lack the Tmco6 protein given the total lack of any recognisable Tmco6-






Fig. 6.2 Tmco6 mRNA transcripts are absent in knockout animals. 
 
RT-qPCR was performed as per section 2.2.12 and revealed total loss of Tmco6 mRNA in 
liver from 3-month-old homozygous knockout (KO) animals (n = 3), normalised to the 
expression of Myh10, and expressed as percentage, compared to homozygous WT mice (n = 
2) and heterozygous mice (n = 1). Data are presented as mean ± range. Measurements were 
performed in technical triplicates per animal. *** p < 0.0005, calculated by one-way ANOVA 
with Tukey’s multiple comparisons post hoc test applied.  
 
Lastly, we attempted to confirm the absence of endogenous Tmco6 steady-state level in KO 
mouse tissues by Western blotting and immunodetection using two commercial antibodies 
raised against the human TMCO6 protein. Both antibodies were advertised by their respective 
manufacturer to recognise the murine orthologue. The first (Catalogue Number: 20117-1-AP, 
Proteintech®) is a rabbit polyclonal antibody raised against the last 87 residues at the C-
terminus of the human TMCO6 primary sequence: NVAEKGPAYCQRLWPGPLLPALLHTLA 
FSDTEVVGQSLELLHLLFLYQPEAVQVFLQQSGLQALERHQEEAQLQDRVYALQQTALQG. 
This peptide shared 76 % sequence identity with the murine primary sequence. The second 
(Catalogue Number: NBP1-57660, Novus Biologicals), also a rabbit polyclonal antibody, was 
raised against 50 residues towards the N-terminus of the human TMCO6 primary sequence: 
LRQAQRGTEEKEREGALVSLRRGLQHPETQQTFIRLEGSMRTLVGLLTSN, and shared 90 
% sequence identity with the murine protein sequence. The estimated molecular weight of 
mouse Tmco6 is 54.9 kDa, and both manufacturers alleged the antibodies to recognise a single 
band of this size. As shown in Fig. 6.3 A. and B., no specific bands corresponding to the 
predicted size were observed in brain or skeletal muscle tissue homogenates using either 
primary antibody. Instead, a large number of unspecific bands were present at a similar 
intensity in the heterozygous, wildtype and knockout samples for both tissues. We concluded 
from this that these commercially available endogenous antibodies raised against the human 

































Fig. 6.3. Tmco6 Immunodetection Trials in brain and skeletal muscle tissues. 
 
SDS-PAGE (4-12 % NuPAGE Bis-Tris, Thermo Fisher Scientific), Western blot analysis and 
immunodetection of 30 μg of protein lysates from heterozygous (HET), homozygous wildtype 
(WT) or homozygous knockout (KO) brain and skeletal muscle tissues. (A.) Immunodetection 
was carried out using an anti-TMCO6 primary antibody from Proteintech® (Catalogue Number: 
20117-1-AP). (B.) Immunodetection was carried out using an anti-TMCO6 primary antibody 
from Novus Biologicals (Catalogue Number: NBP1-57660). 
 
 
 Phenotypic Characterisation of Tmco6-KO Mice 
6.2.2.1  Skewed Mendelian Segregation of Tmco6-KO Mice  
Mating of heterozygous mice and genotyping of offspring from 35 litters (n = 250) revealed a 
non-Mendelian distribution with statistically significant lower representation of the knockout 
genotype, as determined by Chi-squared analysis (χ2 = 6.664 with 2 df, p = 0.0357) (Table 
6.1). This suggested that a proportion of knockout mice died during gestation or in the postnatal 
period prior to weaning, and thus genotyping. Males and females were observed within 
expected ratios, with 50.8 % males (n = 127) and 49.2 % females (n = 123) recorded; therefore, 
no sex bias was observed. Matings of homozygous knockout males (KO M) or females (KO F) 
with a heterozygous partner (HET M or HET F) also produced a skewed distribution from the 
expected 1:1 Mendelian ratio for HET:KO, showing again a lower percentage of the KO 
genotype than expected (Table 6.2). These results yielded statistically significant differences 
by Chi-squared analysis (χ2 = 5.565 with 1 df, p = 0.0183 for KO M x HET F (n = 46), and χ2 = 
5.918 with 1 df, p = 0.0150 for KO F x HET M (n = 61)). Mating of homozygous knockout mice 
(KO M x KO F) resulted in small litters of between 3 and 6 pups, with total postnatal lethality in 
A.  B.  
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the first few days of life. Genotyping of dead pups not cannibalised by parents revealed 100 % 
occurrence of the KO genotype, as expected. 
 
Table 6.1. Distribution of Tmco6 Genotypes from HET x HET Interbreeding 
 
Genotype Number Expected [%] Number Observed [%] 
WT 62.5         [25 %] 66          [26 %] 
HET 125         [50 %] 139         [56 %] 




Table 6.2. Distribution of Tmco6 Genotypes from HET x KO Interbreeding 
 
Cross Genotype Number Expected [%] Number Observed [%] 
KO M x HET F HET 23          [50 %] 31         [67 %] 
 
KO 23          [50 %] 12         [33 %] 
KO F x HET M HET 30.5      [50 %] 40         [66 %] 
 




In order to investigate the possibility of embryonic lethality, embryos from matings of 
heterozygous mice were analysed. Mendelian ratios for embryos collected at E11.5 or E12.5 
(n = 39) were as expected for heterozygous interbreeding (Table 6.3), with the observed 
number of wild-type, heterozygous and knockout animals considered non-significant by Chi-
squared analysis (χ2 = 0.436 with 2 df, p = 0.8042). This result suggests that the non-Mendelian 
ratios seen in adult offspring from HET x HET crosses (Table 6.1) resulted most likely from 




Table 6.3. Distribution of Tmco6 Genotypes from HET x KO Interbreeding 
 
Genotype Number Expected [%] Number Observed [%] 
WT 9.75        [25 %] 8         [21 %] 
HET 19.5       [50 %] 21       [54 %] 




6.2.2.2 Tmco6-KO Mice Display Reduced Body Weight and Hindlimb Feet Clasping 
Body weights of knockout and control (heterozygous and wildtype) genotypic groups were 
measured weekly from the time of weaning to 10 months of age (40 weeks). Knockout mice 
consistently presented lower body weights than those of control littermates, with statistically 
significant differences from 12 weeks of age for males (Fig 6.4 A.) and 28 weeks of age for 
females (Fig 6.4 B.). As a consequence, Fig 6.4 C. shows the substantial difference in body 
sizes of two 8-month-old male littermates positioned side-by-side. 
 
A phenotypic behaviour of Tmco6 knockout animals was hindlimb clasping (Fig 6.4 D.), which 
became steadily more pronounced with age. Hindlimb clasping is commonly observed in 
murine models of neurodegenerative disease (Guyenet et al., 2010), and can be used to mark 
neurological symptom progression with age. Moreover, approximately 15 % of all Tmco6-
knockout mice (n = 7, consisting of 2 females and 5 males) developed epilepsy from 6 months 
of age onwards, characterised by recurrent and spontaneous myoclonic seizures, in which the 
mouse suffered sudden, full-body spasms frequently over the course of several minutes 
(videos available upon request). A timeline of physical and neurological phenotypic 








Fig. 6.4. Body composition and neurobehavioral phenotypes of Tmco6-knockout mice. 
 
Body weight as a function of age was measured in wildtype and heterozygous mice, grouped 
together as ‘controls’, and Tmco6-knockout mice for (A.) males and (B.) females over 10 
months on a weekly basis (n = 6 for each group). Student t- tests determined statistically 
different differences (p < 0.5) for males from 12 weeks of age, and for females from 28 weeks 
of age. (C.) Body sizes were noticeably different amongst litters for the knockout genotype 
compared to both heterozygous and wildtype counterparts, shown here by two 8-month old 
male littermates positioned side-by-side. (D.) Knockout animals displayed prominent hindlimb 
feet-clasping clearly observed from 3 months of age onwards, and which progressed in 






6.2.2.3 Tmco6-KO Mice Show Impaired Exercise Tolerance and Motor Coordination  
Leading on from these observations, we next sought to assess the motor capabilities and 
neuromuscular coordination of Tmco6-knockout mice relative to wildtype and heterozygous 
age-matched controls. Maximal exercise capability and endurance were evaluated by 
exhaustion trials, in which an automated treadmill and standardised program for increasing the 
belt speed by 0.3 m/min to a maximum speed of 75 m/min was used to run animals until they 
reached exhaustion, as defined in section 2.5.4. Both male and female Tmco6-knockout mice 
displayed significant exercise intolerance compared to heterozygous and wildtype littermates 
at 3 months of age to ~40 % of control levels (Fig. 6.5 A.). A statistically significant decrease 
for KO animals was also found at 12 months of age for female and male mice (Fig. 6.5 B.). 
Due to the large weights of the 12 month old males (> 52 g in most cases), and the natural 
loss of exercise capability with aging, the distance reached at exhaustion by WT and HET male 
controls at 12 months of age was less than for the young adult age group. 
 
Neuromuscular coordination, balance and motor performance were next assessed using a 
Rotarod apparatus (Ingram and Reynolds, 1986). Mice were tasked with adapting to an 
increasing walking speed whilst maintaining balance on a cylindrical rod for a duration of 5 
min. The latency to fall (s) was recorded manually per animal for three separate test trials, and 
these values were averaged per animal (as per section 2.5.5). As shown in Fig. 6.5 C., 
Tmco6-knockout mice showed statistically significant decreases in latencies to fall at 3 months, 
6 months and 12 months of age. This impaired balance and motility was progressive with age 
for both males and females, with 12-month-old knockout animals falling in approximately half 
of the time observed in knockout animals at 3 months of age for both genders. Males performed 




                
       
 
 
Fig. 6.5. Tmco6-knockout mice display impaired motor performance and coordination. 
Motor performance and capability was assessed for male (M) and female (F) Tmco6-knockout 
(-/-), heterozygous (+/-) and homozygous wildtype (+/+) mice (n = 5 per group) at (A.) 3 months 
and (B.) 12 months of age by treadmill (as per section 2.5.4). Distance reached at exhaustion 
was recorded per animal. Data represent mean ± SEM. Statistical analysis: * p < 0.05, ** p < 
0.01, calculated by one-way ANOVA with Tukey’s multiple comparisons post hoc test applied. 
(C.) Latency to fall (s) was recorded in three separate trials, with values averaged per animal 
for male and female 3-month, 6-month and 12-month old Tmco6-knockout (-/-), heterozygous 
(+/-) and homozygous wildtype (+/+) mice run on a rotarod apparatus (n = 5 per group). Data 
represent mean ± SEM. Statistical analysis: * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 
0.001, calculated by two-way ANOVA with Sidak’s multiple comparisons post hoc test applied. 






















































































































































































The pole test was then used to assess proprioception, which is the subconscious awareness 
of body orientation relative to the ground, and bradykinesia, the impaired ability to move the 
body or limbs in a coordinated way on command (Rial et al., 2014). As shown in Fig. 6.6, male 
and female knockout showed increases in the time taken to turn 180o and descend a 50 cm 
pole compared to both heterozygous and wildtype age-matched controls at all three ages 
tested, with statistically significant differences at 6 months and 12 months of age. It is worth 
noting that the knockout mice were often able to turn without difficulty in a comparable time to 
heterozygous and wildtype controls, suggesting no problem with proprioception, but could not 
descend the pole in a controlled manner engaging all four limbs, suggesting bradykinesia. 
Knockout animals often did not engage their hind limbs and instead wrapped them around the 
pole, using only their forelimbs to descend towards the home cage in sharp, jerky movements. 
Wildtype and heterozygous animals did not display this phenotype in any instance. In addition, 
approximately 30 % of knockout male and female mice in the 12 month age groups would not 
grasp the pole when performing the two adaptation trials, and if they did, some would fall 






Fig. 6.6. Tmco6-knockout mice exhibit impaired coordination. 
 
The pole test was performed as per section 2.5.7 for male and female mice at 3 months, 6 
months and 12 months of age to assess proprioception, the subconscious awareness of body 
orientation relative to the ground, and impaired coordination. The time (s) taken to turn 180o 
and descend a 50 cm pole was recorded for 3 replicate trials per animal and these values 
averaged (n = 6 mice per genotypic group); data are presented as mean ± SEM. Statistical 
analysis: * p < 0.05, ** p < 0.01, calculated by two-way ANOVA with Sidak’s multiple 






























6.2.2.4 Tmco6-KO Mice Have Decreased Motility and In Vivo Energy Metabolism 
Given that Tmco6-knockout mice showed impaired exercise tolerance and neuromotor 
abnormalities in tests that assessed balance and motor coordination (section 6.2.2.2), we next 
sought to assess the impact of Tmco6-ablation on spontaneous motility, including locomotor 
and exploratory behaviours. The Oxymax Comprehensive Lab Animal Monitoring System 
(CLAMS) (Columbus Instruments, Ohio, USA) was used to monitor total movement, 
ambulatory movement, and rear movements in homeostatic conditions. This was achieved by 
infrared beam sensors in the x-, y- and z- planes surrounding each cage, with any beam breaks 
termed as 1 ‘count’. Total movement was defined as all infrared beam interruptions (total 
counts). When mice broke a series of infrared beams in sequence, meaning that they were 
moving deliberately, such as traversing the cage, counts were defined as ambulatory 
movements, and movements in the y-axis, i.e. when mice were standing upright on the hind-
limbs in order to visually explore their environment, were counted as rear movements. Since 
male and female mice exhibited identical differences, only data from male mice are included 
here as representative. Night and day cycles were evaluated separately owing to the nocturnal 
nature of mice, and no significant differences were observed for measurements taken during 
the day. During the night, significant differences in rear movements were observed between 
wildtype (WT) and knockout (KO) male mice at 3 (Fig. 6.7 A.), 6 (Fig. 6.7 B.) and 12 months 
of age (Fig. 6.7 C.). In addition, total movement was decreased for KO mice at all ages, with 
statistically significant differences observed in 6 month and 12 month age groups. Although 
there was a trend in 3 month and 6 month knockout animals to explore less, as denoted by 
ambulatory movement, the only significant difference was observed in aged mice at 12 months 
of age. These results showed progressive deficiencies in locomotor and exploratory 
behaviours for KO animals with age, suggesting neuromuscular implications for ablation of the 








Fig. 6.7. Movement monitoring via CLAMS. 
 
Total movement of male Tmco6-knockout (KO) or homozygous wildtype (WT) mice at (A.) 3, 
(B.) 6 and (C.) 12 months of age for 2 night and 1 day 12 h cycles via CLAMS, as per section 
2.5.3. Total movement is defined as all infrared beam interruptions in the x-, y-, and z- axes 
(total counts). Ambulatory movement is defined as deliberate movement, i.e., traversing the 
cage, characterised by a sequence of infrared beam breaks in at least 2 planes. Rear 
movement is defined as infrared beam breaks in the y-axis, i.e. when mice were standing 
upright on the hind-limbs in order to visually assess their environment. Data are presented as 
mean ± SEM. 3 months: WT (n = 3), KO (n = 4), 6 months: WT (n = 3), KO (n = 3), 12 months: 
WT (n = 3), KO (n = 5). Statistical analysis: * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, 












































































































































































































The CLAMS was also used to measure nutritional intake, including food and water 
consumption, and several metabolic parameters, including O2 consumption, CO2 production, 
heat production and the respiratory exchange ratio (RER) for KO and WT control male mice at 
3 months, 6 months and 12 months of age for 12 h day and night cycles (Fig. 6.8). All values 
were corrected for body mass per animal. There was a general trend that knockout animals 
consumed more food and water than did their age-matched wildtype controls, although these 
differences were not statistically significant. RER is a ratio between the amount of carbon 
dioxide produced and oxygen consumed by an aerobically respiring organism, with the 
resulting value indicating what type of substrate is being preferentially metabolised to produce 
energy, ie. sugars or fat. A RER of 0.7 indicates that the main fuel is fat, a RER of 0.85 means 
that both fat and carbohydrates are used, and a RER of 1.0 or above indicates that the main 
substrate used for energy is carbohydrate. Mice in both experimental groups at all ages 
showed normal RER values of around 0.85. Oxygen consumption and carbon dioxide 
production were used as variables by the CLAMSTM software for indirect calorimetry to 
calculate heat production, which is directly related to energy expenditure, and was unchanged 
in knockout compared to wildtype mice at all ages. Significant increases in CO2 production and 
O2 consumption were observed at 12 months of age for KO animals, although the younger age 
groups showed a similar trend. Tmco6-KO mice are consuming more oxygen and producing 
more carbon dioxide than age-matched controls throughout the day and night (Fig. 6.8). This 
is unexpected given that male Tmco6-KO mice are moving less (Fig 6.7) than their wildtype 
littermates. Therefore, Tmco6-KO animals are undergoing higher than normal metabolic 
activity just to maintain basal survival. This finding could indicate that KO animals are requiring 
more energy that WT controls to regulate their body temperature, or to fulfil some other 





























































































































































































































































































Fig. 6.8. Energy metabolism monitoring via CLAMS. 
Male Tmco6-knockout (KO) or homozygous wildtype (WT) mice were monitored at 3, 6 and 
12 months of age for nutritional intake and various metabolic parameters for 2 night and 1 day 
12 h cycles via CLAMS, as described in section 2.5.3. Total food (g) and water (ml) consumed 
was recorded per animal at the end of the experiment to assess overall consumption in the 36 
h period. The sum of the volume of oxygen consumed (ml/kg/hr) and volume of carbon dioxide 
produced (ml/kg/hr) was recorded also. These were both used to calculate the respiratory 
exchange ratio (RER) and heat production (Kcal/hr) per animal, for day and night cycles in 
each case. Data are presented as mean ± SEM. 3 months: WT (n = 3), KO (n = 4), 6 months: 
WT (n = 3), KO (n = 3), and 12 months: WT (n = 3), KO (n = 5). Statistical analysis: * p < 0.05, 
** p < 0.01, *** p < 0.005, **** p < 0.001, calculated by two-way ANOVA with Sidak’s multiple 
comparisons post hoc test applied. 
 
 Histological Analyses of Tissues from Tmco6-KO Mice  
6.2.3.1 Histopathological Alterations Observed in Brains of Tmco6-KO Mice 
Murine tissues were subjected to histochemical and histological examination to assess 
whether Tmco6-ablation yielded structural or functional hallmarks of neurological disease. 
Both male and female tissues were analysed and showed identical phenotypes; therefore, as 
representative of both genders, only results showing male tissues are included herein.  
 
Firstly, we assessed the presence of degenerating neurons in the brains of 3 and 12 month 
old male wildtype (WT) and knockout (KO) mice by means of the anionic fluorescent 
histofluorescent dye, PathoGreen™. As shown in Fig. 6.9., PathoGreen™ staining highlighted 
degenerating neurons in sections from the striatum, thalamus and cerebral cortex in young 
adult (3 months) and aged (12 months) KO animals. WT animals show no PathoGreen™ signal 
in either age group, indicating that the neurodegeneration detected in KO animals is a result 
of Tmco6-abalation and not simply a by-product of regular aging.  
 
In order to provide further support to this observation, astrogliosis was next evaluated by 
immunohistochemistry (IHC) with an anti-glial fibrillary acidic protein (GFAP) antibody (brown 
staining). Increased expression of GFAP in the brain is observed following neuronal cell death 
or damage to the central nervous system, and is a common marker of severe neuropathology. 
As shown in Fig. 6.10, Tmco6-KO animals display extensive accumulation of GFAP at both 3 
and 12 months of age in PathoGreen™-positive regions of the brain. Far greater GFAP 
accumulation is observed in brains of the 12 month-old age group, ultimately indicating 





Fig. 6.9. Neurodegeneration observed throughout the brains of Tmco6-knockout mice. 
 
Representative PathoGreen™ histofluorescent staining of the striatum, thalamus and cerebral 
cortex of 3 month and 12 month old male Tmco6-knockout (KO) or homozygous wildtype (WT) 
mice shows prominent neurodegeneration in these brain areas in KO animals. Scale bar = 50 
μm, images taken at 20 X magnification. Sample preparation and imaging performed entirely 






Fig. 6.10. Increased gliosis observed in brains of Tmco6-KO mice. 
 
Representative GFAP immunohistochemistry of the thalamus, frontal cerebral cortex and 
mesencephalon of 3 month and 12 month old male Tmco6-knockout (KO) or homozygous 
wildtype (WT) mice shows increased astrogliosis in KO animals. Images taken at 4 X 
magnification. Sample preparation and imaging performed entirely by Raffaele Cerutti, as per 
section 2.5.9.   
 
Protein aggregates (inclusions) containing ubiquitinylated proteins are sometimes found in 
neurons and other cell types in the central nervous system, indicative of neurological illness, 
as found in Alzheimer’s disease, Parkinson’s disease, polyglutamine disease, and rarer forms 
of neurodegenerative disease (Hegde and Upadhya, 2011). Ubiquitin accumulation was 
assessed by immunohistochemistry with an anti-ubiquitin antibody (brown staining) as shown 
in Fig. 6.11 for 3 month and 12 month-old KO animals. Both age groups displayed focalised 
regions of ubiquitin signal accumulation, which was not seen in age-matched WT controls. 
There appears to be progression in ubiquitin accumulation from the 3 month- to 12 month-age 
groups for KO animals for thalamus, cerebral cortex and mesencephalon brain sections, in 








Fig. 6.11. Aggregation of ubiquitinated proteins observed in brains of Tmco6-KO mice. 
 
Representative ubiquitin histofluorescent staining of the thalamus, cerebral cortex and 
mesencephalon of 3 month and 12 month old male Tmco6-knockout (KO) or homozygous 
wildtype (WT) mice shows increased aggregation of ubiquitinated proteins in KO animals, 
suggesting either dysfunction of the ubiquitin-proteasome system or proteolytic resistance of 
the protein aggregates. Images taken at 40 X magnification; insets show 80 X magnification. 
Sample preparation and imaging performed by Raffaele Cerutti, as per section 2.5.9. 
 
Demyelination of axons impairs the conduction of nerve signals, and can lead to atrophy or 
degeneration of the affected neurons. Cyclic nucleotide 3’-phosphodiesterase (CNPase) is 
expressed only by myelin-forming cells and histofluorescent staining of CNPase can be used 
to detect myelinated axons in brain sections (brown staining). Fig 6.12 shows representative 
sections of the neocortex from 3 month and 12 month old WT and KO mice, showing 
substantially less neuronal myelination in KO animals, especially in Layer I of the neocortical 
sections. Demyelination of neurons is one possible cause or contributing factor for the 
extensive neuronal degeneration seen by PathoGreen™ staining (Fig. 6.9), and corroborated 
by the increased astrogliosis detected by GFAP staining (Fig. 6.10) in 3 month- and 12 month-






Fig. 6.12. Loss of myelinated neurons observed in brains of Tmco6-KO mice. 
 
Representative CNPase histofluorescent staining of the neocortex of 3 month and 12 month 
old male Tmco6-knockout (KO) or homozygous wildtype (WT) mice shows decreased 
myelination of neurons in KO animals. Images taken at 20 X magnification. Sample 
preparation and imaging performed by Raffaele Cerutti, as per section 2.5.9. 
 
Microglial cells are macrophagic cells that function in mediating immune responses in the 
central nervous system by targetting and removing dead or damaged neurons by 
phagocytosis. Thus, immunohistochemistry was used to identify the presence of CD68, 
expressed by activated microglial cells, in the brains of 3 month and 12 month old WT and KO 
mice. As shown in Fig. 6.13, KO brain sections show positive regions of CD68 signal (brown 
staining), indicating accumulation of activated microglial cells at these sites and an activated 
immune response. There seems to be similar abundances in CD68 expression in both 3 month 
and 12 month age groups, suggesting that at 3 months of age the maximum immune response 
has been achieved. If no further immune response is possible, this would result in neurological 








Fig. 6.13. CD68 IHC reveals increased amounts of microglia in brains of Tmco6-
knockout mice. 
 
Representative CD68 IHC of the thalamus and frontal cerebral cortex of 3 month and 12 month 
old male Tmco6-knockout (KO) or homozygous wildtype (WT) mice shows the presence of 
activated microglial cells in KO animals. Images taken at 40 X magnification. Sample 
preparation and imaging performed by Raffaele Cerutti, as per section 2.5.9. 
 
 
6.2.3.2 Histochemical and Histological Analyses of Other Tissues of Tmco6-KO mice 
Following on from investigation of the brain, we next sought to analyse other high-energy 
tissues from 3 month-old KO animals. We had previously observed impaired motor endurance 
via treadmill and test for Tmco6-KO mice (Fig. 6.5), and hypothesised that skeletal and cardiac 
muscles of these animals may be affected. Hematoxylin and eosin (H&E) histological staining 
of skeletal muscle sections showed normal fibre morphologyin Tmco6-KO animals at 3 months 
of age (Fig. 6.14 A.), despite being slightly smaller in size, which was most likely due to the 
smaller overall body sizes of the KO animals. No centralized nuclei, which would be suggestive 
of a myopathy (Folker and Baylies, 2013), were found. Histochemical evaluation of NADH (Fig. 
6.14 B.), SDH (Fig. 6.14 C.) and COX (Fig. 6.14 D.) revealed no observable differences in 
intensity of the three between WT and KO animals. For cardiac sections, H&E staining again 
revealed no apparent differences in overall morphology, presence of altered fibre structure or 
cellular architecture (Fig. 6.15). Picrosirius red staining was used to reveal the presence of 
fibrosis in the cardiac tissue. Muscle fibres (yellow) and collagen (red) showed no difference 





Fig. 6.14. Skeletal muscle showed no histochemical changes in Tmco6-KO mice. 
 
Representative (A.) H&E histofluorescent staining, (B.) NADH, (C.) SDH and (D.) COX 
histochemical reactions of skeletal muscle sections from 3 month-old male Tmco6-knockout 
(KO) or homozygous wildtype (WT) mice. Images taken at 20 X magnification. Sample 










Fig. 6.15. Hearts showed no histological alterations in Tmco6-KO mice. 
 
Representative (A.) H&E and (B.) Picrosirius red staining of heart sections from 3 month-old 
male Tmco6-knockout (KO) or homozygous wildtype (WT) mice. Images were taken at 4 X 




Kidney and liver tissues were also analysed by H&E staining (Fig. 6.16), revealing no structural 
or cellular abnormalities. Kidneys were also analysed by periodic acid-Schiff staining to detect 
abnormal glomeruli and by cleaved caspase-3 IHC, which detects presence of apoptotic cells, 
and both revealed no differences (data not shown). Liver was also analysed by cleaved 
caspase-3 and Ki-67 IHC, the latter of which marks proliferating cells after liver damage. Again, 
no differences for KO mice compared to counterpart WT animals at 3 months of age were 








Fig. 6.16. Kidney and liver also showed no histological alterations in Tmco6-KO mice. 
 
Representative H&E staining of kidney and liver sections from 3 month-old male Tmco6-
knockout (KO) or homozygous wildtype (WT) mice. Images were taken at 10 X magnification. 
Sample preparation and imaging performed by Raffaele Cerutti, as per section 2.5.9.  
 
In summary, Tmco6-knockout brains showed neurodegeneration, associated with increased 
astrogliosis, accumulation of ubiquitinated protein aggregates, recruitment of inflammatory 
microglial cells and demyelination of axons, in 3 month- and 12 month-old animals. Skeletal 
muscles of 3 month-old KO mice showed small fibres, but no centralised nuclei by H&E staining 
and no qualitative differences detected by NADH, SDH or COX histochemistry. Hearts of KO 
mice displayed no structural abnormalities or fibrosis. Kidneys and liver also revealed no 




 Biochemical Investigation of Tmco6-KO Cells and Tissues 
6.2.4.1 Investigating Mitochondrial Respiratory Chain Activities in Tmco6-KO MEFs 
Patient fibroblasts with a homozygous recessive mutation in human TMCO6 demonstrated no 
mitochondrial respiratory chain enzymatic deficiencies by spectrophotometric analysis (Fig. 
4.14). To assess whether murine fibroblasts showed any alteration to normal respiratory chain 
complex activities, biochemical measurements were carried out for Tmco6-KO MEFs, derived 
from E11.5 and E12.5 embryos as per section 2.5.2. No enzymatic deficiencies were observed 
for CI, CII, SDH, CIII or CIV, with specific activities of each normalised to CS activity (Fig. 
6.17); a non-significant downwards trend was observed for all complexes for KO cells (n = 3) 




Fig. 6.17. Biochemical analysis of the mitochondrial respiratory chain in MEFs. 
 
Complex I (CI), succinate dehydrogenase (SDH), Complex II (CII), Complex III (CIII) and 
Complex IV (CIV) enzymatic activities were performed as per section 2.7.1, with resulting 
values normalised to the activity of citrate synthase (CS) for wildtype and knockout MEFs (n 
= 3 for either genotype). Data are presented as mean ± SEM. Two-way ANOVA with Sidak’s 





6.2.4.2 Investigating Mitochondrial Respiratory Chain Activities in Tmco6-KO Tissues 
To quantify any alteration in the functioning of the mitochondrial respiratory chain in Tmco6-
knockout mice, kinetic measurements of CI, SDH, CII, CIII, and CIV specific enzymatic 
activities were performed spectrophotometrically with tissue homogenates from brain (Fig. 
6.18 A.), heart (Fig. 6.18 B.), liver (Fig. 6.18 C.) and skeletal muscle (Fig. 6.18 D.) from 3 
month old animals. Surprisingly, despite the various neurobehavioral and histopathological 
differences we had observed (sections 6.2.2 and 6.2.3), no differences in CI activity, nor the 
activities of any of the other mitochondrial respiratory complexes, were detected in brain 
homogenates of 3 month old KO mice (n = 3), compared to HET and WT age-matched controls 
(n = 2 per group) (Fig. 6.18 A.). Also, despite having showed no obvious abnormalities by 
histological analyses, heart (Fig. 6.18 B.) and skeletal muscle (Fig. 6.18 D.) homogenates 
both revealed isolated CI deficiency. The more severe CI deficiency was observed in heart, 
with ~70-85 % reduction for KO mice compared to WT and HET controls. For skeletal muscle, 
there was a ~40 % reduction in CI activity for KO animals. These results are highly significant 
since they recapitulate the initial observation made in the muscle biopsy from the patient of an 
isolated CI deficiency, and provide further support to the hypothesis that TMCO6 is the 
causative gene of that defect. 
 
Given that brains of KO animals had clear histopathological abnormalities, we sought to 
separate the different regions of the brain to assess whether a localised mitochondrial 
enzymatic deficiency in one portion of the brain was present, but was being masked by using 
whole brain homogenates. Brains of control (WT and HET) and KO 3 month old mice (n = 4 
for both genotypic groups) were dissected into crude forebrain, midbrain and hindbrain 
sections. Again, we observed no enzymatic deficiencies for CI, SDH, CII, CIII or CIV for 
forebrain (Fig. 6.19 A.), midbrain (Fig. 6.19 B.) or hindbrain (Fig. 6.19 C.) regions, suggesting 
that the neurodegeneration and associated phenotypes observed ubiquitously throughout the 
brain by histology could be due to some cause of Tmco6-ablation not related to respiratory 
chain deficiency. However, values from KO samples tend to be lower than controls, at least in 
fore- and midbrain regions.  
 
Since we had observed reduction of CI supercomplexes by BNGE in patient and shRNA-
knockdown HEK 293T cell lines, we wanted to assess CI activity in relation to the other 
respiratory chain complexes, and not just in isolation. Aerobic respiration, measured by the 
rate of O2 consumption, was determined by Oroboros for brains of 3 month old control (WT 
and HET, n = 3) and knockout (KO, n = 3) mice. Fig. 6.20 shows significant reduction in CI-
linked aerobic respiration for KO animals, calculated as respiration requiring ADP as a 
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substrate minus the residual O2 flux after addition of the CI inhibitor, rotenone. This showed 
that despite there being no specific CI enzymatic deficiency in knockout brains, electron flow 





Fig. 6.18. Biochemical analyses of brain, heart, liver and skeletal muscle homogenates 
from Tmco6-KO mice show tissue-specific metabolic differences. 
 
Complex I (CI), succinate dehydrogenase (SDH), Complex II (CII), Complex III (CIII) and 
Complex IV (CIV)enzymatic activities were performed as per section 2.7.1, with resulting 
values normalised to the activity of citrate synthase (CS) for 3 month old wildtype (WT) (n = 
2), heterozygous (HET) (n = 2) and knockout (KO) (n = 3) (A.) brain, (B.) heart, (C.) liver and 
(D.) skeletal muscle protein homogenates. Data are presented as mean ± range. Statistical 
analysis: * p < 0.05, ** p < 0.01, *** p < 0.005, calculated by two-way ANOVA with Sidak’s 
multiple comparisons post hoc test applied. 
  































































































































A.  B.  





Fig. 6.19. Biochemical analyses of forebrains, midbrains and hindbrains of 3 month old 
Tmco6-KO mice show no differences in respiratory chain enzymatic activities. 
 
Complex I (CI), succinate dehydrogenase (SDH), Complex II (CII), Complex III (CIII) and 
Complex IV (CIV) enzymatic activities were performed as per section 2.7.1, with resulting 
values normalised to the activity of citrate synthase (CS) for 3 month old control, consisting of 
wildtype and heterozygous animals (n = 4), and knockout (KO) (n = 4) (A.) forebrains, (B.) 
midbrains and (C.) hindbrains. Data are presented as mean ± SD. Statistical analysis by two-






























































































Fig. 6.20. CI-linked aerobic respiration is significantly decreased in Tmco6-KO brains. 
 
Mitochondrial O2 consumption rate was measured in brains from 3 month old control (WT and 
HET, n = 3) and knockout (KO, n = 3) genotypic groups in technical duplicates using an 
Oxygraph-2k respirometer (Oroboros Instruments, Innsbruck, Austria) as per section 2.7.3. 
Basal = mitochondrial O2 consumption rate at 37 oC, CI-linked = ADP-dependent O2 
consumption minus residual OXPHOS-independent respiration after addition of rotenone, 
Maximal = maximal respiration following uncoupling of the respiratory chain by CCCP (C2759, 
Sigma-Aldrich®), Oligomycin = halting of aerobic respiration following addition of the CV 
inhibitor, oligomycin (O4876, Sigma-Aldrich®). Data are presented as mean ± SEM (n = 3). 
Statistical analysis: **** p < 0.001, calculated by two-way ANOVA with Sidak’s multiple 
comparisons test applied. No differences in basal, maximal or oligomycin-inhibited respiration 
were detected for the knockout relative to the control group, but CI-linked respiration was 
significantly lower in knockout brains. 
 
 
Since heart and skeletal muscle homogenates showed significant deficiencies in CI enzymatic 
activity for 3 month old Tmco6-knockout animals compared to both wildtype and heterozygous 
controls (Fig. 6.18), we repeated biochemical measurements for 12 month old WT, HET and 
KO mice to observe if this phenotype was also present in older animals. We also wanted to 
observe whether the severity of the CI deficiency was progressive with age. As shown in Fig. 
6.21 A., the isolated CI deficiency in cardiac muscle was comparable to that observed for 3 
month old animals. The same trend was also seen in skeletal muscle (Fig. 6.21 B.), with 
equivalent differences to the 3 month old age group. Interestingly, skeletal muscle of 12 month 
old KO mice also exhibited COX deficiency of approximately 25 % compared to both WT and 
HET controls. 
 


































Fig. 6.21. 12 month old heart and skeletal muscles homogenates show conserved CI 
deficiency for Tmco6-KO mice. 
 
Complex I (CI), succinate dehydrogenase (SDH), Complex II (CII), Complex III (CIII) and 
Complex IV (CIV) enzymatic activities were performed as per section 2.7.1, with resulting 
values normalised to the activity of citrate synthase (CS) for 12month old wildtype (WT), 
heterozygous (HET) and knockout (KO) mice for (A.) heart and  (B.) skeletal muscle tissue 
homogenates. Data are presented as mean ± SEM. Heart: WT (n = 1), HET (n = 1) and KO 
(n = 3), Skeletal muscle: WT (n = 3), HET (n = 3) and KO (n = 4). Statistical analysis: * p < 
0.05, **** p < 0.001, calculated by two-way ANOVA with Sidak’s multiple comparisons post 
hoc test applied. 
  




































































 Molecular Investigation of Tmco6-KO Tissues 
SDS-PAGE, 1D-BNGE and CI in-gel activity were performed for brain, heart, skeletal muscle 
and liver tissues to assess differences in the steady-state levels of CI subunits, assembly 
factors, CI holocomplex abundance and abundances of any subcomplex or supercomplex CI-
containing species, and to visually asses any CI activity differences in these tissues. The 
analysis was used in part to try to narrow down where in the CI biogenesis pathway TMCO6 
may be involved.  
 
Firstly, we analysed total protein homogenates from brains of 3 month old WT, (n = 2), HET (n 
= 2) and KO (n = 3) mice, and immunoblotted various CI subunits localising to each of the CI 
modules, as well as several subunits of the other respiratory complexes. As shown in Fig. 
6.22, no differences in abundances of any OXPHOS subunits were found. 1D-BNGE, Western 
blot analysis showed no difference in CI holocomplex abundance or in the amount of any other 
respiratory chain complex (Fig. 6.23 B.). In addition, 3 month old KO mouse brains again did 







Fig. 6.22. 3 month old brains of Tmco6-knockout mice show no differences in OXPHOS 
subunit abundance by SDS-PAGE and Western blot analysis. 
 
SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from whole tissue 
homogenates obtained from 3 month old WT (n = 2), HET (n = 2) and KO (n = 3) mice. WB 
analysis followed for immunodetection of CI subunits NDUFS1, NDUFS6, NDUFA9, NDUFS2, 
NDUFS3, NDUFS8, NDUFA3, NDUFA10, and NDUFB8, CII subunits SDHA and SDHB, CIII 
subunits UQCRC1 and UQCRC2, CIV subunit MT-CO1, CV subunit ATP5A, mitochondrial 
loading control CS, and cytosolic loading controls GAPDH and VINCULIN using the primary 





Fig. 6.23. 3 month old brains of Tmco6-knockout mice show no differences in CI in-gel 
activity or OXPHOS complex abundances by 1D-BNGE and Western blot analysis. 
 
(A.) CI in-gel activity for 120 μg mitochondrial protein treated with 1 % DDM from 3 month old 
WT, (n = 2), HET (n = 2) and KO (n = 3) hearts was performed by NADH/NBT staining (see 
section 2.7.2). No difference in activity was observed by this qualitative method. (B.) 1D-
BNGE was performed with 120 μg mitochondrial protein treated with 1 % DDM from 3 month 
old WT, (n = 2), HET (n = 2) and KO (n = 3) mice, resolved using 3 – 12 % gradient Novex® 
NativePAGE gels as per section 2.6.3. Immunodetection of native CI, CII, CIII2, and CIV was 
performed by WB analysis by successive incubations with primary antibodies against 
NDUFA9, SDHB, UQCRC2, and MT-CO1, respectively (for antibody manufacturer details and 
concentrations used for each, see Table 2.29). 
 
 
We next analysed total protein homogenates from hearts of 3 month and 12 month old WT, 
HET and KO mice (n = 3 for each group), by SDS-PAGE and WB blotting analysis. As shown 
in Fig. 6.24, differences in abundances of CI subunits in 3 month old animals were not found; 
however 12 month old animals showed a significant difference in the abundance of NDUFS1 
(N-module). The steady-state levels of all other OXPHOS subunits tested for the KO genotype 
were in line with control values. Fresh samples were prepared to verify the difference in 
NDUFS1, again by SDS-PAGE and WB analysis. In addition to NDUFS1, NDUFS6 was also 
immunodetected since it had been found to be pulled down by HA-tagged TMCO6 in 
immunoprecipitation experiments in HEK 293T cells (Fig. 5.21). As shown in Fig. 6.25 A. and 
B., statistically significant differences in NDUFS1 and NDUFS6 abundance were shown 
relative to the loading control, GAPDH. It is significant that both subunits are part of the N-









Fig. 6.24. Hearts from 3 month and 12 month old Tmcco6-knockout mice show no 
significant difference in steady-state levels except for NDUFS1. 
 
SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from whole tissue 
homogenates obtained from 3 and 12 month old WT, HET and KO mice (n = 3 per group). 
WB analysis followed for immunodetection of CI subunits NDUFS1, NDUFA2, NDUFS2, 
NDUFS3, NDUFA10, and NDUFB8, CI assembly factors ACAD9 and NDUFAF3, CII subunit 
SDHB, CIII subunit UQCRC1, CIV subunit MT-CO1, CV subunit ATP5A, mitochondrial loading 
control (L.C.) GRP75, and cytosolic loading control VINCULIN, using the primary antibodies 








Fig. 6.25. 3 month old hearts of Tmco6-knockout mice show significant differences in 
the quantity of CI subunits NDUFS1 and NDUFS6  
 
(A.) SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from whole tissue 
homogenates obtained from 12 month old WT, HET and KO murine hearts (n = 3 for each 
genotypic group). WB analysis followed for immunodetection of CI subunits NDUFA2, 
NDUFS1, and NDUFB8, CII subunit SDHA, CIII subunit UQCRC2, CV subunit ATP5A, 
mitochondrial loading control GRP75, and cytosolic loading controls GAPDH and VINCULIN 
using the primary antibodies and concentrations detailed in Table 2.29. (B.) Densitometric 
analysis was performed by ImageJ Fiji Gel Analysis software for relative band intensities of 
NDUFS1 and NDUFS6, normalised to the signal for GAPDH per sample. Data are presented 
as mean ± SEM. Statistical analysis: ** p < 0.01, calculated by two-way ANOVA with Sidak’s 
multiple comparisons post hoc test. 
 
1D-BNGE was used to analyse respiratory chain complex abundances in hearts of WT (n = 2), 
HET (n = 2) and KO (n = 3) 3 month-old mice. Immunodetection of NDUFA9 (N- module/Q-
module boundary) by Western blotting showed no discernible differences in CI holocomplex 
abundance (Fig. 6.26 B.), but there was a statistically significant ~ 40 % difference in CI in-gel 
activity signal by densitometric quantification (Fig. 6.26 A. and C.). CII (as immunodetected by 






































Fig. 6.26. 3 month old hearts of Tmco6-knockout mice show a difference in CI in-gel 
activity but little difference in OXPHOS complex abundances by 1D-BNGE. 
 
(A.) CI in-gel activity for 120 μg mitochondrial protein treated with 1 % DDM from 3 month old 
WT (n = 2), HET (n = 2) and KO (n = 3) hearts was performed by NADH/NBT staining (see 
section 2.7.2), showing statistically significant differences in staining intensities for KO 
compared to WT samples (see C.). (B.) 1D-BNGE was performed as above using 3 – 12 % 
gradient Novex® NativePAGE gels, as per section 2.6.3. Immunodetection of native CI, CII, 
CIII2, and CIV was performed by WB analysis by successive incubations with primary 
antibodies against NDUFA9, SDHB, UQCRC2, and MT-CO1, respectively (for antibody 
details, see Table 2.29). (C.) Densitometric quantification of CI in-gel band staining relative to 
CII signals revealed statistically significant CI activity reduction by ~ 40 % for KO animals 
compared to WT and HET controls. Data are presented as mean ± range. Statistical analysis: 
* p < 0.01, one-way ANOVA with Tukey’s multiple comparisons post hoc test applied. 
 
Skeletal muscles were next analysed as described above for brain and heart, by SDS-PAGE 
and WB blotting analysis to assess differences in OXPHOS subunit quantities, and by 1D-
BNGE and CI in-gel activity to determine any alterations in abundance of the CI holocomplex 
or its biochemical activity. As shown in Fig. 6.27 A., the only protein whose steady-state level 
was altered consistently in KO mice was NDUFB8 (PD-module). However, densitometric 
analysis (Fig. 6.27 B.) found no statistically significant reduction in the abundance of NDUFB8 








Fig. 6.27. No differences in OXPHOS subunit levels were observed in skeletal muscle. 
 
(A.) SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from 3 month old 
WT (n = 2), HET (n = 2) and KO (n = 3) skeletal muscle homogenates. Immunodetection of CI 
subunits NDUFA9, NDUFS2, NDUFS8, NDUFA3, NDUFA10 and NDUFB8, CII subunit SDHA, 
CIII subunits UQCRC1 and UQCRC2, CIV subunit MT-CO1, CV subunit ATP5A, mitochondrial 
L.C. CS, and cytosolic L.C.s GAPDH and VINCULIN followed (see Table 2.29). (B.) 
Densitometric quantification was performed for NDUFB8, relative to GAPDH. Data are 
presented as mean ± range. No significant differences were found by one-way ANOVA with 































1D-BNGE was used to analyse respiratory chain complex abundances in skeletal muscles of 
3 month old mice (n = 2 for WT, HET and KO genotypes). Immunodetection of NDUFA9 by 
Western blotting showed no discernible differences in steady-state levels of the CI 
holocomplex (Fig. 6.28 B.), and there were no qualitative differences in CI in-gel activity signal 
(Fig. 6.28 A. and C.) for KO compared to control WT and HET animals. The difference 
observed by spectrophotometry (Fig. 6.18) if still present, it is under the sensitivity limit in this 
method. CII (as immunodetected by SDHB), CIII2 (UQCRC2) and CIV (MT-CO1) levels were 





Fig. 6.28. Mitochondrial protein complex levels are unaffected in KO skeletal muscle. 
 
(A.) CI in-gel activity for 120 μg mitochondrial protein treated with 1 % DDM from 3 month old 
WT, HET and KO (all n = 2) skeletal muscle was performed by NADH/NBT staining (see 
section 2.7.2). No difference in activity was observed by this qualitative method. (B.) 1D-
BNGE was performed as per section 2.6.3. Immunodetection of native CI, CII, CIII2, and CIV 
was performed by WB analysis by successive incubations with primary antibodies against 
NDUFA9, SDHB, UQCRC2, and MT-CO1, respectively (for antibody manufacturer details and 
concentrations used for each, see Table 2.29. (C.) Data are presented as mean ± range. 
Densitometric quantification of CI in-gel band intensities the CI holocomplex, both relative to 
CII, revealed no differences by statistical analysis: two-way ANOVA with Sidak’s multiple 



































Finally, we analysed the livers of 3 month KO, HET and WT mice. As shown in Fig. 6.29 A., 
no differences in the abundances of OXPHOS subunits, including those of CI, were found for 
KO mice compared to control groups by SDS-PAGE and WB analysis. Densitometric analysis 
of NDUFS1 (Fig. 6.29 B.) showed a non-significant difference for the KO samples compared 
to controls. For analysis of mature mitochondrial protein complexes by 1D-BNGE, 
mitochondrial protein extracts from liver were solubilised with either 1 % DIG (Fig. 6.30 A.), or 
1 % DDM (Fig. 6.30 B.). DIG-solubilisation was used here to allow for the visualisation of 
supercomplex species to assess any differences resulting from absence of the Tmco6 protein. 
There were no differences observed in the steady-state levels of any of the respiratory chain 
complexes, or in CI activity of the mature CI homocomplex or any CI-containing supercomplex 
species, evaluated qualitatively by in-gel activity. 
 
In summary of the results of the molecular investigation into Tmco6-knockout murine tissues, 
the steady-state levels of N-module subunits NDUFS1 and NDUFS6 were reduced to ~ 40 % 
of control levels in hearts of aged mice. SDS-PAGE and WB analysis did not reveal any other 
significant alterations for subunits of CI, or any subunits of the other respiratory chain 
complexes, for hearts or for all other tissues examined, i.e. brains, skeletal muscles, and liver 
ay 3 or 12 months of age. 1D-BNGE showed no changes in CI abundance, or in the 
abundances of the other mature protein complexes, but coupled with in-gel activity, it only 







Fig. 6.29. No differences in OXPHOS subunit levels were observed in liver. 
 
(A.) SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from 3 month old 
WT, HET and KO (n = 3) liver homogenates. Immunodetection of CI subunits NDUFS1, 
NDUFA9, NDUFS2, NDUFA3, and NDUFB8, CII subunit SDHA, CIII subunit UQCRC2 (Core 
2), CIV subunit COX4, CV subunit ATP5A, and cytosolic loading controls (L.C.) GAPDH and 
VINCULIN followed (see Table 2.29). (B.) Densitometric quantification was performed for 
NDUFS1, relative to GAPDH, and no significant differences were found by one-way ANOVA 






































Fig. 6.30. Mitochondrial protein complex levels are unaffected in KO liver. 
 
TOP: 1D-BNGE was performed with 120 μg mitochondrial protein treated with (A.) 1 % DIG 
or (B.) 1 % DDM from 3 month old WT, HET and KO (all n = 2) livers as per section 2.6.3. 
Immunodetection of native CI, CII, CIII2, and CIV was performed by WB analysis by 
successive incubations with primary antibodies against NDUFA9, SDHB, UQCRC2, and MT-
CO1, respectively (for antibody manufacturer details and concentrations used for each, see 
Table 2.29. BOTTOM: CI in-gel activity was performed by NADH/NBT staining (see section 
2.7.2). No difference in activity was observed by this qualitative method relative to the signals 
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 Analysis of Cardiac Function and Respiratory Rate in Tmco6-KO Mice  
Following on from the observation that Tmco6-ablation results in severe CI deficiency in hearts 
of 3M and 12M KO animals, cardiovascular function and physiology were evaluated by 
echocardiography and electrocardiography using the Vevo 770® High Resolution Imaging 
System (VisualSonics, Inc., Toronto, Canada) for the age group that showed the worse 
phenotype (12 onths old). Imaging was performed by Stephen Moore at the Phenomics 
Laboratory (West Forvie Site, Cambridge, UK).  
 
Aged (12 month old) wildtype (WT) and knockout (KO) mice were sedated with isoflurane gas 
and systematically imaged in parasternal short axis (Fig 2.9 A.), long axis (Fig 2.9 B.) and 
apical four-chamber (Fig 2.9 C.) views in the pulsed-wave (PW) doppler or motion (M) modes, 
as previously described (Gao et al., 2011). These acquired images were used to calculate a 
large number of functional parameters. The ones of interest to us were those that assessed 
cardiac function for different areas of the heart. These were: aortic ejection time (AET), left 
ventricle (LV) myocardial performance index (MPI), mitral valve (MV) atrial (A) and early (E) 
peak wave flows (mm/s), MV E/A peak ratio, right ventricular outflow tract mean velocity time 
integral (RVOT VTI) (mm/s), cardiac output (CO) (ml/min), ejection fraction (EF) (%), fraction 
shortening (FS) (%), HR (bpm), stroke volume (SV) (μl), and volumes expelled in diastole and 
systole (V;d, V;s) (μl), all calculated by the Vevo LAB and Auto LV Analysis software packages 
(VisualSonics).  
 
No obvious morphological defects were observed in KO hearts by echocardiography. As 
shown in Table 6.4, the only statistically significant difference in echocardiographic parameters 
detected between KO and WT 12 month old cohorts was for RVOT VTI, which is used to 
assess right ventricular systolic function. Decreased RVOT VTI is associated with hypotension 
and decreased flow of deoxygenated blood to the lungs. Importantly, reduction of right 
ventricular systolic function has been found in humans to correlate with impaired exercise 
tolerance (Ojji et al., 2016), as seen in Tmco6-KO 3 and 12 month old mice by exhaustion trials 
(Fig. 6.5 A. and B.). Despite not yielding a significant difference by statistical analyses, the 
CO, EF, SV, FS, V;d and V;s values were all decreased to varying extents for the KO mice, all 
normalised to body weights per animal. These values together suggest impaired ability of KO 
hearts to efficiency pump blood around the body, and can result from a range of underlying 
causes. One of which is contractility. Indeed, KO animals showed far less contractility in 
parasternal short axis views compared to controls (video available upon request). In addition, 
we observed a decrease in the HR of KO animals compared to age-matched WT controls. This 
result was explored further by ECG, as described below.  
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Table 6.4. Echocardiography Results for 12-Month Old Male Tmco6-KO Mice 
 
For WT and KO, n = 4. Data are presented as mean ± SEM. Statistical analysis: two-way 
ANOVA with Sidak’s multiple comparisons post hoc test applied. n.s. = non-significant. 
 
Parameter Unit WT KO Significant? 
Aortic Ejection Time (AET) ms 41.7 ± 2.2 49.3 ± 5.5 n.s. 
Left Ventricle Myocardial 
Performance Index (LV MPI) 
- 0.8 ± 0.1 0.8 ± 0.2 n.s. 
Mitral Valve E/A Peak Ratio (M/V 
E/A) 
- 1.7 ± 0.4 1.6 ± 0.1 n.s. 
Right Ventricular Outflow Tract Mean 
Velocity Time Integral (RVOT VTI) 
mm/s -511.7 ± 22.9 -428.4 ± 39.9 p = 0.003 
Cardiac Output (CO) ml/min 24.4 ± 3.7 19.0 ± 4.4 n.s. 
Ejection Fraction (EF) % 57.5 ± 6.9 52.3 ± 3.2 n.s. 
Fraction Shortening (FS) % 30.3 ± 4.6 26.7 ± 1.8 n.s. 
Heart Rate (HR) bpm 467 ± 58.2 427.5 ± 60.1 n.s. 
Stroke Volume (SV) μl 52.4 ± 5.6 42.2 ± 7.9 n.s. 
Volume Expelled In Diastole (V;d) μl 92.3 ± 13.8 82.4 ± 19.0 n.s. 




Electrocardiogram (ECG) traces of KO and WT mice (n = 4 per group) determined signs of 
perturbed electrophysiology in 12 month-old Tmco6-KO hearts. Firstly, WT (Fig. 6.31 A.) 
animals were always found to have faster heart rates than for KO (Fig. 6.31 B.) littermates, 
with approximately 3 beats for the KO for every 4 of the WT. This trend was true for all 4 
knockouts. Secondly, KO animals displayed 4:1 with occasional 3:1 atrial flutter (both as 
labelled in Fig. 6.31 B.), in which instead of a single P-wave, denoting atrial depolarisation at 
the beginning of a heartbeat, there are instead three or four separate waves. Typical atrial 
flutter results from a re-entrant circuit around the tricuspid valve (Masè, Disertori and Ravelli, 
2009). Fig. 6.32 shows two representative KO and two representative WT traces, where this 
pattern is clearly shown in KOs, but is completely absence for WTs. It is worth noting that the 






Fig. 6.31. 12 month old KO mice have 3 heart beats for every 4 of WT controls. 
 
Cardiovascular function and physiology were evaluated by echocardiography for 12 month old 
male (A.) wildtype (WT) and (B.) knockout (KO) mice (n = 4 per group) using the Vevo 770® 
High Resolution Imaging System (VisualSonics, Inc., Toronto, Canada). Electrocardiogram 
(ECG) traces for representative WT (black) and KO (red) mice shows a pattern of 4 heart 
beats for the WT for every 3 of the KO. For an overview of the components of a murine ECG 










Fig. 6.32. KO 12 month old animals display 3:1 or 4:1 atrial flutter. 
 
Representative electrocardiogram traces for two wildtype (WT) and two knockout (KO) 12 M 
mice are shown, displaying 3:1 or 4:1 atrial flutter in the KO. Traces were generated by the 
Vevo 770® High Resolution Imaging System (VisualSonics, Inc., Toronto, Canada). 










































To quantify these differences, PQ, QRS and ST intervals (see Fig. 6.31 A. for the respective 
span of each) were calculated per animal by averaging the durations per interval for three 
separate heart beats (Table 6.5). These results (n = 4 biological replicates for WT and KO 
genotypic groups) suggest that the decreased HR seen in KO animals is most likely caused 
by the atrial flutter, since there is only statistically significant increase in the PQ interval, which 
is almost doubled compared to that of age-matched WT controls. The QRS interval is 
comparable between WT and KO animals, suggesting no problem with the ventricular 
depolarisation. The ST interval is shorter in KO animals versus WT animals, but not considered 
to be statistically significant. The ST interval marks the time taken for ventricular repolarization, 
and has been found to be shortened following myocardial infarction and ischaemia (Hurst, 
1997). The decreased ST interval could also be related to decreased right ventricular function, 
as observed by reduction in RVOT VTI in KO animals by echocardiography (Table 6.4). 
 
Table 6.5. Electrocardiography Results for 12-Month Old Male Tmco6-Knockout Mice 
 
For WT and KO, n = 4. Data are presented as mean ± SEM. Statistical analysis: two-way 
ANOVA with Sidak’s multiple comparisons post hoc test applied. n.s. = non-significant. 
 
Interval Unit WT KO Significant? 
PQ ms 38.5 ± 6.7 58.4 ± 7.6 p = 0.0286 
QRS ms 29.6 ± 4.1 30.4 ± 0.9 n.s. 
ST ms 37.4 ± 3.3 23.9 ± 3.1 n.s. 
 
 
Additionally, respiration rate per animal was monitored throughout cardiac imaging, and 
interestingly, striking differences were observed between WT and KO genotypic groups (n = 4 
each). Fig. 6.33 shows overlap of representative KO and WT respiration curves, showing a 
three-fold average increase in respiration rate for KO animals compared to WT counterparts. 
Fig. 6.34 shows full traces of 2 representative WT and 2 representative KO 12 month old mice 
over 3 seconds. The quantification of this data is shown in Table 6.6. KO animals breathed 
similarly whilst under anaesthetic than when conscious. It is possible that if the blood of KO 
animals is not being oxygenated quickly enough to sustain homeostatic function due to 
decreased right ventricular function (Table 6.4), then these mice are forced to breath in air 
more rapidly to compensate for the amount of oxygen needed to meet the body’s various 
aerobic demands. This also explains the result observed by CLAMS of higher O2 consumption 
and CO2 production in 12 M KO male mice (Fig. 6.8), despite significantly less overall 
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movement (Fig. 6.7). Lastly, increased respiration rate is also commonly found in human 





Fig. 6.33. 12 month old KO mice have a three-fold faster breathing rate than WT controls. 
 
Respiration was recorded by electro-contact pads on the VEVO mouse handling platform 
positioned underneath wildtype (WT) and knockout (KO) male mice at 12 months of age during 
electrocardiographic monitoring (n = 4 per genotypic group), and as shown by two 
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Fig. 6.33. 12 month old KO mice have a three-fold faster breathing rate than WT controls. 
 
Respiration for 2 wildtype (WT) and 2 knockout (KO) male mice at 12 months of age, recorded 
during electrocardiographic monitoring; KO animals had a three-fold faster breathing rate than 

















































Table 6.6. Respiratory Rates of 12-Month Old Male Tmco6-Knockout Mice 
 
For WT and KO, n = 4. Data are presented as mean ± SEM. Statistical analysis: two-tailed 
Student’s t-test. n.s. = non-significant. 
 
  
Unit WT KO Significant? 
Respiratory Rate Breaths/sec 2.25 ± 0.25 3.5 ± 0.0 p = 0.0170 
 
 
In summary, Tmco6-KO mice exhibit decreased right ventricular function by echocardiographic 
analysis, and perturbations to electrophysiology, suggesting atrial flutter. No other 
abnormalities in cardiac function or physiology were detected. Furthermore, Tmco6-KO 





The work of this chapter: 1) characterises neurological, behavioural and motor phenotypes of 
a Tmco6-knockout murine model, 2) investigates histopathological abnormalities of different 
tissue types, 3) assesses the molecular and metabolic consequences of Tmco6-ablation in a 
tissue-specific manner and 4) evaluates cardiac function and electrophysiology following 
detection of severe CI deficiency in KO hearts. 
 
A transgenic Tmco6-KO mouse model, B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J, was used in order to 
characterise the effects of Tmco6-ablation on mammalian development, physiology, 
neuromuscular coordination and metabolism. PCR-based genotyping of Tmco6-KO, HET and 
WT genomic DNA indicated absence of two essential coding exons, and RT-qPCR confirmed 
total loss of all coding Tmco6 mRNA transcripts. Native murine Tmco6 protein could not be 
accurately detected by Western blotting and immunodetection using two commercial 
antibodies raised against different regions of the human orthologue. 
Heterozygous matings (n = 250) revealed a non-Mendelian distribution of the KO genotype. 
Phenotypic characterisation of this mouse line revealed that body weights of KO animals are 
significantly lower than for HET and WT control animals, from 12 weeks of age for males and 
28 weeks of age for females. KO mice also exhibit atypical neurobehaviors such as progressive 
hind-limb clasping, and epilepsy, characterised by a series of full-body myoclonic seizures in 
quick succession. KO 3 month-old mice exhibited impaired exercise tolerance by treadmill 
exhaustion tests, and both 3 month and 12 month old animals display a progressive impairment 
of motor coordination and balance at 3, 6 and 12 months of age by rotarod evaluation. 
Additionally, KO animals display bradykinesia at all ages, as determined by the pole test. 
CLAMS evaluation found a significant lack of exploratory and locomotor behaviours in KO 
animals at 3, 6 and 12 months of age. Curiously, KO animals also consumed more oxygen 
and expelled more carbon dioxide than age-matched controls, suggesting that they must 
undergo higher than normal metabolic activity in order to maintain basal survival. 
Histopathological investigation of Tmco6-KO brains showed neurodegeneration, increased 
astrogliosis, accumulation of ubiquitin-rich inclusion bodies, recruitment of inflammatory 
microglial cells, and hypomyelination of axons in 3 month and 12 month age groups.  
Cultured MEFs did not harbor any mitochondrial respiratory complex deficiencies, similarly to 
what was observed for human patient-derived fibroblasts (Fig. 4.14). Biochemical 
measurement of respiratory chain complex activities (CI-CV) in the brains of 3 month-old KO 
animals showed no appreciable differences compared to controls; however, CI-linked O2 
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consumption was significantly reduced as measured by Oroboros using fresh brain tissue. 
Skeletal muscle and heart showed isolated CI deficiencies at 3 and 12 months of age, whereas 
the liver showed no biochemical abnormalities. 
CI N-module subunits NDUFS1 and NDUFS6 were found significantly decreased in 12 month 
old Tmco6-KO hearts by SDS-PAGE and Western blot analyses. Furthermore, in-gel activity 
measurement revealed isolated CI deficiency by qualitative means. Echocardiography 
detected a statistically significant reduction in right ventricle systolic function in 12 month-old 
Tmco6-KO mice. These animals were also found to exhibit atrial flutter by electrocardiography. 
We observed increased respiration rates and slower heart rates in these animals compared 
with age-matched WT controls. 
The study of this murine model was crucial in beginning to understand where and how TMCO6 
functions in humans. Tmco6-KO mice developed epilepsy and presented with poor motor 
endurance and coordination, similarly to the human patient described in Chapter 4, suggesting 
both neurological and muscular impairment. Indeed, histopathological analyses indicated 
neurodegeneration throughout the brain, as well as an activated immune response. No CI 
deficiency, nor any other mitochondrial respiratory chain complex functional deficiencies, were 
observed in KO brains, which was at first surprising, but they did reveal statistically significant 
reduction in CI-dependent O2 consumption. Perhaps lack of the Tmco6 protein is indirectly 
causing these phenotypes, or the protein has another functional role that does not concern its 
physical interaction with CI. Further experimentation is needed to investigate this. We also 
observed tissue-specific metabolic and molecular effects of Tmco6-ablation. Liver appeared 
metabolically functional in KO animals, whereas the heart displayed a range of molecular and 
biochemical abnormalities, including a significant, isolated CI deficiency. Given these results, 
we next endeavoured to assess whether it would be possible to rescue the CI deficiency 
observed in KO hearts by AAV-mediated functional complementation with the wildtype human 
gene, TMCO6. Administration of the patient mutant variant was performed concurrently to 
determine whether the patient mutant TMCO6 variant exacerbates or does not alter any of the 















Chapter 7  
Investigating the Effects of AAV-Mediated Gene Delivery of 





As described in Chapter 6, we observed severe, isolated CI deficiency in hearts of young adult 
(3 months old) and aged (12 months old) Tmco6-knockout (KO) mice. We hypothesised that 
gene delivery of wildtype (WT) human TMCO6 may functionally complement and thereby 
rescue the cardiac phenotype of this strain. In addition, delivery of the human patient mutant 
TMCO6 genomic variant (c.271C>T, as described in Chapter 4) was also performed in order 
to confirm or deny the pathogenicity of this mutation. In particular, we sought to determine 
whether stable expression of the patient mutant variant (termed here as ‘MUT’) is capable of 
rescuing the CI deficiency in KO hearts, or whether it would instead exacerbate the observed 
neuromotor, cardiac and biochemical phenotypes, and/or lead to pathogenic phenotypes not 
originally observed in 3 month-old Tmco6-KO mice. Hence, young adult KO and WT animals 
underwent adeno-associated virus (AAV)-mediated systemic delivery of human WT or MUT 
TMCO6 cDNA by tail-vein intravenous injections, using cardiotropic serotype AAV9 particles. 
When mice were nearing 3 months of age, we evaluated neuromotor behaviours by treadmill, 
rotarod, pole tests and CLAMS, and cardiac function and physiology by echocardiography and 
electrocardiography. Upon collection of tissues at 3 months of age, histological analyses were 
used to discern differences in the structural architecture and histopathological presentation of 
hearts in these animals. Cardiac CI activity was measured following stable expression of WT 
human TMCO6 or the MUT variant in both WT and KO genotypic groups. This gene delivery 
method was not intended as a gene therapy approach, but rather as a means of confirming 
whether the patient TMCO6 mutation is pathogenic in vivo. That said, the information gained 




 AAV-mediated Gene Delivery of Human WT and Patient MUT TMCO6  
In the previous chapter, a Tmco6-knockout mouse model, B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J, was 
studied to understand where and how the uncharacterised protein, Tmco6, functions in vivo. 
Tmco6-KO mice displayed hindlimb clasping and a proportion of these mice developed 
myoclonic epilepsy from 6 months of age (Fig. 6.4). Both male and female KO animals were 
generally smaller in mass and size compared to age-matched controls (Fig. 6.4), and 
presented with poor motor endurance and coordination (Fig. 6.5). These findings were similar 
to those found for a human mitochondrial disease patient with a homozygous recessive 
mutation in TMCO6 (c.271C>T), as described in detail in Chapter 4. Spectrophotometry and 
Oroboros techniques revealed tissue-specific mitochondrial enzymatic deficiencies in Tmco6-
KO mice brains, skeletal muscles and hearts. Despite there being no specific CI enzymatic 
deficiency (Fig. 6.18 A.) in brains of KO mice at 3 months of age, electron flow through the 
electron transport chain was impaired at the CI point of entry (Fig. 6.20). Hearts and skeletal 
muscle of 3 month and 12 month old KO males both showed isolated CI deficiency. The more 
severe CI deficiency was observed in KO hearts, with molecular abnormalities discovered as 
well, including a significant reduction in steady-state levels of N-module subunits NDUFS1 and 
NDUFS6 by SDS-PAGE and Western blot analysis. Echocardiography showed decreased 
right ventricular function and electrocardiography determined atrial flutter in KO mice hearts. 
No other abnormalities in cardiac function or physiology were detected at this time. 
 
These results led us to question whether we could use the hearts of this Tmco6-KO model in 
order to 1) perform functional rescue experiments, and 2) to assess the pathogenicity of the 
human patient mutation (p.Arg91Cys) in causing mitochondrial disease. We devised an AAV9-
mediated gene delivery strategy to administer either the WT cDNA sequence of human 
TMCO6 (CCDS4233.2, CCDS Database), or its patient mutant c.271C>T counterpart (termed 
in this work as ‘MUT’, for ‘mutant’), both labelled with C-terminal HA tags, to KO or WT young 
adult mice. It has been shown that in animal models, AAV-mediated viral genomes persist, in 
an episomal state, for essentially the entire life-span of the lab animal, most reliably in post-
mitotic or slowly-dividing tissues (Gammage et al., 2016). A titre of 4.5 x 1011 AAV particles 
carrying either WT, AAV2-HSA-TMCO6-cDNA-HA (Fig. 2.10), or MUT, AAV2-HSA-
TMCO6_MUT-cDNA-HA, cardiotropic AAV9 vectors were administered by tail-vein 
intravenous injection into 5 – 8 week old, weaned KO and WT mice (Fig. 7.1 A.). This process 
led to the creation of 4 distinct transgenic groups: Tmco6+/+ (AAV WT), Tmco6+/+ (AAV MUT), Tmco6-/- 




Figure 7.1. Gene delivery of human WT or patient MUT TMCO6 cDNA to a Tmco6-
knockout transgenic mouse line, and experimental timeline.  
 
(A.) Transgenic Tmco6-knockout (KO, Tmco6-/-) mice (B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J, The 
Jackson Laboratory) and counterpart wildtype (WT, Tmco6+/+) mice of this strain were 
administered a titre of 4.5 x 1011 AAV particles carrying either AAV2-HSA-TMCO6-cDNA-HA 
or AAV2-HSA-TMCO6_MUT-cDNA-HA AAV9 vectors (derived from the AAV2 serotype, 
hence the vector name) by tail-vein intravenous injections at 5-8 weeks of age, as shown. 
Injections were performed by Dr. Carlo Viscomi (Senior Investigator Scientist, Mitochondrial 
Medicine Laboratory, MRC MBU, University of Cambridge, UK). The resulting four genotypes 
of this process are included in the grey box. (B.) Experimental timeline for procedures 
(highlighted in green), including injection of serotype AAV9 vectors at 5-8 weeks of age, in 
vivo assessment as listed, and culling at 3 months of age. At this time, various tissues were 










 Physical and Neuromotor Behaviours of AAV9-Transduced Mice  
In vivo assessment of the four transgenic groups was performed using the methods listed in 
Fig. 7.1 B. Firstly, body weights were recorded weekly from the day of injection until three 
months of age separately for males (Tmco6+/+ (AAV WT), n = 4, Tmco6+/+ (AAV MUT), n = 4, Tmco6-/- 
(AAV WT), n = 3, and Tmco6-/- (AAV MUT), n = 3) (Fig. 7.2 A.) and females (Tmco6+/+ (AAV WT), n = 4, 
Tmco6+/+ (AAV MUT), n = 4, Tmco6-/- (AAV WT), n = 4, and Tmco6-/- (AAV MUT), n = 5) (Fig. 7.2 B.). 
Statistically significant differences were shown by two-way ANOVA with Sidak’s multiple 
comparisons test in males at 4 weeks post-injection, and for females from 2 weeks post-
injection for the Tmco6-/- (AAV MUT) mice compared to the experimental control group, Tmco6+/+ 
(AAV WT), for both sexes. Tmco6-/- (AAV MUT) females showed a complete “plateau” in weight gain 
after a month, whereas counterpart male mice started to gain weight from one week after 
injection. Interestingly, wildtype male and female Tmco6+/+ animals that were injected with the 
mutant TMCO6 vector (Tmco6+/+ (AAV MUT)) also showed a plateau in weight gain for two or three 
weeks following injection, unlike the Tmco6+/+ (AAV WT) controls. Conversely, knockout Tmco6-/- 
animals expressing the wildtype TMCO6 cDNA sequence (Tmco6-/- (AAV WT)) showed consistent 
weight gains, considered to be non-significant compared to the control group for both sexes. 
This indicates that whilst stable expression of WT TMCO6 led to normal weight gain in 
Tmco6+/+ and Tmco6-/- animals, MUT TMCO6 did not. 
 
Next, the atypical neurobehavior of hindlimb clasping was assessed (see section 2.5.6), and 
was found only in Tmco6-/- strains, as before, despite expression of WT or MUT versions of 
TMCO6 (Fig 7.3). The phenotype was less severe for Tmco6-/- (AAV WT) animals, with no obvious 
twisting of the body and intervals of normal extended limb posture, as opposed to Tmco6-/- (AAV 
MUT) mice, who had pronounced hindlimb clasping, often with a twisted body, and no extension 
of hindlimbs away from the abdomen at any time during the 10 s test duration. Tmco6+/+ (AAV 
MUT) animals did not show hindlimb clasping per se, but would kick their hindlimbs quickly in 
bursts, a phenotype not observed in control Tmco6+/+ (AAV WT) animals. In summary, this test 
showed no rescue in the hindlimb clasping phenotype of knockout animals as a result of WT 
TMCO6 overexpression. However, there was relative worsening of this neurobehavior in MUT 
TMCO6-expressing animals (Tmco6+/+ (AAV MUT) and Tmco6-/- (AAV MUT)) compared to WT TMCO6-







Figure 7.2. Body weights of Tmco6+/+ and Tmco6-/- mice stably expressing WT or MUT 
TMCO6 over 1 month following AAV9-mediated gene delivery by tail-vein injection.  
 
Body weight as a function of age was measured for (A.) male (Tmco6+/+ (AAV WT), n = 4, Tmco6+/+ 
(AAV MUT), n = 4, Tmco6-/- (AAV WT), n = 3, and Tmco6-/- (AAV MUT), n = 3) and female (Tmco6+/+ (AAV 
WT), n = 4, Tmco6+/+ (AAV MUT), n = 4, Tmco6-/- (AAV WT), n = 4, and Tmco6-/- (AAV MUT), n = 5) mice 
over 1 month on a weekly basis from the day of AAV9 injection. Data are presented as mean 
± SEM. Statistical analysis: n.s. = non-significant, * p < 0.05, ** p < 0.01, calculated by two-
way ANOVA with Sidak’s multiple comparisons post hoc test. 
  





















































Figure 7.3. Hindlimb clasping of Tmco6+/+ and Tmco6-/- mice stably expressing WT or 
MUT TMCO6 at 3 months of age.  
 
Hindlimb clasping was assessed for Tmco6+/+ (AAV WT) (n = 7), Tmco6+/+ (AAV MUT) (n = 7), Tmco6-
/- (AAV WT) (n = 8), and Tmco6-/- (AAV MUT) (n = 7) mice; one representative animal for each 
genotypic group is shown.  
 
 
No epilepsy was observed in any of the mice for Tmco6+/+ (AAV WT) (n = 7), Tmco6+/+ (AAV MUT) (n 
= 7), Tmco6-/- (AAV WT) (n = 8), or Tmco6-/- (AAV MUT) (n = 7) groups. This was expected given that 
Tmco6-/- (also termed KO) animals did not display onset of epilepsy until 6 months of age at 
the earliest (Fig. 6.4 E.). Perhaps observing these mice for longer would reveal changes in the 
proportion of animals that developed epilepsy, or perhaps the average age of onset; however, 
it was not possible to deduce this information from the 3 month animals studied here. 
 
We next sought to assess the motor capabilities and neuromuscular coordination of Tmco6-
knockout or wildtype mice stably expressing human WT or patient MUT TMCO6. Maximal 
exercise tolerance and motor endurance was evaluated by exhaustion trials using an 
accelerating treadmill (see section 2.5.4). As shown in Fig. 7.4 A., the Tmco6-/- (AAV WT) group 
ran significantly further than the Tmco6-/- (AAV MUT) group (n = 7) for both, in line with the Tmco6+/+ 
(AAV WT) control group. This indicates that the MUT human TMCO6 protein variant is not capable 
of recovering the exercise intolerance we had observed in these animals (Fig. 6.5 A.), perhaps 
owing to impaired protein function, whereas the WT TMCO6 protein can. Indeed, there is a 
statistically significant difference between the distance run for the experimental control group 
Tmco6+/+ (AAV WT) (n = 7) and the Tmco6-knockout MUT group, Tmco6-/- (AAV MUT), in line with what 
was observed for Tmco6-/- and Tmco6+/+ mice (Fig. 6.5 A.). Although there was not a significant 
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difference between the Tmco6+/+ (AAV WT) and Tmco6+/+ (AAV MUT) groups, there was a downwards 
trend for animals expressing the MUT protein variant (NP_001287909.1:p.Arg91Cys).   
 
Next, rotarod tests were performed for the four genotypic groups (Fig. 7.4 B.) in order to assess 
neuromuscular coordination and balance; a statistically significant difference was observed 
only between Tmco6-/- (AAV MUT) mice and the experimental control group, Tmco6+/+ (AAV WT) (n = 
7 for both), with the former losing grip and falling within approximately half of the time of the 
latter. This observation was in line with the difference that had been observed previously 
between Tmco6-/- and Tmco6+/+ mice (Fig. 6.5 C.), and suggests that MUT TMCO6 expression 
does not exacerbate or alter the abnormal neuromotor phenotype observed in 3 month old 
Tmco6-/- mice. Also, the WT-complemented Tmco6-/- (AAV WT) group (n = 8) displayed only a 
slight increase in the latency to fall compared to Tmco6-/- (AAV MUT) animals, and the mean value 
was not similar to that of either Tmco6+/+ (AAV WT) or Tmco6+/+ (AAV MUT) (n = 7) groups. This 
suggests that WT TMCO6 expression does not rescue neuromuscular coordination and 
balance to a significant extent in Tmco6-/- animals.  
 
The pole test was then used to assess proprioception and neuromotor coordination. As shown 
in Fig. 7.4 C., Tmco6+/+ (AAV MUT) and Tmco6-/- (AAV MUT) mice showed increases in the time taken 
to turn 180o and descend a 50 cm pole compared to age-matched control Tmco6+/+ (AAV WT) and 
Tmco6-/- (AAV WT) groups, although no statistically significant differences were identified. The time 
taken to descend the pole for Tmco6-/- (AAV MUT) mice mirrors that of 3 month old Tmco6-/- male 
and female mice (Fig. 6.6). Qualitatively, Tmco6-/- (AAV MUT) mice had difficulty engaging all four 
limbs to descend the pole, and instead wrapped their hindlimbs around the pole and slid, or 
descended by only independently moving the forelimbs. Tmco6-/- (AAV WT) mice displayed instead 
controlled descents, engaging all four limbs the majority of the time. Tmco6+/+ (AAV MUT) mice 
also showed a small increase in time taken to descend the pole compared to the experimental 





                           
  
Fig. 7.4. Complementation of WT TMCO6 in Tmco6-/- mice rescues exercise capability 
but does not completely rescue neuromotor coordination and balance. 
 
(A.) Motor performance and capability was assessed for Tmco6+/+ (AAV WT) (n = 7), Tmco6+/+ (AAV 
MUT) (n = 7), Tmco6-/- (AAV WT) (n = 8), and Tmco6-/- (AAV MUT) (n = 7) mice at 3 months of age by 
treadmill (as per section 2.5.4). Distance reached at exhaustion was recorded per animal. 
(B.) Latency to fall (s) was recorded in three separate trials for the four genotypic groups 
mentioned in A., with values averaged per animal. (C.) The pole test was performed as per 
section 2.5.7 to assess proprioception and bradykinesia. The time (s) taken to turn 180o and 
descend a 50 cm pole was recorded for 3 replicate trials per animal and these values 
averaged. Data represent mean ± SEM. Statistical analysis: * p < 0.05, ** p < 0.01, calculated 



















































































































































 MUT TMCO6 Expression Causes Impaired Locomotor Behaviours In Vivo  
Given that Tmco6-/- (AAV MUT) mice showed impaired exercise tolerance compared to Tmco6-/- 
(AAV WT) mice and the experimental control group, Tmco6+/+ (AAV WT) (section 7.2.2), we next 
sought to assess if spontaneous motility, including locomotor and exploratory behaviours, was 
impacted as a result of MUT TMCO6 expression. For this, CLAMS monitoring was performed 
for non-transduced Tmco6+/+ (n = 3)  and Tmco6-/- (n = 4) mice, and the four transduced 
Tmco6+/+ (AAV WT) (n = 3), Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) 
(n = 4) groups. Despite no statistically significant differences determined for total (Fig. 7.5 A.), 
and ambulatory (Fig. 7.5 B.) movements, Tmco6-/- (AAV WT) mice displayed values closer to 
Tmco6+/+ than to Tmco6-/- animals. As shown previously for 3 month old Tmco6-+/+ and Tmco6-
-/- mice, nocturnal rearing  movements (Fig. 7.5 C.) were found to be significantly reduced in 
Tmco6-/- (AAV MUT) animals, to the same extent as Tmco6-/- animals. Rearing movements require 
muscle tone and maintained posture for mice to sit up and visually explore their environment. 
Tmco6-/- (AAV WT) mice displayed more of these rearing movements than did the Tmco6-/- (AAV MUT) 
group, suggesting improvement of muscle tone and posture in the former. In terms of 
ambulatory movement (Fig. 7.5 B.), Tmco6-/- (AAV WT) mice behaved as both Tmco6+/+ non-
transduced and Tmco6+/+ (AAV WT) experimental control groups. Whereas, Tmco6-/- (AAV MUT) mice 
traversed the cage less during both day and night cycles than any of the other genotypic 
groups, including Tmco6-/- mice. The amount of total movements (Fig. 7.5 A.) of the different 
groups was variable, but notably, Tmco6-/- (AAV WT) mice moved more than did counterpart 
Tmco6-/- non-transduced and Tmco6-/- (AAV MUT) mice. These results indicate that WT TMCO6 
expression improves spontaneous locomotor and exploratory behaviours of Tmco6-knockout 
animals, particularly rearing movements, and MUT TMCO6 expression reproducible did not. 
No similar trends were observed for the transduced Tmco6+/+ groups Tmco6+/+ (AAV WT) and 









Fig. 7.5. Complementation of WT TMCO6 in Tmco6-/- mice improves locomotor and 
exploratory behaviours. 
 
(A.) Total, (B.) ambulatory and C.) rearing movements of Tmco6+/+ (n = 3), Tmco6+/+ (AAV WT) (n 
= 3), Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (n = 4), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) 
(n = 4) mice at 3 months of age was recorded by CLAMS for 2 night and 1 day cycles (see 
section 2.5.3). Data are presented as mean ± SEM.  Statistical analysis: ** p < 0.01, 
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 In Vivo Metabolic Evaluation of AAV-Transduced Mice via CLAMS 
The CLAMS was additionally used for metabolic evaluation to measure O2 consumption (Fig. 
7.6 A.) and CO2 production (Fig. 7.6 B.), which in turn were used to calculate heat production 
(Fig. 7.6 C.), and the respiratory exchange ratio (RER) (Fig. 7.6 D.) for non-transduced 
Tmco6+/+ (n = 3)  and Tmco6-/- (n = 4) mice, and the four transduced Tmco6+/+ (AAV WT) (n = 3), 
Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) (n = 4) mouse lines. 
Expression of either WT or MUT TMCO6 in Tmco6+/+ mice led to non-significant changes in O2 
consumption (Fig. 7.6 A.) and CO2 production (Fig. 7.6 B.) compared to untreated Tmco6+/+ 
mice. Tmco6-/- (AAV MUT) mice still consumed more oxygen than Tmco6+/+, Tmco6+/+ (AAV WT) and 
Tmco6+/+ (AAV MUT) groups. In the case of Tmco6-/- mice, expression of WT or MUT TMCO6 did 
not change O2 consumption. However, both Tmco6-/- (AAV WT) and Tmco6-/- (AAV MUT) mice showed 
significant reductions in CO2 production compared to counterpart Tmco6-/- mice. 
 
RER values indicate which substrate is preferentially metabolised to produce energy in an 
aerobically respiring organism. Fig. 7.6 C. shows a significant reduction in RER to 
approximately 0.7 for Tmco6-/- (AAV WT) and Tmco6-/- (AAV MUT) mouse lines, indicating that almost 
all the energy in these animals is being produced from fat as a substrate, and not through the 
catabolism of sugars. This result suggests that both WT and MUT TMCO6 protein variants 
prompt a change in metabolic state in these mice in which fats are preferentially used over 
carbohydrates, perhaps to avoid mitochondrial OXPHOS. This result was true for both night 
and day cycles revealing that this is a constant feature of these animals. 
 
Lastly, heat production had not been found to be significantly altered between Tmco6+/+ and 
Tmco6-/- groups previously (Fig. 6.8). This result was shown again (Fig. 7.6 D.); however, both 
WT and MUT TMCO6 expression in either Tmco6+/+ or Tmco6-/- mice produced statistically 
significant reductions in overall heat production, indicating impaired thermogenesis in these 
animals. It appears that AAV-mediated gene delivery of either WT or MUT human TMCO6 
leads to a reduction in overall heat production, suggesting less respiration in these animals. 
We cannot discount that this finding is a by-product of the AAV gene delivery approach used, 
since all transduced mouse lines show reductions in heat production compared to non-










Fig. 7.6. Metabolic monitoring via CLAMS.  
 
Non-transduced Tmco6+/+ (n = 3)  and Tmco6-/- (n = 4) mice and transduced Tmco6+/+ (AAV WT) 
(n = 3), Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) (n = 4) mouse 
lines were monitored at 3 months of age for various metabolic parameters for 2 night and 1 
day 12 h cycles via CLAMS, as described in section 2.5.3. The sum of the volumes of (A.) 
oxygen consumed (ml/kg/hr) and (B.) volume of carbon dioxide produced (ml/kg/hr) was 
recorded. These were used to calculate the (C.) respiratory exchange ratio (RER) and (D.) 
heat production (Kcal/hr) per animal, for day and night cycles in each case. Data are presented 
as mean ± SEM. Statistical analysis: * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, 
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 Echocardiography and Electrocardiography of AAV9-Transduced Mice  
Cardiovascular function and physiology were measured by echocardiography and 
electrocardiography using the Vevo 770® High Resolution Imaging System (VisualSonics, Inc., 
Toronto, Canada) for the Tmco6+/+ (AAV WT) (n = 5), Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n 
= 7), and Tmco6-/- (AAV MUT) (n = 7) mouse lines, with all measurements performed by Stephen 
Moore at the Phenomics Laboratory (West Forvie Site, Cambridge, UK). Our aim was to 
assess whether WT TMCO6 expression could improve or entirely rescue the right ventricular 
systolic functional defect observed in Tmco6-/- mice (Table 6.4), and secondly, whether MUT 
TMCO6 expression would rescue or exacerbate this defect, or potentially cause others. Mice 
were sedated with isoflurane gas and systematically imaged in parasternal short axis (Fig 2.9 
A.), long axis (Fig 2.9 B.) and apical four-chamber (Fig 2.9 C.) views in the pulsed-wave (PW) 
doppler or motion (M) modes, as previously described (Gao et al., 2011). Again, these acquired 
images were used to calculate aortic ejection time (AET), left ventricle (LV) myocardial 
performance index (MPI), mitral valve (MV) atrial (A) and early (E) peak wave flows (mm/s), 
MV E/A peak ratio, right ventricular outflow tract mean velocity time integral (RVOT VTI) 
(mm/s), cardiac output (CO) (ml/min), ejection fraction (EF) (%), fraction shortening (FS) (%), 
HR (bpm), stroke volume (SV) (μl), and volumes expelled in diastole and systole (V;d, V;s) (μl) 
with the associated Vevo LAB and Auto LV Analysis software packages (VisualSonics).  
 
No obvious morphological abnormalities were observed for any of the Tmco6+/+ (AAV WT), 
Tmco6+/+ (AAV MUT), Tmco6-/- (AAV WT), or Tmco6-/- (AAV MUT) mouse lines by echocardiography. As 
shown in Table 7.1, the only statistically significant difference in echocardiographic parameters 
between Tmco6-/- (AAV MUT) mice and the experimental control, Tmco6+/+ (AAV WT), was RVOT VTI. 
Notably, the difference between the WT TMCO6-complemented knockout line, Tmco6-/- (AAV 
WT), and Tmco6-/- (AAV MUT) mouse lines was considered to be highly significant by two-way 
ANOVA with Sidak’s multiple comparisons test. Recovery of right heart systolic function was 
found as a result of WT TMCO6 expression in adult Tmco6-/- animals, as shown by the rescued 
RVOT VTI value. However, expression of the human patient mutant variant did not result in 
any phenotypic rescue for Tmco6-/- (AAV MUT) mice. Despite no significant differences determined 
by statistical analyses for CO, EF, SV, FS, V;d and V;s for any of the mouse lines, these values 
were all decreased to similar extents for both the Tmco6-/- (AAV MUT) and Tmco6-/- (AAV WT) groups, 
suggesting that cardiac function may still be impaired to some extent in WT TMCO6-expressing 
Tmco6-/- animals. Heart rates of Tmco6-/- (AAV MUT) and Tmco6-/- (AAV WT) groups were similarly 
lower compared to the age-matched Tmco6+/+ (AAV WT) and Tmco6+/+ (AAV MUT) control groups. We 
next sought to assess this difference in HR further by electrocardiographic analyses.  
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Table 7.1. Echocardiography Results for AAV9-Transduced Mice Reveal Recovery of RVOT 
VTI by WT TMCO6 Expression 
 
Tmco6+/+ (AAV WT), n = 5, Tmco6+/+ (AAV MUT), n = 3, Tmco6-/- (AAV WT), n = 7, and Tmco6-/- (AAV MUT), n = 
7. Data are presented as mean ± SEM. Statistical analysis: two-way ANOVA with Sidak’s multiple 
comparisons post hoc test applied. n.s. = non-significant. 
 









AET ms 46.5 ± 5.0 53.0 ± 2.1 47.1 ± 2.3 50.8 ± 3.6 n.s. 
LV MPI - 0.87 ± 0.17 0.78 ± 0.07 0.77 ± 0.05 0.73 ± 0.08 n.s. 
M/V E/A - 1.64 ± 0.08 1.67 ± 0.06 1.65 ± 0.08 1.80 ± 0.11 n.s. 
RVOT VTI mm/s -518.8 ± 21.7 
**** 





****p = <0.001 
****p = <0.001 
CO ml/min 22.1 ± 1.3 21.7 ± 2.0 17.6 ± 1.3 16.3 ± 1.0 n.s. 
EF % 61.7 ± 2.7 63.3 ± 2.9 62.1 ± 3.2 59.4 ± 2.5 n.s. 
FS % 33.1 ± 1.9 34.1 ± 2.0 33.3 ± 2.3 31.2 ± 1.8 n.s. 





SV μl 52.5 ± 3.9 51.4 ± 2.5 42.4 ± 2.2 39.7 ± 2.3 n.s. 
V;D μl 85.3 ± 6.3 81.8 ± 7.0 68.8 ± 3.4 67.1 ± 3.9 n.s. 




Representative ECG traces for Tmco6+/+ (AAV WT) (n = 5) (Fig. 7.7 A.), Tmco6+/+ (AAV MUT) (n = 3) 
(Fig. 7.7 B.), Tmco6-/- (AAV WT) (n = 7) (Fig. 7.7 C.), and Tmco6-/- (AAV MUT) (n = 7) (Fig. 7.7 D.) 
mouse lines show signs of perturbed electrophysiology for Tmco6+/+ (AAV MUT), Tmco6-/- (AAV WT) 
and Tmco6-/- (AAV MUT) hearts. Tmco6-/- (AAV MUT) animals were found to display 4:1 atrial flutter 
(Fig 7.7 D.) in which instead of a single P-wave, denoting atrial depolarisation at the beginning 
of a heartbeat, there were instead four separate waves resulting from re-entrant circuits around 
the tricuspid valve. This was observed previously, along with 3:1 atrial flutter, in the non-
transduced Tmco6-/- mouse line (Fig. 6.31 A.). The mice of the Tmco6+/+ (AAV WT) experimental 
control group showed comparable waveforms to the non-transduced Tmco6+/+ mouse line (Fig. 
6.31 A.), with no obvious electrophysiological abnormalities. However, the Tmco6+/+ (AAV MUT) 
and Tmco6-/- (AAV WT) genotypic groups both presented with J waves (also termed Osborn 
waves), which are abnormal positive deflections occurring at the junction between the QRS 
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complex and the ST segment (highlighted by the blue arrowheads in Fig. 7.7 B and C.). J 
waves are found in ventricular fibrillation, denoting early repolarisation of the ventricles, brain 
injury, hypothermia, myocardial infarction, and several types of cardiac myopathies (Thiene et 
al., 1988). The J waves of Tmco6+/+ (AAV MUT) mice are more prominent than those shown by the 
Tmco6-/- (AAV WT) group. Additionally, these two groups show less overall QRS peak amplitude 
than the Tmco6+/+ (AAV WT) experimental control mice, suggesting weaker pumping of the hearts 
of these animals. 
 
In summary, Tmco6-/- (AAV WT) mice showed a rescue of the atrial flutter but also revealed lower 
amplitudes, denoting weaker pumping, and clear presence of J waves, which are hallmarks of 
ventricular dysfunction. Tmco6+/+ (AAV MUT) mice also displayed J-waves, with greater severity 
than shown in Tmco6-/- (AAV WT) mice. It is not possible to discern from these ECG traces alone 
what is the underlying cause of this altered electrophysiology, although ventricular dysfunction 
is a potential cause. Together these data strongly suggest that perturbations to the steady-
state levels of MUT or WT TMCO6 can have adverse effects on cardiac function, including 









Fig. 7.7. ECG reveals pathological electrophysiology in AAV9-transduced mice.  
Cardiovascular function was evaluated by electrocardiography with representative ECG traces 
over 800 ms are shown for 3 month old (A.) Tmco6+/+ (AAV WT) (n = 5), (B.) Tmco6+/+ (AAV MUT) (n 
= 3), (C.) Tmco6-/- (AAV WT) (n = 7), and (D.) Tmco6-/- (AAV MUT) (n = 7) mouse lines. For an overview 
of the components of a murine ECG waveform, see Fig. 2.9 D. Blue arrowheads = J waves. 























































Next, respiration rate was assessed for Tmco6+/+ (AAV WT) (n = 5) (Fig. 7.8 A.), Tmco6+/+ (AAV MUT) 
(n = 3) (Fig. 7.8 B.), Tmco6-/- (AAV WT) (n = 7) (Fig. 7.8 C.), and Tmco6-/- (AAV MUT) (n = 7) (Fig. 7.8 
D.) mouse lines. We had observed a statistically significant three-fold increase in respiratory 
rate for non-transduced Tmco6-/- mice (Table 6.6), and therefore sought to determine if this 
phenotype were worsened or rescued following expression of human WT or MUT TMCO6. As 
shown in Fig. 7.8 C., Tmco6-/- (AAV WT) mice showed normal respirator in line with the 
experimental control group, Tmco6+/+ (AAV WT). In addition, this result was quantified for all 
biological replicates (Table 7.2), and showed a statistically significant reduction in breathing 
rate for Tmco6-/- (AAV WT) animals relative to Tmco6-/- (AAV MUT) mice. Interestingly, Tmco6+/+ (AAV 
MUT) mice showed a mild, but not statistically significant, increase in respiratory rate compared 
to the Tmco6+/+ (AAV WT) experimental control group, and Tmco6-/- (AAV WT) mice showed a mild 
recovery in the observed respiratory rate. Tmco6-/-(AAV MUT) animals also breathed far more 
shallowly than did mice of the other three genotypic groups. Together this suggests that either 
directly or indirectly, TMCO6 significantly affects respiration in vivo. 
 
 
Table 7.2. Respiratory Rates of AAV9-Transduced Mice 
 
Tmco6+/+ (AAV WT), n = 5, Tmco6+/+ (AAV MUT), n = 3, Tmco6-/- (AAV WT), n = 5, and Tmco6-/- (AAV MUT), 
n = 5. Data are presented as mean ± SEM. Statistical analysis: two-way ANOVA with Sidak’s 
multiple comparisons post hoc test applied. n.s. = non-significant. 
 
 
Group Unit Respiration Rate 
(Breaths per 3 s) 
Significant? 
Tmco6+/+ (AAV WT) Breaths/sec 2.4 ± 0.25* n.s. 
Tmco6+/+ (AAV MUT) Breaths/sec 3.0 ± 0.00 n.s. 
 
Tmco6-/- (AAV WT) Breaths/sec 
3.2 ± 0.20 n.s. 









Fig. 7.8. WT TMCO6-expression in Tmco6-/- mice rescues breathing rate to normal levels. 
 
Representative respiratory curves for (A.) Tmco6+/+ (AAV WT) (n = 5), (B.) Tmco6+/+ (AAV MUT) (n = 











































































 Hearts of Tmco6-/- (AAV MUT) Mice Show Severe Cardiac Fibrosis 
Hematoxylin and eosin (H&E) staining of cardiac sections was performed for Tmco6+/+ (AAV WT), 
Tmco6+/+ (AAV MUT), Tmco6-/- (AAV WT), and Tmco6-/- (AAV MUT) mice. Picrosirius red staining was 
performed on serial sections to stain muscle fibres (yellow) and collagen (red), with presence 
of the latter used as an indicator of cardiac fibrosis. As shown by the representative images in 
Fig. 7.9 A. – D., all of the four transduced mouse lines displayed some degree of fibrosis (red 
staining). It is likely that the small amounts of fibrosis detected for Tmco6+/+ (AAV WT) (Fig. 7.9 
A.), Tmco6+/+ (AAV MUT) (Fig. 7.9 B.), and Tmco6-/- (AAV WT) (Fig. 7.9 C.) groups is a consequence 
of the AAV9-mediated gene delivery strategy. A very different pattern was observed for Tmco6-
/- (AAV MUT) mice (Fig. 7.9 D., one representative image shown of 4) where  extensive collagen 
staining throughout the cardiac muscle was detected, indicating severe cardiac fibrosis. This 
result was not ever observed in 3 month old or 12 month old Tmco6-/- hearts (Fig. 6.15), and 
seems to be a unique pathological effect of the MUT TMCO6 protein. Cardiac fibrosis is 
characterised by cardiomyocyte death and proliferation of cardiac fibroblasts that result in 
thickening of the ventricle walls, and subsequently reduced contractility of the heart (Lexow et 
al., 2013). This is often found to lead to impaired systolic function, as we observed to be 
significantly decreased for these Tmco6-/- (AAV MUT) mice compared to the WT TMCO6-






Fig. 7.9. MUT TMCO6-expression in Tmco6-/- mice causes severe cardiac fibrosis. 
 
Representative H&E and Picrosirius red staining of heart sections from 3 month-old (A.)  
Tmco6+/+ (AAV WT), (B.) Tmco6+/+ (AAV MUT),  (C.) Tmco6-/- (AAV WT), and (D.) Tmco6-/- (AAV MUT) mice. 
Images were taken at 4 X magnification. Sample preparation performed and image compiled 






 WT TMCO6 Expression Rescues CI Deficiency in Tmco6-/- Hearts Whilst 
MUT TMCO6 Expression Does Not 
Using snap-frozen hearts from non-transduced Tmco6+/+ (n = 5)  and Tmco6-/- (n = 6) mice, and 
the four transduced Tmco6+/+ (AAV WT) (n = 3), Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n = 3), 
and Tmco6-/- (AAV MUT) (n = 4) mouse lines, specific biochemical activity for CI was determined 
by spectrophotometric measurement (see section 2.7.1), with CS activity used to normalise 
all values. As shown clearly in Fig. 7.10 and evidenced by statistical analysis (one-way ANOVA 
with Tukey’s multiple comparisons test applied), the Tmco6-/- (AAV WT) group shows complete 
rescue of CI activity to normal levels, relative to the non-transduced Tmco6+/+ group, and both 
transduced groups,Tmco6+/+ (AAV WT) and Tmco6+/+ (AAV MUT). This indicates that human WT 
TMCO6 is able to complement the CI activity of young adult Tmco6-/- mice. What is critical to 
observe is that the patient mutant variant, as shown by the Tmco6-/- (AAV MUT) group, is only 
slightly increase compared to the original 3 month old cohort (Tmco6-/-), but still significantly 
lower than the Tmco6-/- (AAV WT) group. Therefore, the patient mutant variant (MUT TMCO6) is 
most likely non-functional or inherently pathogenic. Our in vivo assessment of the Tmco6-
knockout mouse model determined similar pathogenic phenotypes compared to the human 
patient described in Chapter 4, namely development of epilepsy, poor locomotor ability and 
reduced spontaneous movement, atypical neurobehaviors, histopathological findings in the 
brain including hypomyelination and neurodegeneration, and ultimately, the isolated CI 
deficiencies found in certain highly aerobic tissue types. In combination with this result, the 
inability of MUT TMCO6 to restore CI/CS activity to homeostatic levels in Tmco6-ablated mice 






Fig. 7.10. MUT TMCO6-expression in Tmco6-/- mice hearts does not rescue CI enzymatic 
activity to normal levels whilst WT TMCO6-expression does. 
 
Complex I (CI) enzymatic activity was measured as per section 2.7.1, with resulting values 
normalised to the activity of citrate synthase (CS) for 3 month-old wildtype non-transduced 
Tmco6+/+ (n = 5)  and Tmco6-/- (n = 6) mice, and the four transduced Tmco6+/+ (AAV WT) (n = 3), 
Tmco6+/+ (AAV MUT) (n = 3), Tmco6-/- (AAV WT) (n = 3), and Tmco6-/- (AAV MUT) (n = 4) mouse lines. 
Data are presented as mean ± SEM. Statistical analysis: * p < 0.05, ** p < 0.01, ** p < 0.005 








































































 Molecular Investigation of Hearts from AA9-Transduced Mice 
SDS-PAGE was performed for murine hearts from non-transduced Tmco6+/+ (n = 3)  and 
Tmco6-/- (n = 3) mice, and the four transduced Tmco6+/+ (AAV WT) (n = 3), Tmco6+/+ (AAV MUT) (n = 
3), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) (n = 4) mouse lines (Fig. 7.11 A.).  Subsequent 
Western blotting and immunodetection with an anti-HA antibody showed the relative 
expression of the WT or MUT TMCO6 protein in transduced mice, normalised to the signal of 
the cytosolic loading control, GAPDH. Densitometric quantification of the HA signal, 
corresponding to the TMCO6.1-HA protein, relative to GAPDH signal intensity per animal (Fig. 
7.11 B.) showed great variation in the relative levels of transgene expression. This is likely due 
to the systemic delivery approach, where in some animals a large viral load made its way to 
the heart and in others this delivery would be less efficient and/or specific. Indeed, we observed 
basal levels of TMCO6 transgene expression in other tissues, including the liver, diaphragm, 
kidneys and skeletal muscle of transduced animals (data not shown). Direct injection into the 
heart, as previously described (Prasad et al., 2011), could minimise systemic exposure of the 
viral vectors and concentrates delivery directly to the heart in future.  
 
Secondly, NDUFS1, which had been found to be reduced to a third of normal levels in hearts 
of aged (12 month old) Tmco6-/- mice (Fig. 6.25) showed no overall reduction in abundance 
for Tmco6-/- (AAV MUT) or Tmco6-/- (AAV WT) mice. NDUFS3 (Q-module) and NDUFA10 (PP- module) 
also showed no variations in relative abundance following transduction of WT or MUT human 
TMCO6 of either Tmco6+/+ or Tmco6-/- mice, normalised to the loading control GAPDH. This is 
somewhat expected given that no molecular differences were observed in 3 month-old animals 

















   
 
Fig. 6.24. Relative TMCO6.1-HA, NDUFS1, NDUS3 and NDUFA10 steady-state levels in 
AAV9-transduced mice. 
 
(A.) SDS-PAGE was performed as per section 2.6.2 with 20 μg of protein from whole tissue 
homogenates from Tmco6+/+ (n = 3) , Tmco6-/- (n = 3), Tmco6+/+ (AAV WT) (n = 3), Tmco6+/+ (AAV 
MUT) (n = 3), Tmco6-/- (AAV WT) (n = 4), and Tmco6-/- (AAV MUT) (n = 4) mice. WB analysis followed 
for immunodetection of CI subunits NDUFS1, NDUFS3, and NDUFA10, and cytosolic loading 
control GAPDH, using the primary antibodies and concentrations detailed in Table 2.29. (B.) 
Densitometric quantification was performed using Fiji Image J Gel Analysis software. Data are 
presented per mouse line. 
TMCO6+/+ TMCO6+/+(AAV WT) TMCO6+/+(AAV MUT)
TMCO6-/- TMCO6-/-(AAV WT) TMCO6-/-(AAV MUT)






























The work of this chapter: 1) details an AAV-mediated gene delivery strategy for stably 
expressing WT or MUT human TMCO6 in hearts of Tmco6-knockout or WT mice, 2) 
investigates physical, behavioural and neuromotor phenotypes of these transduced mice, 3) 
assesses the function consequences of expressing WT or MUT TMCO6 in Tmco6-ablated 
mice hearts by echocardiography and electrocardiography, 4) shows cardiac fibrosis 
specifically resulting from MUT TMCO6-expression by histological staining and 4) confirms the 
pathogenicity of the human patient protein variant, NM_018502: c.271C>T. 
 
In summary of the results of this chapter, intravenous administration of cardiotropic serotype 
AA9 vectors encoding WT or MUT TMCO6 cDNA sequences, each with C-terminal HA-tags, 
was used to create four distinct transgenic groups: Tmco6+/+ (AAV WT), Tmco6+/+ (AAV MUT), Tmco6-
/- (AAV WT), and Tmco6-/- (AAV MUT). Mice transduced with MUT TMCO6 displayed a plateau in 
weight gain for one or more weeks following injection. Conversely, animals transduced with 
WT TMCO6 showed consistent weight gains form the day of injection. The hindlimb clasping 
phenotype originally observed in Tmco6-/- mice was not rescued by WT TMCO6 expression, 
but was alleviated.  
Expression of the MUT TMCO6 transgene did not rescue motor capability and exercise 
tolerance of Tmco6-/- mice, as shown by treadmill experiments. Conversely, animals 
transduced with WT TMCO6 showed significant recovery in motor performance. Motor 
coordination and balance for these mice was assessed by rotarod, and motor coordination 
evaluated by pole tests. Both showed a mild improvement in Tmco6-/- (AAV WT) compared to 
Tmco6-/- (AAV MUT) animals, and an inverse trend observed for Tmco6+/+ (AAV MUT) mice compared 
to the experimental control group, Tmco6+/+ (AAV WT).CLAMS revealed statistically significant 
improvements in locomotor and exploratory behaviours in Tmco6-/- mice expressing WT 
TMCO6 versus the MUT variant. Interestingly, CLAMS also showed a hypothermia-like 
phenotype for both transduced Tmco6-/- mice groups (Tmco6-/- (AAV WT) and Tmco6-/- (AAV MUT)) 
compared to non-transduced Tmco6+/+ and Tmco6-/- mice, with decreases in overall heat 
production and RER. 
In terms of cardiac function, echocardiography showed a significant recovery of right heart 
systolic function (as indicated by RVOT VTI values) for Tmco6-/- (AAV WT) animals compared to 
the Tmco6-/- (AAV MUT) group. Expression of the human patient mutant variant, TMCO6 MUT, did 
not result in any phenotypic rescue. Electrocardiography revealed that whilst Tmco6-/- (AAV MUT) 
mice still displayed atrial flutter, both Tmco6+/+ (AAV MUT) and Tmco6-/- (AAV WT) mouse lines showed 
a novel pathogenic ECG feature, a J wave, which denotes early repolarisation of the ventricles 
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and is characteristic of hypothermia and several cardiomyopathies. Respiration rates were 
improved in Tmco6-/- (AAV WT) animals compared to the Tmco6-/- (AAV MUT) group. MUT TMCO6 
expression in wildtype Tmco6+/+ mice also seemed to increase the respiratory rate in these 
animals compared to the Tmco6+/+ (AAV WT) control group. Histopathological staining of hearts 
from the Tmco6-/- (AAV MUT) group displayed extensive cardiac fibrosis, not seen for any of the 
other transduced or non-transduced mouse lines. Cardiac fibrosis is often found to lead to 
impaired systolic function and cardiac failure. 
Biochemical measurement by spectrophotometry revealed total recovery of the isolated CI 
deficiency in Tmco6-/- (AAV WT) hearts, and no such rescue in Tmco6-/- (AAV MUT) mice, indicating 
that the human patient TMCO6 protein variant (NP_060972.3: p.Arg91Cys) is most likely non-
functional. Lastly, SDS-PAGE and Western blot analysis showed variable expression of 
TMCO6.1 HA in the different genotypic groups, and no differences in the abundances of CI 
subunits NDUFS1 (N-module), NDUFS3 (Q-module) or NDUFA10 (PP-module). 
This gene delivery strategy was crucial in assessing the pathogenicity of the human TMCO6 
mutant protein (NP_001287909.1:p.Arg91Cys). In additional to no recovery of any of the 
phenotypes observed for age-matched Tmco6-/- mice, Tmco6-/- (AAV MUT) animals displayed 
additional pathogenic phenotypes including extensive cardiac fibrosis. Critically, Tmco6-/- (AAV 
MUT) mice hearts revealed no functional complementation of CI activity, as was shown for 
Tmco6-/- (AAV WT) animals. All other phenotypes were similar to those described for the human 
patient described in Chapter 4. Given these results, we are confident that the novel mutation 
in TMCO6 described in this work is responsible for the phenotype of the human patient, 
including the isolated CI deficiency. Additional experiments are necessary to pinpoint the exact 
mitochondrial role(s) of TMCO6, and to further elucidate its role in CI biogenesis and stability. 
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 The Revolution of Mitochondrial Disease Gene Discovery by WES 
Mitochondrial diseases present a diagnostic challenge for both clinicians and scientists due to 
their phenotypic and genetic heterogeneity. The molecular diagnosis of mitochondrial disease 
is complicated by the dual genomic regulation of mitochondria, with a pathogenic gene variant 
potentially being found in either mitochondrial or nuclear genomes (Gorman et al., 2016). In 
addition to causal genes often being subunits or assembly factors directly involved in 
OXPHOS (Ghezzi and Zeviani, 2012), mitochondrial diseases have also been found to result 
from alterations to the cofactors of the OXPHOS complexes (Stenton and Prokisch, 2018), 
proteins responsible for mitochondrial dynamics (Suárez-Rivero et al., 2016), namely the 
fission and fusion processes, and from those necessary for the maintenance and regulation 
of the mtDNA (Viscomi and Zeviani, 2017). In fact, the advent of whole exome sequencing 
(WES) and bioinformatic analyses have allowed for the detection of mitochondrial disease 
genes not previously known to have mitochondrial functions. The stalwart techniques of 
homozygosity mapping (Seelow et al., 2009), used for identifying recessive traits in 
consanguineous families, and Sanger sequencing of single genes or panels of suspected 
candidate genes (Wortmann et al., 2017), are both effective strategies still used today, but 
they are comparatively laborious and time-consuming methods that rely on a narrowing down 
of potential genetic candidates, either from selecting genes based on a characteristic clinical 
phenotype or from knowing the aetiology of a disease within a family. In contrast, WES allows 
for the unbiased sequencing of all exonic regions of the human genome, in which ~85 % of 
known monogenic disease-causing mutations are found (Botstein and Risch, 2003), and has 
been crucial to the rapid rate of discovery of new mitochondrial disease genes in recent years, 
even by investigating single patients, as in this study.  
 
Along with the many advantages of WES comes the challenge of interpreting the significance 
of the results. Particularly in the case of mitochondrial diseases, variant filtering must be 
applied in order to prioritise proteins with known or suspected mitochondrial localisation, and 
those already found to be associated with the particular respiratory chain defect(s) observed 
in a patient (Choi et al., 2009). This is because, by querying exome-wide, WES enables the 
identification of pathogenic variants in non-mitochondrial genes that are presenting clinically 
as mitochondriopathy (Panneman, Smeitink and Rodenburg, 2018). Increasingly, 
interrogation of transcriptomic, proteomic and metabolic data is complementing genomic 
molecular diagnostics (Stenton and Prokisch, 2018), and the growing number of large-scale 
patient cohort studies (Theunissen et al., 2018) is aiding our collective understanding of 
genotype-phenotype correlations in mitochondrial disease. However, individual patient case 
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reports owing to genetic diagnosis by WES remain a powerful tool of identifying new and 
unstudied mitochondrial disease genes. 
 
To date, more than 300 individual human genes have been identified in causing mitochondrial 
diseases (Stenton and Prokisch, 2018), including more recently, animal-specific factors, such 
as APOPT1 (more recently renamed COA8) (Signes et al., 2019), LRPPRC (Cui et al., 2019), 
and TMEM126B (Alston et al., 2016), only present in Metazoan species. Much of what is 
currently known regarding human OXPHOS protein complex assembly has been possible due 
to genetic manipulation and study of orthologues in lower order model organisms, such as 
baker’s yeast, Saccharomyces cerevisiae (Stoldt et al., 2018), and the fruit fly, Drosophila 
melanogaster (Garcia et al., 2017). However, in order to identify and characterise higher order 
OXPHOS assembly factors and associated proteins requires the study of cultured cell lines, 
principally from humans, and in vivo mammalian models. The existence of these animal-
specific factors could relate to the fact that OXPHOS assembly and regulation is more complex 
in higher organisms, owing to the tissue-specific demands for energy, and the relatively higher 
overall dependency on aerobic respiration for survival of these organisms. Ultimately, the list 
of OXPHOS assembly factors and associated regulatory proteins found only in higher 
organisms is most likely incomplete, and requires further elucidation.  
 
In this work, two patients that had been diagnosed with mitochondrial diseases by means of 
clinical, biochemical and histopathological findings were selected from enrolment in the 
present study, since initial mtDNA sequencing and Sanger sequencing of a panel of pre-
selected OXPHOS-related genes had failed to yield any potential genetic candidates. 
Therefore, WES was undertaken to examine the entire exome of these individuals, and found 
mutant variants in two proteins that are only present in vertebrates, and were relatively 
unstudied at the time of their identification. These variants were compound heterozygous 
mutations in COA7 (c NM_023077.3:c.410A>G;c.287+1G>T) and a homozygous recessive 
mutation in TMCO6 (NM_018502.5: c.271C>T). Both of these genes were selected for 
experimental investigation given that COA7 mutations had never before been implicated in 
mitochondrial disease, despite its putative designation as a COX assembly factor (Kozjak-
Pavlovic et al., 2014), and TMCO6 had never before been linked to mitochondrial function in 
general, or in fact, any intracellular role or the pathology of  human disease of any kind. We 
therefore sought to assess whether these genomic variants were 1) responsible for the 
observed clinical and biochemical phenotypes relating to COX or CI deficiency, respectively, 




 Implications of Confirming Pathogenicity and Subcellular Localisation of COA7 
Patient-derived skin fibroblasts served as the molecular basis of our investigation into COA7, 
Extraction of total RNA from primary patient skin fibroblasts, and retrotranscription to cDNA, 
revealed that each of the two compound heterozygous COA7 mutations were very likely 
pathogenic; the former owing to disruption of a highly conserved tyrosine residue and a drastic 
substitution to cysteine (Fig. 3.6), and the latter due to skipping of the entirety of the second 
of three coding exons during transcription, leading to an in-frame 47 amino acid deletion in the 
gene product (NP_075565.2: p.Tyr137Cys; p.Cys37_Gly84del) (Fig. 3.5). Indeed, we 
observed complete loss of detectable COA7 protein by SDS-PAGE and Western blot analysis 
(Fig. 3.7). Biochemical measurements determined COX deficiency to a third of control levels 
(Fig. 3.10), to an identical extent as had been shown for shRNA-mediated COA7 gene 
silencing in HeLa cells (Kozjak-Pavlovic et al., 2014). We also observed an equivalent 
reduction in mature COX steady-state level (Fig. 3.8), with significant decreases found in the 
quantities of the COX subunits MT-CO2 and COX5B (Fig. 3.7). A “global” reduction was found 
by 2D-BNGE and Western blot analysis for the abundance of COX intermediates, the COX 
holocomplex and COX-containing supercomplexes (Fig. 3.9), suggesting impaired COX 
assembly and stability in these cells. This time using patient-derived fibroblasts that had 
undergone immortalisation, we performed functional complementation by lentiviral 
transduction of the wildtype COA7 cDNA sequence. This process rescued both COX activity 
(Fig. 3.15) and assembly, shown by the recovered levels of COX subunits (Fig. 3.11), the fully 
assembled COX holocomplex (Fig. 3.12), and COX intermediates and supercomplexes (Fig. 
3.13 and 3.14), to normal levels, providing further support to the pathogenicity of the 
mutations.  
 
In addition to proving the pathogenicity of these two novel COA7 variants, this investigation 
highlighted in which part of COX biogenesis COA7 most likely participates. Human COX 
assembly is mediated by more than 30 known assembly factors, with roles including the 
control of mtRNA stability and translation, insertion of mtDNA encoded subunits into the IMM, 
biosynthesis of copper and heme prosthetic groups, and the stabilisation of the three separate 
COX modules, which include one of each of the three mtDNA-encoded subunits (MT-CO1, 
MT-CO2 and MT-CO3) (Timón-Gómez et al., 2017). In our experiments, MT-CO1 abundance 
was only slightly reduced, and not to a statistically significant extent, in primary patient skin 
fibroblasts by SDS-PAGE, Western blotting and subsequent densitometric quantification (Fig. 
3.7 B.), and its abundance was completely unaffected following lentiviral transduction of the 
wildtype COA7 cDNA sequence (Fig. 3.11). In addition, COX5A abundance was unaffected 
in the latter (Fig. 3.11). Together, these results signified no disruption to early-stage COX 
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assembly involving the MT-CO1/MITRAC module (Signes and Fernandez-Vizarra 2018) as a 
result of the loss-of-function mutations in COA7. In contrast, MT-CO2 and COX5B abundance 
were significantly reduced in primary patient fibroblasts (Fig. 3.7 A. and B.), and specifically, 
MT-CO2 steady-state level was found to be completely restored to control levels following 
complementation of immortalised cells with the wildtype COA7 cDNA sequence (Fig. 3.11). 
Initial reduction, and then complementation, of MT-CO2 levels following complementation 
suggests involvement of COA7 in facilitating correct MT-CO2 module assembly, before 
incorporation of MT-CO3 module. In support of this, COA7 protein levels were found very 
recently to be increased following CRISPR/Cas9-mediated knockout of hypoxia induced gene 
1 domain family members HIGD2A and HIGD2A, human orthologues of yeast Rcf1 and Rcf2 
(named for respiratory complex factors), by quantitative mass-spectrometry (Hock et al., 
2019). COX assembly factors COA4, COA6, CMC2 and COX11 were also found to be 
increased following ablation of HIGD2A, in particular. All of these assembly factors are 
involved in steps of COX biogenesis before MT-CO3 module integration, and in fact, HIGD2A 
was concluded to act as the first protein to mediate MT-CO3 module integration into COX 
(Hock et al., 2019). Therefore, COA7 is most likely to be involved only in MT-CO2 module 
assembly, but the exact role of this protein in this stage of COX biogenesis remains unknown. 
The principal aim of any future directions of this work would be to determine and detail the 
role of COA7 in COX assembly, as will be discussed below. 
 
As a second aim of this research, we endeavoured to confirm the submitochondrial localisation 
of COA7. The only seminal work regarding this protein had experimentally determined COA7 
to be both soluble and mitochondrial, and had specifically designated its submitochondrial 
localisation to be the IMS by subcellular fractionation, SDS-PAGE and Western blot analysis 
(Kozjak-Pavlovic et al., 2014). However, the experimental control in this case were mitoplasts 
from HeLa cells solubilised first with 1 % Triton and then incubated with 50 μg/ml of proteinase 
K, which should have eliminated all presence of the COA7-specific band detectable by SDS-
PAGE and Western blotting. However, presence of a band at a slightly smaller size was found 
in this sample at a similar intensity as for untreated samples. Therefore, we sought to verify, 
and if necessary, correct, the submitochondrial localisation of this protein. As described in 
Chapter 3, our initial results were misleading owing to the relative protease insensitivity of the 
COA7 protein, which led to the presence of a COA7-specifc signal at the correct size by SDS-
PAGE and Western blot analysis despite subjection to protease treatment, this time in the 
form of two different concentrations of trypsin (25 and 50 μg/ml). However, recent evidence 
that COA7 is an interactor of CHCHD4/MIA40, the principal component of the disulphide-relay 
system responsible for the import and targeting of IMS proteins (Mohanraj, et al. 2019), led us 
to reconsider this finding and attempt to resolve this apparent contradiction. We opted for two 
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biochemical approaches, one employing protease digestion and the other only using OMM 
solubilisation by digitonin. In addition, we used super-resolution microscopy of HA-tagged 
COA7 in a COA7-HA overexpressing HeLa cell line to determine COA7 localisation relative to 
markers for each of the mitochondrial compartments. For the first of the biochemical 
experiments, a range of digitonin (DIG) concentrations were used to gradually open the OMM 
of isolated mitochondria from HEK 293T cells, and both supernatant and pelleted samples 
were collected following ultracentrifugation (Fig. 3.16 A.). COA7 is detectable in supernatant 
fractions from 150 μg/ml digitonin onwards, with associated decrease in the pelleted fractions. 
This is similar to the behaviour of OMM protein TOMM20 and IMS proteins AIF and CYT C, 
and contrasted to the pattern shown for IMM protein COX4, and MM protein SOD2, both of 
which did not appear in the supernatant fractions with any concentration of digitonin. Secondly, 
when the same procedure was followed but with the subsequent addition of 150 μg/ml trypsin 
to each fraction (Fig. 3.16 B.), COA7 was degraded from 150 μg/ml DIG onwards, similarly to 
AIF and CYT C, COX4, and SOD2, and unlike TOMM20, which was degraded immediately 
following addition of protease. Taken together, these two biochemical experiments strongly 
indicated that COA7 is an IMS protein. Super-resolution fluorescence microscopy was 
employed to visually determine the submitochondrial localisation of HA-tagged COA7 in HeLa 
cells overexpressing the wildtype COA7 cDNA sequence. The resulting HA signal overlapped 
significantly with that of the IMS marker SMAC (Fig. 3.17). This multi-part method supplied 
conclusive evidence that COA7 is a mitochondrial protein localising to the IMS. 
 
Upon publication of these first pathogenic mutations in COA7 (Martinez Lyons et al. 2016), 
investigations were conducted by other research groups into 1) the mitochondrial import 
pathway of the COA7 protein into the IMS though interaction with MIA40, part of the MIA 
pathway, and the application of proteasome inhibition as a novel therapeutic strategy 
(Mohanraj et al., 2019), and 2) into the diagnoses of additional mitochondrial disease patients 
whose conditions arose from pathogenic COA7 mutations (Higuchi et al., 2018).  
 
For the former, Mohanraj et al. investigated our patient cells and generated additional cellular 
models with equivalent mutant variants as a means of studying impaired mitochondrial protein 
import in mitochondrial disease (Mohanraj et al., 2019). Both pathogenic mutant variants were 
found to be imported into the mitochondria more slowly than the wildtype COA7 protein, and 
in addition, the majority of the intracellular steady-state levels of both were found to mis-
localise to the cytosol and become degraded by the action of the UPS. The phenomenon of 
retro-translocation to the cytosol and subsequent protease degradation of improperly folded 
IMS proteins has been described previously (Bragoszewski et al., 2015). Protease inhibition 
experiments partially rescued COX activity in patient cells, suggesting a conceptually novel 
Chapter 8 
277 
therapeutic approach for mitochondrial diseases. Separately from these findings, this research 
characterised COA7 as a non-canonical substrate of MIA40, establishing interaction between 
the two through disulphide bonding, and confirming that COA7 is imported into the IMS by the 
MIA pathway (Stojanovski, Bragoszewski and Chacinska, 2012). Also, of the 13 known COA7 
cysteine residues, the authors determined that 10 were found to be crucial to its intrinsic 
tertiary structure by forming 5 separate disulphide bonds, and the three cysteine residues were 
present in a reduced, unbound state through a combination of in silico modelling and thiol 
trapping experiments. Furthermore, these methods indicated that the 5 predicted SEL-1 
domain repeats in COA7 (Fig. 1.7 B.) are stabilised by these disulphide bridges, with each 
domain characterised by a specific arrangement of cysteine residues. Lastly, homology 
modelling and molecular dynamics simulations demonstrated that the patient’s paternally 
inherited mutant protein variant (NP_075565.2: p.Tyr137Cys), by adding another cysteine 
residue, most likely affects the disulphide bonds naturally occurring between residues C100 
and C111, causing misfolding and destabilisation of the native COA7 protein. This research 
not only suggested a role for protease inhibition as a means of therapeutic treatment for 
mitochondrial diseases arising from protein degradation, but also characterised the 
intramolecular stability of COA7 in terms of its SEL-1 like repeat motifs and disulphide bridge 
composition, in turn allowing for better understanding of why the human patient mutant 
variants are pathogenic in vivo. 
 
Secondly, this research stemmed diagnoses of additional mitochondrial disease patients 
whose conditions arose from pathogenic COA7 mutations. Higuchi et al. identified four 
unrelated Japanese patients from a case series of patients with Charcot-Marie-Tooth (CMT) 
disease or other suspected inherited peripheral neuropathies, each found to harbour 
pathogenic mutations in COA7 by WES (Higuchi et al., 2018). The mutant variants were 
different from the two we had described in all cases; these were 
NM_023077:c.17A>G,p.Asp6Gly for patient 1, NM_023077:c.115C>T,p.Arg39Trp in patient 
2, NM_023077:c.17A>G;446G>T,p.Asp6Gly;p.Ser149Ile in patient 3, and 
NM_023077:c.17A>G;430delG,p. Asp6Gly;Gly144fs in patient 4. COX deficiency is 
notoriously heterogeneous in its clinical presentation (Rak et al., 2016); however, it is worth 
noting that our proband displayed some classical hallmarks of syndromes linked to COX 
deficiency. For example, the mode of inheritance was autosomal recessive, with infantile onset 
of symptoms characteristic of encephalomyopathy, including developmental delay, ataxia, 
dysarthria, cognitive impairment, hyporeflexia and muscle wasting, white matter degeneration 
(leukodystrophy), and demyelinating sensory peripheral neuropathy. The additional four 
patients shared a characteristic set of neurological features, including sensory peripheral 
neuropathy, ataxia with cerebellar atrophy, and some patients showed progressive 
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leukodystrophy and spinal cord atrophy by MRI. The authors have suggested naming this 
unique clinical presentation as spino-cerebellar ataxia with axonal neuropathy type 3. COX 
deficiency was the predominant mitochondrial respiratory chain defect found in biochemical 
measurement of fibroblasts from patients 1-3, although CI deficiency was detected in 
fibroblasts of patient 1. However, this CI deficiency was not found in measurement of a muscle 
biopsy from the same patient, in which only isolated COX deficiency was found, indicating that 
perhaps the former was an anomalous result. Notably, the conditions of each of the four 
patients, and the proband described in this work, remained stable well into adulthood, which 
could be related to a partially dispensable role of COA7 in COX biogenesis. Indeed, the oldest 
of the patients described was 63 years of age at the time of diagnosis. In conclusion, this 
research has cemented COA7 as a mitochondrial disease gene owing to COX deficiency, now 
associated with a characteristic clinical presentation.  
 
 Investigating TMCO6 as a Novel Mitochondrial Disease Protein  
TMCO6, an entirely uncharacterised, nuclear-encoded protein found only in vertebrates, was 
identified by WES and subsequent bioinformatic filtering to be the most likely causal genetic 
candidate in a paediatric mitochondrial disease patient exhibiting CI deficiency (see section 
4.2.2). CI deficiency is the most frequently occurring isolated mitochondrial respiratory chain 
defect associated with mitochondrial disease (Rodenburg, 2016), and although genotype-
phenotype correlations are notoriously difficult to deduce, the majority of CI deficient patients 
present with neurodegeneration, leukoencephalopathy and associated neuromotor symptoms 
(Distelmaier et al., 2009). However, additional tissue-specific consequences of this condition 
beyond perturbations to the brains are being increasingly studied, including the emerging role 
of CI deficiency in causing cardiovascular diseases (Forte et al., 2019).  
 
The clinical presentation of the proband described in this work aligns well with characteristic 
neuromuscular phenotypes of nuclear-encoded CI deficiency (Distelmaier et al., 2009), with 
disease onset in the first year of life including  psychomotor delay, muscular hypotonia, 
nystagmus, no acquisition of motor or language milestones and epilepsy. MRI scans 
performed at 16 months and 7 years of age discovered cortical and subcortical 
hypomyelination, and progressive cerebral and cerebellar atrophy, with sparing of the spinal 
cord (Fig. 4.3). Cerebellar atrophy is not a common phenotype of nuclear-encoded CI 
deficiency, nor is an absence of lesions of the brainstem; however, the extensive 
leukodystrophy is typical and cerebellar atrophy has been well-documented in mtDNA-
encoded variants that cause CI deficiency (Lebre et al., 2011). The proband also displayed an 
increase in intraventricular lactate (22 mg/dl, n.v. 9-19 mg/dl) and a reduction of N-acetyl 
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aspartate (NAA) (Fig. 4.4), the most prominent MRS signal abnormalities observed in 
mitochondrial disorders (Lunsing et al., 2017), and indicative of lactic acidosis, which is very 
commonly found in paediatric mitochondrial disease cases (Loeffen et al., 2000). Additionally, 
the autosomal recessive mode of inheritance of a rare mutant variant (NM_018502.5: 
c.271C>T) owing to consanguineous parents (Fig. 4.5) is fitting of this group of disorders 
(Kirby and Thorburn, 2008). Overall, the proband in this work presents with typical clinical 
hallmarks of mitochondrial disease owing to CI deficiency. 
 
Cell-based strategies were used to determine TMCO6 subcellular localisation, and following 
on from this, immunoprecipitation experiments independently concluded physical interaction 
between TMCO6 and CI. Cellular models were then generated to probe the role of TMCO6 in 
CI biogenesis, stability and/or function. ICC was used to determine for the first time the 
subcellular localisation of endogenous TMCO6 in HeLa and 143B cells relative to the 
mitochondrial network, as stained by MitoTrackerTM Red CMXRos and nuclei, as stained by 
DAPI (Fig. 5.1). Despite prediction of an IBB domain (Fig 4.2), found only in nuclear proteins, 
TMCO6 was found to be totally absent in the nucleus of these cells and instead localised 
entirely to the mitochondria (Fig. 5.1), suggesting misleading annotation or alternative function 
of this domain feature, or possibly some sort of protein shuttling role for TMCO6 between the 
nucleus and CI within mitochondria. It is worth noting TMCO6 is not predicted by the MitoCarta 
2.0 database to localise to mitochondria. Subcellular fractionation and molecular analyses 
independently determined TMCO6 to be a mitochondrial protein (Fig. 5.2). Hypotonic swelling 
and protease digestion experiments found TMCO6 to be protected in all conditions, 
suggesting localisation to the IMM or MM (Fig. 5.3). Lastly, TMCO6 was found to be present 
in membrane fractions of sonicated mitochondria in isotonic conditions, and only upon 
increased salt concentration would it become dissociated from the membrane (Fig. 5.4). We 
concluded IMM localisation of TMCO6, in a membrane-tethered fashion as opposed to total 
embedment, given its susceptibility to dissociation. Following this, immunoprecipitation 
experiments confirmed physical interaction between native CI and TMCO6 (Fig. 5.14). This 
result was reproducible no matter the method of elution used. In reverse, pulldown 
experiments using the endogenous TMCO6 antibody were inconclusive, likely due to the fact 
that the natural abundance of the endogenous protein is very low. Instead, we used a cellular 
model of inducible HA-tagged TMCO6 (isoform 1) (NM_001300980.1) expression to perform 
immunoprecipitation experiments, with subsequent SDS-PAGE and Western blot analyses 
(Figs. 5.14 and 5.15). This method showed presence of NDUFS6 in eluate fractions eluted by 
two different methods (Fig. 5.15). This supports a role for TMCO6 in N-module assembly or 
modulation, of which NDUFS6 is a part. It is possible that longer exposures of these 
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membranes could have revealed other potential interactors; however, more rigorous 
proteomic strategies would be preferable for deducing protein interactors of TMCO6 in vivo.  
 
In the same vein as described above for COA7, we first sought to verify the pathogenicity of 
the homozygous recessive mutant variant in TMCO6 (NM_018502.5:c.271C>T) and 
determine its molecular and biochemical impact using patient-derived skin fibroblasts in both 
cases. Initial in silico assessment had predicted strong likelihood of pathogenicity of the 
mutant TMCO6 variant (Fig. 4.6). However, this process proved not to be straightforward early 
on given that the endogenous TMCO6 protein was still detectable in protein lysates from 
patient-derived primary and immortalised skin fibroblasts by SDS-PAGE and Western blot 
analysis (Fig. 4.8 and 4.9). No reduction in steady-state level of fully assembled CI was 
consistently found (Fig. 4.10), although a slight reduction of holocomplex abundance was 
detected following immunodetection of NDUFS1 (Fig. 4.11). Most importantly, the severe CI 
deficiency originally detected in patient skeletal muscle was not found to be present in these 
cultured fibroblasts (Fig. 4.15). It is worth noting that lack of CI deficiency in fibroblasts, but 
presence in skeletal muscle, has been well documented in CI deficient mitochondrial disease 
patients (Ruitenbeek et al., 1996; Swalwell et al., 2011), and is perhaps due to a tissue-specific 
effect of a mutant variant, or only detrimental effects occurring in tissues that have higher 
demands in aerobic metabolism than fibroblasts. The lack of any observable CI deficiency in 
these cells made them unsuitable for functional complementation experiments, and 
necessitated the generation and study of additional cellular models (Chapter 5). However, the 
two results that came out of this initial investigation that pointed strongly in the direction of a 
role for TMCO6 in CI function, biogenesis and/or regulation were 1) specific co-migration of 
endogenous TMCO6 with fully-assembled CI by 2D-BNGE (Fig 4.13), and 2) significant 
reduction in the abundances of CI-containing supercomplex species (Fig. 4.12). 
 
The obvious question this raises is why has TMCO6 not been identified in mass spectrometry-
based complexomics screens highlighting factors involved in assembly and structure of CI 
(Lopez-Fabuel et al., 2016; Stroud et al., 2016; Guerrero-Castillo et al., 2017), nor in any of 
the completed mammalian CI structures (Zhu, Vinothkumar and Hirst, 2016; Agip et al., 2018; 
Fiedorczuk and Sazanov, 2018)? For the former, this absence from complexomics results 
could be due to a fleeting association of TMCO6 with CI during its biogenesis, or to fragile 
interaction between the two, so that no significant accumulation of TMCO6 would ever be 
found to occur with CI subassembly intermediates. This same result has been shown in the 
case of assembly factors NUBPL, NDUFAF5, NDUFAF6, and NDUFAF7, all of whom could 
not be found in association with the CI holocomplex or any CI subassemblies by complexomics 
(Stroud et al., 2016). This same reasoning could apply to its absence from mammalian 
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structures of CI. Principally, these structures are compiled by using purified mature CI 
holocomplexes, lacking all assembly factors, so the absence of TMCO6 in these structures is 
largely expected. Additionally, if TMCO6 is indeed somehow involved in the interaction of CI 
with other respiratory chain complexes to form supercomplexes, as seemed to be the case 
from 1D-BNGE and Western blot results in patient fibroblasts (Fig. 4.12) and following shRNA-
knockdown in HEK 293T cells (Fig. 5.8 A.), its physical association with CI could be even 
more difficult to establish. This difficulty has been shown for COX7A2L, which acts as a 
checkpoint of assembly in the integration of CIII2 into supercomplex configurations (Lobo-
Jarne et al., 2018), but was not found in any holocomplex structures or complexomics data for 
any of the individual respiratory chain complexes previously (Lapuente-Brun et al., 2013; Hock 
et al., 2019). Even a structural subunit of Cl, NDUFV3 (N-module), was found to be 
consistently missing in models of CI’s interaction with CIII2 and CIV (Wu et al., 2016), so it is 
plausible that TMCO6 may not be detectable by such approaches either, despite interaction 
with CI of CI-containing supercomplexes in vivo.  
 
Immortalised patient skin fibroblasts showed the greatest decrease in the steady-state levels 
of N- and Q-module CI subunits (Fig. 4.9), suggesting perturbation to assembly of these 
modules, and less or no effect on the assembly of the PP and PD modules. One patient of a 
study of four with pathogenic mutations in NDUFA6, which encodes a Q-module structural 
subunit, demonstrated no CI holocomplex reduction or CI enzymatic deficiency in patient skin 
fibroblasts despite clear perturbation to CI assembly and reduction in abundance of N- and Q-
module subunits by complexomics analysis (Alston et al., 2018). This similar presentation to 
that of our proband suggests that the CI assembly defect in our proband’s fibroblasts is still a 
true pathological defect leading to mitochondrial disease, despite no associated CI deficiency 
(Fig. 4.15) in this cell type. Sometimes, subassembly species containing N- or Q-module 
subunits are found to be accumulated in abundance as a result of deleterious mutations to 
genes encoding CI assembly factors, as is the case for null mutations in NDUFAF2 (McKenzie 
and Ryan, 2010). Patients were found to have accumulated intermediates containing the Q-
module subunits NDUFS2 and NDUFS3 (Hoefs et al., 2009). Looking into the modular 
assembly of CI further suggests that the accumulation of a ~ 680 kDa NDUFB8-containing 
subcomplex in patient cells (Fig. 4.10 A.) is in fact portion of the PP and PD modules waiting 
for incorporation with the Q-module (Guerrero-Castillo et al., 2017), perhaps stalled at this 
point of assembly. In addition, immunodetection of 1D-BNGE gels with NDUFS3 and NDUFB8 
showed lack of a ~900 kDa subunit, most likely to be CI lacking the N-module with associated 
assembly factors still attached (McKenzie and Ryan, 2010). It is possible that TMCO6 is 
involved in some part of Q-module stability/N-module assembly owing to these results. 
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However, further experiments are needed to validate or negate this hypothesis, as will be 
described below. 
 
Lastly regarding these patient fibroblasts, we observed evidence of reduced mitochondrial 
mass in both primary (Fig. 4.8) and immortalised (Fig. 4.9) forms, evidenced through 
decreases in the steady-state levels of mitochondrial proteins from each of the respiratory 
chain complexes and of several mitochondrial mass markers not involved in OXPHOS (CS, 
HSP60 and TOMM20) by SDS-PAGE and Western blot analysis. Confocal microscopy 
experiments were conducted (data not included) to compare organisation and density of the 
mitochondrial network in primary patient fibroblasts compared to controls. The signal intensity 
of MitoTracker™ Red CMXRos staining in both cell lines did not reveal any obvious differences 
in overall mass; however, this approach did reveal some hyperfusion of the mitochondrial 
network, which can be indicative of cellular stress (Hoitzing, Johnston and Jones, 2015). This 
line of investigation requires more rigorous and high-resolution imaging strategies (see 
section 8.2).  
 
Cellular models were next generated, including shRNA-mediated knockdown cell lines in HEK 
293T cells, inducible overexpression models of both major wildtype TMCO6 isoforms (termed 
here as TMCO6.1 and TMCO6.2), and equivalent overexpressing cell lines expressing the 
patient mutant variants of both of these isoforms. Firstly, TMCO6 gene silencing in HEK 293T 
cells was successful at the transcript level, shown by RT-qPCR (Fig. 5.5), and protein level, 
shown by SDS-PAGE and Western blotting (Fig. 5.6), with recovery in protein abundance 
observed soon after transduction. Gene silencing of TMCO6 was also associated with 
statistically significant slower growth rate in glucose media (Fig. 5.7), and notably, isolated CI 
deficiency (Fig. 5.8 B.), as determined by spectrophotometric measurements and supported 
qualitatively by in-gel CI activity (Fig. 5.8 A.). TMCO6 was again found to co-localise with fully 
assembled CI in these cells by 2D-BNGE, and also in two discrete CI sub-assemblies, the 
ratios of which were skewed following TMCO6 gene silencing (Fig. 5.9). Our inducible 
overexpression cellular models showed that the TMCO6.1 protein isoform is more abundant 
than TMCO6.2 in these cells, and overexpression of the HA-tagged variants were associated 
with a knock-on increase in the abundance of the endogenous protein (Fig. 5.11 A. and B.). 
In these samples, NDUFA9 (N-module/Q-module boundary) followed the pattern shown by 
abundance of TMCO6 most faithfully; however, no significant differences in CI holocomplex 
abundance (Fig. 5.12 B. and C.) or specific CI activity (Fig. 5.12 A.) were found using this 
cellular model. Attempts to generate a TMCO6 knockout in HAP1 cells and also a knockin for 
the patient mutation using the same sgRNA (Fig. 5.17), were conducted but failed to introduce 
any detectable mutations or changes (detailed in section 5.2.4). This is possibly due to poor 
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target site fidelity or PAM motif recognition by this sgRNA. At the time of this research, work 
had begun to characterise a knockout murine model, so attempts at generation of a cellular 
TMCO6-knockout model ceased. In summary, the results gained from studying these cellular 
models supported in vivo interaction between TMCO6 and CI, and suggested that TMCO6 
depletion or reduction impairs CI activity to a significant extent. 
 
We then sought to characterise a commercially available Tmco6-knockout mouse model, 
B6N(Cg)-Tmco6tm1.1(KOMP)Vlcg/J, in order to assess and investigate the role of Tmco6 in 
homeostatic development and function. Tmco6-KO mice displayed atypical neurobehaviors 
such as hindlimb clasping that progressed with age, and a proportion of KO animals developed 
myoclonic epilepsy from 6 months of age (Fig. 6.4). Both female and male KO animals were 
generally smaller in mass and size compared to age-matched controls (Fig. 6.4), and 
presented with poor motor endurance and coordination (Fig. 6.5). Spectrophotometry and 
Oroboros-based oxygraphic techniques revealed tissue-specific mitochondrial enzymatic 
deficiencies in Tmco6-KO mice brains, skeletal muscles and hearts, and no deficiency in 
murine fibroblasts. Despite there being no specific CI enzymatic deficiency in brains of KO 
mice at 3 months of age (Fig. 6.18 A.), which was a surprising finding given the extent of 
histopathological abnormalities (section 6.2.3), electron flow through the electron transport 
chain was impaired at the CI point of entry (Fig. 6.20). Also, hearts and skeletal muscle of 3 
month and 12 month old KO males showed isolated CI deficiency. The more severe CI 
deficiency of the two was observed in heart, with molecular abnormalities discovered as well, 
including a significant reduction in steady-state levels of N-module subunits NDUFS1 and 
NDUFS6 by SDS-PAGE and Western blot analysis, giving more weight to the involvement of 
Tmco6 in the assembly of this module. Lastly, echocardiography showed decreased right 
ventricular function and electrocardiography determined atrial flutter in KO mice hearts. No 
other abnormalities in cardiac function or physiology were detected at this time.  
 
These findings were very similar to those found for the human mitochondrial disease patient 
with a homozygous recessive mutation in TMCO6 (NM_018502.5: c.271C>T), as described in 
detail in Chapter 4. Firstly, MEFs did not show CI deficiency (Fig. 6.17), as had been the case 
for patient-derived fibroblast cells (Fig. 4.15). Also, isolated CI deficiency was shown in murine 
Tmco6-KO skeletal muscle to a comparable extent to what had been shown in a skeletal 
muscle biopsy from the patient (~ 40 % reduction). Epilepsy was observed in both the human 
patient and the KO mice, along with impaired locomotor behaviours and neuromotor control. 
Very few spontaneous epilepsy models in mice exist (Gu and Dalton, 2017), and none 
describing myoclonic seizures in mice as a result of ablation of a mitochondrial protein have 
been previously published in the literature so this is a curious finding. The only striking 
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difference we identified between the patient and murine knockout model was cardiac 
dysfunction (section 6.2.6), and associated severe, isolated cardiac CI deficiency in Tmco6-
KO hearts (Fig. 6.18 B.). The human proband had only ever had physical assessment of the 
heart carried out by means of a cardiac ultrasound, performed at 16 months of age, which had 
not been accompanied by echocardiography or electrocardiography. It is possible that an 
underlying, similar cardiac phenotype exists for the patient but is unknown at this time. Or 
equally, cardiomyopathy could be an idiosyncratic manifestation of murine Tmco6-ablation. 
However, cardiac dysfunction has been found in several cases of human CI deficiencies, 
including those associated with pathogenic mutations in NDUFS2 and NDUFA11 (Irwin, 
Parameshwaran and Pinkert, 2013), to name a couple. Furthermore, CI deficiency in murine 
models is being increasingly studied as the basis of cardiovascular dysfunction and disease 
(Forte et al., 2019); deletion of Ndufs6 has been found to result in specific cardiomyopathy and 
oxidative stress (Ke et al., 2012) and heterozygous systemic Ndufc2 deletion has been found 
to induce cardiovascular complications including ischemic stroke (Ohkubo et al., 2002). The 
result for Ndufs6 is particularly interesting since we have found the human NDUFS6 and 
TMCO6 proteins to interact by immunoprecipitation experiments in cultured HEK293T cells 
(Fig. 5.16), and both seemingly have associated cardiomyopathies in murine models. In 
addition to cardiac dysfunction, the phenotypic differences we observed such as decreased 
body weight and muscular weakness are similar to Ndufs4-knockout CI deficiency murine 
model mice that display ataxia and impaired growth (Kruse et al., 2008). Lastly, rescuing CI 
deficiency in an idiopathic murine epilepsy model was found to result in anti-seizure effects 
(Simeone et al., 2014), which if considered in reverse, could indicate a causal link between the 
epilepsy we have observed and the impaired CI-linked aerobic respiration in brains of these 
mice (Fig. 6.20). In summary, the physical and neurological findings, and biochemical 
phenotypes of this strain, indicate it to be a credible and useful in vivo model for studying the 
pathological effects of Tmco6-protein ablation in causing mitochondrial disease. 
 
Comparing the results of this stable knockout in vivo model to the transient shRNA-mediated 
knockdown model in HEK293T cells, we observed some similarities and some differences. 
Firstly, CI deficiency was observed to approximately ~ 60 % of control levels for three separate, 
successful shRNA-knockdown cell lines (Fig. 5.8 B.), whereas the murine Tmco6-KO model 
showed great variability in the extent of CI deficiency in different tissues. Liver and brains, for 
example, displayed no specific CI deficiencies (Fig. 6.18 A. and C.), whereas skeletal muscle 
revealed an equivalent reduction to the cellular knockdown model of ~ 40 % reduction (Fig. 
6.18 D.), and cardiac muscle showed a far greater reduction of approximately 80 % (Fig. 6.18 
B.). Next, CI-containing supercomplexes were found significantly reduced as a result of gene 
silencing by 1D-BNGE and Western blot analysis (Fig. 5.8 A.), but livers of Tmco6-KO 3 
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month-old male mice showed no reduction in quantity of a single CI-containing supercomplex 
(Fig. 6.30). Perhaps repeating this experiment in CI deficient tissues such as skeletal muscle 
and hearts would show differently. These models demonstrate CI deficiency owing to depletion 
or reduction of TMCO6/Tmco6 steady-state levels, independently linking TMCO6 to CI 
function, assembly and/or stability. 
 
Lastly, we questioned whether we could use the hearts of 3 month-old Tmco6-KO mice in order 
to 1) perform functional complementation rescue experiments with the human WT TMCO6 
cDNA sequence (NM_018502.5), and 2) to validate the pathogenicity of the human patient 
mutation (NP_060972.3: p.Arg91Cys) in causing mitochondrial disease. We devised an AAV9-
mediated gene delivery strategy to administer either the WT or patient mutant human cDNA 
sequences to KO or WT young adult mice (Fig. 7.1 A.). This process led to the creation of 4 
distinct transgenic groups: Tmco6+/+ (AAV WT), Tmco6+/+ (AAV MUT), Tmco6-/- (AAV WT), and Tmco6-/- 
(AAV MUT). In summary of the various results pertaining to the Tmco6-/- (AAV MUT) mice group, these 
animals were generally smaller than the complemented Tmco6-/- (AAV WT) group (Fig. 7.2)., 
exhibited more severe hindlimb clasping (Fig. 7.3), significantly worse performance by 
treadmill testing (Fig. 7.4 A.), somewhat worse performances for rotarod and pole tests (Fig. 
7.4 B. and C.), displayed less overall locomotor exploratory and movement via CLAMS 
monitoring during the day and night (Fig. 7.5), exhibited significantly worst right ventricular 
function and presence of atrial flutter (Table 7.1), whereas Tmco6-/- (AAV MUT) mice did not, and 
they showed statistically faster respiratory rates (Table 7.2), severe cardiac fibrosis (Fig. 7.9), 
and finally, significantly reduced CI/CS activity (Fig. 7.10). Conversely, Tmco6-/- (AAV WT) mice 
showed rescued CI deficiency in cardiac tissue (Fig. 7.10) and no such cardiac fibrosis (Fig. 
7.9). These results were crucial in verifying pathogenicity of the human mutant variant and its 
inability to rescue CI deficiency due to Tmco6-ablation.  
 
In summary we have shown that TMCO6 is a new human mitochondrial disease gene, leading 
to isolated, tissue-specific CI deficiency, epilepsy, neuropathy, and potentially cardiomyopathy. 
The patient mutant variant originally identified by WES (NM_018502.5: c.271C>T, 
NP_060972.3: p.Arg91Cys) is not capable of rescuing CI deficiency, nor any of its associated 
phenotypes, in a Tmco6-ablated murine model, and in fact, leads to novel onset of cardiac 
fibrosis. We do not yet know a mechanism of action for the human TMCO6 protein but suggest 




8.2 Future Aims 
 
 COA7 Project Future Aims 
Any objectives of future work regarding COA7 would be to better define its role in COX 
biogenesis. This could be achieved in a number of ways; three are mentioned below. 
 
Pulse-chase labelling of mitochondria-encoded peptides with [35S]-methionine could be used 
to verify whether COA7 does in fact only affect downstream of MT-CO1 assembly during COX 
biogenesis. Cell pellets could be collected at specific time points following an original 
incubation with radiolabelled [35S]-methionine for patient and control cells. 2D-BNGE and 
Western blotting could then be performed with subsequent immunodetection of various COX 
subunits to establish COX assembly kinetics of patient cells, control cells and patient cells 
complemented with COA7WT. This technique has been used previously to determine impaired 
COX biogenesis in cultured skin fibroblasts from a human patient with a pathogenic mutant in 
PET100 (Lim et al., 2014).  
As another means of investigation, immunoprecipitation experiments using primary antibodies 
raised against subunits of the MT-CO2 module, MT-CO2, COX5B, COX6C, COX7C, COX8A 
and, potentially, COX7B (Signes and Fernandez-Vizarra 2018), could be performed to observe 
whether COA7 co-interacts with any of these. This method could also be performed in reverse 
with anti-COA7 as the cross-linked bait antibody. 
Generation of a COA7-knockout cellular model by CRISPR/Cas9, either in haploid or diploid 
human cells, could be useful to determine whether COA7 ablation is indeed viable in human 
cells, since this cannot be proven (but is not expected to be the case). Additionally, these cells 
could be assessed using the two methods described above to better study the exact step in 




 TMCO6 Project Future Aims 
Much is still needed to elucidate the function of TMCO6 and to better understand its 
association with CI in vivo. In addition to main efforts being to determine the functional role of 
TMCO6, work should also be conducted to identify and characterise other mitochondrial 
disease patients whose syndromes are caused by TMCO6 mutant variants, in order to better 
understand any variabilities in presentations of mitochondrial disease arising from TMCO6 
mutations, and also to investigate therapeutic options using the Tmco6-KO mice. 
 
For the latter, searching through databases of patients with CI deficiencies that have 
undiagnosed molecular causes could yield other pathogenic TMCO6 mutant variants. 
Detection of additional patients would also allow for phenotypic comparison with the proband 
described in this work, potentially leading to a defined set of characteristics for mitochondrial 
diseases resulting from pathogenicity of TMCO6. 
For functional determination, CI complexomics combined with SILAC and quantitative mass 
spectrometry (Wang and Huang, 2008), could be used to determine perturbations to normal 
CI biogenesis as a result of changes to TMCO6 steady-state level. The aim of this work would 
be to investigate the role of TMCO6 in CI biogenesis by identifying whether it is found 
accumulated in certain CI subassemblies. For this, the inducible TMCO6.1-HA overexpressing 
HEK 293T cellular model could be used as the cellular basis of this experiment so that the 
TMCO6 steady-state level was higher than normal. Additionally, Tmco6-KO MEFs could be 
used since they are fast-growing and would showcase any CI assembly stalling or 
abnormalities due to total lack of Tmco6 protein, even if these cells do not have CI enzymatic 
deficiency. 
2D-BNGE using samples prepared from transduced mice hearts (from the Tmco6+/+ (AAV WT) 
group, for example) and immunodetection with an anti-HA antibody could be used to verify the 
result we found so far using the endogenous human anti-TMCO6 antibody that TMCO6 co-
migrates partially with fully assembled CI. We have shown that HA-tagged TMCO6 localises 
to the mitochondria in immunoprecipitation experiments using the inducible overexpression 
HEK 293T cellular model, but have not shown the co-migration of HA-tagged TMCO6 and CI 
by 2D-BNGE in these cells. So far we have not proven this 2D-BNGE result by an independent 
means, and have only done so with the anti-TMCO6 endogenous antibody. 
In order to better determine whether there was in fact a reduction in mitochondrial mass as a 
result of the human mutant variant of the TMCO6 protein, super resolution microscopy 
techniques could be used for patient fibroblasts and counterpart control cell lines. Staining of 
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the mitochondrial network using a mitochondrial marker, such as TOMM20, could reveal 
disruptions to the mitochondrial network and quantification methods could be used to quantify 
the signal intensity per cell area to reveal any significant differences in overall mitochondrial 
mass for patient cells versus controls. 
The Tmco6-knockout murine model could be used for therapeutic treatment experiments to 
observe any ameliorative effects on the neurological, locomotor and physical presentation of 
this strain by using established or novel therapeutic treatments; either those that are already 
approved in the treatment of mitochondrial diseases, such as supplemental CoQ10 (Nightingale 
et al., 2016), or novel therapeutic options for countering cardiomyopathy or CI deficiency could 
be explored if desired. This Tmco6-knockout model could also be used in the study of anti-
epileptic drugs since it is a novel model of spontaneous epilepsy.  
Mice electrocardiography could be additionally assessed by invasive electrode monitoring 
using classical ECG leads (Gao et al., 2011). This would aid in generating consistent and 
strong electrophysiological data for comparison. We found that the non-invasive approach 
used here led to some differences in amplitudes and variable qualities of traces between mice 
of different sizes (smaller mice yielded higher quality traces than did larger/fatter mice), which 
proved difficult for monitoring 12 month old wildtype animals. 
Repeating SDS-PAGE and blotting for various CI subunits should be performed for 12 month-
old (aged) tissues to determine if the decreases in NDUFS1 and NDUFS6 N-module subunits 
seen in aged hearts are similarly changed in other tissue types. This method could also identify 
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